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Abstract 
Store-operated Ca
2+
 entry (SOCE) is an important Ca
2+
 influx pathway existing in 
almost all types of mammalian cell. STIM1, ORAI and TRPC have been regarded as 
the molecular basis of SOCE. Once the endoplasmic reticulum (ER) Ca
2+
 store is 
depleted, STIM1 proteins move to the plasma membrane and activate ORAI and 
TRPC channels to allow Ca
2+
 influx. In this thesis, the pharmacological aspects and 
regulatory mechanisms of SOCE were investigated using HEK293 cells 
overexpressing STIM1, ORAI or TRPC genes. The expression and function of 
TRPC channels and their spliced variants in native cells were also examined. 
Using live-cell imaging, the cytosolic clustering of STIM1-EYFP was observed 
after challenging with the compounds including 2-APB, flufenamic acid, 4-chloro-
3-ethylphenol, U73122 and FCCP. The aggregation of STIM1 in the cytosol coud be 
a novel mechanism for the inhibition of SOCE, and  the process did not rely on the 
depletion of ER Ca
2+
 store. The ryanodine receptor agonist 4-chloro-3-ethylphenol 
not only caused Ca
2+
 release and cytosolic STIM1 clustering, but also nonselectively 
inhibited ORAI1/2/3 and TRPC3/4/5/6 channels.  
The sensitivity of TRP channels to metal ions was also investigated using patch 
clamp. Micromolar Cu
2+
 significantly increased the currents of TRPC3/4/5/6 
channels. The glutamic acid (E542/E543) and cysteine (C554) residues in the 
extracellular pore region of TRPC4 were involved in the channel opening by Cu
2+
. 
Moreover, Cu
2+
 showed inhibitory effect on TRPM2 channel. 
TRPC1/3/4/6 and multiple alternatively spliced variants were detected in the human 
ovarian adenocarcinoma-derived SKOV3 cells. Blockade of TRPC channel activity 
by 2-APB, SKF-96365, TRPC pore-blocking antibodies or transfection with TRPC 
siRNA significantly inhibited SKOV3 cell proliferation. Overexpression of TRPC 
genes promoted colony growth of SKOV3 cells. 
It is concluded that cytosolic STIM1 movement could be a new pharmacological 
target for SOCE. 4-Chloro-3-ethylphenol and Cu
2+
 are new modulators of ORAI and 
TRP channels. TRPC channels and their spliced variants are important for cancer 
cell growth. These findings provide novel insights into the pharmacology and 
pathophysiology of store-operated channels. 
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1.1. Introduction 
Calcium is a crucial element for all living organisms. Apart from the content of 
calcium stored in certain tissues and bound to proteins, free calcium ions (Ca
2+
) play 
a pivotal role in the regulation of physiological functions of the cells. Within a 
typical mammalian cell, the concentration of Ca
2+ 
varies in different subcellular 
compartments. The Ca
2+ 
concentration in the cytoplasm at resting state is generally 
within the range of 100-200 nM (Putney, 2010). In some organelles, such as 
endoplasmic/sarcoplasmic reticulum (ER/SR), mitochondria and lysosomes, the 
Ca
2+ 
concentrations are much higher, which may achieve  1-2 mM (Bygrave and 
Benedetti, 1996). Due to such a big difference between the Ca
2+ 
contents in 
cytoplasm and organelles, these organelles are termed as “Ca2+ stores”, which serve 
as an important source of cytoplasmic Ca
2+
. Another major Ca
2+ 
source for a cell is 
the extracellular  fluid, which contains a large amount of Ca
2+ 
with relatively stable 
concentrations at 1-2 mM (Larsson and Ohman, 1978). The entering of extracellular 
Ca
2+ 
into the cell, i.e., Ca
2+
 influx, is tightly controlled by various types of Ca
2+
-
permeable channels or transporters residing in the plasma membrane and regulated 
by intracellular Ca
2+ 
stores. 
1.2. Store-operated Ca
2+
 entry 
In non-excitable cells, such as fibroblasts, platelets and endothelial cells, the most 
important pathway for cytoplasmic Ca
2+
 supplement is the so called “store-operated 
Ca
2+
 entry” (SOCE), which means that the Ca2+ influx from extracellular fluid is 
triggered by the Ca
2+
 release from the stores. The physiological signals that induce 
Ca
2+
 release in non-excitable cells are mostly generated by the stimulation of G 
protein-coupled receptors (GPCRs) by agonists at the cellular surface. The 
activation of GPCRs triggers the signal transduction from G proteins to 
phospholipase C (PLC), which cleaves the membrane constituent 
phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol 
1,4,5-trisphosphate (IP3). The receptors of IP3 (IP3Rs) are Ca
2+
 channels located in 
the luminal membrane of the ER, and thus the elevated level of IP3 in the cytoplasm 
will result in the activation of IP3Rs and Ca
2+
 release from the ER. A decrease in the 
luminal Ca
2+
 level of the ER will eventually open the store-operated Ca
2+
 channels 
in the plasma membrane that mediate Ca
2+
 influx from extracellular liquid. As 
- 3 - 
 
SOCE is a fundamental process in many cell types, it plays important roles in 
various cellular functions, such as proliferation of endothelial cells (Abdullaev et al., 
2008), exocytosis (Bakowski et al., 2003), migration and metastasis of cancer cells 
(Yang et al., 2009a), and insulin secretion (Henquin et al., 2012). 
1.3. Discovery of store-operated Ca
2+
 entry 
The association between Ca
2+
 release from stores and Ca
2+ 
entry from extracellular 
medium was originally described in a series of studies by James W. Putney in the 
1970s (Putney, 1976a; Putney, 1976b; Putney, 1977). As the fluorescent Ca
2+
 
indicators were not available at that time, Putney used rat parotid acinar cells that 
express Ca
2+
-dependent K
+
 channels, in which the cytosolic Ca
2+
 levels can be 
indirectly monitored by observing the efflux rates of K
+
 or Rb
+ 
(Putney, 1976a). He 
found that carbachol and phenylephrine, which are agonists for muscarinic and 
adrenergic receptors respectively, elicited a biphasic 
86
Rb
+ 
release from the cells 
preloaded with this radioisotope. The first phase of release was independent of 
extracellular Ca
2+
, but the second phase could be blocked by external Ca
2+ 
chelator 
and La
3+
. These results suggested a fluctuation of intracellular Ca
2+ 
levels after 
receptor stimulation, which was confirmed by direct Ca
2+
 assay using 
45
Ca
2+ 
in the 
same type of cells (Putney, 1976b). Further experiments demonstrated that 
carbachol, phenylephrine and substance P (an agonist of neurokinin 1 receptor) all 
induced the first phase of 
86
Rb
+ 
efflux by releasing Ca
2+
 from the same store, which 
was followed by Ca
2+ 
influx from external solution that resulted in the second phase 
of 
86
Rb
+ 
efflux (Putney, 1977). A later independent study on rabbit smooth muscle 
cells showed that the amplitude of 
45
Ca
2+ 
influx in the cells with Ca
2+ 
store depleted 
by repetitive stimulation with noradrenaline in Ca
2+
-free solution was larger than 
that in cells kept in Ca
2+
-free solution only (Casteels and Droogmans, 1981). This 
study suggested a direct pathway of communication between the Ca
2+ 
store and 
extracellular medium. After a review on previous findings, Putney (1986) proposed 
a “capacitative Ca2+ influx” model for the receptor-regulated Ca2+ entry. In this 
model, the signalling molecule IP3 controls the Ca
2+ 
release from the store, which in 
turn regulates the Ca
2+ 
influx from extracellular space. The depletion of Ca
2+ 
store 
will automatically trigger Ca
2+ 
entry into the cell, and when the store is refilled to a 
certain level the Ca
2+ 
influx will be terminated. 
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The introduction of fluorescent Ca
2+ 
indicators (Grynkiewicz et al., 1985), especially 
fura-2, has significantly accelerated the  Ca
2+ 
signalling research. By using these 
membrane-permeable probes, it became feasible to monitor intracellular Ca
2+ 
level 
in a live cell in real time. Another landmark in SOCE research is the discovery of 
thapsigargin as a specific blocker of sarco/endoplasmic reticulum Ca
2+ 
ATPase 
(SERCA) (Thastrup et al., 1989; Thastrup et al., 1990) . Depletion of SR/ER Ca
2+ 
stores by thapsigargin does not rely on IP3 signalling, thus providing a means to 
investigate the role of Ca
2+ 
store depletion without concerning unknown effects of 
the second messengers generated by  GPCR activation. It was soon demonstrated 
that depletion of Ca
2+ 
store alone by thapsigargin was sufficient to induce Ca
2+ 
influx 
across the plasma membrane in rat parotid acinar cells (Takemura et al., 1989; 
Takemura and Putney, 1989). Taking the advantage of thapsigargin, the existence of 
SOCE in various types of cells was then reported by a number of independent 
research groups across the world. The findings on the cells including immune cells, 
epithelial and endothelial cells, cancer cells and smooth muscle cells implied that 
SOCE may be an ubiquitous cellular process in both excitable and non-excitable 
cells (Parekh and Penner, 1997). 
The application of patch-clamp techniques provided biophysical evidences for 
SOCE. Penner et al. (1988) reported a small inward current after Ca
2+ 
store 
depletion by IP3 in rat mast cells. A small Ca
2+
-selective current was also observed 
in human leukemic T cells by Lewis and Cahalan (1989), who used a mitogenic 
lectin, phytohemagglutinin, to stimulate internal Ca
2+
 release and found the elicited 
current was voltage-independent. Although both studies had described the 
correlation between Ca
2+
 release and the inward Ca
2+
 current, the authors did not 
consider Ca
2+
 release as a direct signal that triggered the Ca
2+
-influx current. The 
causal relation between Ca
2+ 
store depletion and the accompanying inward Ca
2+
 
current was firstly demonstrated by Hoth and Penner (1992) and the current was 
termed “Ca2+ release-activated Ca2+ current” (ICRAC). The ICRAC was characterised by 
an inward rectification, very high selectivity for Ca
2+ 
and voltage-independence. 
Later, store-operated currents with different biophysical properties were identified in 
many types of non-excitable cells, such as human umbilical vein endothelial cells 
(Oike et al., 1994), pancreatic beta cells (Bordin et al., 1995; Bertram et al., 1995) 
and rat basophilic leukaemia cells (Hoth, 1995), and  some excitable cells, such as 
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smooth muscle cells (Zakharov et al., 2004) and sensory neurons (Gemes et al., 
2011).  
1.4. STIM and Orai as molecular basis of store-operated Ca
2+
 entry 
Although the presence of SOCE in various cell types was well demonstrated by 
intracellular Ca
2+ 
measurement and electrophysiological recordings over the past 
three decades, the molecular identities of store-operated channels (SOCs) had 
remained elusive until the discovery of STIM1 (stromal interaction molecule 1) and 
Orai1 in 2005 and 2006, respectively (Roos et al., 2005; Liou et al., 2005; Vig et al., 
2006b; Feske et al., 2006). The crucial role of STIM1 in SOCE was revealed by 
RNA interference (RNAi)-based gene-screening studies in Drosophila S2 cells, 
human Jurkat T and Hela cells, in which the knockdown of STIM1 expression 
significantly reduced thapsigargin-induced or receptor-triggered Ca
2+ 
influx (Roos et 
al., 2005; Liou et al., 2005). STIM1 was found to be the Ca
2+ 
sensor in the ER and 
translocate to the plasma membrane upon Ca
2+ 
store depletion (Liou et al., 2005; 
Zhang et al., 2005). Genome-wide RNAi screen in Drosophila S2 cells and genetic 
linkage analysis of patients with defective SOCE in T cells identified Orai1, the 
essential component of SOCs located at the plasma membrane (Vig et al., 2006b; 
Feske et al., 2006; Zhang et al., 2006). Coexpression of STIM1 and Orai1 
reconstituted the function of SOCs and greatly potentiated ICRAC (Peinelt et al., 
2006; Soboloff et al., 2006; Mercer et al., 2006). Further mutational studies on 
Orai1 validated its role as the pore-forming subunit of SOCs (Prakriya et al., 2006; 
Vig et al., 2006a; Yeromin et al., 2006). The RNAi study by Liou et al. (2005) also 
found STIM2, the conserved analogue of STIM1 in vertebrates (Cai, 2007a). 
Sequence similarity search against Drosophila Orai characterised Orai1, Orai2 and 
Orai3 in human genome (Feske et al., 2006), of which Orai1 and Orai2 are 
conserved in vertebrates, and Orai3 is specific for mammals (Cai, 2007b). 
Functional similarities were shared between STIM1 and STIM2 (Liou et al., 2005), 
and among the three Orai isoforms (Mercer et al., 2006). These fundamental studies 
established a principal machinery of SOCs, which has substantially facilitated our 
understanding on the physiological and pathophysiological regulation of SOCE. 
 
 
- 6 - 
 
1.5. Mechanism of STIM1/Orai1-mediated Ca
2+
 entry 
STIM1 is an ER-localised protein with a single transmembrane segment (Fig. 1.1). 
The N-terminus of STIM1, which resides in the ER lumen, contains EF hand and 
sterile α motif (SAM) domains (Stathopulos et al., 2008; Zheng et al., 2008). The 
EF hand is a Ca
2+
-binding motif and thus functions as a sensor to detect luminal 
Ca
2+ 
level in the ER. The SAM domain is responsible for the oligomerisation of 
STIM1 proteins. The cytosolic part of STIM1contains two predicted coiled-coil 
regions, a serine/proline-rich and a lysine-rich domain (Deng et al., 2009). A STIM1 
segment within the coiled-coil regions was found to activate Orai1 channel directly, 
thus being named CRAC activation domain (CAD) (Park et al., 2009) or STIM1-
Orai activating region (SOAR) (Yuan et al., 2009b). In addition, an acidic motif has 
been recognised from the first coiled-coil region of STIM1, and a basic motif was 
found in the CAD/SOAR (Korzeniowski et al., 2010). Each Orai1 protein has four 
transmembrane segments, with both the N- and C-termini facing the cytosol (Fig. 
1.1). An acidic motif within the coiled-coil region of the C-terminus of Orai1 is 
believed to interact with the CAD/SOAR of STIM1 (Muik et al., 2008; Calloway et 
al., 2009). As the two acidic motifs in STIM1 and Orai1 have substantial similarity 
and the basic motif in the CAD/SOAR can bind to either of them, a molecular 
switching model has been proposed for the CAD/SOAR-controlled Orai1 activation 
(Fig. 1.1) (Korzeniowski et al., 2010). At resting state, the CAD/SOAR is 
inactivated by binding to the acidic motif of STIM1. This intramolecular bond is 
disrupted after Ca
2+ 
ions disassociate from the EF hand of STIM1, and the 
CAD/SOAR is exposed the cytosol and binds the acidic motif of Orai1 when the 
distance between STIM1 and Orai1 is close enough.  
In a cell, the depletion of ER Ca
2+ 
store induces aggregation and translocation of 
STIM1 proteins toward the plasma membrane (Liou et al., 2005). The interaction of 
STIM1 and Orai1 occurs in the junctional area between the plasma membrane and 
the ER (PM-ER junction), which may be pre-existing or newly formed after Ca
2+ 
store depletion (Wu et al., 2006). The subplasmalemmal STIM1 clusters are able to 
induce local aggregation of Orai1 channels, forming a large number of puncta at the 
plasma membrane (Xu et al., 2006a; Luik et al., 2006), and causing the opening of 
Orai1 channels, which  allows massive Ca
2+ 
influx into the cell to refill the Ca
2+ 
store and regulate cellular functions. 
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Fig. 1.1 Molecular mechanism of STIM1/Orai1-mediated Ca
2+
 influx. The upper 
part shows the structure of STIM1 at resting state, and the lower part illustrates the 
architecture of STIM1/Orai1 complex after Ca
2+ 
ions disassociate from STIM1. The 
symbols of positive and negative charges indicate the basic and acidic motifs, 
respectively. Abbreviations: N, amino-terminus; C, carboxyl-terminus; EF, EF hand 
domain; SAM, sterile α motif; TM, transmembrane segment; CC, CC1 and CC2, 
coiled-coil regions; CAD/SOAR, CRAC activation domain and STIM1-Orai 
activating region; S/P, serine/proline-rich domain; K, lysine-rich domain; S1-S4, 
transmembrane segment 1-4. 
1.6. TRPC channels in store-operated Ca
2+
 entry 
Before the discovery of STIM1 and Orai1, the most possible candidates of SOCs 
have been considered to be transient receptor potential canonical (TRPC) channels. 
TRPC channels belong to the large family of TRP channels, which includes a total 
of 28 members in mammalian genome. These members are divided into six 
subfamilies according to the sequence similarities: TRPA1 (ankyrin), TRPV1-6 
(vanilloid), TRPM1-8 (melastatin), TRPP1-3 (polycystin), TRPML1-3 (mucolipin) 
and TRPC1-7. Most TRP channels are non-selective cation channels with a 
selectivity of Ca
2+
 over Na
+
 variable among different members. A number of TRP 
channels, in particular TRPCs, are activated following GPCR stimulation, and thus 
referred to as “receptor-operated channels” (ROCs). There is evidence that TRPC 
channels are potentiated by activated G proteins (TRPC4/5) (Jeon et al., 2012), the 
PLC-cleavage product DAG (TRPC3/6/7) (Hofmann et al., 1999; Okada et al., 
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1999) and the depletion of Ca
2+ 
store (Salido et al., 2009). Among all TRPC 
members, TRPC1 has been most consistently considered a SOC channel in many 
cell types, such as salivary gland (Liu et al., 2000), smooth muscle (Xu and Beech, 
2001), DT40 (Mori et al., 2002) and epithelial cells (Rao et al., 2006). In these 
studies, inhibition of TRPC1 activity or knockdown of TRPC1 expression attenuated 
SOCE evoked by thapsigargin or GPCR agonists in vitro. In TRPC1-knockout mice, 
the endogenous SOCE was significantly reduced in salivary gland cells (Liu et al., 
2007), but not affected in platelets and cerebral artery smooth muscle cells (Varga-
Szabo et al., 2008a; Dietrich et al., 2007), suggesting the essential role of TRPC1 in 
SOCE may be limited to some specific cell types. It has been showed that TRPC1 
interacted with both STIM1 and Orai1, and formed a ternary complex (Ong et al., 
2007; Zhang et al., 2010). Further studies in salivary gland cells demonstrated that 
the insertion of TRPC1 into the plasma membrane and its activation after Ca
2+ 
store 
depletion were triggered by the Ca
2+ 
influx through Orai1 channel (Cheng et al., 
2008; Cheng et al., 2011). These studies provided an important mechanism for the 
functional interaction of STIM1, Orai1 and TRPC1 in salivary gland cells. TRPC1 
was also reported to be gated by STIM1 directly through electrostatic interaction 
between the positively and negatively charged motifs in the C-termini of the two 
proteins (Zeng et al., 2008), which may be a universal mechanism in HEK293 and 
other cell types. Apart from TRPC1, TRPC4 and TRPC5 were also found to interact 
with STIM1 (Yuan et al., 2007). Considering that all TRPC isoforms, except TRPC2 
(a pseudogene in human) and TRPC7, are able to form heterotetrameric channels, 
STIM1 was found to regulate TRPC3 and TRPC6 indirectly when they multimerise 
with TRPC1, TRPC4 or TRPC5 (Yuan et al., 2007). Gene knockdown experiments 
suggested that TRPC3, TRPC4 and TRPC7 contributed to SOCE in DT40 (Vazquez 
et al., 2001), HEK293 (Zagranichnaya et al., 2005) or mesangial cells (Wang et al., 
2004b). Blockage of TRPC channels by antibodies revealed that TRPC1 and TRPC5 
were required for SOCs in portal vein, coronary and mesenteric arteries, whereas 
TRPC6 and TRPC7 had such a role only in coronary artery and portal vein, 
respectively (Saleh et al., 2008). An early and a recent study using endothelial cells 
from TRPC4-deficient mice validated the role of TRPC4 as a SOC channel (Freichel 
et al., 2001; Sundivakkam et al., 2012). There are also conflicting observations on 
the Ca
2+
 store-dependent activation of TRPC channels, which excluded the store-
operated functionality of TRPCs. For example, RNA silencing of either TRPC1 or 
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TRPC4 did not affect the SOCE and ICRAC in endothelial cells (Abdullaev et al., 
2008), and no functional association between TRPCs and STIM1/Orai1 was 
observed when they were coexpressed in HEK293 cells (Abdullaev et al., 2008; 
DeHaven et al., 2009). Collectively, these contradictory results may arise from the 
differences in the expression profile of STIM, Orai, TRPC and other unknown 
regulators of SOCE in various cell types. Nonetheless, TRPC channels are able to 
function as components of SOCs in at least some specific cell types. Future studies 
that recognise novel members and regulatory mechanisms of SOCs will be helpful to 
clarify the roles of TRPC channels in SOCE. 
1.7. Physiological and pathophysiological functions of store-
operated Ca
2+
 channels 
1.7.1 Functions of STIM proteins and Orai channels 
Although STIM1 and Orai1 proteins are widely expressed in a large variety of tissue 
and cell types, the genetic defects of STIM1 or Orai1 genes are mostly related to 
immune diseases in human and mice (Feske, 2009). A nonsense mutation in exon 3 
of STIM1 gene, which results in a truncated STIM1 protein, caused 
immunodeficiency, autoimmune hemolytic anemia and other immune-related 
symptoms in the patients (Picard et al., 2009). Studies using cells isolated from fetal 
STIM1-knockout mice demonstrated that STIM1 was essential for the activation of 
mast cells, T cells and macrophages (Baba et al., 2008; Oh-Hora et al., 2008; Braun 
et al., 2009a). Patients bearing a nonsense mutation in Orai1 have a hereditary 
syndrome of severe combined immunodeficiency (SCID), which manifested 
decreased immune response and impaired Ca
2+
-dependent gene expression in T cells 
(Feske et al., 2006). In mast cells from Orai1-deficient mice the degranulation and 
cytokine secretion were defective, and the allergic reactions of the mice were 
inhibited in vivo (Vig et al., 2008). Orai1-knockout mice also exhibited reduced B 
cell proliferation in response to receptor stimulation and attenuated cytokine 
production by T cells (Gwack et al., 2008). These results consistently suggest that 
STIM1/Orai1-mediated SOCE is important for the immune functions. STIM2 has 
been found to share some functions of STIM1 in T cells, such as the regulation of 
cytokine production and nuclear translocation of the transcription factor NFAT 
(nuclear factor of activated T-cells) (Oh-Hora et al., 2008). The functions of Orai2 
and Orai3 in immune system are still lack of investigation thus far.  
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In addition to immune regulation, STIM and Orai also participate in the regulation 
of cardiovascular functions, and are involved in the development of cancer. STIM1 
was found to promote pathological cardiac hypertrophy in rat models (Hulot et al., 
2011; Luo et al., 2012). The activity of STIM1 and Orai1 is required for the 
proliferation and migration of vascular smooth muscle and endothelial cells (Potier 
et al., 2009; Abdullaev et al., 2008; Kuang et al., 2010). The mice lacking STIM1 or 
Orai1 exhibited lowered activity of platelets and thus were less sensitive to ischemic 
brain infarction and arterial thrombosis (Grosse et al., 2007; Varga-Szabo et al., 
2008b; Braun et al., 2009b). The roles of STIM and Orai proteins in breast cancer 
cells have been investigated by different research groups. Yang et al. (2009a) 
demonstrated that STIM1/Orai1-mediated SOCE is critical for the migration and 
metastasis of breast tumour cells in mice. Motiani et al. (2010) found a correlative 
expression of oestrogen receptors and Orai3 in various breast cell lines and 
suggested that STIM1/2 operate Orai3 as major SOCs in breast cells with oestrogen 
receptors, whereas Orai1 plays the role as SOCs in breast cells lacking oestrogen 
receptors. Feng et al. (2010) unveiled a store-independent pathway for the activation 
of Orai1 that promoted the tumourigenesis of breast cancer cells, implying that 
Orai1 is a potential therapeutic target in the treatment of mammary tumours. 
1.7.2 Functions of TRPC channels 
TRPC1, which is the first identified mammalian TRP channel, has been proposed to 
function as component of store-operated (Xu and Beech, 2001), receptor-operated 
(Strubing et al., 2001) and stretch-activated channels (Maroto et al., 2005), and play 
diverse physiological roles in a range of cells such as cardiac, skeletal and smooth 
muscle cells, endothelial cells, neurons and salivary gland cells (Abramowitz and 
Birnbaumer, 2009). TRPC1-deficient mice showed significantly reduced SOCE 
upon agonist- or thapsigargin-stimulation in salivary gland cells (Liu et al., 2007). 
Knock-out of TRPC1 protected the mice subjected to hemodynamic stress from 
cardiac hypertrophy by interrupting mechanosensitive signaling  pathways (Seth et 
al., 2009). Muscles from TRPC1 deficient mice displayed lower Ca
2+
 transients than 
that observed in muscles from wildtype mice. As a result, the TRPC1 deficient mice 
presented less force in muscle contraction and significantly decreased endurance for 
physical activity (Zanou et al., 2010). Another study demonstrated that TRPC1 
contributed to blood pressure regulation by negatively regulating endothelial Ca
2+
-
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activated K
+
 channel-dependent vasodilatations in TRPC1-deficient mice (Schmidt 
et al., 2010).  TRPC1 was found to reside on the endoplasmic reticulum (ER) when 
expressed alone, but could interact with other TRPC channels, particularly TRPC4 
and TRPC5, to form heterotetramers at the plasma membrane when they were 
coexpressed (Hofmann et al., 2002; Alfonso et al., 2008). Thus, it is proposed that 
TRPC1 may form heterotetrameric Ca
2+
-influx channels at the plasma membrane 
and homotetrameric Ca
2+
-release channels at the ER (Alfonso et al., 2008). 
Expression of TRPC3 have been detected in many tissues and cell types, but 
particularly high in brain, smooth and cardiac muscle cells (Clapham, 2003). The 
most studied cardiovascular diseases related to TRPC3 are hypertension and cardiac 
hypertrophy. Upregulation of TRPC3 was found in vasculature from hypertensive 
rats (Liu et al., 2009), hypertrophic hearts from mice and rats (Bush et al., 2006), 
and vascular endothelium of patients with malignant hypertension (Thilo et al., 
2009). The transgenic mice expressing a dominant negative TRPC3 in the heart 
exhibited attenuated cardiac hypertrophic response following either neuroendocrine 
agonist infusion or pressure-overload stimulation (Wu et al., 2010a). In contrast, 
cardiac-specific overexpression of TRPC3 in mice induced spontaneous hypertrophy 
(Nakayama et al., 2006). The hypertrophic growth of cardiomyocytes is considered 
to be mediated by NFAT, a Ca
2+
-responsive transcriptional factor (Rohini et al., 
2010). The Ca
2+
 influx through TRPC3 may activate NFAT, and the activation of 
NFAT triggers the transcription of hypertrophic genes including TRPC3 itself 
(Nakayama et al., 2006). This feedback loop augments the hypertrophic response, 
leading to the overgrowth of cardiomyocytes. The association between Ca
2+
 influx 
and NFAT activation also exists in vascular endothelial cells (Rinne et al., 2009), 
which may relate to the pathology of more cardiovascular diseases. TRPC3 
knockout mice exhibited an impaired walking behaviour (Hartmann et al., 2008), 
but the cardiovascular function of these mice has not been investigated. 
TRPC4 is expressed in endothelium, smooth muscle cells, intestinal pacemaker 
cells, neurons, adrenal glands and kidneys (Gees et al., 2010). The best-
characterised role for TRPC4 is in the regulation of endothelial permeability and 
vascular tone. In aortic endothelial cells isolated from wildtype and TRPC4-
deficient mice, TRPC4 was found to be an indispensable component of SOCs acting 
as pore-forming subunits or other constituents of channel complexes (Freichel et al., 
2001). Both store-operated and agonist-induced receptor-operated Ca
2+
 entry were 
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absent in TRPC4-deficient endothelial cells. Moreover, endothelial-dependent 
vasorelaxation of aortic rings in response to stimulation is markedly impaired in 
TRPC4-deficient mice. In another study, lung endothelial cells from TRPC4-
deficient mice failed to respond to thrombin-stimulated GPCR activation and 
corresponding Ca
2+
 influx was dramatically reduced compared to wildtype mice 
(Tiruppathi et al., 2002). The abnormal Ca
2+
 influx in TRPC4-deficient endothelial 
cells was associated with a lack of thrombin-mediated actin-stress fiber formation 
and a reduced endothelial cell retraction response, suggesting TRPC4 is crucial for 
the regulation of microvascular permeability in the lungs of mice. TRPC4 is also 
involved in hypoxia-induced vascular remodelling (Fantozzi et al., 2003). The 
expression of TRPC4 was upregulated by hypoxia and correlated directly with 
SOCE in human pulmonary artery endothelial cells. This TRPC4-related Ca
2+
 entry 
resulted in the activation of nuclear transcription factors and expression of vascular 
growth factors, leading to remodelling of blood vessels. 
TRPC5 and TRPC4 share the highest homology among all members of TRPC 
subfamily. These two proteins have conserved structural elements in the N-termini 
and membrane-spanning regions, and only differ in the C-termini. TRPC5 is also 
expressed in multiple tissues, including cardiovascular system and central nervous 
system (Plant and Schaefer, 2003). TRPC5 has been reported to participate in 
endothelium-dependent nitric oxide (NO)-mediated vasorelaxation of blood vessels 
(Yoshida et al., 2006). NO plays an important role in the cardiovascular system by 
controlling vasoconstriction and vasorelaxation. NO-induced Ca
2+
 influx in bovine 
aortic endothelial cells was prevented by transfection of siRNA or dominant 
negative isoform of TRPC5 (Yetik-Anacak and Catravas, 2006). This study also 
demonstrated that NO caused cysteine S-nitrosylation of TRPC5 on two cysteine 
residues in the S5-S6 loop region. Mutation of these cysteine residues to serine 
abrogated TRPC5 responses to NO. These two cysteine residues are also present at 
corresponding positions in TRPC1 and TRPC4, and both of them can be activated 
by NO (Freichel et al., 2001). A mechanism is suggested that Ca
2+
 influx induced by 
NO-induced nitrosylation of TRPC channels may lead to increased endothelial NO 
synthase (eNOS) activity, which increases NO production and results in enhanced 
smooth muscle relaxation (Yoshida et al., 2006). However, NO was also reported to 
inhibit Ca
2+
 entry in bovine vascular endothelial cells (Dedkova and Blatter, 2002). 
Other TRPC channel like TRPC3 may also participate in this process to generate 
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promiscuous Ca
2+
 signals observed in different studies (Kwan et al., 2004). 
Knockout of TRPC5 diminished the innate fear levels of mice (Riccio et al., 2009), 
which demonstrated its important role in the central nervous system. 
Expression of TRPC6 was detected in various tissues and cells, such as lung, brain 
and smooth muscle cells (Freichel et al., 2005). TRPC6-knockout mice showed an 
elevated blood pressure and increased vascular smooth muscle contractility, and this 
could only be partly recovered by the constitutively-active TRPC3 channels 
overexpressed  in the smooth muscle cells of TRPC6-knockout mice (Dietrich et al., 
2005). Deletion of TRPC4 and TRPC6 in mice impaired smooth muscle contraction 
and intestinal motility, which was related to voltage-activated Ca
2+
 influx and 
depolarization of intestinal smooth muscle cells (Tsvilovskyy et al., 2009). A 
TRPC5/TRPC6 activation cascade was found to participate in the regulation of 
endothelial cell migration (Chaudhuri et al., 2008), and the mechanism has been 
well explained by a study in podocytes (Tian et al., 2010). The authors suggest 
TRPC5 and TRPC6 regulate the cell migration by binding to different members of 
Rho GTPases. TRPC5 was present in a complex with Rac1 and TRPC6 was 
associated with RhoA, in which the former one promotes the cell migration and the 
latter one inhibits it.  
Studies on TRPC7 are much less than that of other TRPC members and its exact role 
is still unclear. It is suggested that TRPC7 conducts Ca
2+
 in AT1-induced 
myocardial apoptosis via a calcineurin-dependent pathway and can thereby 
contribute to the process of heart failure (Satoh et al., 2007). Ablation of both 
TRPC6 and TRPC7 genes in mice eliminated the light response in iris and retina, 
suggesting their essential roles in the mammalian melanopsin signalling pathway 
(Xue et al., 2011). 
1.8. Pharmacological modulators of store-operated Ca
2+
 channels 
1.8.1. Chemical activators of store-operated Ca
2+
 channels 
The principal way to activate SOCs is depleting Ca
2+ 
from the ER/SR, which can be 
achieved by either stimulating Ca
2+
-release channels in the ER/SR membrane, 
increasing the ER/SR membrane permeability to Ca
2+
, or blocking Ca
2+ 
transportation into the ER/SR (Fig. 1.2A). 
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GPCR agonists and IP3: The GPCR agonist-induced IP3 production is sufficient to 
trigger rapid Ca
2+
 release via IP3Rs. The most widely used chemical agonists are 
carbachol and ATP, which activate muscarinic and purinergic receptors, 
respectively. The use of agonists to deplete the Ca
2+
 store from cell surface requires 
the expression of corresponding receptors in the cells, either endogenous or 
exogenous. Intracellular application of synthetic IP3 is also able to activate IP3Rs and 
thus induce SOCE (Taylor and Tovey, 2010; Smyth et al., 2010). 
RyR agonists: Another family of Ca
2+
-release channels in the ER/SR is ryanodine 
receptors (RyRs). Potentiation of RyRs by caffeine and ryanodine has been shown to 
induce SR Ca
2+
 release and SOCE in smooth muscle cells (Ng et al., 2007).  
Ca
2+
 ionophore: An alternative way to stimulate Ca
2+
 release is to increase the Ca
2+
 
permeability of the ER/SR membrane using ionomycin. Ionomycin is a Ca
2+
 
ionophore that carries Ca
2+
 through the membrane. It is suggested that ionomycin at 
low concentrations (<1 µM) only affects the permeability of intracellular 
membranes and has little effect on the plasma membrane, which renders it the ability 
to activate SOCs without damaging the cells (Putney, 2010).  
SERCA inhibitors: The importation of Ca
2+ 
from cytoplasm into the ER/SR is in the 
charge of SERCA, a class of Ca
2+ 
pumps. The activity of SERCA can be blocked by 
thapsigargin and cyclopiazonic acid. As a passive process relying on the endogenous 
Ca
2+
-leaking activity, the depletion of Ca
2+ 
store by thapsigargin and cyclopiazonic 
acid is very slow, compared to the effects of GPCR and RyR agonists. However, 
because the inhibition of SERCA by thapsigargin is essentially irreversible (Lytton 
et al., 1991), the subsequent SOCE and membrane current are more persistent (Oike 
et al., 1994; Liu and Gylfe, 1997).  
Ca
2+
 chelators: Chelating cytosolic Ca
2+ 
by BAPTA, EGTA or TPEN can also 
prevent Ca
2+ 
from being transported into the store. The onset of Ca
2+ 
store depletion 
depends on the Ca
2+ 
affinity and concentration of the chelators (Zweifach and Lewis, 
1996; Chvanov et al., 2008). Chelation of cytosolic Ca
2+
 is required in the 
eletrophysiological recordings of ICRAC, with BAPTA or EGTA as an essential 
component of the internal solution. 
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Fig. 1.2 Pharmacological mechanisms of chemical modulators of store-operated 
Ca
2+
 channels. (A) activators. (B) inhibitors. The question mark suggests that the 
mechanism is unclear. 
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1.8.2. Chemical inhibitors of store-operated Ca
2+
 channels 
A number of small-molecule inhibitors of SOCs have been identified. Some of these 
chemicals, such as 2-aminoethyldiphenyl borate (2-APB) and ML-9, have inhibitory 
effect on the formation of STIM1 puncta at the plasma membrane, whilst others are 
most likely to block the pore-forming channels directly (Fig. 1.2B).  
 2-APB: 2-APB is generally considered an inhibitor of SOCs; however, it seems to 
directly facilitate Orai channels overexpressed in HEK293 cells. In cells 
coexpressing STIM1/Orai1 or STIM1/Orai2, an inward-rectifying current was 
developed immediately after the exposure to 10-100 µM 2-APB, and then the 
current was rapidly diminished (Peinelt et al., 2008; DeHaven et al., 2008). The 
transient potentiation of Orai1 and Orai2 by 2-APB relied on the pre-existence of 
STIM1/Orai complex induced by Ca
2+
 store depletion, suggesting that the 
conformation of Orai1 and Orai2 proteins determines their response to 2-APB 
(Peinelt et al., 2008). 2-APB within the range 20-100 µM substantially activated 
Orai3 overexpressed alone or together with STIM1, without dependence on Ca
2+
 
store depletion (Peinelt et al., 2008; DeHaven et al., 2008; Zhang et al., 2008; 
Yamashita et al., 2011). The 2-APB-induced Orai3 current showed both inward and 
outward rectification, which was attributed to the non-selective channel permeability 
to divalent and monovalent cations (DeHaven et al., 2008; Zhang et al., 2008). The 
inhibitory effect of 2-APB on global SOCE may be caused by, at least in part, its 
influence on STIM1. In cells overexpressing fluorescent protein-tagged STIM1, 
application of 50 and 100 µM 2-APB not only prevented the formation of STIM1 
puncta after Ca
2+ 
store depletion, but also disassembled STIM1 puncta already 
existed (Peinelt et al., 2008; DeHaven et al., 2008; Tamarina et al., 2008). In 
addition to the complex actions on STIM1 and Orai channels, 2-APB at 
concentrations higher than 50 µM also inhibited IP3Rs and TRPC channels 
(Maruyama et al., 1997; Xu et al., 2005a; Zagranichnaya et al., 2005; Harteneck and 
Gollasch, 2011). 
Lanthanides: La
3+
 was found to inhibit agonist-induced Ca
2+ 
influx since the 1970s 
(Putney, 1976a; Putney, 1976b). Another lanthanide, Gd
3+
, has been shown to 
potently suppress native and Orai-mediated CRAC currents with a lowest 
concentration of 50 nM (Zhang et al., 2006; Yeromin et al., 2006). La
3+ 
and Gd
3+ 
are 
also blockers of TRPC channels at micromolar or higher concentrations, with the 
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exception that TRPC4 and TRPC5 are potentiated within the range 10-100 µM 
(Jung et al., 2003). Lanthanides are generally used in solutions without serum and 
multivalent anions, as these components may form metal-protein complex or 
insoluble salts (Putney, 2009).  
Diethylstilbestrol: The synthetic oestrogen diethylstilbestrol has been reported to 
inhibit SOCs in human platelets, rat basophilic leukemia and vascular smooth 
muscle cells (Zakharov et al., 2004). The inhibition on ICRAC and SOCE was dose-
dependent (IC50 within 0.1-1 µM) and reversible. Diethylstilbestrol was also found 
to reversibly block TRPC5 channel overexpressed in HEK293 cells with an IC50 
around 10 µM (Naylor et al., 2011). Apart from this, the effect of diethylstilbestrol 
has not been tested on exogenously expressed Orai and other TRPC channels.  
ML-9: ML-9 is a myosin light chain kinase inhibitor. It was found to inhibit agonist-
induced Ca
2+ 
influx and SOCE in endothelial cells (Watanabe et al., 1996) and 
monocytes/macrophages (Tran et al., 2001), respectively. The effect of ML-9 on 
SOCs is considered to be independent of myosin light chain kinase, but related to 
STIM1. The action of ML-9 on STIM1 is similar to that of 2-APB. It blocked the 
formation of STIM1 puncta following Ca
2+ 
store depletion, and also reversed the 
pre-existed puncta of a constitutively active STIM1 mutant (Smyth et al., 2008). 
There is no report about the modulation of Orai or TRPC channels to date. 
BTP2: BTP2 is another potent blocker of SOCs. It was originally identified as a 
most effective inhibitor of NFAT activation and T cell cytokine production among a 
number of pyrazole derivatives (Trevillyan et al., 2001; Chen et al., 2002). It was 
then found to inhibit SOCE with IC50 ranging from 10 to 300 nM in different cell 
types (Ishikawa et al., 2003; Zitt et al., 2004; He et al., 2005). The activity of 
TRPC3 and TRPC5 channels overexpressed in HEK293 cells was also substantially 
blocked by BTP2, with the IC50 of 300 nM for the Ca
2+ 
influx and 3 µM for the 
whole-cell currents (He et al., 2005). 
SKF-96365: SKF-96365 was firstly reported to inhibit receptor-mediated Ca
2+
 entry 
(Merritt et al., 1990), and later found to be a general blocker of CRAC and TRPC 
channels (Boulay et al., 1997; Hsu et al., 2001; Kozak et al., 2002; Ohana et al., 
2009). The IC50 of SKF-96365 on SOCE in different cell types is in the range of 1-3 
µM (Liu et al., 2011; McGahon et al., 2012). 
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MRS1845: MRS1845 was screened out from a series of 1,4-dihydropyridines as the 
most potent and relatively selective compound to inhibit SOCE in leukemic HL-60 
cells, with an IC50 of  1.7 µM (Harper et al., 2003). The inhibitory effect of 
MRS1845 on SOCE was then confirmed by studies using human neutrophils, 
salamander photoreceptors and rat pituitary cells (Lee et al., 2005a; Szikra et al., 
2008; Yamashita et al., 2009).  
Synta66 and GSK-7975A: A recent study has compared the potency of five SOC 
inhibitors in platelets, including 2-APB, SKF-96365 and MRS1845, and two new 
compounds, Synta66 and GSK-7975A (van Kruchten et al., 2012). The potency of 
the five compounds on the inhibition of SOCE in platelets was ranked as 
Synta66>2-APB>GSK-7975A>SKF-96365>MRS1845, and the IC50 of Synta66 was 
~0.6 µM (van Kruchten et al., 2012). These results suggest that Synta66 may be a 
promising inhibitor of SOCs, with further studies required to illustrate its selectivity 
on Orai, TRPC and other channels. 
1.9. Aims of this study 
In this PhD project, I aimed to investigate the mechanisms underlying the activation 
and inhibition of SOCs by pharmacological and physiological modulators in 
HEK293 cells overexpressing STIM1, ORAI and TRP channels, and the 
pathological roles of TRPC channels in human ovarian cancer cells.  
New discoveries on the following topics will be demonstrated:  
(1) The pharmacological profile of STIM1, incluing the effects of ER and 
motichondrial Ca
2+
 store regulators, SOC inhibitors, signalling pathway blockers, 
and cytoskeleton depolymerising and stabilising agents. 
(2) Identification of novel small-molecule inhibitors of STIM1/ORAI and TRPC 
channels, including 4-chloro-3-ethylphenol, 4-chloro-m-cresol and 4-chlorophenol. 
(3) Activationof TRPC channels and inhibition of TRPM2 channel by Cu
2+
. 
(4) Function of TRPC channels in human ovarian cancer cells, including the roles of 
TRPCs in cell proliferation, colony growth and cell cycle progression. 
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2.1. Materials 
2.1.1. Chemicals 
Sodium chloride (NaCl), potassium chloride (KCl), magnesium chloride (MgCl2), 
calcium chloride (CaCl2), sodium hydroxide (NaOH), hydrochloric acid (HCl), 
potassium phosphate monobasic (KH2PO4), sodium phosphate dibasic (Na2HPO4), 
ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), D-
glucose, cesium chloride (CsCl), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES), 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA), 
cesium-methanesulfonate (Cs-methanesulfonate), dimethyl sulfoxide (DMSO), 
thapsigargin (TG), 2-aminoethyldiphenyl borate (2-APB), SKF-96365, 
diethylstilbestrol (DES), colchicine, cytochalasin D (CytD), caffeine, 4-chloro-3-
ethylphenol (4-CEP), 4-chloro-m-cresol (4-CmC), 4-chlorophenol (4-ClP), genistein, 
wortmannin, Y-27632 dihydrochloride, GF109203X, chelerythrine (CHE), 1-oleoyl-
2-acetyl-sn-glycerol (OAG), U73122 hydrate, calyculin A (CalyA), flufenamic acid 
(FFA), niflumic acid (NFA), sodium azide, hydrogen peroxide (H2O2), carbonyl 
cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), forskolin, adenosine 5′-
diphosphoribose sodium salt (ADP-Ribose), copper sulphate (CuSO4), gadolinium 
chloride (GdCl3), mercury chloride (HgCl2), Fura-PE3/AM, carbenoxolone, Triton 
X-100, propidium iodide and deoxyribonucleotide triphosphates (dNTPs) were 
purchased from Sigma-Aldrich (Poole, UK).  
2.1.2. Cell culture materials 
D-MEM/F-12 cell culture medium, trypsin-EDTA solution, penicillin and 
streptomycin were purchased from Invitrogen (Paisley, UK). Endothelial cell growth 
medium and supplements were purchased from PromoCell (Heidelberg, Germany). 
Fetal bovine serum (FBS), G418 disulfate salt, tetracycline, ampicillin, kanamycin, 
Luria broth (LB) and Luria agar (LA) media were purchased from Sigma-Aldrich 
(Poole, UK). Super optimal broth with glucose was purchased from Invitrogen 
(Paisley, UK). Cell culture dishes, flasks, pipettes, pipette tips and cryotubes were 
purchased from SARSTEDT (Leicester, UK). Glass coverslips were purchased from 
VWR International (Lutterworth, UK). 
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2.1.3. Enzymes, DNA ladders, nucleic acid extraction and purification 
kits 
Phusion High-Fidelity DNA Polymerase was purchased from New England BioLabs 
(Hitchin, UK). M-MLV reverse transcriptase, ribonuclease (RNase) inhibitor, 
GoTaq Green PCR Master Mix, restriction endonucleases (HindIII, BamHI, XbaI, 
ApaI, EcoRI and BglII), T4 DNA ligase and 100 bp DNA ladder were purchased 
from Promega (Southampton, UK). RNase, TRIzol reagent and 1 kb Plus DNA 
ladder were purchased from Invitrogen (Paisley, UK). QIAprep Spin Miniprep Kit, 
QIAquick PCR Purification Kit and QIAquick Gel Extraction Kit were purchased 
from QIAGEN (Crawley, UK). 
2.1.4. Plasmids, human cell lines and E.coli competent cells 
The pEYFP-N1/STIM1 vector encoding STIM1 fused to the N-terminus of EYFP 
(STIM1-EYFP) was kindly provided by Prof. Alexei V. Tepikin at the University of 
Liverpool. The pIRES-TRPC1-GFP, pcDNA3-TRPC3 and pcDNA3-TRPC6 vectors 
were gifts from Prof. Craig Montell at the Johns Hopkins University. The pcDNA3-
TRPC4 vector was from Prof. Mike X. Zhu at the University of Texas, Houston. The 
RFP-C1 and mCFP-C3 vectors were from Dr. Zhige Wu at the University of 
Dundee. The pIRES-EYFP vector was purchased from Clontech (Mountain View, 
California, USA). The pGEM-T vector was purchased from Promega (Southampton, 
UK). The pcDNA4/TO vector and T-REx HEK293 cell line were purchased from 
Invitrogen (Paisley, UK). TRPC5 and TRPM2 cell lines, in which the expression of 
exogenous genes is regulated by tetracycline, were generated by Dr. Shang-Zhong 
Xu and stored in the laboratory. Primary human aortic endothelial cells (HAECs) 
were purchased from PromoCell (Heidelberg, Germany). Human ovarian 
adenocarcinoma cells (SKOV3) were purchased from LGC Promochem (Middlesex, 
UK). The JM109 and DH5α E. coli competent cells were purchased from Promega 
(Southampton, UK) and Invitrogen (Paisley, UK), respectively. 
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Table 2.1 Primers used in gene cloning and plasmid construction 
Primer name Sequence (5’-3’) 
HindIII-GFP-F TTTTAAGCTTCGCCACCATGGTGAGCAAGG 
BamHI-GFP-R TAGGATCCCTTGTACAGCTCGTCCATGC    
TRPC1mut-F GTTGCTCACAACAAGATTTCAATGGGACAGATGT
TA 
TRPC1mut-R TCTGTCCCATTGAAATCTTGTTGTGAGCAACCACT
TTG 
TRPC1S-F GATGTGCTTGGGAGAAATGC 
TRPC1E1-F GGGAGGTGAAGGAGGAGAAT 
TRPC1E13-R TGCACTAGGCAGCACATCA 
TRPC1E4E5-R CAAGACGAAACCTGGAATGC 
TRPC1E8E11-F TGGTATGAAGGGTTGGAAGAC 
TRPC1E8E11-R AATGACAGCTCCCACAAAGG 
XbaI-TRPC1-F ATATCTAGAGATGATGGCGGCCCTGTACC 
ApaI-TRPC1-R GTGGGCCCTTAATTTCTTGGATAAAACATAGC 
TRPC4E6E11-F CGAAAGGGTTAACCTGCAAA 
TRPC4E7E9-F CAATGTCATCTCTCTGGTTGTTC 
TRPC4E12-R CCTGTAACCCCAGTGTGTCC 
TRPC4E-R ATGCTGTGTTCTTACCCCT 
TRPC4-E542Q-
E543Q-F 
ATTGTACTTCTATTATCAACAAACGAAAGGGTTA
ACCTGC 
TRPC4-E542Q-
E543Q-R 
CCCTTTCGTTTGTTGATAATAGAAGTACAATTGAT
TTAGG 
TRPC4-C555W-F CCTGCAAAGGCATAAGATGGGAAAAGCAGAATA
ATGCATTTTCAACG 
TRPC4-C555-R CATCTTATGCCTTTGCAGGTTAACCCTTTCGTTTCT
TC 
TRPC4-T549-R TTAACCCTTTCGTTTCTTCATAATAGAAGTACAAT
TGATTTAGGC 
TRPC4-E556Q-F CCTGCAAAGGCATAAGATGTCAAAAGCAGAATAA
TGCATTTTCAACG 
TRPC4-K557E-F CCTGCAAAGGCATAAGATGTGAAGAGCAGAATAA
TGCATTTTCAACG 
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Table 2.1 Primers used in gene cloning and plasmid construction (continue) 
BamHI-TRPC3-F TAGGATCCATGGAGGGAAGCCCATCCCTGAG 
EcoRI-TRPC3-R GCGAATTCCAGGTTGCTGCATCATTCACATCTC 
BamHI-TRPC6-F AAGGATCCATGAGCCAGAGCCCGGCGTTC 
EcoRI-TRPC6-R CGGAATTCGCATTATCTATTGGTTTCCTCTTG 
TRPC3E3E5-F TGGAGATCTGGAATCAGCAG 
TRPC3E3E5-R GAGGCATTGAACACAAGCAG 
TRPC6E8E12-F TACGATGGTCATTGTTTTGC 
TRPC6E8E12-R TCTGGGCCTGCAGTACATATC 
BglII-ORAI1-F  AATAGATCTGCGGCGTGCTCCATGCATCC 
EcoRI-ORAI1-R ATGAATTCGGGCCTAGGCATAGTGGCTG 
BglII-ORAI2-F AGTAGATCTCCCACCATGAGTGCTGAGCTT 
EcoRI-ORAI2-R TAGAATTCCCTCACAAGACCTGCAGGCT 
BamHI-ORAI3-F TAGGATCCAGGATGAAGGGCGGCGAG 
EcoRI-ORAI3-R TATGAATTCTCACACAGCCTGCAGCTCC 
ORAI1-F AGGTGATGAGCCTCAACGAG 
ORAI1-R CTGATCATGAGCGCAAACAG 
ORAI2-F CATAAGGGCATGGATTACCG 
ORAI2-R CGGGTACTGGTACTGCGTCT 
ORAI3-F GGCTACCTGGACCTCATGG 
ORAI3-R GGTGGGTACTCGTGGTCACT 
Lifeact-GFP-F ATTCGAAAGCATCTCAAAGGAAGAAGTGAGCAA
GGGCGAGGAGCTGTTC 
Lifeact-Kozak-R TTCTTGATCAAATCTGCGACACCCATGGTGGCGA
AGCTTAAGTTTAAACG 
Lifeact-G GGTGTCGCAGATTTGATCAAGAAATTCGAAAGC
ATCTCAAAGGAAGAAG 
The underlined sequences indicate recognition sites of restriction endonucleases or 
the Lifeact-coding sequence.
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Table 2.2 Primers used in the detection of TRPC variants in SKOV3 cells 
Primer 
pair 
Forward primer (5’-3’) Reverse primer (5’-3’) 
TRPC1-P1 GATGTGCTTGGGAGAAATGC CAAGACGAAACCTGGAATGC 
TRPC1-P2 TGCACCTGTCATTTTAGCTG CAAGACGAAACCTGGAATGC 
TRPC1-P3 TGGTATGAAGGGTTGGAAGA
C 
GGTATCATTGCTTTGCTGTTC 
TRPC1-P4 TGGTATGAAGGGTTGGAAGA
C 
AATGACAGCTCCCACAAAGG 
TRPC1-P5 TGCTTACCAAACTGCTGGTG AACTGTTTTGCCGTTTGACC 
TRPC3-P0 AACAAGCAAGGGTGACCTTC GAGGCATTGAACACAAGCAG 
TRPC3-P1 AAGGGTGCCAGGATCGAG GAGGCATTGAACACAAGCAG 
TRPC3-P2 TGGAGATCTGGAATCAGCAG GAGGCATTGAACACAAGCAG 
TRPC3-P3 CTGGGTCTGCTTGTGTTCAA ATGGACAGCATCCCAAAGTC 
TRPC3-P4 TGACTTCCGTTGTGCTCAAAT
ATG 
CCTTCTGAAGTCTTCTCCTTC
TGC 
TRPC4-P1 CTCCAGCTTCGATCGTTTTC TCTGAACTGGACACGCATTC 
TRPC4-P2 CTCGGATCCCATCACTTCAG TCCCATGATTCTCGTGGATT 
TRPC4-P3 CGAAAGGGTTAACCTGCAAA CAGGACTTCAAAGCGGAAAC 
TRPC4-P4 GGATCAGACGAGAAGTTCCA
G 
TAGTCCTGAAGTCCGCCATC 
TRPC4-P5 TCTGCAGATATCTCTGGGAAG
GATGC 
AAGCTTTGTTCGAGCAAATTT
CCATTC 
TRPC4-P6 CAATGTCATCTCTCTGGTTGT
TC 
TGGTATTGGTGATGTCTTCTC
AAG 
TRPC4-P7 CAATGTCATCTCTCTGGTTGT
TC 
CCTGTAACCCCAGTGTGTCC 
TRPC4-ε CAATGTCATCTCTCTGGTTGT
TC 
ATGCTGTGTTCTTACCCCT 
TRPC5 TGAGAACGAGAACCTGGAG  TACTCGGCCTTGAACTCATTC 
TRPC6-P1 GCCTTGCTACGGCTACTACC TCCCAGAAAAATGGTGAAGG 
TRPC6-P2 AGTTTTAAGACACTGTTCTGG TTCTGATATTGTCTTGGAGG 
TRPC6-P3 TACGATGGTCATTGTTTTGC TCTGGGCCTGCAGTACATATC 
TRPC7 ATCTTCGTGGCCTCCTTCAC AACGCTGGGTTGTATTTGGC 
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Table 2.3 Small interfere RNA (siRNA) used in this study 
siRNA name Sequence (5’-3’) 
 si-TRPC1 GCCCGGAAUUCUCGUGAAU[dT][dT] 
 si-TRPC1_as AUUCACGAGAAUUCCGGGC[dT][dT] 
 si-TRPC4 UGCUCCCUAUAGAGACCGC[dT][dT] 
 si-TRPC4_as GCGGUCUCUAUAGGGAGCA[dT][dT] 
 si-TRPC5 GCAACCUUGGGCUGUUCAU[dT][dT] 
 si-TRPC5_as AUGAACAGCCCAAGGUUGC[dT][dT] 
 si-TRPC6 GCAUGACUCGUUUAGCCAC[dT][dT] 
 si-TRPC6_as GUGGCUAAACGAGUCAUGC[dT][dT] 
The TRPC3, Bcl-2 and scramble siRNA used in this study were commercial 
products and the sequences are not available. 
 
2.1.5. Oligonucleotides and antibodies 
PCR primers (Table 2.1 and 2.2) and custom small interfere RNA (siRNA) (Table 
2.3) were ordered from Sigma-Aldrich (Poole, UK). The TRPC3 siRNA was 
purchased from Santa Cruz Biotechnology (Santa Cruz, USA). The Bcl-2 and 
scramble siRNA were purchased from Upstate Biotechnology (New York, USA). 
Oligo d(T) and random primers were purchased from Promega (Southampton, UK). 
Rabbit polyclonal anti-TRPC antibodies against the extracellular third loop (E3) 
region near the channel pores or targeting to C-termini were generated and the 
specificities were verified in previous studies (Xu et al., 2005b; Xu et al., 2006b). 
2.2 Methods 
2.2.1. Gene cloning and plasmid construction  
2.2.1.1. Identification of novel TRPC1 and TRPC4 spliced variants in human 
aortic endothelial cells 
Human aortic endothelial cells (HAECs) were cultured in endothelial growth 
medium with supplements and 10% FBS, and maintained at 37 °C in a humidified 
atmosphere with 95% air and 5% CO2. Total RNA was extracted from HAECs using 
TRIzol reagent according to the manufacture’s instruction. The mRNA was reverse-
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transcribed to cDNA using M-MLV reserve transcriptase and oligo d(T) primers. 
TRPC1 and TRPC4 fragments were amplified from the cDNA with different primer 
pairs using GoTaq Green Master Mix. The PCR mixture contained 1 µl cDNA 
(~200 ng), 0.5 µM forward primers, 0.5 µM reverse primers, and 1× GoTaq Green 
Master Mix. The PCR conditions were an initial denaturation at 95 
o
C for 30 s, 35 
cycles of 94 
o
C for 30 s, 57 
o
C for 30 s and 72 
o
C for 1 min, and a final extension at 
72 
o
C for 5 min. PCR products were analysed by electrophoreses on 1.5% agarose 
gel containing 0.5 µg/ml ethidium bromide. Positive bands were cut from the gel 
under UV light and purified with a QIAquick Gel Extraction Kit. The purified 
TRPC1 fragments were directly sent to Eurofins MWG Operon (London, UK) for 
sequencing. The purified TRPC4 fragments were ligated into pGEM-T vectors using 
T4 DNA ligase at room temperature for 4 h. The ligation mixtures were gently 
mixed JM109 E. coli competent cells, placed on ice for 30 min, heat-shocked at 42 
o
C for 1 min, transferred into super optimal broth with glucose and cultured at 37 
o
C 
for 1 h in a shaking incubator (300 rpm). The cells were then spread on LB agar 
plates containing 100 µg/ml ampicillin and incubated at 37 
o
C overnight. On the 
next day the bacterial colonies were picked into LB medium and cultured at 37 
o
C 
for 2 h. Positive colonies were characterised by PCR using cell suspensions as 
templates. The PCR mixture contained 1 µl cell suspension, 0.5 µM forward 
primers, 0.5 µM reverse primers, and 1× GoTaq Green Master Mix. The PCR 
conditions were an initial denaturation at 95 
o
C for 30 s, 30 cycles of 94 
o
C for 30 s, 
57 
o
C for 30 s and 72 
o
C for 1 min, and a final extension at 72 
o
C for 3 min. The 
colonies showing a positive band in the PCR products were inoculated into 5 ml LB 
medium containing 100 µg/ml ampicillin and cultured at 37 
o
C overnight in a 
shaking incubator (200 rpm). The plasmids were extracted using a QIAprep Spin 
Miniprep Kit and sent for sequencing. The sequences were aligned with MEGA 4 
software (Tamura et al., 2007) to find out insertions and deletions. 
2.2.1.2. Cloning of fluorescent protein genes into pcDNA4/TO vectors 
The coding sequences of enhanced yellow fluorescent protein (EYFP), monomeric 
red fluorescent protein (mCherry) and monomeric cyan fluorescent protein (mCFP) 
were amplified with the primers HindIII-GFP-F and BamHI-GFP-R from the vectors 
pIRES-EYFP, RFP-C1 and mCFP-C3, respectively. The PCR mixture contained 1× 
Phusion HF Buffer, 200 µM dNTPs (50 µM each), 0.5 µM forward primers, 0.5 µM 
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reverse primers, 40 pg/µl template DNA, and 0.02 units/µl Phusion High-Fidelity 
DNA Polymerase. The PCR conditions were an initial denaturation at 98 
o
C for 30 s, 
35 cycles of 98 
o
C for 10 s and 72 
o
C for 1 min, and a final extension at 72 
o
C for 5 
min. PCR products were analysed by electrophoreses on 1.5% agarose gel 
containing 0.5 µg/ml ethidium bromide and successful amplifications were 
characterised by a band of 733 bp under UV light. The PCR products were purified 
with a QIAquick PCR Purification Kit. The purified PCR products and pcDNA4/TO 
plasmids were digested with HindIII and BamHI restriction endonucleases at 37 
o
C 
overnight. The digested PCR products and plasmids were electrophoresed on 1% 
agarose gel and then the gel slices containing the DNA bands were cut out under UV 
light. The DNA fragments in the gel slices were purified with a QIAquick Gel 
Extraction Kit. The EYFP, mCherry and mCFP-encoding DNA fragments were 
ligated into digested pcDNA4/TO plasmids and transformed into JM109 E. coli 
competent cells. Positive colonies were characterised by PCR using cell suspensions 
as templates. The PCR mixture contained 1 µl cell suspension, 0.5 µM HindIII-
GFP-F and BamHI-GFP-R primers, and 1× GoTaq Green Master Mix. The PCR 
conditions were an initial denaturation at 95 
o
C for 30 s, 30 cycles of 94 
o
C for 30 s, 
65 
o
C for 30 s and 72 
o
C for 45 s, and a final extension at 72 
o
C for 5 min. The 
colonies showing a 733-bp band in the PCR products were inoculated into 5 ml LB 
medium containing 100 µg/ml ampicillin and cultured at 37 
o
C overnight in a 
shaking incubator (200 rpm). The plasmids were extracted using a QIAprep Spin 
Miniprep Kit. Small amount of cell suspensions were mixed into LB medium 
containing 20% glycerol and stored in a -80 
o
C freezer. The three constructs 
generated in this section were named pcDNA4/TO-EYFP, pcDNA4/TO-mCherry 
and pcDNA4/TO-mCFP. 
2.2.1.3. Cloning of TRPC1and TRPC1δ into pcDNA4/TO-mCFP vectors 
TRPC1δ is a newly identified isoform with exon 9 deletion compared to the longer 
isoform of TRPC1 (NM_003304) (see result in Chapter 2). The complete coding 
sequence of TRPC1δ was produced by PCR mutagenesis from pIRES-TRPC1-GFP 
vector. Primers TRPC1mut-F and TRPC1mut-R were designed to anneal with the 5’ 
end of exon 10 and 3’ end of exon 8, respectively. Each primer has an overhang 
sequence at the 5’ end complementary to each other so that they can bind to each 
other and skip the exon 9 during PCR.  As direct amplification of TRPC1 plasmid 
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with TRPC1mut-F and TRPC1mut-R failed, a multistep mutagenesis method was 
used to delete exon 9 from the full-length TRPC1 gene as following steps:  
(1) Amplification of exon1-8 with primers TRPC1E1-F and TRPC1mut-R (1239 
bp); 
(2) Amplification of exon10-13 with primers TRPC1mut-F and TRPC1E13-R (654 
bp); 
(3) Overlapping amplification of exon1-13 (1861 bp, without exon 9) with primers 
TRPC1E1-F and TRPC1E13-R, using products from Step 1 and 2 as template; 
(4) Amplification of the backbone of the TRPC1 plasmid with primers TRPC1mut-F 
and TRPC1E4E5-R (~6 kb); 
(5) Hybridisation of DNA fragments from Step 3 and 4, the single-stranded gaps 
were repaired by DNA polymerase in a routine PCR; 
(6) Transformation of product from Step 5 into JM109 E. coli competent cells, 
characterisation of positive colonies (with exon 9 deleted) by PCR with primers 
TRPC1E8E11-F and TRPC1E8E11-R (405 bp for TRPC1δ); 
(7) Extraction of pIRES-TRPC1δ-GFP plasmids from positive clones and 
sequencing.  
Phusion High-Fidelity DNA Polymerase was used in Step 1-5, and GoTaq Green 
Master Mix was used in Step 6.  
The coding sequences of TRPC1 and TRPC1δ were amplified with the primers 
XbaI-TRPC1-F and ApaI-TRPC1-R from the vectors pIRES-TRPC1-GFP and 
pIRES-TRPC1δ-GFP, respectively. The PCR mixtures contained 1× Phusion HF 
Buffer, 400 µM dNTPs (100 µM each), 0.5 µM each primer, 40 pg/µl template 
DNA, and 0.02 units/µl Phusion High-Fidelity DNA Polymerase. The PCR 
conditions were an initial denaturation at 98 
o
C for 30 s, 35 cycles of 98 
o
C for 10 s, 
60 
o
C for 30 s and 72 
o
C for 2 min, and a final extension at 72 
o
C for 7 min. The 
expected product sizes for TRPC1 and TRPC1δ were 2298 bp and 2154 bp, 
respectively. The PCR products were purified, digested with XbaI and ApaI, ligated 
into pcDNA4/TO-mCFP vector, and transformed into JM109 E. coli competent 
cells. Positive colonies were screened by PCR with primers TRPC1E8E11-F and 
TRPC1E8E11-R (549 bp for TRPC1, 405 bp for TRPC1δ) using GoTaq Green 
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Master Mix. The PCR conditions were an initial denaturation at 95 
o
C for 30 s, 30 
cycles of 94 
o
C for 30 s, 57 
o
C for 30 s and 72 
o
C for 30 s, and a final extension at 72 
o
C for 3 min. Plasmids pcDNA4/TO-mCFP-TRPC1 and pcDNA4/TO-mCFP-
TRPC1δ were extracted from positive clones and the vector structures were 
confirmed by sequencing. 
2.2.1.4. Constructs for fluorescent protein-tagged TRPC4 and TRPC4 mutants 
in pcDNA4/TO vectors 
The constructs pcDNA4/TO-mCFP-TRPC4α, pcDNA4/TO-EYFP-TRPC4α, 
pcDNA4/TO-EYFP-TRPC4β1, pcDNA4/TO-EYFP-TRPC4ε1, pcDNA4/TO-EYFP-
TRPC4α-E542Q/E543Q, pcDNA4/TO-EYFP-TRPC4α-C555W, pcDNA4/TO-
EYFP-TRPC4α-E556Q and pcDNA4/TO-EYFP-TRPC4α-K557E were generated in 
this section. Full-length TRPC4α coding sequence (NM_016179) was cut from 
pcDNA3-TRPC4 vector by BglII and ApaI, and ligated into pcDNA4/TO-mCFP 
and pcDNA4/TO-EYFP plasmids digested with BamHI and ApaI. The ligation 
products were transformed into JM109 E. coli competent cells. Positive colonies 
were screened by PCR with primers TRPC4E7E9-F and TRPC4E12-R (956 bp) 
using GoTaq Green Master Mix. The PCR conditions were an initial denaturation at 
95 
o
C for 30 s, 30 cycles of 94 
o
C for 30 s, 57 
o
C for 30 s and 72 
o
C for 1 min, and a 
final extension at 72 
o
C for 5 min. Successful cloning was confirmed by sequencing. 
TRPC4β1 and TRPC4ε1 are two new TRPC4 isoforms identified from HAECs in 
this study (see result in Chapter 2). TRPC4β1 has a deletion of 255 bp in exon 11 
compared to TRPC4α, whilst TRPC4ε1 has a 15-bp longer exon 8 and also the 255-
bp deletion in exon 11. To make the full-length coding sequences of TRPC4β1 and 
TRPC4ε1, the DNA fragment including exon 8-12 was cut off from pcDNA4/TO-
EYFP-TRPC4α plasmid and replaced by corresponding parts in TRPC4β1 and 
TRPC4ε1. Firstly, partial sequences of all TRPC4 isoforms were amplified from 
cDNA of human aortic endothelial cells with primers TRPC4E6E11-F and 
TRPC4E12-R. The expected product sizes for TRPC4α/β1/ε1 were 1137/882/897 
bp, respectively. The PCR mixture contained 1× Phusion HF Buffer, 200 µM dNTPs 
(50 µM each), 0.5 µM each primer, 10 ng/µl cDNA, and 0.02 units/µl Phusion High-
Fidelity DNA Polymerase. The PCR conditions were an initial denaturation at 98 
o
C 
for 30 s, 35 cycles of 98 
o
C for 10 s, 64 
o
C for 30 s and 72 
o
C for 30 s, and a final 
extension at 72 
o
C for 3 min. The PCR products were purified and digested with 
- 30 - 
 
KpnI (recognition site in exon 8) and XhoI (in exon 12). After digestion, the DNA 
fragments were separated by electrophoresis in 1.5% agarose gel. The exon 8-12 
fragments for TRPC4β1 (405 bp) and TRPC4ε1 (420 bp) were harvested from the 
gel, whilst the TRPC4α exon 8-12 fragment (660 bp) and other two flanking 
fragments (374 and 103 bp) were discarded. The pcDNA4/TO-EYFP-TRPC4α 
plasmids were also digested by KpnI and XhoI, and the linear plasmids without exon 
8-12 (~8 kb) were purified from the gel. The TRPC4β1 and TRPC4ε1 fragments 
were then ligated into the linear plasmids without exon 8-12 and transformed into 
JM109 E. coli competent cells. Positive colonies were screened by PCR using 
GoTaq Green Master Mix. As the products of TRPC4β1 and TRPC4ε1 generated by 
primers TRPC4E7E9-F and TRPC4E12-R were difficult to be separated in the gel 
(701 bp for TRPC4β1, 716 bp for TRPC4ε1), another primer TRPC4E-R was used 
in pair with TRPC4E7E9-F, which produce a 283-bp fragment from TRPC4ε1, but 
have no amplification from TRPC4β1. The PCR conditions were an initial 
denaturation at 95 
o
C for 30 s, 30 cycles of 94 
o
C for 30 s, 56 
o
C for 30 s and 72 
o
C 
for 45 s, and a final extension at 72 
o
C for 3 min. Successful cloning was confirmed 
by sequencing. 
Point mutations in the pore-forming region of TRPC4 were introduced by PCR 
mutagenesis using pcDNA4/TO-EYFP-TRPC4α plasmid as template. The 
E542Q/E543Q mutant was generated by PCR amplification with overlapping 
primers TRPC4-E542Q-E543Q-F and TRPC4-E542Q-E543Q-R. The C555W 
mutant was generated by overlapping primers TRPC4-C555W-F, TRPC4-C555-R 
and TRPC4-T549-R. The E556Q mutant was generated by overlapping primers 
TRPC4-E556Q-F, TRPC4-C555-R and TRPC4-T549-R. The K557E mutant was 
generated by overlapping primers TRPC4-K557E-F, TRPC4-C555-R and TRPC4-
T549-R. The expected product size for all mutant plasmids was ~8.8 kb. The PCR 
mixtures contained 1× Phusion GC Buffer, 800 µM dNTPs (200 µM each), 0.5 µM 
each primer, 40 pg/µl template DNA, and 0.02 units/µl Phusion High-Fidelity DNA 
Polymerase. The PCR conditions were an initial denaturation at 98 
o
C for 30 s, 35 
cycles of 98 
o
C for 10 s and 72 
o
C for 4 min, and a final extension at 72 
o
C for 10 
min. The PCR products were directly transformed into DH5α E. coli competent 
cells. Colonies were cultured and the extracted plasmids were sequenced to confirm 
the successful introduction of point mutations in the gene. 
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2.2.1.5. Constructs for fluorescent protein-tagged TRPC3 and TRPC6 in 
pcDNA4/TO vectors 
Full-length TRPC3 coding sequence (U47050) was amplified with the primers 
BamHI-TRPC3-F and EcoRI-TRPC3-R from the vector pcDNA3-TRPC3. TRPC6 
(BC093660) was amplified with the primers BamHI-TRPC6-F and EcoRI-TRPC6-R 
from the vector pcDNA3-TRPC6. The PCR mixtures contained 1× Phusion HF 
Buffer, 400 µM dNTPs (100 µM each), 0.5 µM each primer, 40 pg/µl template 
DNA, and 0.02 units/µl Phusion High-Fidelity DNA Polymerase. The PCR 
conditions were an initial denaturation at 98 
o
C for 30 s, 35 cycles of 98 
o
C for 10 s, 
70 
o
C for 30 s and 72 
o
C for 1.5 min, and a final extension at 72 
o
C for 7 min. The 
expected product sizes were 2575 bp and 2815 bp for TRPC3 and TRPC6, 
respectively. The PCR products were purified, digested with BamHI and EcoRI, 
ligated into pcDNA4/TO-mCherry and pcDNA4/TO-mCFP vectors, and 
transformed into DH5α E. coli competent cells. Positive colonies were screened by 
PCR with primers TRPC3E3E5-F and TRPC3E3E5-R (351 bp), and TRPC6E8E12-
F and TRPC6E8E12-R (476 bp), using GoTaq Green Master Mix. The PCR 
conditions were an initial denaturation at 95 
o
C for 30 s, 30 cycles of 94 
o
C for 30 s, 
56 
o
C for 30 s and 72 
o
C for 30 s, and a final extension at 72 
o
C for 3 min. Plasmids 
from positive clones were further confirmed by sequencing. The constructs 
generated in this section were named pcDNA4/TO-mCherry-TRPC3 and 
pcDNA4/TO-mCFP-TRPC6. 
2.2.1.6. Constructs for fluorescent protein-tagged ORAIs in pcDNA4/TO 
vectors 
The constructs pcDNA4/TO-mCherry-ORAI1, pcDNA4/TO-mCFP-ORAI1, 
pcDNA4/TO-mCherry-ORAI2, pcDNA4/TO-mCFP-ORAI2 and pcDNA4/TO-
mCFP-ORAI3 were generated in this section. Full-length ORAI1, ORAI2 and 
ORAI3 coding regions were amplified from cDNA of HAECs. The paired primers 
BglII-ORAI1-F and EcoRI-ORAI1-R, BglII-ORAI2-F and EcoRI-ORAI2-R, and 
BamHI-ORAI3-F and EcoRI-ORAI3-R were used. The expected product sizes for 
ORAI1, ORAI2 and ORAI3 were 939 bp, 790 bp and 902 bp, respectively. The PCR 
mixture contained 1× Phusion HF Buffer, 200 µM dNTPs (50 µM each), 0.5 µM 
each primer, 10 ng/µl cDNA, and 0.02 units/µl Phusion High-Fidelity DNA 
Polymerase. The PCR conditions were an initial denaturation at 98 
o
C for 30 s, 35 
cycles of 98 
o
C for 10 s, 68 
o
C for 30 s and 72 
o
C for 1 min, and a final extension at 
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72 
o
C for 5 min. PCR products were purified from the gel after electrophoresis using 
a QIAquick Gel Extraction Kit. ORAI1 and ORAI2 were digested with BglII and 
EcoRI, and cloned into pcDNA4/TO-mCherry and pcDNA4/TO-mCFP vectors cut 
by BamHI and EcoRI. ORAI3 was digested with BamHI and EcoRI, and ligated into 
pcDNA4/TO-mCFP vector in a same way. The ligation products were transformed 
into DH5α E. coli competent cells and positive colonies were screened by PCR with 
paired primers ORAI1-F/R (238 bp), ORAI2-F/R (210 bp) and ORAI3-F/R (176 bp) 
using GoTaq Green Master Mix. The PCR conditions were an initial denaturation at 
95 
o
C for 30 s, 30 cycles of 94 
o
C for 30 s, 56 
o
C for 30 s and 72 
o
C for 20 s, and a 
final extension at 72 
o
C for 3 min. Plasmids extracted from positive clones were sent 
for sequencing to confirm the successful cloning of the three ORAI genes. 
2.2.1.7. pcDNA4/TO-Lifeact-mCFP 
The Lifeact peptide is the first 17 amino acids at the N-terminus of the yeast protein 
Abp140, which binds to filamentous actin (F-actin) in eukaryotic cells (Riedl et al., 
2008). The Lifeact-encoding sequence was introduced into pcDNA4/TO-mCFP 
vector by PCR mutagenesis to create a Lifeact-mCFP fused gene. Three overlapping 
primers Lifeact-GFP-F, Lifeact-Kozak-R and Lifeact-G were used and the expected 
product size for the whole plasmid was ~5.8 kb. The PCR mixture contained 1× 
Phusion HF Buffer, 600 µM dNTPs (150 µM each), 0.5 µM each primer, 40 pg/µl 
template DNA, and 0.02 units/µl Phusion High-Fidelity DNA Polymerase. The PCR 
conditions were an initial denaturation at 98 
o
C for 30 s, 35 cycles of 98 
o
C for 10 s, 
and 72 
o
C for 3 min, and a final extension at 72 
o
C for 7 min. The PCR product was 
directly transformed into DH5α E. coli competent cells. Positive colonies were 
characterised by PCR with primers Lifeact-G and BamHI-GFP-R (761 bp) using 
GoTaq Green Master Mix. The PCR conditions were an initial denaturation at 95 
o
C 
for 30 s, 30 cycles of 94 
o
C for 30 s, 65 
o
C for 30 s and 72 
o
C for 45 s, and a final 
extension at 72 
o
C for 3 min. Plasmids were extracted from positive clones. 
2.2.2. Generation of stably transfected cell lines 
2.2.2.1. STIM1 cell line 
T-REx HEK293 cells were cultured in D-MEM/F-12 medium supplemented with 
10% FBS, 100 units/ml penicillin and 100 mg/ml streptomycin, and maintained at 
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37 °C in a humidified atmosphere with 95% air and 5% CO2. The cells were seeded 
in a 35-mm culture dish and grown for 24 h to reach 90% confluency. STIM1-EYFP 
plasmids (3 µg) and 5 µl Lipofectamine 2000 transfection reagent (Invitrogen, 
paisley, UK) were separately mixed with 250 µl Opti-MEM I Reduced Serum 
Medium (Invitrogen, Paisley, UK), and kept at room temperature for 5 min. The two 
mixtures were merged into one tube, shaken vigorously and then incubated at room 
temperature for 20 min. During incubation, the DMEM/F-12 medium was removed 
from the cell culture dish and replaced by 1 ml Opti-MEM medium. Then the 
plasmid-Lipofectamine mixture was gently dropped into the dish. The dish was 
rocked for several times and moved into the incubator. The Opti-MEM medium was 
changed back to DMEM/F-12 medium 6 h later. On the next day (~24 h after 
transfection), G418 was added into the cell culture dish to a final concentration of 
400 µg/ml. The cells were maintained for 1 week under G418 selection and the 
medium was changed on the 2
nd
, 3
rd
, 4
th
 and 6
th
 days to remove dead cells. The 
survived cells were trypsinized and seeded into 60-mm culture dishes at a density of 
500 cells/dish. Cells were cultured in medium without G418 and grew into clumps 
after 5-7 days. After inspecting STIM1-EYFP expression under a Nikon Eclipse Ti-
E inverted fluorescence microscope, cell clumps showing EYFP fluorescence 
(excitation/emission wavelengths of 500/535 nm) were manually picked out from 
the dishes by 200-µl tips on a pipetman. These cells (in ~20 µl medium) were 
carefully transferred into 50 µl 0.05% trypsin/EDTA solution and kept at room 
temperature for 3 min. Then the cells were mixed into DMEM/F-12 medium and 
cultured as usual. The cells were stored in medium containing 10% DMSO in liquid 
nitrogen when it is necessary. 
2.2.2.2. TRPC1, TRPC4, TRPC3, TRPC6, ORAI1, ORAI2 and ORAI3 cell lines 
The tetracycline-regulated gene expression cell lines including TO-mCFP-TRPC1, 
TO-mCFP-TRPC1δ, TO-EYFP-TRPC4α, TO-EYFP-TRPC4β1, TO-EYFP-
TRPC4ε1, TO-EYFP-TRPC4α-E542Q/E543Q, TO-EYFP-TRPC4α-C555W, TO-
EYFP-TRPC4α-E556Q, TO-EYFP-TRPC4α-K557E, TO-mCherry-TRPC3, TO-
mCFP-TRPC6, TO-mCherry-ORAI1, TO-mCherry-ORAI2 and TO-mCFP-ORAI3 
were generated by transfecting corresponding plasmids into T-REx HEK293 cells. 
For each transfection, 3 µg plasmids and 5 µl Lipofectamine were mixed in Opti-
MEM medium and incubated with the cells for 6 h. The cells were trypsinized and 
seeded into 60-mm culture dishes at a density of 500 cells/dish 24 h after 
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transfection. After 5-7 days of culture with 1 µg/ml tetracycline in the DMEM/F-12 
medium, the cell clumps showing mCFP, EYFP or mCherry fluorescence under 
microscope were picked out and cultured as usual. The excitation/emission 
wavelengths for mCFP and mCherry were 440/480 and 540/590 nm, respectively. 
2.2.2.3. STIM1/TRPC1, STIM1/ORAI1, STIM1/ORAI2 and STIM1/ORAI3 cell 
lines 
The STIM1-EYFP plasmids were transfected into TO-mCFP-TRPC1, TO-mCherry-
ORAI1, TO-mCherry-ORAI2 and TO-mCFP-ORAI3 cells to generate STIM1-
EYFP/TO-mCFP-TRPC1, STIM1-EYFP/TO-mCherry-ORAI1, STIM1-EYFP/TO-
mCherry-ORAI2 and STIM1-EYFP/TO-mCFP-ORAI3 cell lines, in which the 
expression of STIM1 is stable and the expression of ORAI genes is regulated by 
tetracycline. The transfection and selection procedures were similar to that used in 
the generation of STIM1 cell line (Section 2.2.2.1). 
2.2.2.4. STIM1/TRPC4 and STIM1/TRPC6 cell lines 
The pcDNA4/TO-mCFP-TRPC4α and pcDNA4/TO-mCFP-TRPC6 plasmids were 
transfected into STIM1 cells to generate STIM1-EYFP/TO-mCFP-TRPC4α and 
STIM1-EYFP/TO-mCFP-TRPC6 cell lines. The transfection and selection 
procedures were similar to that described in Section 2.2.2.2.  
2.2.3. Live-cell imaging and Ca
2+
 measurement 
The cells were seeded on 13-mm glass coverslips and cultured for 24-48 h. Live-cell 
images for mCFP, EYFP and mCherry fluorescence were captured using the 
microscope equipped with a Nikon Plan Fluor 100×/1.30 oil objective (Nikon, 
Tokyo, Japan) and a CCD camera (ORCA-R2, Hamamatsu, Japan). The images 
were analysed with NIS-Elements 3.2 software (Nikon, Tokyo, Japan). For 
intracellular Ca
2+
 measurement, STIM1/ORAI1 cells were loaded with 2 µM Fura-
PE3/AM in standard bath solution for 30 min at 37°C, followed by 5 min wash in 
Ca
2+
-free solution at room temperature. Cells were excited alternately by 340 and 
380 nm light and emission was collected via a 510-nm filter. Images were sampled 
every 5 s in pairs for the two excitation wavelengths. The ratio of 340/380 nm 
fluorescence was used to represent the intracellular Ca
2+
 level. The standard bath 
solution contained (mM): NaCl 130, KCl 5, MgCl2 1.2, HEPES 10, D-glucose 8, 
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and CaCl2 1.5 (pH 7.4). Ca
2+
-free solution contained (mM): NaCl 130, KCl 5, 
MgCl2 1.2, HEPES 10, D-glucose 8, and EGTA 0.4 (pH 7.4). All experiments were 
performed at room temperature. The n values given are the numbers of cells from at 
least three independent Ca
2+
 imaging experiments. 
2.2.4. Patch-clamp recordings 
Patch-clamp recordings were performed at room temperature (23-26C). The 
currents were amplified with an Axopatch
 
200B or Axoclamp 2B patch clamp 
amplifier controlled by pClamp software 10 (Molecular Devices, Wokingham, UK). 
For whole-cell and outside-out recordings, a 1-s ramp voltage protocol ranging from 
–100 mV to +100 mV was applied at a frequency of 0.2 Hz. Signals were sampled at 
3 kHz and filtered at 1 kHz (low pass). Step pulses from -100 mV to 100 mV were 
used to record single-channel activities under outside-out configuration. The voltage 
increment for each step was 10 mV and the duration for each pulse was 3 s. The 
microelectrodes with resistance of 3-5 MΩ were made from borosilicate glass 
caplillaries (1.2 mm O. D. x 0.69 mm I. D., Harvard Apparatus, Kent, UK) using a 
glass micropipette puller (Narishige, London, UK). The standard bath solution was 
used in all recordings. The recording chamber had a volume of 200 µl and was 
perfused at a rate of about 5 ml/min. 
The pipette solution for ORAI1/2/3 recordings contained (mM): 145 Cs-
methanesulfonate, 10 BAPTA, 10 HEPES and 8 MgCl2 (pH titrated to 7.2 using 
CsOH). In some experiments 1 µM TG was added into the pipette solution to 
deplete the Ca
2+
 stores. The pipette solution for TRPC4/5/3/6 recordings contained 
(mM): 115 CsCl, 10 EGTA, 2 MgCl2, 10 HEPES, and 5.7 CaCl2 (pH 7.2 adjusted 
with CsOH, osmolarity ~290 mOsm adjusted with mannitol, and the calculated free 
Ca
2+
 was 200 nM). For TRPM2 recordings the same 200 nM free Ca
2+
 pipette 
solution with additional 0.5 mM ADP-ribose was used. 
2.2.5. Detection of TRPC spliced variants in SKOV3 cells 
SKOV3 cells were cultured in D-MEM/F-12 medium supplemented with 10% FBS, 
100 units/ml penicillin and 100 µg/ml streptomycin, and maintained at 37°C under 
95% air and 5% CO2. Total RNA was extracted from cultured cells using TRIzol 
reagent. The mRNA was reverse-transcribed to cDNA using M-MLV reserve 
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transcriptase and random primers. The primer sets were designed across introns and 
the sequences were given in Table 2.2. The PCR mixture contained 1 µl cDNA 
(~200 ng), 0.5 µM forward primers, 0.5 µM reverse primers, and 1× GoTaq Green 
Master Mix. The PCR conditions were an initial denaturation at 95 
o
C for 30 s, 35 
cycles of 94 
o
C for 30 s, 57 
o
C for 30 s and 72 
o
C for 1 min, and a final extension at 
72 
o
C for 5 min. PCR products were examined on 2% agarose gel, purified with a 
QIAquick Gel Extraction Kit and confirmed by direct sequencing.  
2.2.6. Cell proliferation and colony growth assays 
Cell proliferation was determined by WST-1 assay (Roche, Burgess Hill, UK), 
which reflects the metabolic activity of cultured cells. SKOV3 cells were seeded in 
96-well microplates, and then incubated with drugs or antibodies, or transfected with 
siRNA. After desired time of the treatment, the cells were incubated with WST-1 in 
phenol red-free D-MEM/F-12 medium for 2-4 h. During this incubation period, 
viable cells convert WST-1 to a water-soluble formazan dye. The absorbance of 
formazan dye in each well was measured on a microplate reader with a test 
wavelength at 450 nm and a reference wavelength at 630 nm. The 630 nm 
background absorbance was subtracted from the 450 nm measurement, which 
produced a value correlating with the number of viable cells in each well. 
For colony growth assay, SKOV3 cells were transfected with TRPC cDNA plasmids 
using Lipofectamine 2000, and plated in 60-mm culture dishes at a density of 500 
cells per dish to allow the formation of cell colonies after 3-8 days culture. The 
colonies were fixed with 25% methanol, stained with 0.5% crystal violet dye in 
phosphate buffered saline (PBS), and automatically counted by CellC software 
(Selinummi et al., 2005). For soft agar colony assay, the bottom layer of agar (0.7 
%) was prepared in a 35-mm culture dish with 1.5 ml of D-MEM/F-12 medium 
containing agar, 10% FBS, 50 µg/ml penicillin and 50 µg/ml streptomycin. After 
solidification of the bottom layer, SKOV3 cells were suspended in 1 ml medium 
containing 0.35% agar at a density of 5000 cells/ml and poured into the dish to form 
a second layer. The dish was kept at 4 
o
C for 5 min and then the solidified second 
layer was covered with 1 ml medium to prevent the agar layer from drying out. The 
cells were incubated at 37°C in a humidified incubator and the top layer of medium 
was gently changed every 3 days. After 21 days of culture, the cells were stained 
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with 0.005% crystal violet and the cell colonies with diameters >100 µm were 
counted under a light microscope with a 4× objective. 
2.2.7. Transfection of TRPC siRNA into SKOV3 cells 
For cell proliferation assay, TRPC siRNAs were transfected into SKOV3 cells using 
Lipofectamine 2000. The wells or dishes without siRNA (no siRNA) or with 
scramble siRNA or non-specific pool siRNA were set as negative control in parallel. 
The Bcl-2 siRNA was used as positive control. For cell cycle experiment, SKOV3 
cells were transfected with TRPC siRNAs using the Neon electroporation system 
(Invitrogen, paisley, UK). The cells were resuspended to a density of 5×10
6
/ml and 
mixed with 200 nM siRNA, and then pulsed twice at 1,170 V for 30 ms in a 100 l 
tip. After electroporation the cells were maintained in antibiotic-free medium for 72 
h and harvested for flow cytometry assay. 
2.2.8. Cell cycle and apoptosis analyses 
Simultaneous measurement of cell cycle and apoptosis was conducted using flow 
cytometric assay with propidium iodide staining as described by Riccardi and 
Nicoletti (2006). SKOV3 cells at 70-80% confluency in a 100-mm culture dish were 
trypsinized, washed with PBS, fixed with 70% cold ethanol, incubated with DNA 
extraction buffer (0.2 M Na2HPO4, 0.004% Triton X-100, pH 7.8) , treated with 
RNase (200 µg/ml) and stained with propidium iodide (20 µg/ml). The cells were 
then analysed with BD FACSCalibur Flow Cytometry System with the CellQuest 
software (Becton Dickinson, Oxford, UK). Events were counted at the limit of 
20,000 or 10,000 for the drug-treated or siRNA-transfected groups. Cell debris was 
gated out according to the scatter plot and the percentages of cells at different phases 
of cell cycle were calculated based on the histogram plot of fluorescent intensities. 
2.2.9. Statistics 
All values are expressed as mean ± SEM. The paired t test was used to assess the 
statistical difference between two groups and a P value less than 0.05 was 
considered as significant.  
- 38 - 
 
Chapter 3 Localisation and Electrophysiological Properties of 
STIM1, ORAI and TRPC Proteins in the Stably Transfected 
HEK293 Cells 
 
 
 
 
Chapter 3 
Localisation and Electrophysiological Properties of STIM1, ORAI 
and TRPC Proteins in the Stably Transfected HEK293 Cells 
- 39 - 
 
3.1. Introduction 
Store-operated Ca
2+
 entry (SOCE) is implemented by the Ca
2+
-sensing protein 
STIM1 at the ER and Orai (and possibly TRPC) channels at the plasma membrane. 
The subcellular localisation of these proteins is important for their roles as store-
operated channels (SOCs). STIM1 senses the ER Ca
2+ 
level with its N-terminus and 
regulates Orai and TRPC channels with the C-terminus (Yuan et al., 2007; Zeng et 
al., 2008; Korzeniowski et al., 2010). The translocation of STIM1 from the ER to 
the subplasmalemmal regions is the key and unique signalling process in SOCE. 
STIM1 has been reported to gate Orai1/2/3 and TRPC1/4/5 channels directly, and 
TRPC3/6 channels indirectly (Yuan et al., 2007; Zeng et al., 2008; Liao et al., 2008; 
Vaca, 2010). The diversity of these pore-forming subunits has rendered SOCs a 
broad range of cellular functions (Yuan et al., 2009a; Vaca, 2010). Apart from the 
differences among the members of Orai and TRPC families, alternative splicing of a 
single Orai or TRPC gene may also produce channel isoforms with distinct 
functions. Comparing with other Orai and TRPC genes, TRPC1 and TRPC4 have 
exhibited much higher splicing activities. There are more than ten spliced variants of 
human TRPC1 and TRPC4 reported in GenBank, but the functional studies on these 
isoforms are very limited (Dedman et al., 2011; Mery et al., 2001; Schaefer et al., 
2002).  As the alternatively spliced variants of other members of TRP channels, e.g. 
TRPV1, TRPM3 and TRPM8, have been shown to possess distinct functions 
compared to their full-length counterparts (Wang et al., 2004a; Oberwinkler et al., 
2005; Gracheva et al., 2011; Bidaux et al., 2012), it is very important to examine the 
functional properties of the spliced variants TRPC1 and TRPC4. 
In a mammalian cell, there are hundreds of different types of ion channels expressed 
(Gabashvili et al., 2007). The endogenous activities of these miscellaneous channels 
make it difficult to study the function of a certain type of ion channels, particularly 
in non-excitable cells. SOCE is believed to be the most important Ca
2+
 influx 
pathway in non-excitable cells, and the currents mediated by SOCs are generally 
very small (whole-cell currents at lower picoampere level) in native cells (Parekh 
and Penner, 1997; Parekh and Putney, 2005). After the discovery of STIM1 and 
Orai1 as the most important components of SOCs, a relatively huge store-operated 
current (100-800 nA for a whole cell) was obtained by overexpressing STIM1 and 
Orai1 in HEK293 and Jurkat T cells (Peinelt et al., 2006; Soboloff et al., 2006; 
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Mercer et al., 2006). The use of STIM1/Orai1-overexpressing cells has greatly 
promoted the functional research of SOCs. Moreover, the overexpression systems of 
TRPC channels have also been proved to be very useful in physiological and 
pharmacological studies. Many new interaction proteins and modulators of these 
channels have revealed by using TRPC-overexpressing cells (Yuan et al., 2003; Xu 
et al., 2005b; Xu et al., 2008a; Harteneck and Gollasch, 2011).  
In this chapter, I identified and cloned the alternatively spliced isoforms of TRPC1 
and TRPC4 from human aortic endothelial cells (HAECs). Considering the 
advantages of ion channel-overexpressing cells as research tools, I generated stable 
overexpression cell lines for fluorescent protein-tagged STIM1, ORAI and TRPC 
channels. The inducible protein expression system composed of T-REx HEK293 
cells and pcDNA4/TO vectors was used, in which the expression of transfected 
genes is repressed in the absence of tetracycline and induced in the presence of 
tetracycline. To verify the functional properties of these cell lines, channel activators 
including thapsigargin (TG, for STIM1 and ORAI1/2/3), 2-aminoethyldiphenyl 
borate (2-APB, for ORAI3), Gd
3+
 (for TRPC4/5) and trypsin (for TRPC3/4/5/6)were 
used in fluorescent microscopy and patch-clamp recordings.  
3.2. Results 
3.2.1. Novel TRPC1 and TRPC4 variants expressed in HAECs 
Alternatively spliced isoforms of TRPC1 and TRPC4 were detected by PCR with 
different sets of primers across introns and the cDNA of HAECs was used as 
template. The PCR products generated by primer pairs TRPC1S-F/TRPC1E4E5-R, 
TRPC1E8E11-F/TRPC1E8E11-R and TRPC4E6E11-F/TRPC4E12-R showed 
multiple bands in agarose gel after electrophoresis, indicating the existence of 
spliced variants of TRPC1 and TRPC4 in HAECs (Fig. 3.1). Three alternatively 
spliced isoforms of TRPC1 were identified by direct sequencing, including TRPC1α 
(full-length), TRPC1β (exon 3 deletion) and a new isoform with exon 9 deletion 
(named as TRPC1δ in this thesis) (Fig. 3.2A and C). In addition, three spliced 
variants of TRPC4 were identified by sequencing the subcloned PCR products in 
pGEM-T vectors. The longer isoform was TRPC4α, and two new shorter isoforms 
were characterised and named as TRPC4β1 and TRPC4ε1 (Fig. 3.2B and C). 
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TRPC4β1 has three more nucleotides deleted in exon 11 compared to the TRPC4β 
isoform reported in GenBank (NM_001135955). TRPC4ε1 has the same deletion as 
TRPC4β1, but bears an additional 15 bp fragment after exon 8, which is the feature  
 
Fig. 3.1 Detection of TRPC1 and TRPC4 spliced variants in human aortic 
endothelial cells (HAECs). (A) PCR amplification with primers TRPC1S-F and 
TRPC1E4E5-R from cDNA of HAECs generated two bands, one is bright and the 
other is very faint, after electrophoresis in 1.5% agarose gel, which correspond to the 
β (301 bp) and α (403 bp) isoforms of TRPC1. (B) The amplification with primers 
TRPC1E8E11-F and TRPC1E8E11-R produced two bands with expected sizes of 
the α and β isoforms (549 bp) and a new δ isoform with Exon 9 deleted (405 bp). 
(C) Primers TRPC4E6E11-F and TRPC4E12-R amplified DNA fragments with the 
sizes of the α (1137 bp), β1 (882 bp) and ε1 (897 bp) isoforms of TRPC4. (D) A 
fragment of the ε1 isoform (283 bp) was amplified using the forward primer 
TRPC4E7E9-F and the ε-specific reverse primer TRPC4E-R. 
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A 
 
B 
 
C 
Fig. 3.2 Sequence alignment and schematic illustration of the spliced variants of 
TRPC1 and TRPC4. (A) The alignment of partial amino-acid sequences of 
TRPC1α, TRPC1β and TRPC1δ. Dashes indicate the deletion of amino acids. (B) 
The alignment of partial amino-acid sequences of TRPC4α, TRPC4β1 and 
TRPC4ε1. (C) Structures of the spliced variants of TRPC1 and TRPC4. 
- 43 - 
 
of the TRPC4ε isoform (NM_003306). The variations in these TRPC1 or TRPC4 
isoforms do not cause any shifting in the open reading frames, suggesting these 
isoforms are able to encode functional ion channels in HAECs. 
3.2.2. Localisation of STIM1, ORAI and TRPC proteins in HEK293 cells 
3.2.2.1. STIM1, ORAI1, ORAI2 and ORAI3 
The STIM1-EYFP fused proteins were predominantly localised at the intracellular 
compartments including perinuclear region and ER-like structures across the 
cytoplasm at resting state (Fig. 3.3A, left). Once the cells were treated with TG and 
the Ca
2+
 stores were depleted, some of the STIM1-EYFP proteins aggregated at the 
plasma membrane, forming bright puncta (Fig. 3.3A, right). 
The mCherry-ORAI1 and mCherry-ORAI2 proteins were present at the plasma 
membrane and also in some intracellular vesicles (Fig. 3.3B, left and middle). The 
mCFP-ORAI3 proteins were mostly distributed at the plasma membrane, with small 
amount of aggregations in the cells (Fig. 3.3B, right). 
In STIM1/ORAI-coexpressing cells, the localisation of STIM1-EYFP and 
mCherry/mCFP-ORAI proteins was similar to those proteins expressed alone in the 
cells at resting state (Fig. 3.3C, left). When the Ca
2+
 stores were depleted by TG, the 
STIM1 puncta were induced and colocalised with ORAI proteins at the plasma 
membrane. Among the three ORAI proteins, mCFP-ORAI3 showed most evident 
puncta with STIM1, whilst mCherry-ORAI1 retained a smooth distribution at the 
plasma membrane (Fig. 3.3C, right). 
3.2.2.2. TRPC1, TRPC4, TRPC3 and TRPC6 
The mCFP-TRPC1 and mCFP-TRPC1δ proteins showed an ER-like localisation in 
T-REx HEK293 cells and had almost no distribution at the plasma membrane (Fig. 
3.4A). The EYFP-TRPC4α/β1/ε1 proteins were mostly evident at the plasma 
membrane, with very little distribution in the cells (Fig. 3.4B). The mCherry-TRPC3 
proteins were localised at the plasma membrane and in some vesicular 
compartments in the cells (Fig. 3.4C, left). The mCFP-TRPC6 proteins were 
exclusively distributed at the plasma membrane (Fig. 3.4C, right).  
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Fig. 3.3 Subcellular localisation of STIM1 and ORAI proteins in HEK293 cells. 
(A) STIM1-EYFP before and after TG (1µM) treatment. (B) mCherry-ORAI1, 
mCherry-ORAI2 and mCFP-ORAI3 at resting state. (C) STIM1-EYFP coexpressed 
with mCherry-ORAI1, mCherry-ORAI2 or mCFP-ORAI3 before and after TG 
(1µM) treatment. The mCFP fluorescence is converted into red pseudocolour in the 
pictures at the bottom. The STIM1 puncta at the plasma membrane are indicated by 
arrows. 
- 45 - 
 
 
Fig. 3.4 Subcellular localisation of TRPC channels in HEK293 cells. (A) mCFP-
TRPC1β and mCFP-TRPC1δ. (B) EYFP-TRPC4α, EYFP-TRPC4β1 and EYFP-
TRPC4ε1. (C) mCherry-TRPC3 and mCFP-TRPC6. 
 
3.2.2.3. STIM1/TRPC1, STIM1/TRPC4 and STIM1/TRPC6 
STIM1-EYFP and mCFP-TRPC1 proteins exhibited colocalisation at the perinuclear 
region and ER-like structures when they were coexpressed in the cells (Fig. 3.5A, 
left). However, mCFP-TRPC1 did not move to the plasma membrane and form 
puncta with STIM1-EYFP after Ca
2+
 store depletion by TG (Fig. 3.5A, right). The 
same phenomenon was observed in STIM1-EYFP cells transiently transfected with 
mCFP-TRPC1δ (Fig. 3.5B). Coexpression of STIM1 with TRPC4 or TRPC6 did not 
change the localisation of these proteins (Fig. 3.5C-D, left). TRPC4 and TRPC6 did 
not affect TG-evoked translocation of STIM1, and the formation of STIM1 puncta at 
the plasma membrane did not induce clustering of TRPC4 or TRPC6 neither (Fig. 
3.5C-D, right). 
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Fig. 3.5 Subcellular localisation of STIM1 and TRPC proteins coexpressed in 
HEK293 cells. (A) STIM1-EYFP and mCFP-TRPC1β before and after TG (1µM) 
treatment. (B) STIM1-EYFP and mCFP-TRPC1δ. (C) STIM1-EYFP and mCFP-
TRPC4α. (D) STIM1-EYFP and mCFP-TRPC6. The mCFP fluorescence is 
converted into red pseudocolour in the pictures. The STIM1 puncta at the plasma 
membrane are indicated by arrows. 
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3.2.3. Electrophysiological properties of STIM1/ORAI and TRPC 
channels overexpressed in HEK293 cells 
3.2.3.1. STIM1/ORAI1, STIM1/ORAI2, STIM1/ORAI3 and ORAI3 
Inward-rectifying whole-cell currents were elicited by 1 µM TG in STIM1/ORAI1 
and STIM1/ORAI2 cells (Fig. 3.6A-B). In the control cells without exogenous 
expression of STIM1 and ORAIs (non-induced), TG (1 µM) did not stimulate any 
inward or outward current (Fig. 3.6C). 2-APB at 100 µM potently activated ORAI3 
current, showing an inward current similar to those of ORAI1 and ORAI2, and a 
much larger outward current (Fig. 3.6D). In cells overexpressing ORAI3 alone a 
current with same properties was observed after 2-APB perfusion (Fig. 3.6E). In the 
non-induced ORAI3 cells, application of 100 µM 2-APB only suppressed the 
endogenous current (Fig. 3.6F). 
3.2.3.2. TRPC4α, TRPC4β1, TRPC4ε1, TRPC3 and TRPC6 
After perfusion with 100 µM Gd
3+
, the whole-cell currents of TRPC4α and 
TRPC4β1 cells were rapidly increased, showing a typical “N”-shape I-V relationship 
(Fig. 3.7A-B). The whole-cell current of TRPC4ε1 cells was partially inhibited by 
100 µM Gd
3+
 (Fig. 3.7C).The current in the non-induced TRPCα cells was rather 
small, and also inhibited by 100 µM Gd
3+
 (Fig. 3.7D).  
In TRPC4α and TRPC4β1 cells, the whole-cell currents were significantly 
augmented by 0.5 μM trypsin (Fig. 3.8A-B). The activation process was fast and 
transient, with the currents decreased to a lower level within 2 min. The whole-cell 
current in TRPC4ε1 cells was also increased by 0.5 μM trypsin but the amplitude 
was very small (0.47±0.09 nA, -0.15±0.03 nA, n=4), compared to that of TRPC4α 
(5.10±0.65 nA, -3.04±0.35 nA, n=4) and TRPC4β1 (3.55±0.31 nA, -2.59±0.32 nA, 
n=4), and the I-V curve was almost linear (Fig. 3.8C). In the control cells without 
exogenous TRPC4 expression, trypsin (0.5 μM) gradually stimulated the whole-cell 
current and this current did not decay in 4 min (Fig. 3.8D). Similar as in TRPC4α 
and TRPC4β1 cells, trypsin (0.5 μM) showed stimulatory effect on the whole-cell 
currents of TRPC3 and TRPC6 cells, and the characteristic “N”-shape I-V curves 
were also observed (Fig. 3.8E-F).  
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Fig. 3.6 Activation of ORAI channels by TG and 2-APB. (A-B) TG (1 μM) 
induced store-operated currents in STIM1/ORAI1 and STIM1/ORAI2-coexpressing 
HEK293 cells. (C) No TG (1 μM)-induced current in non-induced control cell. (D-
E) Potentiation of ORAI3 currents by 100 μM 2-APB in STIM1/ORAI3 and ORAI3 
cells. (F) 2-APB (100 μM) inhibited the endogenous current in non-induced control 
cell. The currents in the time-course plots were measured at +80 and -80 mV. The I-
V curves of the currents at the end of each recording are inset. 
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Fig. 3.7 The effects of Gd
3+
 on the whole-cell currents of TRPC4 variants. (A-B) 
Gd
3+
 (100 µM) activated typical “N”-shape TRPC currents in TRPC4α and 
TRPC4β1 cells. (C) The current of TRPC4ε1 cell was inhibited by 100 µM Gd3+. 
(D) In non-induced control cell 100 µM Gd
3+
 showed no potentiating effect on the 
whole-cell current. The I-V curves of the currents at the end of each recordingare 
inset. 
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Fig. 3.8 The effects of trypsin on TRPC channels. (A-B) Trypsin (0.5 μM) 
transiently activated typical “N”-shape whole-cell currents in TRPC4α and 
TRPC4β1 cells. (C) Trypsin (0.5 μM) slightly increased the current in TRPC4ε1 
cell. (D) Trypsin (0.5 μM) potentiated the current in non-induced control cell. (E-F) 
The effects of 0.5 μM trypsin on the whole-cell currents of TRPC3 and TRPC6 cells. 
The I-V curves of the peak currents (A, B, E and F) or currents at the end of 
recordings (C and D) are inset. 
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3.3. Discussion  
3.3.1. Localisation and interaction of fluorescent protein-tagged STIM1, 
ORAI and TRPC proteins 
In this study I generated HEK293 cell lines overexpressing store-operated channel 
proteins including STIM1, ORAI1/2/3 and TRPC1/3/4/6. The localisation of these 
proteins was revealed by the tagged fluorescent proteins mCFP, EYFP and mCherry. 
STIM1-EYFP and mCFP-TRPC1 are present at ER-like intracellular compartments, 
whilst mCherry-ORAI1, mCherry-ORAI2, mCFP-ORAI3, mCherry-TRPC3, EYFP-
TRPC4 and mCFP-TRPC6 are mostly found at the plasma membrane. These results 
are as expected and suggest that the three fluorescent proteins are useful tools for 
protein localisation studies. However, it is noticeable that the proteins tagged with 
mCherry (ORAI1, ORAI2 and TRPC3) showed more intracellular aggregations 
compared with other proteins tagged with mCFP or EYFP (Fig. 3.3-3.4). These 
vesicle-like protein aggregations are most likely in lysosomes, which are responsible 
for intracellular protein degradation. The inclusion of mCherry-tagged proteins in 
lysosome-like organelles suggests that these proteins are probably misfolded and 
thus being degraded. The misfolding of these proteins may be caused by the 
conjugation with mCherry, because the cells overexpressing mCFP or EYFP-tagged 
proteins do not have so many intracellular vesicles with bright fluorescence. 
Accordingly, it is suggested that mCFP and EYFP are better than mCherry for 
protein localisation studies using fluorescent protein conjugation method. 
The characteristic feature of STIM1 is its movement from intracellular 
compartments to the plasma membrane upon Ca
2+ 
store depletion. This translocation 
process is confirmed in STIM1-EYFP cells, and also in cells coexpressing ORAI or 
TRPC channels with STIM1. Colocalisation of STIM1 puncta and ORAI channels at 
the plasma membrane was observed; however, there was no such phenomenon in 
STIM1/TRPC-coexpressing cells after Ca
2+ 
store depletion. These results suggest 
that the affinity between STIM1 and TRPC proteins is much lower than that 
between STIM1 and ORAI proteins, if the direct interaction between STIM1 and 
TRPC proteins really exists. There is evidence that Ca
2+ 
influx through ORAI1 is 
crucial for the activation of TRPC1 during SOCE (Cheng et al., 2011), which may 
be a common mechanism for the STIM1/ORAI/TRPC complex. Future studies using 
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STIM1/ORAI/TRPC-coexpressing cells and gene knockout/down techniques will 
give more important evidences on this topic. 
3.3.2. Electrophysiological properties of STIM1/ORAI channels 
According to previous reports, overexpression of STIM1 and ORAI1 resulted in a 
large and characteristic ICRAC (Peinelt et al., 2006; Soboloff et al., 2006; Mercer et 
al., 2006). This is confirmed in present study, i.e. the whole-cell current elicited by 
TG in STIM1/ORAI1 cells showed an inward-rectifying property (Fig. 3.6A). 
However, the outward current observed in this study was larger than that described 
by other groups, which may result from the opening of other endogenous SOCs, 
probably TRPC channels. A similar phenomenon was observed in STIM1/ORAI2 
cells (Fig. 3.6B). The lack of TG-induced current in non-induced control cells 
suggests that the inward-rectifying currents in STIM1/ORAI1 and STIM1/ORAI2 
cells are due to the overexpression of STIM1, ORAI1 and ORAI2, and the activation 
of these exogenous channels enhances the activity of other endogenous SOCs.  
2-APB is a direct activator of ORAI3 channel, so it was used to verify the 
functionality of STIM1/ORAI3 and ORAI3 cells. Chacraristic ORAI3 currents were 
evoked in these two types of cells after 2-APB application, which is distinct from 
the inhibition of current in non-induced control cells with the same treatment. The 
comparable currents in STIM1/ORAI3 and ORAI3 cells suggest that the 
overexpression of STIM1 does not affect the activation of ORAI3 by 2-APB, which 
is consistent with previous studies (DeHaven et al., 2008; Peinelt et al., 2008). 
Although the activation of ORAI3 channel by 2-APB has been well addressed in 
overexpression systems, there is no report stating this effect in native cells. This may 
be due to the low expression of ORAI3 channels in native cells, where the increased 
ORAI3 activity is masked by the inhibition of other channels when 2-APB is 
applied. Moreover, the assembly of ORAI1 and ORAI3 as heteromeric channel has 
been demonstrated (Mignen et al., 2009; Schindl et al., 2009), which may be another 
reason for the lack of 2-APB-evoked current in native ORAI3-expressing cells, 
because the activity of ORAI1/3 heteromeric channel is greatly reduced compared to 
homomeric ORAI3 channel in the presence of 2-APB (Schindl et al., 2009). 
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3.3.3. Functions of novel TRPC1 and TRPC4 variants 
TRPC1β and TRPC1δ are two TRPC1 isoforms detected in endothelial cells in this 
study. After transfection into HEK293 cells, they were found to be localised at 
intracellular compartments, most probably the ER. This is inconsistent with previous 
reports using fluorescent protein-tagged TRPC1 in HEK293 cells (Hofmann et al., 
2002; Alfonso et al., 2008). It was found that TRPC1 could move to the plasma 
membrane when it was coexpressed with TRPC4 or TRPC5 channels; however, 
there are still considerable amount of TRPC1 proteins remaining in the cells 
(Hofmann et al., 2002; Alfonso et al., 2008). Apart from forming heteromeric 
channels with other TRPCs at the plasma membrane, TRPC1 can also operate as 
homomeric Ca
2+
-leaking channels at the sarcopalsmic reticulum, as found in skeletal 
muscle cells (Berbey et al., 2009). The ER-localised TRPC1 in HEK293 cells may 
have the same function, which needs to be confirmed by future studies using ER-
specific Ca
2+ 
indicators. The intracellular localisation of TRPC1 has hindered the 
electrophysiological studies on homomeric TRPC1 channels. So far there is no 
convincing report for the whole-cell current of TRPC1-overexpressing cells, 
probably because the current is very small and difficult to be distinguished from the 
endogenous currents. For the same reason, I have not compared the 
electrophysiological difference of the two TRPC1 isoforms in this study. 
The eletrophysiological property of the new TRPC4 isoform TRPC4ε1 was found to 
be distinct from other two TRPC4 isoforms, TRPC4α and TRPC4β1. The TRPC4ε1 
cells did not respond to the TRPC4/5 selective activator Gd
3+
, and showed very little 
activation by the GPCR agonist trypsin. However, this trypsin-stimulated current 
(0.47±0.09 nA, -0.15±0.03 nA, n=4) was even smaller than that in the non-induced 
control cells (0.81±0.09 nA, -0.52±0.07 nA, n=4), suggesting that TRPC4ε1 may 
serve as a negative regulator of endogenous receptor-operated channels. The 
dominant negative modulation of TRP channels by their alternatively spliced 
variants have been reported, such as the inhibition of full-length TRPV1 and 
TRPM8 channels by their short variants (Wang et al., 2004a; Bidaux et al., 2012; 
Fernandez et al., 2012). The exact role of TRPC4ε1 needs to be investigated by 
coexpression with other functional TRPC isoforms in the future. 
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3.3.4. Activation mechanisms of TRPC channels 
Lanthanides are selective activators of TRPC4 and TRPC5 channels. The actions of 
La
3+
 and Gd
3+
 on TRPC5 are complex, including the increase of channel open 
probability, reduction of channel conductance, potentiation at low concentrations 
(10-100 μM) and inhibition at high concentrations (>100 μM) (Jung et al., 2003). 
The molecular targets of La
3+
 and Gd
3+
 on TRPC5 are the negatively charged 
glutamic acid residues (E543, E595 and E598) situated in the extracellular pore 
region of the channel. Neutrolisation of these residues resulted in the inhibition of 
TRPC5 channels by La
3+
. These residues are conserved in TRPC4 and TRPC5, but 
absent in other TRPC members. Therefore, La
3+
 and Gd
3+
 have only inhibitory 
effect on TRPC3/6/7 channels (Jung et al., 2003). The TRPC4ε1 isoform identified 
in this study has the same pore region as TRPC4α and TRPC4β1, and possesses only 
five additional amino acids (VRTQH) in the cytoplasmic  C-terminus. This amino 
acid stretch may work as a molecular lock that keeps the channel at closing 
conformation. The loss of Gd
3+ 
potentiation on TRPC4ε1 may be related to this 
speculative mechanism. 
Trypsin is a searine proteinase and the agonist of proteinase-activated receptor 2 
(PAR2). Trypsin activates PAR2 by cleaving the N-terminus of the receptor, which 
leads to the activation of G proteins (Macfarlane et al., 2001). It has been reported 
that TRPC4 and TRPC5 channels are directly activated by the specific G protein 
isoform Gαi (Jeon et al., 2012), which is coupled to PAR2 (Ricks and Trejo, 2009). 
The G proteins then activate phospholipase C (PLC) in the subplasmalemmal area. 
PLC cleaves the plasma membrane component phosphatidylinositol 4,5-
bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol 
(DAG). DAG is a direct activator of TRPC3 and TRPC6 channels, and also activates 
protein kinase C (PKC) (Hofmann et al., 1999). Because activated PKC blocks 
TRPC channel activity (Venkatachalam et al., 2003), the effect of trypsin on TRPC 
currents will be activation at first and then inhibition, which is confirmed in current 
study (Fig. 3.8). The decay of TRPC currents should be taken into consideration 
when trypsin or other GPCR agonist is used as channel activators in the experiment 
to test TRPC blockers. PKC inhibitors, such as cheletythrine and GF109203X, may 
be used in future studies to prevent the rundown of TRPC currents stimulated by 
GPCR agonists. 
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3.4. Conclusions 
In this chapter I identified three novel alternatively spliced isoforms of TRPC1 and 
TRPC4 (TRPC1δ, TRPC4β1 and TRPC4ε1) from HAECs. Expression vectors 
containing the complete coding sequences of STIM1, ORAI1/2/3 and TRPC1/4/3/6, 
including the three new isoforms, were constructed and transfected into HEK293 
cells. Stable cell lines for STIM1, ORAI1/2/3 and TRPC1/4/3/6, and coexpression 
cell lines for STIM1-ORAI1/2/3 and STIM1-TRPC1/4/6 were generated and the 
functional properties of these cell lines were tested by fluorescence microscopy and 
patch-clamp recordings.  
TRPC1β, TRPC1δ and STIM1 showed a similar ER-like localisation in HEK293 
cells at resting state. TRPC4α/β1/ε1, TRPC3/6 and ORAI1/2/3 were mostly 
localised at the plasma membrane. Depletion of ER Ca
2+ 
store induced STIM1 
translocation to the plasma membrane, where it formed complex with ORAI1/2/3. 
TRPC1β and TRPC1δ did not move to the plasma membrane with STIM1 upon Ca2+ 
store depletion. TRPC4 and TRPC6 were not colocalised with STIM1 puncta at the 
plasma membrane.  
Store-operated Ca
2+ 
currents were observed in STIM1-ORAI1/2 coexpressing cells, 
and the ORAI3 current was substantially potentiated by its selective activator 2-APB 
in STIM1/ORAI3 and ORAI3 cells. The eletrophysiological property of TRPC4ε1 
was distinct from TRPC4α and TRPC4β1, as it did not respond to the channel 
activators Gd
3+
 and trypsin. TRPC3 and TRPC6 channels were significantly 
activated by trypsin. All these results suggest that the STIM1, ORAI and TRPC 
proteins are functionally expressed in the stably transfected cell lines generated in 
this study, which can be used in further electrophysiological and pharmacological 
studies. 
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4.1. Introduction 
The activation of G protein-coupled receptors (GPCRs) and receptor tyrosine 
kinases (RTKs) induces a Ca
2+
 release from internal stores, which in turn triggers a 
sustained Ca
2+
 influx across the plasma membrane (PM) via store-operated Ca
2+
 
channels (SOCs). This Ca
2+
 influx through SOCs, termed as store-operated Ca
2+
 
entry (SOCE) or capacitative Ca
2+
 entry, mediates numerous physiological functions 
including cell growth, muscle contraction, exocytosis, gene transcription and 
apoptosis (Parekh and Putney, 2005). The molecular basis for SOCs has been linked 
to the two major ion channel families, i.e., ORAI channels and transient receptor 
potential (TRP) channels. ORAI channels mediate a highly Ca
2+
-selective and 
inward rectifying Ca
2+
 release-activated Ca
2+
 current (ICRAC) (Vig et al., 2006a; 
Yeromin et al., 2006), while TRPC channels mediate a non-selective Ca
2+
-
permeable cationic current with a current-voltage (IV) relationship of outward 
rectification, such as TRPC1, TRPC3, TRPC7 and the heteromeric TRPC1/TRPC5 
channel (Xu et al., 2012; Xu et al., 2006b; Yuan et al., 2007), or “N” shape I-V 
curve with inward and outward rectification (Xu et al., 2008a). ORAI channels, as 
well as TRPCs, are interacted or triggered by the endoplasmic reticulum (ER) Ca
2+
 
sensor STIM1 (stromal interaction molecule 1) that signals the Ca
2+
 depletion of ER 
to the SOCs (Hogan et al., 2010; Liou et al., 2005; Zhang et al., 2005; Lee et al., 
2010; Pani et al., 2009).  
STIM1 was originally identified as a stromal cell molecule that is potentially 
relevant for interactions with precursor B cells. It is a type I membrane protein and 
mainly located in the ER, but also to a limited extent in the PM (Spassova et al., 
2006; Hogan et al., 2010). STIM1 relocation has been suggested as the mechanism 
for coupling the ER Ca
2+
 store depletion to SOCs in the PM (Liou et al., 2005; 
Zhang et al., 2005). It has been demonstrated that the ER-luminal domain of STIM1 
is responsible for Ca
2+
 sensing, and the dissociation of Ca
2+
 from STIM1 leads to 
oligomerization (clustering) and redistribution of STIM1 to the subplasmalemmal 
area (translocation) (Smyth et al., 2008; Hogan et al., 2010). STIM1 then triggers 
ORAI channels (ORAI1, 2 and 3) in the PM via the binding to the N-terminus of 
ORAI, which results in Ca
2+
 entry into the cell (Hogan et al., 2010).  
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Dysfunction of SOCs causes some diseases, for example, the mutations of ORAI1 
and STIM1 causing the deficiency of ICRAC in T cells that has been regarded as the 
aetiology of severe combined immune deficiency syndrome (Feske et al., 2010). 
ORAI1 deficiency in mice results in resistance to pathological thrombus formation, 
which is an important new clue for preventing ischemic cardiovascular and 
cerebrovascular events (Braun et al., 2009b). In addition, the alteration of channel 
expression or channel activity is implicated in angiogenesis (Grigoriev et al., 2008), 
smooth muscle cell proliferation and migration (Potier et al., 2009) and 
cardiomyocyte hypertrophy (Ohba et al., 2009), suggesting the signalling of STIM1-
associated activation of SOCs could act as new therapeutic targets. However, the 
regulation of STIM1 movement is still unclear.  
In order to examine the possibility of STIM1 movement as a new potential drug 
target, the pharmacological profile of STIM1 translocation and clustering was 
investigated in this study using a variety of modulators that potentially change the 
activity of SOCs or target to the signalling pathways associated with SOCE. 
HEK293 cells stably transfected with STIM1-EYFP fused gene were used. It is 
demonstrated that the localisation of STIM1 puncta has two different patterns in 
response to different regulators, i.e., cytosolic clusters and subplasmalemmal 
clusters. The ER Ca
2+
 store-independent mechanism for the cytosolic STIM1 
movement is crucial for the pharmacological regulation of SOCE. 
 
4.2. Results 
4.2.1. STIM1 translocation induced by Ca
2+ 
store depletion  
Passive depletion of ER Ca
2+
 store by sarco/endoplasmic reticulum Ca
2+
-ATPase 
(SERCA) inhibitor thapsigargin (TG, 1µM) induced STIM1-EYFP 
subplasmalemmal translocation and puncta formation (Fig. 4.1A), which is 
consistent with previous reports (Liou et al., 2005; Zhang et al., 2005; Walsh et al., 
2010). The STIM1 puncta at PM became evident after 4 min incubation with TG 
and achieved maximum after ~6 min (Fig. 1A). The TG-induced STIM1 clustering 
and translocation occurred in both Ca
2+
 free and Ca
2+
 containing bath solution, 
suggesting the extracellular Ca
2+
 is not the determinant for intracellular STIM1 
movement.  
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Fig. 4.1 STIM1 subplasmalemmal translocation and clustering in response to 
Ca
2+
-store depletion in the stably transfected STIM1-EYFP cells. (A) TG (1 µM) 
induced STIM1 puncta formation at the PM of cells in Ca
2+ 
bath solution. The time 
course of STIM1 subplasmalemmal translocation and clustering in the boxed area is 
showed in the lower panels. The arrow indicates the subplasmalemmal STIM1 
clusters (puncta). The ratio of fluorescent intensity in the PM (FPM) and the cytosol 
(Fcytosol) of cells in response to TG (1 µM) in 1.5 mM Ca
2+
 or Ca
2+
-free bath solution 
(n = 5 cells in each group). The regions of interest (ROIs) of the PM and the nearby 
cytosol were manually selected. (B) Trypsin-induced STIM1 clustering and 
translocation in standard bath solution. The dynamic changes of ratio of fluorescent 
intensity (FPM/Fcytosol) for the STIM1 translocation induced by trypsin (0.1 nM) are 
shown in the chart (n = 5 cells in each group). 
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The time course for the onset of the TG-induced STIM1 translocation was a slow 
process, which could be due to the slow Ca
2+
 leakage from the ER induced by 
passive Ca
2+
 store depletion.  
The depletion of ER Ca
2+
 store via GPCR activation is another way to induce 
STIM1 translocation. Protease-activated receptor is a unique subclass of GPCR and 
can be activated by cleavage of the extracellular N-terminus with trypsin or 
thrombin (Hollenberg and Compton, 2002). Trysin at 0.1 nM significantly induced 
STIM1 clustering and translocation in standard bath solution or Ca
2+
 free bath 
solution (Fig. 4.1B). Unlike the SERCA blockers or Ca
2+
 chelators, the STIM1 
translocation evoked by trypsin was much faster, but the subplasmalemmal 
clustering was transient and the puncta gradually disappeared after 4 min in standard 
bath solution containing 1.5 mM Ca
2+
 (Fig. 4.1B), however, the disassembly of 
STIM1 puncta was not observed in Ca
2+
 free solution, suggesting that this process is 
dependent on Ca
2+
 influx that leads to ER Ca
2+
 store refilling. The relocation of 
STIM1 from PM to cytosol seen in the active store-depletion suggests that the 
STIM1 clustering and translocation is a reversible process, which may act as a drug 
target. 
4.2.2. Ryanodine-sensitive Ca
2+
 store and STIM1 movement 
The entire ER/SR Ca
2+
 store could also be depleted by activation of ryanodine 
receptors (RyRs), which leads to SOCE (Fellner and Arendshorst, 2000). Therefore, 
STIM1 movement in response to the depletion of ryanodine-sensitive Ca
2+
 store was 
investigated. The expression of endogenous RyRs has been demonstrated in the 
HEK293 cells (Querfurth et al., 1998). Application of RyR direct activator 4-chloro-
3-ethylphenol (4-CEP, 500 µM) led to STIM1 translocation toward the PM. 
Interestingly, unlike trypsin, the 4-CEP-induced STIM1 puncta at the PM 
disappeared after 3 min incubation with 4-CEP, and was followed by substantial 
STIM1 clusters retained in the cytosol (Fig. 4.2A). However, caffeine ranged from 
10 to 50 mM that can increase the sensitivity of RyRs to Ca
2+
 did not cause cytosolic 
STIM1 puncta, instead the formation of subplasmalemmal STIM1 puncta (Fig. 
4.2B). Both 4-CEP and caffeine induced intracellular Ca
2+ 
release, however, Ca
2+ 
release induced by 4-CEP was higher and lasted longer than that by caffeine. In 
addition, 4-CEP nearly abolished the Ca
2+ 
influx when external 1.5 mM Ca
2+ 
was 
added, but caffeine 
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Fig. 4.2 STIM1 translocation induced by RyR agonists in the STIM1-EYFP 
cells. (A) 4-CEP (500 µM) induced transient STIM1 puncta formation at the PM and 
then cytosolic clustering in Ca
2+ 
bath solution. The time course of STIM1 
translocation in the boxed area is shown in the lower figures. The arrow indicates 
the subplasmalemmal STIM1 puncta. (B) Caffeine (10 mM) induced STIM1 puncta 
formation at the PM in Ca
2+ 
bath solution. (C) 4-CEP (500 µM) induced Ca
2+ 
release 
but abolished Ca
2+ 
entry in STIM1-EYFP cells (n = 23). (D) Caffeine (10 mM) 
induced Ca
2+ 
release and Ca
2+ 
entry in the STIM1-EYFP cells (n = 21). (E) STIM1-
EYFP cells perfused with tetracaine (500 µM) for 10 min and followed by 4-CEP 
and 1.5 mM Ca
2+
 (n = 21). (F) Tetracaine (500 µM) prevented the formation of 
subplasmalemmal STIM1 puncta, but not the cytosolic clusters, in Ca
2+ 
bath 
solution. (G) The time course of fluorescent intensity changes (FPM/Fcytosol) for the 
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STIM1 translocation induced by 4-CEP (500 µM) in the absence or presence of 500 
µM tetracaine (n = 10 cells in each group). 
 had no such effect (Fig. 4.2C-D), suggesting the pharmacological difference 
between the two agonists in the regulation of STIM1 clustering and Ca
2+
 influx. In 
order to examine the relationship of cytosolic STIM1 clustering and Ca
2+
 release, 
the STIM1-EYFP cells were pretreated with RyR antagonist tetracaine (500 µM) for 
10 min and then perfused with  4-CEP (500 µM). The 4-CEP-induced Ca
2+
 release 
signal and STIM1 subplasmalemmal translocation were completely blocked by 
tetracaine pretreatment, however, the cytosolic clustering of STIM1 was still present 
(Fig. 4.2E-F), suggesting that the cytosolic STIM1 clustering is independent of ER 
Ca
2+
 store release or store depletion.  
4.2.3. Mitochondrial Ca
2+
 release is involved in cytosolic STIM1 
clustering 
Mitochondria are important Ca
2+
-storing organelles closely associated with ER. 
Although it has been established that depletion of ER Ca
2+
 stores leads to STIM1 
translocation to the PM, little is known about the effect of mitochondrial Ca
2+
 
release on STIM1 movement. Flufenamic acid (FFA) is a non-steroidal anti-
inflammatory drug with Ca
2+ 
releasing effect from mitochondria whereas its 
analogue niflumic acid (NFA) has little effect on mitochondrial Ca
2+
 release (Tu et 
al., 2009; Jiang et al., 2012), which suggests that the two chemicals are ideal for 
investigating the effect of mitochondrial Ca
2+
 release on STIM1 movement. In the 
current study, FFA (100 µM) caused STIM1 clustering in the cytosol, and further 
addition of 1 µM TG failed to induce STIM1 puncta translocation toward the PM in 
the standard bath solution (Fig. 4.3A). However, NFA (100 µM) neither induced any 
cytosolic STIM1 clusters nor blocked the TG-induced STIM1 subplasmalemmal 
translocation to the PM, although much more sparse puncta were also observed in 
the cytosol after addition of TG (Fig. 4.3A-B). The differences of FFA and NFA on 
Ca
2+
 release and store-depleted Ca
2+
 entry in the STIM1-EYFP cells were also 
observed. The Ca
2+
 release induced by FFA was much higher than the group treated 
by NFA, but the inhibition on the store-depleted Ca
2+
 entry was similar (Fig. 4.3C-
E).  
The effect of mitochondrial metabolic inhibitors on STIM1 movement was 
examined. The uncoupling agent FCCP, which abolishes the obligatory linkage 
between the respiratory chain and the phosphorylation system, can also cause 
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mitochondrial Ca
2+
 release (Gurney et al., 2000). Pretreatment with FCCP (5 µM) 
for 10 min did not prevent TG-induced STIM1 puncta formation near the plasma 
membrane, however, some STIM1 puncta were observed in the cytosol after FCCP 
treatment in both TG- or non-TG-treated cells (Fig. 4.3F), which could be due to its 
small transient Ca
2+
 release effect from mitochondria (Fig. 4.3G). 
 
Fig. 4.3 Effects of flufenamic acid (FFA), niflumic acid (NFA) and 
mitochondrial metabolic inhibitors on STIM1 movement and store-operated 
Ca
2+
 entry in STIM1-EYFP cells. (A) FFA (100 µM) caused cytosolic STIM1 
clustering and blocked TG-induced STIM1 subplasmalemmal translocation. NFA 
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(100 µM) did not change STIM1 localisation at resting state, but potentiated 
cytosolic STIM1 clustering after addition of TG (1 µM). (B) The number of STIM1 
clusters induced by FFA or NFA before and after addition of 1 µM TG (n = 10 cells 
in each group). (C) FFA (100 µM) induced robust cytosolic Ca
2+
 increase in the 
absence of external Ca
2+
, but NFA (100 µM) had no significant effect on Ca
2+
 
release in the STIM1-EYFP cells. (D) Effect of FFA and NFA on TG-induced Ca
2+ 
release and Ca
2+ 
entry. The standard bath solution containing 1.5 mM Ca
2+
 was 
perfused after store depletion. (E) Comparison of Ca
2+ 
release and Ca
2+ 
influx 
induced by FFA (100 µM), NFA (100 µM) and TG (1 µM) (n = 16-37 cells in each 
group). (***P<0.001). (F) Example of FCCP (5 µM) induced cytosolic STIM1 
clusters. (G) FCCP (5 µM) induced a small Ca
2+
 release (n =26). (H) Sodium azide 
(2.5 mM), H2O2 (500 µM) and Hg
2+
 (5 µM) did not alter TG (1 µM)-induced 
STIM1 puncta formation at the PM. 
 
 
Fig. 4.4 2-APB induced STIM1 clustering in STIM1-EYFP cells. (A) Application 
of 100 µM 2-APB resulted in STIM1 clustering in the cytosol. Lower small figures 
show the time course of STIM1 clustering in the boxed area. (B) Cytosolic STIM1 
clusters induced by 100 µM 2-APB were fully reversed after washing out for 20 
min. (C) No effect of 2-APB (100 µM) on Ca
2+
 release in the STIM1-EYFP cells. 
(D) 2-APB (50 µM) blocked the STIM1 subplasmalemmal translocation after 
addition of 1 µM TG and caused cytosolic STIM1 clustering. (E) The mean ± SEM 
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data for the number of STIM1 at the PM or in the cytosol induced by TG (1 µM) in 
the absence or presence of 2-APB (5-100 µM) (n = 5 cells in each group).  
Sodium azide is a potent inhibitor of mitochondrial respiration that blocks 
cytochrome c oxidase. Pretreament with sodium azide (2.5 mM) for 5 min did not 
change the TG-induced STIM1 subplasmalemmal translocation and clustering (Fig. 
4.3H). Application of azide alone did not evoke STIM1 clustering and translocation. 
Moreover, the reagents affecting mitochondrial oxidative stress were examined. 
Incubating the cells with H2O2 (100-1000 µM) for 15 min did not evoke STIM1 
clustering, and showed no effect on TG-induced STIM translocation (Fig. 4.3H). 
Mercury is a toxic heavy metal that causes severe mitochondrial oxidative damage 
leading to cell death, but STIM1 clustering and translocation showed no changes in 
the presence of Hg
2+
 (5 µM) for 10 min. Hg
2+
 also showed no effect on TG-induced 
STIM translocation and subplasmalemmal clustering (Fig. 4.3H). These data 
suggested the mitochondrial Ca
2+
 release is involved in the formation of cytosolic 
STIM1 clustering, as with FFA and FCCP, but the other inhibitors not affecting 
mitochondrial Ca
2+
 movement may have less or no direct effect on STIM1 
movement.  
4.2.4. Cytosolic STIM1 clustering induced by 2-APB in cells with replete 
ER Ca
2+
 store 
2-APB is a non-specific blocker of SOCs with multiple effects on other cationic 
channels (Xu et al., 2005a). 2-APB at 100 µM significantly induced STIM1 
clustering in the cytosol in the absence of TG (Fig. 4.4A), and the clustering induced 
by 2-APB was reversible (Fig. 4.4B). In addition, 2-APB at 100 µM did not cause 
Ca
2+
 release (Fig. 4.4C), which suggests that the 2-APB-induced cytosolic STIM1 
clustering is independent of Ca
2+
 store depletion. The inhibitory effect of 2-APB on 
TG-induced STIM1 translocation was also observed. 2-APB at low concentrations 
(5-50 µM) did not cause STIM1 clustering in the cells, but prevented the 
subplasmalemmal translocation and clustering evoked by 1 µM TG, and resulted in 
the retention of STIM1 puncta in the cytosol (Fig. 4.4D-E). 
2-APB has been reported to inhibit ORAI1 and ORAI2, but activate ORAI3 
channels (Peinelt et al., 2008). To understand the difference, the effect of 2-APB on 
STIM1 movement was also investigated in STIM1/ORAI-coexpressing cells. 2-APB 
induced a small transient increase of ORAI1 and ORAI2 currents, which was  
followed by a sustained inhibition, but activated ORAI3 current (Fig. 4.5A).  
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Fig. 4.5 Effects of 2-APB on STIM1/ORAI-coexpressing cells. (A) 2-APB (100 
µM) transiently increased and then blocked the whole-cell currents of 
STIM1/ORAI1 and STIM1/ORAI2 cells. The current in STIM1/ORAI3 cells was 
substantially activated by 100 µM 2-APB. (B) 2-APB (100 µM) induced cytosolic 
STIM1 clustering in STIM1/ORAI1, STIM1/ORAI2 and STIM1/ORAI3 cells. The 
STIM1 only and STIM1/ORAI-merged images are shown. The mCFP fluorescence 
was converted into red pseudocolour in the merged images. (C) Application of 2-
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APB (100 µM) disassembled the subplasmalemmal STIM1 clusters induced by TG 
(1 µM) in STIM1-EYFP cells, but no disassembling effect was observed in the 
STIM1-EYFP cells coexpressing mCherry-ORAI1, mCherry-ORAI2, or mCFP-
ORAI3. The boxed area is amplified and shown under each corresponding picture 
with STIM1 clusters alone (green) or co-localised with ORAI channels (red) at the 
PM.  
 
The I-V relationship of STIM1/ORAI1 and STIM1/ORAI2 induced by TG or 
STIM1/ORAI3 induced by 2-APB was similar to the report (Peinelt et al., 2008). 2-
APB-evoked cytosolic STIM1 clustering occurred in all the three cell lines 
coexpressing each ORAI isoform with STIM1 (Fig. 4.5B). However, the 
subplasmalemmal clusters induced by TG were disassembled by perfusion with 2-
APB in the STIM1-EYFP cells, but 2-APB did not disassemble the 
subplasmalemmal clusters in the cells coexpressing STIM1 with ORAI channels 
(Fig. 4.5C). 
4.2.5. Coexpression with TRPC1 does not affect cytosolic STIM1 
clustering 
The functional interaction of TRPC1 with STIM1 has been demonstrated (Pani et 
al., 2009; Zeng et al., 2008), implying the potential interference of STIM1 
movement by TRPC1. The stable STIM1-EYFP cells were transfected with human 
TRPC1 tagged with mCFP. Like the localisation of STIM1-EYFP, the 
overexpressed mCFP-TRPC1 was mainly located in the cytosol, which is consistent 
with previous report (Gervasio et al., 2008). The cytosolic STIM1 clusters induced 
by 2-APB were evident and the logarithmic fluorescence spectra showed many 
fluctuations by line-scan intensity analysis, but the TRPC1 did not show significant 
clusters after 2-APB treatment, although the distribution pattern of STIM1 and 
TRPC1 in the cells looked similar before the treatment of 2-APB (Fig. 4.6A). 
Moreover, the co-expression of TRPC1 did not change the TG-induced STIM1 
subplasmalemmal translocation (Fig. 4.6B). These results suggest that the cytosolic 
TRPC1 does not form STIM1/TRPC1 complex in the cytosol or change the 
cytosolic STIM1 movement.  
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Fig. 4.6 Coexpression of TRPC1 does not affect 2-APB or TG-induced STIM1 
clustering. (A)  The localisation of STIM1-EYFP and mCFP-TRPC1 expressed in 
the same cells. The logarithmic fluorescence spectra show the florescence intensity 
of STIM1 (green) and TRPC1 (blue) of the arrow area using line-scan intensity 
software. Cytosolic STIM1 clusters induced by 2-APB (100 µM) and more small 
fluctuations were observed, but no more fluctuations for TRPC1. (B) TRPC1 did not 
translocate to and form puncta at the PM with STIM1 after TG (1 µM) treatment. 
The images focusing on the top, middle and bottom sections of the cells are shown. 
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4.2.6. Effects of other store-operated channel blockers on STIM1 
movement 
Since the formation of cytosolic STIM1 clusters is related to application of 2-APB, 
4-CEP and FFA, and the three reagents are inhibitors of SOCs or cationic channels, I 
therefore examined other commonly used SOC blockers for pharmacological 
comparison. Both SKF-96365 and Gd
3+
 showed no effect on TG-induced STIM1 
clustering and translocation (Fig. 4.7A-B). Pretreatment with diethylstilbestrol 
(DES, 10 µM), a potent inhibitor of ICRAC and SOCE (Zakharov et al., 2004), had no 
effect on STIM1 clustering and translocation (Fig. 4.7C). These results suggest that 
the blockade on SOCs or Ca
2+
 influx does not change the cytosolic STIM1 
clustering, and also suggest the pharmacological difference on STIM1 movement 
among the modulators of SOCs.  
 
Fig. 4.7 Effect of store-operated Ca
2+
 channel blockers Gd
3+
, SKF-96365 and 
diethylstilbestrol (DES) on STIM1 translocation. (A) Gd
3+
 (50 µM). (B) SKF-
96365 (100 µM). (C) Diethylbestrol (DES) (10 µM). The STIM1 subplasmalemmal 
translocation (indicated by arrow) was induced by 1 µM TG. 
 
4.2.7. Effects of signalling pathway modulators on STIM1 movement 
STIM1 has been suggested as an important protein in regulating cell survival. It is 
unknown whether the pharmacological agents targeting to cell signalling pathways 
related to cell survival affect the STIM1 movement. Genistein at micromolar 
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concentrations has been regarded as a specific inhibitor for receptor tyrosine kinase 
(RTK) (Xu et al., 2009b). Pretreatment with genistein (10 µM) for 5 min did not 
alter the STIM1 clustering and translocation toward PM evoked by store depletion 
(Fig. 4.8A). Incubation with phosphatidylinositol 3-kinase (PI3K) inhibitor 
wortmannin (20 µM) for 30 min also showed no significant effect on TG-induced 
STIM1 translocation and clustering (Fig. 4.8B), suggesting the activity of 
RTK/PI3K/Akt/mTOR pathway will not change the STIM1 movement. 
 
Fig. 4.8 Effect of signalling pathway regulators on TG-induced STIM1 
translocation. (A) The protein tyrosine kinase (PTK) inhibitor genistein (10 µM). 
(B) Phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin (20 µM). (C) Rho-
associated protein kinase (ROCK) inhibitor Y-27632 (30 μM). (D) Protein kinase C 
(PKC) inhibitor GF109203X (30 µM). (E) PKC activator OAG (100 µM). (F) PKA 
activator forskolin (50 µM). (G) U73122 (10 µM) abolished TG-induced STIM1 
translocation to the PM, and caused STIM1 clustering in the cytosol. 
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The RhoA/Rho kinase pathway has been implicated in various cellular functions 
including cytoskeleton reorganization, cell adhesion, motility and contraction and Y-
27632 is a selective inhibitor of Rho-associated protein kinase (ROCK). Incubation 
with Y-27632 (30 μM) showed no effect on the TG-evoked STIM1 clustering and 
translocation (Fig. 4.8C).  
The protein kinase C (PKC) inhibitor GF109203X (30 µM) and activator OAG (100 
µM) were examined. Both of them did not change the TG-induced STIM1 
movement (Fig. 4.8D-E). In addition, the protein kinase A (PKA) activator forskolin 
was also tested. Incubation with forskolin (50 µM) for 10 min did not cause 
cytosolic STIM1 clusters. Forskolin also had no effect on the TG-induced STIM1 
translocation (Fig. 4.8F). Surprisingly, I found that the phospholipase C (PLC) 
inhibitor U73122 (10 µM) not only abolished TG-induced STIM1 translocation to 
the PM, but also caused STIM1 clustering in the cytosol (Fig. 4.8G). This unique 
effect of U73122 could be independent of the inhibition of PLC, because the TG-
induced STIM1 translocation is unrelated to the PLC pathway. 
4.2.8. Disruption of cytoskeleton does not prevent STIM1 translocation 
Microtubules are filamentous polymers essential for cell viability and STIM1 has 
been shown to associate with the growth of microtubule ends (Grigoriev et al., 
2008), therefore, the involvement of cytoskeleton in STIM1 movement was 
examined. Incubation with CytD (10 µM) for 1 h, which inhibits actin 
polymerization (Patterson et al., 1999), showed no effect on TG-induced STIM1 
subplasmalemmal clustering and translocation (Fig. 4.9A), suggesting the actin is 
not directly involved in STIM1 movement. The effect of colchicine, a microtubule 
polymerization inhibitor, was also examined. Pretreatment of STIM1-EYFP cells 
with 100 µM colchicine for 30 min changed the cell morphology, but did not show 
any effects on TG-induced STIM1 subplasmalemmal clustering and translocation 
(Fig. 4.9A). The combined treatment with CytD and colchicine also showed no 
effect (Fig. 4.9A). However, the TG-induced SOCE was significantly reduced by the 
two agents (Fig. 4.9B-C). In addition, I found that the formation of cytosolic STIM1 
clusters did not rely on cytoskeleton as well, because cells pretreated with CytD or 
colchicine showed the STIM1 clustering induced by 2-APB or 4-CEP similar to that 
in the untreated cells (Fig. 4.9D-E). 
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Fig. 4.9 Depolymerisation of cytoskeleton did not affect STIM1 clustering but 
reduced store-operated Ca
2+ 
entry in STIM1-EYFP cells. (A) The cells were 
pretreated with 10 µM CytD for 1 h, or 100 µM colchicine for 30 min, or a 
combination of 10 µM CytD and 100 µM colchicine for 1 h. These procedures of 
cytoskeleton disruption did not prevent TG-induced STIM1 translocation. (B) The 
effects of CytD and colchicine on TG-induced Ca
2+ 
release and Ca
2+ 
entry (n = 22-
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33 cells in each group). (C) CytD and colchicine significantly reduced TG-induced 
Ca
2+ 
influx in STIM1-EYFP cells. (***P<0.001) (D) Pretreatment with CytD (10 
µM, 1 h) or colchicine (100 µM, 30 min) did not affect cytosolic STIM1 clustering 
induced by 100 µM 2-APB in STIM1-EYFP cells. (E) Same as in (D), but 500 µM 
4-CEP was used. 
4.2.9. STIM1 subplasmalemmal translocation is inhibited by U73122 and 
calyculin A 
It has been demonstrated that the cellular architecture of PM-ER junctions is the 
place for docking STIM1 clusters near PM and coupling to ORAI channels (Luik et 
al., 2006). The PLC inhibitor U73122 at 1-10 µM has also been suggested to 
increase F-actin content (Kimata et al., 2006; Scott et al., 2005). Because the 
increase of F-actin is able to disrupt the PM-ER junctions and inhibit SOCE 
(Patterson et al., 1999), I then examined this mechanism of U73122 on STIM1 
movement. The STIM1-EYFP cells were cotransfected with Lifeact-mCFP cDNA, a 
marker to visualise F-actin (Riedl et al., 2008). I found the fluorescence of Lifeact-
mCFP at the PM was increased by U73122 (Fig. 4.10A), suggesting the 
accumulation of F-actin in the subplasmalemmal regions which spatially involve 
PM-ER junctions. The STIM1 subplasmalemmal translocation was blocked by the 
pretreatment of U73122, instead some STIM1 puncta in the cytosol (Fig. 4.10A). In 
cells pretreated with 10 µM CytD for 1 h to depolymerise F-actin filaments and then 
incubated with U73122 and TG, the TG-induced STIM1 subplasmalemmal 
translocation and puncta formation was restored (Fig. 4.10B-C), suggesting that the 
regulation of F-actin by U73122 is a novel mechanism for regulating SOC channels. 
In order to confirm the involvement of F-actin in the STIM1 translocation, calyculin 
A (CalyA), a serine/threonine phosphatase inhibitor that can disrupt the PM-ER 
junctions by increasing F-actin content, was also used (Lee et al., 2005b; Patterson 
et al., 1999). The STIM1-EYFP cells incubated with CalyA (10 nM) for 10 min 
showed no STIM1 subplasmalemmal translocation after TG treatment. Pretreatment 
with 10 µM CytD for 1 h abolished the effect of CalyA (Fig. 4.10B-C). Moreover, 
U73122 significantly reduced the SOCE, but had no effect on the amplitude of TG-
induced Ca
2+
 release (Fig. 4.10D). Pretreatment with CytD partially reversed the 
inhibitory effect of U73122, but the Ca
2+
 entry was still much less than that in cells 
challenged with TG alone (Fig. 4.10F). CalyA treatment did not affect TG-induced 
Ca
2+
 release, and showed an effect on Ca
2+
 entry similar to that of U73122 (Fig. 
4.10E-F). 
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Fig. 4.10 Increase of F-actin content blocked TG-induced STIM1 translocation 
toward the PM and inhibited store-operated Ca
2+
 entry in STIM1-EYFP cells. 
(A) U73122 (10 µM) increased the F-actin content marked as Lifeact-mCFP (blue) 
in the STIM1-EYFP cells cotransfected with Lifeact-mCFP. The TG-induced 
STIM1 clustering and subplasmalemmal translocation were prevented by U73122. 
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(B) Pretreatment with CytD abolished the effect of U73122 (10 µM) and CalyA (10 
nM) on STIM1 movement. (C) The number of TG-induced STIM1 clusters in the 
cytosol and the PM in the presence of U73122 (10 µM) or CalyA (10 nM), with or 
without CytD (10 µM) pretreatment (n = 10 cells in each group). (D) U73122 (10 
µM) inhibited TG-induced Ca
2+
 entry that was partially reversed by CytD 
pretreatment (n = 19-27 cells in each group). (E) CalyA (10 nM) inhibited TG-
induced Ca
2+
 entry and partially reversed by CytD (n = 21-25 cells in each group). 
(F) Mean ± SEM data show the comparison of TG-induced Ca
2+
 influx among the 
groups treated with U73122, CalyA and CytD (***P<0.001). 
 
4.3. Discussion 
4.3.1. ER Ca
2+
 store modulators and STIM1 translocation 
Since the discovery of STIM1 as an essential component of SOCs, the coupling 
mechanisms of STIM1 to the pore-units of SOCs in the PM have been described and 
the ER Ca
2+
 store depletion is an essential step for STIM1 movement, such as by the 
application of SERCA blockers TG and cyclopiazonic acid (Zhang et al., 2005; Liou 
et al., 2005), or through IP3R activation by many GPCR agonists including 
carbachol (Smyth et al., 2008) and ATP/UTP (Chvanov et al., 2008; Ross et al., 
2007). To further confirm the ER-dependent mechanism, I examined the ryanodine-
sensitive Ca
2+
 store in this study. The Ca
2+
 release induced by RyR agonists also 
evoke STIM1 subplasmalemmal translocation, suggesting that STIM1 translocation 
can be regulated by the cooperation of the intracellular Ca
2+
 release channel IP3Rs 
and RyRs. This finding could be an explanation of SOCs activated by RyR 
activators seen in some studies (Fellner and Arendshorst, 2000). In addition, I 
noticed the difference of the two RyR agonists, 4-CEP and caffeine, on cytosolic 
STIM1 clustering, Ca
2+
 release and Ca
2+
 influx. The concentration of 4-CEP used in 
this study is similar to the report on Ca
2+
 release (Islam et al., 1998). 4-CEP at this 
concentration may cause membrane depolarization (Westerblad et al., 1998), 
however, STIM1 movement is independent of extracellular Ca
2+
, which suggests the 
contribution of membrane depolarization-induced Ca
2+
 influx, mainly through 
voltage-gated Ca
2+
 channels, should be very little. RyR antagonist tetracaine can 
prevent the Ca
2+
 release and STIM1 subplasmalemmal translocation induced by 4-
CEP, but the cytosolic STIM1 clustering is still present, suggesting that the cytosolic 
STIM1 clustering is an ER Ca
2+
 store-independent mechanism.  
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4.3.2. Store-operated channel blockers and STIM1 movement 
The existence of ER Ca
2+
 store-independent mechanism for cytosolic STIM1 
clustering is also confirmed by the application of 2-APB. 2-APB at high 
concentrations inhibits IP3Rs and blocks the IP3-evoked ER Ca
2+
 release. Therefore 
the ER store should be regarded as non-depleted or filled. However, the STIM1 
clustering can be quickly (~10 s) induced by 2-APB and the STIM1 puncta are 
retained in the cytosol without subplasmalemmal translocation. 2-APB at high 
concentrations has been shown to inhibit SERCA (Bilmen et al., 2002), however I 
have not observed any Ca
2+
 release signal induced by 2-APB at 100 µM. In addition, 
the STIM1 translocation induced by SERCA blocker is a slow process with 1-2 min 
delay, however the cytosolic clusters induced by 2-APB induced is a fast process, 
which suggests that the effect of 2-APB on STIM1 clustering is unrelated to the 
SERCA inhibition. These findings further suggest that the 2-APB-induced STIM1 
clustering is an ER store-independent process. I also observed that 2-APB at lower 
concentrations (10 and 50 µM) prevented the TG-induced STIM1 subplasmalemmal 
translocation, which is consistent with the recent report (He et al., 2012). The 
detailed mechanism of cytosolic STIM1 clustering is still unclear, but it could be 
unrelated to the inhibition on Ca
2+
 influx, because other SOC blockers Gd
3+
, 
SKF96365 and DES without ER Ca
2+
 store releasing effect do not induce cytosolic 
STIM1 clustering. It is also unrelated to the coexpression of TRPC1 and ORAI 
channels, because the two associated proteins do not change the pattern of cytosolic 
STIM1 clustering, although the ORAI channel coexpression can stabilize the 
subplasmalemmal clusters of STIM1/ORAI complexes.  
4.3.3. Mitochondrial Ca
2+
 release and STIM1 clustering 
FFA is a fenamate anti-inflammatory drug with a mitochondrial Ca
2+
 release effect, 
but has less effect on ER Ca
2+
 release (Tu et al., 2009; Jiang et al., 2012). In this 
study I found that FFA induced cytosolic STIM1 clustering, but its analogue NFA 
without affecting mitochondrial Ca
2+
 release did not cause cytosolic STIM1 
clustering, further suggesting that the cytosolic STIM1 clustering is independent of 
ER store depletion, but the mitochondrial Ca
2+
 release could be related to cytosolic 
STIM1 clusters. To further confirm this, I tested the inhibitors of mitochondrial 
respiratory phosphorylation chain and metabolic pathways. FCCP, a mitochondrial 
uncoupler, causes STIM1 clustering in the cytosol, which could be due to the 
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mitochondrial Ca
2+
 release effect (Gurney et al., 2000), however, FCCP does not 
block the TG-induced the STIM1 translocation. Similarly, the TG-induced STIM1 
translocation cannot be prevented by oligomycin and antimycin A (Singaravelu et 
al., 2011). Sodium azide, H2O2 and Hg
2+
 are mitochondrial metabolic inhibitors, 
however, acute application of these agents have no significant effect on STIM1 
clustering and translocation, further suggesting that the agents only affecting 
mitochondrial Ca
2+
 release may change the intracellular STIM1 movement.  
4.3.4. Signalling pathways and STIM1 translocation 
The signalling pathway modulators of PTK and PI3K, PKC and ROCK pathways 
have been examined in this study and no significant effects on TG-induced STIM1 
movement are found, which is similar to the previous report (Smyth et al., 2008). I 
have not tested those inhibitors on the STIM1 puncta induced by GPCR activation, 
because unlike TG-induced STIM1 clustering and subplasmalemmal translocation, 
the STIM1 puncta or movement induced by GPCR activation is transient and 
difficult to be quantified precisely.  
4.3.5. Cytoskeleton and STIM1 movement 
The importance of PM-ER junctions in the activation of SOCs has been described 
(Carrasco and Meyer, 2011). The increase of F-actin content in the PM-ER 
junctional regions resulted in the inhibition of SOCE (Lee et al., 2005b; Patterson et 
al., 1999). Both CalyA and U73122 are PM-ER disruptors by condensation of F-
actin in the region. The inhibition of SOCE by U73122 and CalyA could be 
explained by the interruption of PM-ER junctions by the inhibition of STIM1 
subplasmalemmal translocation, which leads to the uncoupling of STIM1 with the 
SOCs in the PM. However, other mechanisms for U73122 and CalyA may also 
exist, because the restoration of STIM1 translocation by CytD only partially 
recovered their inhibition on the SOCE. Moreover, I also examined the involvement 
of cytoskeleton in the STIM1 movement. CytD significantly inhibits  SOCE in the 
STIM1-EYFP transfected cells, which is consistent to the observations in platelets 
(Harper and Sage, 2007), polymorphonuclear neutrophil (Itagaki et al., 2004), 
hepocytes (Wang et al., 2002), and vascular endothelial cells (Holda and Blatter, 
1997), but no or increasing effects were reported in A7r5 cells, glioma C6 cells and 
transfected HEK293 cells (Sabala et al., 2002; Galan et al., 2011; Patterson et al., 
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1999). I found that the TG-induced SOCE was inhibited by CytD in STIM1-EYFP 
cells; however, CytD had no effect on the TG-induced STIM1 movement. In this 
study, CytD at 10 μM was used, because a significant cell death occurred at the 
concentration of 100 μM, although this concentration was used in the A7r5 cells 
(Patterson et al., 1999). The rearrangement of microtubules in the regulation of 
SOCE has also been demonstrated by the application of colchicine (Hajkova et al., 
2010; Galan et al., 2011; Smyth et al., 2007), however, colchicine has no effect on 
TG-induced STIM1 movement. In addition, disruption of lipid rafts in the PM does 
not change the STIM1 movement (DeHaven et al., 2009). 
 
Fig. 4.11 Models for pharmacological regulation of STIM1 translocation and 
clustering. (A) STIM1 at resting state. (B) ER Ca
2+
 store-dependent STIM1 
clustering and translocation to the newly formed PM-ER junction and Ca
2+
 influx 
through ORAI channel, which are induced by ER Ca
2+
 store depletion by GPCR 
agonist, thapsigargin or caffeine. (C) ER Ca
2+
 store-independent STIM1 clustering 
in the cytosol. 2-APB inhibits ER Ca
2+ 
release through IP3R and induces cytosolic 
STIM1 clustering. FFA and 4-CEP release Ca
2+
 from mitochondrion and ER 
respectively, and cause the formation of cytosolic STIM1 clusters. (D) U73122 
blocks the activity of PLC, increases the cellular F-actin content and potentiates 
cytosolic STIM1 clustering in the presence of thapsigargin. Calyculin A also 
increases the F-actin content, prevents the formation of PM-ER junction and STIM1 
translocation toward the PM. 
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4.4. Conclusions 
In this study, it is confirmed that STIM1 translocation and clustering is regulated by 
ER Ca
2+
 store, and the extracellular Ca
2+
 level is not the determinant for this 
process. I found two patterns of STIM1 clustering in the cells that can be 
pharmacologically distinguished, i.e, subplasmalemmal clusters and cytosolic 
clusters. The subplasmalemmal clusters are mainly formed by STIM1 translocation 
after passive or active ER Ca
2+
 store depletion, whilst the cytosolic STIM1 
clustering is specific for some drug effects, such as 2-APB, FFA, 4-CEP, U73122 
and FCCP. The formation of cytosolic STIM1 clusters is independent of the ER 
Ca
2+
 store. In addition, increased content of F-actin in the PM-ER junctions by 
U73122 and CalyA blocks the STIM1 subplasmalemmal translocation. The 
proposed models for STIM1 movement are given in Fig. 4.11. The cytosolic STIM1 
clustering independent of ER Ca
2+
 store discovered in this study is a new 
mechanism for the pharmacology of some channel blockers, which could be a useful 
target for future drug development. 
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5.1. Introduction 
Ca
2+
 is a second messenger that regulates a wide variety of physiological functions 
in human body. The cytosolic Ca
2+
 level is tightly controlled by Ca
2+
-permeable 
channels residing in the plasma membrane and membranes of intracellular Ca
2+
 
stores. Apart from IP3 receptors (IP3Rs), ryanodine receptors (RyRs) are another 
major class of ER/SR Ca
2+
 release channels. The RyR family consists of three 
members, RyR1-3, which are differentially expressed in many cell types including 
both electrically excitable and non-excitable cells (Lanner et al., 2010). It has been 
demonstrated that activation of RyRs by ryanodine or repetitive depolarisation  
induced store-operated Ca
2+
 entry (SOCE) and Ca
2+ 
release-activated current (ICRAC) 
in smooth muscle and skeletal muscle cells, respectively (Fellner and Arendshorst, 
2000; Yarotskyy and Dirksen, 2012), suggesting the functional coupling between 
RyRs and store-operated channels (SOCs) in excitable cells.  
Chlorophenols and their derivatives are generally used as bactericides, fungicides or 
preservatives. Some of these compounds, including 4-chloro-3-ethylphenol (4-CEP) 
and 4-chloro-m-cresol (4-CmC) (Fig. 5.1), have been found to induce intracellular 
Ca
2+ 
release by stimulating the RyRs (DiJulio et al., 1997; Islam et al., 1998; 
Westerblad et al., 1998; Jacobson et al., 2006), whlist their analogue 4-chlorophenol 
(4-ClP) (Fig. 5.1) is ineffective in triggering Ca
2+
 release through RyRs (Jacobson et 
al., 2006). The activity of RyRs is considered particularly important in excitable 
cells such as cardiac and skeletal muscle cells. In these cells, Ca
2+
 entry through 
dihydropyridine receptor (Cav1.1, a voltage-gated L-type Ca
2+ 
channel), which 
results in the depolarization of membrane potential, and subsequent Ca
2+
 release 
from the sarcoplasmic reticulum (SR), are believed to be the triggering mechanism 
of muscle contraction. This process, referred as excitation–contraction (EC) 
coupling, essentially relies on the activity of RyRs (Endo, 2009). RyR1 is the 
primary isoform expressed in skeletal muscles (Zorzato et al., 1990; Lanner, 2012). 
The dysfunction of RyR1 has been associated with muscular or muscle-related 
diseases, such as central core disease (CCD) and malignant hyperthermia (MH). 
Patients affected by CCD or MH are mostly found to bear mutations in RyR1, which 
increase the sensitivity of the channel to anaesthetics and depolarizing muscle 
relaxants, such as halothane and succinylcholine (Robinson et al., 2006). When the 
patients are exposed to such agents in general anaesthesia, drastic SR Ca
2+
 release 
and hypermetabolic responses including very high body temperature, tachycardia, 
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rigid muscles and rhabdamyolysis will be induced, which could be fatal if not 
treated quickly (Stowell, 2008). 4-CEP and 4-CmC have been used to test human 
and animal samples for malignant hyperthermia in vitro (Gerbershagen et al., 2002; 
Gerbershagen et al., 2005; Herrmann-Frank et al., 1996; Baur et al., 2000). 4-CmC 
was shown to trigger malignant hyperthermia in susceptible swine but not normal 
animals (Iaizzo et al., 1999; Wappler et al., 1999). These studies suggest that both 4-
CEP and 4-CmC are useful tools in the diagnosis of malignant hyperthermia. 
In Chapter 4, I found that the RyR sensitiser caffeine evoked Ca
2+ 
release and SOCE 
in STIM1-overexpressing HEK293 cells. The RyR agonist 4-CEP also induced a 
robust Ca
2+ 
release, but the following Ca
2+ 
influx was completely abolished. This 
unexpected result implies that 4-CEP may be an inhibitor of SOCs, which is additive 
to its role as a RyR agonist. Indeed, as I have demonstrated in Chapter 4, 4-CEP 
triggers not only the formation of STIM1 puncta at the plasma membrane, but also 
cytosolic STIM1 clustering in the STIM1-overexpressing cells. In addition, it is also 
possible that 4-CEP may block Ca
2+
-permeable
 
channels in the plasma membrane 
directly. To address this question, I investigated the effects of 4-CEP on the 
activities of ORAI and TRPC channels, and compared the effects with the two 
analogues, 4-CmC and 4-ClP. 
 
 
Fig. 5.1 Chemical structures of 4-chloro-3-ethylphenol (4-CEP), 4-chloro-m-
cresol (4-CmC) and 4-chlorophenol (4-ClP). 
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5.2. Results 
5.2.1. Effects of 4-CEP, 4-CmC and 4-ClP on Ca
2+
 release and SOCE in 
STIM1/ORAI1-coexpressing HEK293 cells 
To characterise the functional contribution of RyRs in T-REx HEK293 cells 
overexpressing STIM1-EYFP and mCFP-ORAI1, 4-CEP (500 μM) was applied to 
the cells in Ca
2+
-free solution. A robust Ca
2+ 
release was observed immediately after 
the application of 4-CEP (Fig. 5.2A). In contrast, the cells exposed to 500 μM 4-
CmC or 500 μM 4-ClP did not show any Ca2+ release signals (Fig. 5.2A). The 
differential responses to 4-CEP and 4-CmC suggest that the dominant isoform of 
RyRs expressed in these cells is most probably RyR3, because RyR3 is substantially 
activated by 4-CEP but almost insensitive to 4-CmC (Venkatachalam et al., 2003; 
Hopkins, 2011). The effect on Ca
2+ 
influx was also examined. As shown in Fig. 
5.2A, Ca
2+
 influx in the 4-CEP-treated cells was nearly abolished after the addition 
of external Ca
2+
, which is similar to the observation in the STIM1-overexpressing 
cells (Chapter 4, Fig. 4.2C). In 4-CmC-treated cells the Ca
2+
 influx was much higher 
than that in the 4-CEP group, but lower than that in the cells treated with 4-ClP (Fig. 
5.2A and C). To further investigate the effect of 4-CEP, it was used together with 
thapsigargin (TG) to examine the Ca
2+
 release and SOCE in STIM1/ORAI1 cells. 
As expected, the application of 500 μM 4-CEP significantly increased the Ca2+ 
release signal, which was higher than the Ca
2+
 release evoked by 1 μM TG (Fig. 
5.2B-C). However, the subsequent Ca
2+
 influx was completely inhibited in the 4-
CEP/TG group (Fig. 5.2B-C). These results confirmed the role of 4-CEP as an 
inhibitor of SOCs. The inhibition of TG-induced SOCE by 4-CEP was found to be 
dose-dependent, with a 50% inhibitory concentration (IC50) of 203.6 μM (Fig. 
5.2D). In addition, 4-CmC and 4-ClP also showed dose-dependent inhibition on TG-
induced SOCE with the IC50 of 830.9 μM and 1437.1 µM, respectively (Fig. 5.4D). 
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Fig. 5.2 The effects of 4-CEP, 4-CmC and 4-ClP on the Ca
2+ 
release and store-
operated Ca
2+
 entry in STIM1/ORAI1-coexpressing HEK293 cells. (A) The 
effects of 4-CEP, 4-CmC and 4-ClP (500 µM) on the cytosolic Ca
2+
 levels of 
STIM1/ORAI1 cells. The cells were maintained in Ca
2+ 
free solution at first and 
then perfused with each drug in Ca
2+ 
free and 1.5 mM Ca
2+ 
solution as indicated by 
the arrows. (B) 4-CEP (500 µM) abolished TG (1 µM)-induced Ca
2+ 
influx in 
STIM1/ORAI1 cells. (C) Comparison of the maximum amplitudes of Ca
2+
 release 
and influx induced by 4-ClP, 4-CmC, 4-CEP and TG in STIM1/ORAI1 cells (n = 
18-26 cells in each group). (D) Dose-response curves of 4-CEP, 4-CmC and 4-ClP 
on the inhibition of store-operated Ca
2+
 entry in STIM1/ORAI1 cells (n = 17-29 
cells for each point). The cells were pretreated with 1 µM TG for 30 min and then 
cytosolic Ca
2+
 were measured using the protocol in (A). The IC50 of 4-CEP, 4-CmC 
and 4-ClP are 203.6, 830.9 and 1437.1 µM, respectively. 
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Fig. 5.3 4-CEP, but not 4-CmC and 4-ClP, induces STIM1 translocation in 
STIM1/ORAI1-3 cells. (A) Direct application of 500 µM 4-CEP induced persisted 
STIM1 puncta at the plasma membrane in STIM1-EYFP/mCFP-ORAI1-3 cells, 
whilst cytosolic clustering of STIM1 was not observed. The mCFP fluorescence was 
converted into red pseudocolour in the pictures. (B) The cells were successively 
challenged with 500 µM 4-ClP, 4-CmC and 4-CEP in 1.5 mM Ca
2+ 
solution. Only 4-
CEP induced STIM1 puncta at the plasma membrane. The STIM1 puncta are 
indicated by arrows. 
5.2.2. 4-CEP, but not 4-CmC and 4-ClP, induces STIM1 translocation in 
STIM1/ORAI cells 
In Chapter 4, I found 4-CEP induced STIM1 translocation to the plasma membrane 
at first, and then the formation of cytosolic STIM1 clusters in cells overexpressing 
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STIM1-EYFP alone. However, there was difference for such phenomenon in the 
STIM1/ORAI-coexpressing cells. The initial phase of STIM1 puncta formation at 
the plasma membrane was reproducible in the STIM1-EYFP/mCFP-ORAI1 cells 
after the exposure to 500 µM 4-CEP in Ca
2+
 solution. However, these puncta did not 
disappear, and there were almost no STIM1 clusters in the cytosol (Fig. 5.3A). A 
similar phenomenon was observed in STIM1-EYFP/mCFP-ORAI2 and STIM1-
EYFP/mCFP-ORAI3 cells (Fig. 5.3A). These results suggest that the STIM1/ORAI 
complex is more stable than STIM1 oligomers, which is in consistent with the 
conclusion from the 2-APB experiments in Chapter 4. Furthermore, the persistence 
of STIM1/ORAI complexes implies that the STIM1 proteins may still be active to 
open ORAI channels, and the inhibition of SOCE by 4-CEP could be a direct action 
on ORAI channels. The effect of 4-CmC and 4-ClP was also tested in 
STIM1/ORAI1-3 cells. 4-ClP and 4-CmC at 500 µM failed to induce STIM1 
translocation in all the three cell lines, whereas the subsequent perfusion of 500 µM 
4-CEP clearly potentiated the formation of STIM1 puncta at the plasma membrane 
(Fig. 5.3B). These results are in accordance with the different abilities of these three 
drugs in triggering Ca
2+ 
release from internal stores. 
5.2.3. Inhibition of ORAI channels by 4-CEP, 4-CmC and 4-ClP 
In STIM1/ORAI1-coexpressing cells, extracellular application of 1 µM TG elicited 
a store-operated current exhibiting distinct properties at different time points (Fig. 
5.4A). A typical TRPC-like “N-shape” I-V curve was gradually developed after the 
addition of TG, and then both the inward and outward currents decreased to a 
medium level, showing a transitional type of I-V curve between the “N-shape” and 
the inward-rectifying shape. The currents kept decreasing and an ICRAC-like inward-
rectifying I-V curve was observed ~3 min after the occurrence of “N-shape” I-V 
curve. The dynamic changing of I-V curves was also observed in STIM1/ORAI1-3 
cells with Ca
2+ 
stores depleted by 1 µM TG in the internal solution, as shown by 
representative I-V curves with variable shapes in Fig. 5.4B-J. The store-operated 
currents induced in these cells were substantially inhibited by 500 µM 4-CEP in the 
bath solution without regard to the types of I-V curves (Fig. 5.4B-D). The currents 
were also inhibited by 500 µM 4-CmC and 4-ClP, and the residual currents could 
still be inhibited by 500 µM 4-CEP (Fig. 5.4E-J).  
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Fig. 5.4 4-CEP, 4-CmC and 4-ClP inhibited whole-cell currents evoked by TG 
or 2-APB in STIM1/ORAI1-3 cells. (A) The time course of TG (1 µM)-induced 
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currents measured at +80 and -80 mV in STIM1/ORAI1 cells. The I-V relationships 
at different time points are inset. (B-D) 4-CEP (500 µM) inhibited whole-cell 
currents evoked by TG (1 µM in pipette solution) in STIM1/ORAI1-3 cells. (E-J) 4-
CmC and 4-ClP (500 µM) reduced TG-induced currents in STIM1/ORAI1-3 cells, 
which were further inhibited by 500 µM 4-CEP. (K) 4-ClP, 4-CmC and 4-CEP (500 
µM) attenuated 2-APB (50 µM)-evoked currents in ORAI3 cells. (L) Percentages of 
inhibition on the whole-cell currents measured at +80 and -80 mV in 
STIM1/ORAI1-3 (with TG) and ORAI3 (with 2-APB) cells by 4-ClP, 4-CmC and 4-
CEP (n = 5-10 in each group). 
 
As TG failed to induce pure ICRAC in STIM1/ORAI-coexpressing cells, I turned to 
use cells overexpressing ORAI3 alone to test whether the pure ORAI3 current could 
be inhibited by the three drugs. As shown in Fig. 5.4K, 2-APB (50 µM) potentiated 
a large outward current and a relatively small inward current in ORAI3 cells, which 
is independent of STIM1 and Ca
2+ 
store depletion. The currents were then inhibited 
by 500 µM 4-ClP, 4-CmC and 4-CEP successively. These results suggested that 
both the TG-induced store-operated currents and 2-APB-activated ORAI3 currents 
were inhibited by the three drugs with potencies in the order of 4-CEP > 4-CmC > 4-
ClP (Fig. 5.4L). 
5.2.4. Inhibition of TRPC channels by 4-CEP, 4-CmC and 4-ClP  
The effects of 4-CEP, 4-CmC and 4-ClP were further investigated in cells 
overexpressing TRPC4, TRPC5, TRPC3 or TRPC6 channels. Gd
3+
 (100 µM) was 
used to potentiate the whole-cell currents in TRPC4 and TRPC5 cells, which 
exhibited a typical “N-shape” I-V curve. The TRPC4 and TRPC5 currents were 
suppressed by 500 µM 4-ClP, 4-CmC and 4-CEP, among which 4-CEP was most 
effective and completely blocked the currents (Fig. 5.5A-B). The whole-cell currents 
in TRPC3 and TRPC6 cells were activated by trypsin (0.5 µM) via the G protein-
coupled receptor PAR2 (proteinase-activated receptor 2) and phospholipase C 
pathway. The PKC inhibitor chelerythrine (10 µM) was added into the pipette 
solution to antagonise the PKC-induced decaying of TRPC3 and TRPC6 currents. 
Both the TRPC3 and TRPC6 currents were successively inhibited by 500 µM 4-ClP, 
4-CmC and 4-CEP (Fig. 5.5C-D). These results suggest that these compounds are a 
new class of TRPC inhibitors with the potencies ranked as 4-CEP > 4-CmC > 4-ClP 
(Fig. 5.5E). 
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Fig. 5.5 4-ClP, 4-CmC and 4-CEP inhibited TRPC channels. (A-B) 4-ClP, 4-
CmC and 4-CEP (500 µM) inhibited whole-cell currents potentiated by 100 µM 
Gd
3+
 in TRPC4 and TRPC5 cells. The time courses for currents measured at +80 
and -80 mV are shown, and the I-V curves are inset. (C-D) 4-ClP, 4-CmC and 4-CEP 
(500 µM) inhibited whole-cell currents triggered by trypsin (0.5 µM) in TRPC3 and 
TRPC6 cells. The PKC inhibitor chelerythrine (10 µM) was added in the pipette 
solution to prevent the inhibition of TRPC3 and TRPC6 by PKC activation. (E) 
Percentages of inhibition on the whole-cell currents measured at +80 and -80 mV in 
TRPC4/5 (with Gd
3+
) and TRPC3/6 (with trypsin) cells by 4-ClP, 4-CmC and 4-
CEP (n = 5-7 in each group). 
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Fig. 5.6 Dose-dependent and reversible inhibition of ORAI3 and TRPC 
channels by 4-CEP. (A) Dose-response curves of 4-CEP on the inhibition of 
ORAI3, TRPC4 and TRPC6 channels (n = 4-10 for each point). The whole-cell 
currents measured at +80 mV were used for fitting with logistic model. The IC50 for 
ORAI3, TRPC4 and TRPC6 are 71.0, 85.6 and 108.4 µM, respectively. (B-F) The 
inhibitory effects of 500 µM 4-CEP on ORAI3 and TRPC4/5/3/6 channels were 
quickly reversed after 4-CEP was removed from the external solution.  
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5.2.5. Concentration-dependent and reversible inhibition of ORAI3 and 
TRPC channels by 4-CEP 
4-CEP is the most potent blocker for ORAI and TRPC channels among the three 
compounds as shown above (Section 5.2.3 and 5.2.4) by comparing the effect at a 
single concentration (500 µM). To further determine the effect of 4-CEP, the  dose-
response experiments were conducted in ORAI3, TRPC4 and TRPC6 cells 
challenged by 50 µM 2-APB, 100 µM Gd
3+
 and 0.5 µM trypsin, respectively.  
Within the range of 0.1-1000 µM, the inhibition of these channels by 4-CEP is 
concentration-dependent, and the IC50 for ORAI3, TRPC4 and TRPC6 were found 
to be 71.0, 85.6 and 108.4 µM, respectively (Fig. 5.6A). The reversibility of 4-CEP 
inhibition was also examined. The inhibition of ORAI3 current in the presence of 50 
µM 2-APB was gradually reversed after 4-CEP was removed (Fig. 5.6B). The 
TRPC4 and TRPC5 currents were fully restored after both the activator Gd
3+
 and 
inhibitor 4-CEP were washed away (Fig. 5.6C-D). Similarly, the whole-cell currents 
in TRPC3 and TRPC6 cells recovered quickly after the removal of trypsin and 4-
CEP from the bath solution (Fig. 5.6E-F). 
5.2.6. Extracellular effects of 4-CEP on ORAI3 and TRPC4 channels 
The action side of 4-CEP on ORAI3 and TRPC4 channels was examined by two 
strategies. Firstly, the outside-out patch-clamp recordings was used and the 
characteristic ORAI3 and TRPC4 currents evoked by 50 µM 2-APB or 100 µM 
Gd
3+
 were inhibited by  500 µM 4-CEP in the external solution (Fig. 5.7A-B). 
Secondly, the intracellular application of 500 µM 4-CEP in the pipette solution 
failed to block the activation of ORAI3 by 50 µM 2-APB and TRPC4 currents by  
100 µM Gd
3+
 in whole-cell configuration, whereas the subsequent addition of 500 
µM 4-CEP into the extracellular solution rapidly abolished the currents (Fig. 5.7C-
D). These results demonstrated that 4-CEP inhibited ORAI3 and TRPC4 activities 
from the extracellular side of the channels. 
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Fig. 5.7 4-CEP inhibits ORAI3 and TRPC4 channels from the cell surface. (A-
B) 4-CEP (500 µM) inhibited ORAI3 and TRPC4 currents in outside-out patch 
configuration. The time courses for currents measured at +80 and -80 mV are 
shown, and the I-V curves are inset. (C-D) Intracellular application of 500 µM 4-
CEP did not block the activation of ORAI3 and TRPC4 channels by 2-APB and 
Gd
3+
, respectively. 
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5.3. Discussion 
5.3.1. Structure determinants of 4-CEP analogues for the inhibition of 
ORAI and TRPC channels 
In this chapter I found that the RyR agonist 4-CEP is a non-selective blocker of 
ORAI1/2/3 and TRPC3/4/5/6 channels. The inhibition of these channels, together 
with the cytoslic clustering of STIM1, lead to the abolishment of SOCE by this 
compound, despite the fact that it initially induces Ca
2+
 release from the ER store 
and STIM1 translocation toward the plasma membrane. The action of inhibition is 
independent of the Ca
2+
 release from RyRs because the other two analogues, 4-CmC 
and 4-ClP, also inhibit ORAI and TRPC channels, whilst they are unable to induce 
Ca
2+
 release in the HEK293 cells used in this study. The potency of the three 
compounds for channel inhibition is positively correlated with the length of the 3-
alkyl group, i.e. 4-CEP (with an ethyl group) is the more effective than 4-CmC (with 
a methyl group) and 4-ClP (no side chain at 3’ position). Nonetheless, the potency of 
4-CEP (IC50 within 70-200 µM) is still much lower than that of other non-selective 
store-operated channel blockers, such as 2-APB (IC50 within 3-20 µM) (Xu et al., 
2005a; McGahon et al., 2012) and SKF-96365 (IC50 within 1-3 µM) (Liu et al., 
2011; McGahon et al., 2012). Elongation of the 3-alkyl chain of 4-CEP may produce 
analogues with higher potency, however this is not investigated in this study due to 
the availability of the compounds. The length of the alkyl side chain of chlorophenol 
derivatives is also associated with their potency on activating RyR1 (Beeler and 
Gable, 1993). Therefore, new compounds with longer alkyl chains may not only 
have increased potency on store-operated channel inhibition, but also strongly 
interfere with the ER/SR Ca
2+
 stores.  
5.3.2. Action sites of 4-CEP on ORAI and TRPC channels 
It has been widely acknowledged that 4-CEP and 4-CmC stimulate intracellular Ca
2+ 
release by directly activating RyRs in intact cells. This suggests that these two 
compounds are highly membrane-permeable and thus may affect ion channels at the 
plasma membrane from the intracellular side. To test this hypothesis, I included 4-
CEP in the pipette solution and performed whole-cell patch-clamp recordings on 
ORAI3 and TRPC4 channels. The results showed that intracellular application of 4-
CEP do not inhibit the channels, suggesting that the action sites of 4-CEP should be 
located at the cell surface. Outside-out recordings confirmed the extracellular action 
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of 4-CEP on ORAI3 and TRPC4 channels. In another aspect, the 4-CEP-inhibited 
ORAI3 and TRPC currents were quickly restored when 4-CEP was removed from 
the bath solution, and the most reasonable explanation for this phenomenon is that 
the binding between 4-CEP and the channel proteins occurs at the cell surface and is 
easy to be disassociated. In addition to ORAI and TRPC channels, 4-CEP analogues 
also inhibit voltage-gated Na
+
 channels (Haeseler et al., 1999; Haeseler et al., 2001). 
As these three types of ion channels have distinct structures and regulatory 
mechanisms, the action sites of 4-CEP on these channels are most likely located 
close to the outer pore-forming regions, where the channel activities can be directly 
modulated. Detailed work such as drug-amino acid binding assay and site-directed 
mutagenesis of ion channels will clarify the exact target positions of 4-CEP on these 
channels.   
5.3.3. Implication for the use of 4-CEP and 4-CmC in diagnosis of 
malignant hyperthermia  
SOCE has been shown to occur in skeletal muscle cells (Kurebayashi and Ogawa, 
2001; Dirksen, 2009; Launikonis et al., 2010) and proposed to contribute to the 
sustainment of hypermetabolic reactions in malignant hyperthermia (Duke et al., 
2010; Hopkins, 2011). SOCE is coupled to SR Ca
2+
 release in both normal and 
malignant hyperthermia-susceptible skeletal muscles (Launikonis et al., 2003; 
Lyfenko and Dirksen, 2008; Duke et al., 2010). High levels of STIM1 and ORAI1 
have been detected in skeletal muscles and proved to be crucial for the SOCE after 
depletion of the SR Ca
2+
 store (Stiber et al., 2008; Vig et al., 2008; Stiber and 
Rosenberg, 2011). In addition, skeletal muscles also express multiple TRPC 
channels, including TRPC1/3/4/6 (Vandebrouck et al., 2002; Brinkmeier, 2011; 
Gailly, 2012). The expression of these channels suggests that the regulation of 
myoplasmic Ca
2+ 
may be more complicated than that in the classical model of 
muscle contraction. Although 4-CEP and 4-CmC have been found very useful in 
triggering Ca
2+ 
release and promising for the diagnosis of malignant hyperthermia, it 
should be taken into consideration that these chemicals also affect the myoplasmic 
Ca
2+ 
level by inhibiting SOCE, especially at concentrations over 100 µM. It has been 
shown that 4-CEP at 75 µM clearly distinguishes between the MH susceptible and 
nonsusceptible human skeletal muscle samples in the in vitro muscle contracture 
tests, however 4-CEP at 100 and 200 µM were not diagnostically useful due to the 
overlapped results from two groups (Gerbershagen et al., 2005). This can be 
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attributed to the maximum activation of both wildtype and mutant RyR1 channels in 
response to 4-CEP over 100 µM, and the inhibition of SOCE may further diminish 
the difference between two groups.  
 
5.4. Conclusions 
In this chapter I discovered that the RyR agonists 4-CEP and 4-CmC, as well as their 
analogue 4-ClP, are non-selective inhibitors of ORAI1/2/3 and TRPC3/4/5/6 
channels. The potencies of inhibition are ranked as 4-CEP > 4-CmC > 4-ClP for all 
channels. These findings provided a new insight for the pharmacological mechanism 
of these compounds.  
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6.1. Introduction 
Metal ions are important factors or cofactors in cellular physiology (Mathie et al., 
2006). Among them, copper is a redox-active element and participates in many 
important cellular functions by binding to a variety of proteins such as 
ceruloplasmin, cytochrome c oxidase and superoxide dismutase (Jomova et al., 
2010). Both deficiency and elevated level of copper can induce oxidative stress that 
leads to cell or tissue damage (Uriu-Adams and Keen, 2005). Copper deficiency is 
seen in infants with Menkes’ disease that is caused by genetic mutations in the 
copper transporter ATP7A (Chelly et al., 1993) and in patients with gastrointestinal 
surgery, such as gastric bypass surgery (Shahidzadeh and Sridhar, 2008). In contrast, 
patients showing excessive copper accumulation in the body are due to exposure to 
excess copper in drinking water or other environmental sources (Brewer, 2009), or a 
genetic disorder with copper accumulation in the liver and the basal ganglia of the 
brain (Wilson’s disease), which is caused by mutations in ATP7B, a transporter 
responsible for exporting copper out of the cells (Tanzi et al., 1993). Moreover, the 
elevated copper level has also been reported in the plasma of diabetic patients 
(Walter et al., 1991) and in the brain of patients with neurodegenerative disorders 
(Lovell et al., 1998). It is unclear that the increased blood copper concentration is 
just a consequence of diabetes or the cause of dysfunction of insulin signaling and 
glucose homeostasis, however, treatment with a Cu
2+
 chelator to reverse diabetic 
copper overload seems effective in preventing diabetic organ damage (Cooper, 
2011). With regard to neurological disorders, copper has been implicated in the 
pathogenesis of many neurodegenerative disorders including Alzheimer’s disease, 
amyotrophic lateral sclerosis, Huntington’s disease, Parkinson’s disease, and prion 
disease (Desai and Kaler, 2008; Squitti, 2012). Excess copper can initiate or 
stimulate the progression of Alzheimer’s disease by promoting the aggregation of 
amyloid-β peptides to form senile plaques in the brain (Meloni et al., 2008; Tougu et 
al., 2011) or by oxidative stress-driven cell death (Jomova et al., 2010). 
Nevertheless, the effect of copper in Alzheimer’s disease is still in much debate. The 
protective effect of copper against the formation of beta-sheet, the toxic secondary 
structure of amyloid-β, has also been demonstrated (Lin et al., 2010; House et al., 
2009). These complex results could be due to the imbalance of copper in the 
affected region, rather than a bulk copper accumulation or deficiency (Faller, 2012; 
James et al., 2012). The regulation of copper homeostasis and its 
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(patho)physiological consequences are not fully understood. In addition to its role in 
regulating oxidative stress,  it is important to identify new functions of copper to 
further understand the pathogenesis of copper-related disorders.  
Transient receptor potential (TRP) channels are a large family of cationic channels 
with a total of 27 members in mammalian genome. It has been found that the heat-
sensitive channels TRPA1 and TRPV1, which belong to the ankyrin and vanilloid 
subfamily of TRP channels respectively, are activated by micromolar or millimolar 
Cu
2+
 (Gu and Lin, 2010; Riera et al., 2007). To date there are no reports about the 
effect of Cu
2+ 
on other TRP channels. The canonical subfamily of TRP channels are 
widely expressed Ca
2+
-permeable channels consisting of seven members (TRPC1-
7), among which TRPC2 is a pseudogene in human genome (Vannier et al., 1999). 
TRPC channels can be activated by physiological stimulations such as G protein-
coupled receptor (GPCR) signalling and depletion of intracellular Ca
2+ 
stores, thus 
being involved in a variety of cellular and physiological functions. TRPC channels 
are also suggested to play important roles in copper-related diseases such as diabetes 
and neurological disorders. TRPC channels have been found to be associated with 
the development of diabetic complications including diabetic nephropathy, 
vasculopathy and neuropathy (Graham et al., 2012). In neurodegenerative diseases, 
such as Parkinson’s and Alzheimer’s diseases, TRPC channels may contribute to the 
disturbance of cellular Ca
2+
 homeostasis in affected regions of the brain (Selvaraj et 
al., 2010). As an important pathological factor in these diseases, oxidative stress has 
been shown to regulate the activity of TRPC channels. TRPC3, TRPC4 and TRPC6 
are sensitive to reactive oxygen species (ROS) or H2O2 (Poteser et al., 2006; Graham 
et al., 2010; Cioffi, 2011). TRPC5 and TRPC1/5 heteromeric channels are activated 
by reduced thioredoxin, an endogenous redox protein (Xu et al., 2008a). 
Considering the property of copper as a redox-active element in the body, it is likely 
that copper also participates in the regulation of TRPC channels in a direct or 
indirectly way.  
TRPM2 is a member of the melastatin subfamily of TRP channels. It was previously 
known as TRPC7 or LTRPC2 with abundant expression in the brain (Nagamine et 
al., 1998; Perraud et al., 2001). Later studies showed that TRPM2 is a ubiquitously 
expressed channel found in many tissues including bone marrow, spleen, heart, 
liver, lung, pancreatic islets and immunocytes (Sumoza-Toledo and Penner, 2011). 
Several important physiological functions of TRPM2 channel have been 
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demonstrated using knockout animals or in vitro models including insulin release 
(Togashi et al., 2006; Uchida et al., 2011), cytokines and ROS production (Di et al., 
2011), cell motility and cell death (Hara et al., 2002), and immune response 
(Knowles et al., 2011). The genetic variants of TRPM2 have been linked to the 
pathogenesis of several neurological diseases like bipolar disorder (Xu et al., 
2009a), western pacific amyotrophic lateral sclerosis and parkinsonism-dementia 
(Hermosura et al., 2008), and the regulation of amyloid beta-peptide (Aβ)-induced 
striatal cell death that involves in the Alzheimer's disease (Fonfria et al., 2005). In 
addition, a number of endogenous modulators for TRPM2 channel have been 
identified, among which the most efficient direct channel activator is adenosine 
diphosphate ribose (ADPR). Free ADPR opens TRPM2 channels by binding to the 
Nudix-like motif in the C-terminus, and evokes a current with linear current-voltage 
(I-V) relationship (Perraud et al., 2001; Sano et al., 2001). The activation of TRPM2 
channel by ADPR is dependent on the intracellular Ca
2+
 concentration (McHugh et 
al., 2003) and negatively regulated by adenosine monophosphate (AMP) (Kolisek et 
al., 2005) and acidic pH (Du et al., 2009; Starkus et al., 2010). H2O2 is another 
activator for TRPM2 channel, although the mechanism of H2O2-induced TRPM2 
activation is still unclear (Sumoza-Toledo and Penner, 2011). Therefore, TRPM2 is 
a ROS-sensitive Ca
2+
-permeable channel, which may play important roles in the 
oxidative stress-related diseases.  
Given the evidences that TRPCs and TRPM2 are redox-sensitive channels and their 
association with neurodegenerative disorders and diabetes which are oxidative 
stress-related diseases, it is intriguing to suppose that the activity of TRPC and 
TRPM2 channels could be modulated by certain pathological factors related to these 
diseases, such as Cu
2+
 that plays an important role in regulating oxidative status in a 
cell. In this chapter, I investigated the effects of Cu
2+
 on TRPC3/4/5/6 and TRPM2 
channels overexpressed in T-REx HEK293 cells by electrophysiological approaches.  
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6.2. Results 
6.2.1. Cu
2+
 is a potent activator of TRPC channels 
In TRPC4-overexpressing T-REx HEK293 cells, the whole-cell currents were 
inhibited immediately after the perfusion of 10 µM Cu
2+ 
in bath solution, and then 
gradually potentiated to very large amplitude in 5 min, with the typical “N-shape” I-
V curve (Fig. 6.1A). However, the whole-cell currents in the control cells, i.e. 
TRPC4 cells without tetracycline induction, were relatively small and the current 
amplitude was slightly increased after perfusion with 10 µM Cu
2+ 
for 5 min (Fig. 
6.1B). This suggests that the Cu
2+
-evoked current is due to the activation of 
overexpressed TRPC4 channel, not the activity of endogenous ion channels. As in 
TRPC4-overexpressing cells, 10 µM Cu
2+ 
also initially inhibited and then robustly 
stimulated both the inward and outward whole-cell currents of TRPC5, TRPC3 or 
TRPC6-overexpressing cells (Fig. 6.1C and Fig. 6.2). The I-V curves of these 
currents all exhibited a characteristic “N-shape”, suggesting these exogenously 
expressed channels are responsible for the effect of Cu
2+
. 
6.2.2. Cu
2+
 activates TRPC4 channel in a dose-dependent manner 
The effective range of Cu
2+ 
on activation of TRPC4 channel was determined to be as 
low as to 1 µM (Fig. 6.3A). The potentiation of the whole-cell TRPC4 currents by 1 
µM and 5 µM Cu
2+ 
was very slow, whereas 10 µM and higher concentrations of 
Cu
2+ 
showed a relatively fast effect (Fig. 6.3A-D). There are no significant 
differences among the amplitudes of currents measured at 2 min after application of 
Cu
2+ 
at 10, 50, 100 and 500 µM. In contrast the currents evoked by 1 and 5 µM Cu
2+ 
at the same time point were very small (Fig. 6.3E). 
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Fig. 6.1 Activation of TRPC4 and TRPC5 channels by Cu
2+
. (A) The effect of 
extracellular Cu
2+
 (10 µM) on the whole-cell currents of T-REx HEK293 cells 
overexpressing EYFP-TRPC4. The currents measured at +80 and -80 mV were 
initially inhibited and then strongly potentiated by Cu
2+
. The I-V curves before and 
after the application of Cu
2+ 
are shown on the right. (B) Extracellular Cu
2+
 (10 µM) 
showed very little stimulation on the endogenous currents of control cells, where the 
expression of TRPC4 was not induced. The corresponding I-V curves are shown on 
the right. (C) In TRPC5-overexpressing T-REx HEK293 cells, extracellular Cu
2+
 (10 
µM) had a similar effect on the whole-cell currents as in TRPC4 cells. The I-V 
curves before and after Cu
2+ 
activation are shown on the right. 
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Fig. 6.2 Activation of TRPC3 and TRPC6 channels by Cu
2+
. Extracellular Cu
2+
 
(10 µM) initially inhibited and then strongly activated the whole-cell currents of T-
REx HEK293 cells overexpressing mCherry-TRPC3 (A) or mCFP-TRPC6 (B). The 
time-courses of currents measured at +80 and -80 mV are shown on the left. The I-V 
curves before and after the application of Cu
2+ 
are shown on the right.  
6.2.3. Cu
2+
 activates TRPC4 channel from the cell surface 
Due to the expression of Cu
2+
 transporters across the plasma membrane and 
intracellular membranes, and the variable Cu
2+ 
concentrations in the extracellular 
cleft and cytoplasm (Mathie et al., 2006), it is important to determine the action site 
of Cu
2+
 on TRPC channels. Outside-out patch recording was employed to examine 
which cellular side of TRPC4 is targeted by Cu
2+
. Similar to the whole-cell currents, 
the membrane currents in outside-out configuration were suppressed by 10 µM Cu
2+
 
in the external solution at first, and then gradually increased (Fig. 6.4A). This 
extracellular effect was then confirmed by whole-cell recordings with 20 µM Cu
2+
 in 
the internal solution. The intracellular application of Cu
2+ 
did not significantly 
change the whole-cell currents, whereas subsequent perfusion of extracellular Cu
2+
 
(10 µM) dramatically augmented the TRPC4 currents (Fig. 6.4B). 
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Fig. 6.3 Dose-dependent activation of TRPC4 channels by Cu
2+
. (A-D) The 
effects of extracellular Cu
2+
 (1-500 µM) on the whole-cell currents of T-REx 
HEK293 cells overexpressing EYFP-TRPC4. The corresponding I-V curves are 
shown below the time-course plots (A-C) or on the right (D). (E) Comparison of the 
amplitudes of TRPC4 currents after exposure to different concentrations of Cu
2+
 for 
120 s (n=4-6 in each group). The currents were measured at +80 and -80 mV, and 
each of these currents was normalised to the maximum current recorded in the same 
cell.   
6.2.4. Amino acid residues of TRPC4 related to Cu
2+
 activation 
To determine the molecular targets of Cu
2+ 
within TRPC4 channel, three TRPC4 
mutants with altered amino acids in the pore-forming region between the fifth and 
sixth transmembrane segments were generated by PCR mutagenesis from the 
pcDNA4/TO-EYFP-TRPC4α vector. Three negatively charged glutamic acid 
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Fig. 6.4 Cu
2+ 
activates TRPC4 channels from the extracellular side. (A) Cu
2+
 (10 
µM) in external solution facilitated TRPC4 currents measured at +80 and -80 mV in 
outside-out configuration. The corresponding I-V curves are shown on the right. (B) 
Intracellular application of 20 µM Cu
2+
 did not potentiate the whole-cell currents in 
TRPC4 cells, whereas the later perfusion of 10 µM Cu
2+
 in the extracellular solution 
substantially augmented the currents. The I-V curves before and after the perfusion 
of external Cu
2+ 
are shown on the right. 
 
residues at the positions 542, 543 and 555 were changed into neutral glutamine 
residues to generate the mutants E542Q/E543Q and E555Q. The cysteine residue at 
position 554, which potentially forms a disulfide bridge with another cysteine 
residue at 549, was changed into neutral tryptophan residue to produce the mutant 
C554W. The E542Q/E543Q and E555Q mutants were mainly localised at the 
plasma membrane, which is similar to that of wildtype TRPC4 (Fig. 6.5A, E and G). 
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The C554W mutant showed many intracellular aggregations (Fig. 6.5C), suggesting 
the disruption of the disulfide bridge may cause misfolding of TRPC4 proteins, 
which are then transported into lysosomes and degraded. The electrophysiological 
properties also showed differences among the mutants. Cu
2+
 (10 µM) slightly 
increased the whole-cell current in the cells expressing  E542Q/E543Q mutant by 
comparing with the maximum current evoked by  0.5 µM trypsin in the same cell 
(Fig. 6.5B). A similar phenomenon was observed for the C554W mutant (Fig. 6.5D). 
However, the Cu
2+
-induced current was much bigger in cells expressing the E555Q 
mutant, and nearly achieved the maximum activation as trypsin (Fig. 6.5F and H). 
These results suggest that the glutamic acid residues at positions 542 and 543, and 
the cysteine residue at 554 are related to the TRPC4 channel activation by Cu
2+
, 
whereas the receptor-operated channel opening is not affected by these mutations. 
6.2.5. Cu
2+
 is a potent inhibitor of TRPM2 channel 
TRP subfamilies may have different sensitivity to metal ions, such as lanthanides for 
TRPC5 and TRPM2 (Xu et al., 2005a); therefore, I examined the effect of Cu
2+
 on 
TRPM2 channel. Unlike TRPC channels, direct application of Cu
2+
 failed to 
potentiate the whole-cell current in TRPM2 cells (data not shown). To test potential 
inhibitory effect of Cu
2+
 on TRPM2, the intracellular activator ADPR (500 µM) was 
included in the pipette solution.  The whole-cell currents with a typical linear I-V 
curve were quickly evoked by ADPR in the tetracycline-induced TRPM2 cells 
(Tet+) and achieved maximum within 1 min after membrane breakthrough (Fig. 
6.6A), which is consistent with previous reports (Perraud et al., 2001; McHugh et 
al., 2003; Xu et al., 2008b). Perfusion with 10 µM Cu
2+
 abolished the TRPM2 
current (Fig. 6.6A and C). The inhibitory effect of Cu
2+ 
seemed to be irreversible on 
washout, which suggests that Cu
2+
 may form covalent bonds with the channel 
protein. In the control cells without tetracycline induction (Tet-), the whole-cell 
currents evoked by ADPR were very small, and also inhibited by 10 µM Cu
2+
 (Fig. 
6.6B-C), suggesting that there is an endogenous current sensitive to Cu
2+
 in the 
native cells. The inhibition of Cu
2+
 on TRPM2 was concentration-dependent with an 
IC50 of 2.59 ± 0.66 µM and a slope factor of 1.50 ± 0.35 (Fig. 6.6D).  
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Fig. 6.5 Distinct properties of TRPC4 mutants in response to Cu
2+
. (A, C, E and 
G) Subcellular localisation of mutant and wildtype TRPC4 proteins tagged with 
EYFP in T-REx HEK293 cells. (B, D and F) The effects of extracellular Cu
2+
 (10 
µM) and trypsin (0.5 µM) on the whole-cell currents of T-REx HEK293 cells 
overexpressing TRPC4 mutants. The corresponding I-V curves are shown on the 
right. (H) Comparison of the amplitudes of whole-cell currents evoked by 10 µM 
Cu
2+
 in cells overexpressing wildtype and mutant TRPC4 (n=4-6 in each group). 
The currents were measured at +80 and -80 mV, and each of these currents was 
normalised to the maximum current after trypsin stimulation in the same cell. (*** 
P<0.001)  
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Fig. 6.6 Effects of Cu
2+
 on the whole-cell currents of TRPM2-overexpressing 
HEK293 cells. (A) The time course of the currents measured at +80 and -80 mV. 
Cu
2+
 (10 µM) inhibited the whole-cell TRPM2 currents evoked by 500 µM ADPR in 
the pipette solution. The arrow indicates the time point when the whole-cell 
configuration was formed. (B) Representative I-V curves before and after perfusion 
of Cu
2+
 in (A). (C) Cu
2+
 (10 µM) inhibited the endogenous currents in the cell 
without tetracycline induction. (D) Representative I-V curves before and after 
perfusion of Cu
2+
 in (C). (E) Mean ± SEM for the inhibition of Cu
2+
 on the currents 
of Tet-induced and non-induced cells. (n=4-10 in each group, *P<0.05, 
***P<0.001) (F) Dose-response curve for TRPM2 inhibition by Cu
2+
 (n=7-13 for 
each concentration). 
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6.2.6. Extracellular effect of Cu
2+
 on TRPM2 channel 
To determine the action side of Cu
2+ 
on TRPM2 channel, higher concentration (20 
µM) of Cu
2+
 was added into the pipette solution to see whether the activation of 
TRPM2 current can be prevented. I found that intracellular application of Cu
2+
 failed 
to prevent the TRPM2 current induced by ADPR, but the subsequent perfusion of 10 
µM Cu
2+
 in the bath solution abolished the current (Fig. 6.7A-B), suggesting that the 
action site of Cu
2+ 
on TRPM2 is located at the external surface of the channel. To 
further confirm this extracellular effect, the outside-out patch was performed. Cu
2+
 
(10 µM) significantly inhibited the TRPM2 current in the outside-out patches (Fig. 
6.8A). The single channel activity of TRPM2 channel was also recorded (Fig. 6.8B-
C). The slope conductance for TRPM2 channel stimulated by ADPR was 65.8 ±0.23 
pS (n = 4), which is similar to 64 pS (Starkus et al., 2010) and close to 60 pS 
recorded under the conditions of 100 nM Ca
2+
 and 100 μM ADP ribose (Perraud et 
al., 2001). Bath perfusion with 10 μM Cu2+ abolished the single channel activity 
(Fig. 6.8C). 
 
 
Fig. 6.7 Cu
2+
 inhibits TRPM2 channel from the cell surface. (A) Addition of 
Cu
2+
 (20 µM) into the internal solution did not prevent the channel activation by 
ADPR, whereas the perfusion of 10 µM Cu
2+
 in bath solution completely abolished 
the whole-cell currents. The arrow indicates the time point when the whole-cell 
configuration was achieved. (B) Comparison of the peak amplitudes of TRPM2 
currents measured at +80 and -80 mV in the control group and in the presence of 
intracellular or extracellular Cu
2+
 (n = 3 in each group, ***P<0.001).  
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Fig. 6.8 Outside-out patch-clamp recordings showing the extracellular action of 
Cu
2+ 
on TRPM2 channel. (A) Cu
2+
 (10 µM) in the external solution inhibited 
TRPM2 currents measured at +80 and -80 mV in outside-out patch configuration. 
(B) Mean unitary current sizes for ADPR-induced TRPM2 single channel events 
plotted against voltages. Straight line was fitted and the mean unitary slope 
conductance was 66 pS (0.5 mM ADPR). (C) Example of single channel activity of 
TRPM2 recorded by outside-out patches before and after perfusion with Cu
2+
. 
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6.3. Discussion 
6.3.1. Copper, oxidative stress, TRPC and TRPM2 channels in 
neurodegenerative diseases 
Copper has been implicated in the pathogenesis of several neurodegenerative 
disorders including Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington’s 
disease, Parkinson’s disease, and prion disease (Desai and Kaler, 2008; Squitti, 
2012). Excess of copper is associated with the production of ROS, which in turn 
triggers a series of events including oxidative stress-induced cell injury, intracellular 
protein deposits (neurofibrillary tangles), neuronal dysfunction and consequently 
cell death (Gaggelli et al., 2006). On the other hand, ROS activate some Ca
2+
 
channels, such as TRPM2, and cause the disruption of cellular Ca
2+
 homeostasis. 
The common change of Ca
2+
 homeostasis in Alzheimer’s disease is an increased 
intracellular calcium level that could occur either indirectly through Aβ modulating 
an existing Ca
2+
 channel or directly through cation-selective channels formed by Aβ 
(Alarcon et al., 2006). In this study, I found that extracellular Cu
2+ 
significantly 
potentiated TRPC channels but inhibited TRPM2 channel, which provide new 
evidences for the relationship between ROS-sensitive TRP channels and Cu
2+
. These 
channels are activated by ROS or H2O2, but have distinct responses to Cu
2+
, which 
renders Cu
2+
 a complicated role in the regulation of cellular Ca
2+
 homeostasis. It has 
been suggested that TRPM2 mediates oxidative stress-driven neuronal cell death 
(Xie et al., 2010; Naziroglu, 2011; Sumoza-Toledo and Penner, 2011). However, 
because of the extremely high copper levels in senile plaques (393±123 µM) (Lovell 
et al., 1998),  the activity of TRPM2 is likely to be completely inhibited by copper, 
instead of being enhanced by H2O2 and Aβ in the affected regions of the brain. The 
cell death induced by oxidative stress may be a result of hyperactivity of TRPC 
channels, which can be potentiated by ROS, H2O2 and Cu
2+
. In another aspect, a 
recent study using TRPM2-deficient mice demonstrated that activation of TRPM2 
inhibited ROS production in macrophages, which was mediated by the inhibition of 
NADPH oxidase activity through depolarization of the plasma membrane (Di et al., 
2011). This pathway may also exist in microglia, the resident phagocytes in the 
brain. TRPM2 expression has been detected in microglia, and the response to 
ADPR, H2O2 and endotoxin is similar to that in macrophages (Kraft et al., 2004). 
Considering the abundance of microglia in senile plaques (Haga et al., 1989), the 
inactivation of TRPM2 by copper would substantially promote the production of 
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ROS in these cells. Taken together, the oxidative stress in the brain could be 
severely augmented by excessive copper with regard to its oxidant property and 
effects on amyloid-β peptides and TRPM2 channels. The increased oxidative stress 
and excessive copper would lead to Ca
2+ 
overload in the cells by activating TRPC 
channels, which eventually results in cell death. Thus, although TRPM2 and TRPC 
channels response to copper in distinct ways, they are both involved in the 
progression of neurodegenerative diseases.  
6.3.2. Physiological and pathophysiological concentrations of copper in 
human body 
Copper concentration in blood plasma is around 15 μM in normal population 
(Mathie et al., 2006), however, copper accumulates in the brain and displays 
differential distribution patterns in the central nervous system. Much higher 
concentration has been estimated in the cerebrospinal fluid (~70 μM). The 
concentration in the synaptic cleft may reach 200-400 μM in some neuronal 
diseases, whereas the normal extracellular copper concentration in the brain is of the 
order of 0.2–1.7 μM (Mathie et al., 2006). The elevated copper levels have also been 
reported in patients with type 1 or type 2 diabetes (Zargar et al., 1998), which shares 
many pathogenetic mechanisms with Alzheimer's disease and vascular dementia. In 
addition, copper accumulation in the body is caused by genetic variants of copper 
transporter genes (ATP7A and ATP7B), i.e., Menkes syndrome and Wilson disease. 
These data suggest that the activation or inhibition of TRPC and TRPM2 channels 
by micromolar Cu
2+
 should exist in normal subjects and under some disease 
conditions. 
6.3.3. Molecular targets of copper on TRPC4 and TRPM2 channels 
Three amino acid residues are found to be potential Cu
2+
-binding sites in TRPC4 
channel in this study. The negatively charged E542 and E543 residues may bind 
Cu
2+ 
by electrostatic interaction. Cysteine residue is an important ligand in copper-
binding proteins and accounts for 35% of all copper ligands (Wu et al., 2010b). The 
C554 residue in TRPC4 thus may form a complex with Cu
2+
 and then be oxidised. 
The oxidation of cysteine residues may catalyse the formation of disulphide bonds 
between physically adjacent cysteine residues, and thereby indirectly change protein 
structure and function (Song et al., 2011). I have not examined the molecular targets 
of Cu
2+
 on TRPM channel in this study; however, Cu
2+
 may bind directly to amino 
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acids against most likely cysteine or the hydrophilic-charged amino acids (histidine, 
lysine, arginine, aspartate, and glutamate) to alter the channel activity. Indeed, the 
residue substitution in the outer vestibule of the pore including K952, H995 and 
D1002 significantly changed the sensitivity to Zn
2+
 (Yang et al., 2011). Further 
investigation is needed to confirm these binding sites for Cu
2+
. Moreover, a more 
indirect way that copper can modulate protein function is through the generation of 
free radicals, which can profoundly alter protein and cell function, particularly for 
the ROS-sensitive channels. Unlike the extracellular effect of Cu
2+
, the action site 
for ROS or hydroxyl radical that generated by mixing with Fe
2+
 and H2O2 has been 
demonstrated as an intracellular effect, which is mainly related to the C-terminal 
Nudix-like domain (Ishii et al., 2006; Sumoza-Toledo and Penner, 2011). Therefore, 
the channel appears to be opened by intracellular ROS, and closed by extracellular 
Cu
2+
. On the other hand, higher concentrations of extracellular Cu
2+
 may enter cells 
via Cu
2+
 transporters that in turn regulate the ROS production. Recently, Zn
2+
 has 
been shown to inhibit TRPM2 channel, however, the potency of Zn
2+ 
was much 
lower than that of Cu
2+ 
(Yang et al., 2011). The difference in potency for the two 
ions may have important physiological relevance because the plasma levels of 
copper and zinc are oppositely correlated in many diseased conditions such as 
diabetes and hypertension and the ratio of Zn
2+
/Cu
2+
 have been evaluated in some 
diseases (Canatan et al., 2004; Mathie et al., 2006; Viktorinova et al., 2009). 
Excessive copper and deficit of zinc would progressively disrupt the cellular Ca
2+ 
homeostasis by tuning the activity of a number of TRP and other Ca
2+ 
channels 
(Mathie et al., 2006).  
6.3.4. Other Ca
2+
 channels regulated by copper 
Apart from the activation of TRPC and inhibition of TRPM2 channels, Cu
2+
 also 
inhibits the voltage-gated Ca
2+
 channels including T-, L-, N-, P-, and Q-type 
channels (Mathie et al., 2006). The Cav3.2 channel is more sensitive to Cu
2+
 than 
other types of voltage-gated Ca
2+
 channels with an IC50 = 0.9 µM (Jeong et al., 
2003). In addition, high concentrations of Cu
2+
 stimulate TRPV1 and TRPA1 
channels (Gu and Lin, 2010; Riera et al., 2007), suggesting that the overall effect of 
Cu
2+
 on intracellular Ca
2+
 level may vary, which depends on the local concentration 
of Cu
2+
 and the expression of different Ca
2+
 channels.  
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6.4. Conclusions 
In this study, I found that Cu
2+
 at micromolar concentrations potently activated 
TRPC4/5/3/6 channels but inhibited TRPM2 channel activated by ADP-Ribose. The 
action sites of Cu
2+
 on TRPC4 and TRPM2 are both extracellularly located.  The 
E542, E543 and C554 residues of TRPC4 are related to the channel opening by 
Cu
2+
. The inhibitory effect of Cu
2+
 on TRPM2 channel is irreversible. These 
findings provide novel insights into the functions of Cu
2+
 in human physiology. The 
dysfunction of TRP channels caused by excess copper may be one of the 
pathophysiological mechanisms that disrupt cellular Ca
2+
 homeostasis in diabetes 
and neurodegenerative diseases.  
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7.1. Introduction 
Ca
2+
 signalling is believed to play a central role in the signalling cascades of 
tumorigenesis and neoplastic progression by controlling gene expression, 
progression through the cell cycle, and DNA synthesis. Inhibitors of Ca
2+
-dependent 
signalling suppress the proliferation of cancer cells in vitro and in solid tumors in 
vivo (Holmuhamedov et al., 2002). Store-operated Ca
2+
 influx is one of the Ca
2+
 
entry pathways and closely related to cell proliferation and apoptosis. The 
importance of store-operated Ca
2+
 influx or capacitative Ca
2+
 influx in cancer 
development has been recognised for many years, however the role of TRP channels 
that act as the molecular constituents or subunits of SOCs or ROCs in cancer cell 
proliferation are still unclear (Prevarskaya et al., 2007). It has been demonstrated 
that TRPC channel is involved in cell proliferation, and 2-aminoethyldiphenyl 
borate (2-APB) significantly inhibits the proliferation in HEK-293 cells (Xu et al., 
2005a). The mechanism is unrelated to its inhibitory action on inositol 1,4,5-
trisphosphate receptors (IP3R), since 2-APB also inhibits the proliferation of triple 
IP3R knockout DT40 cells (Xu et al., 2005a). This suggests the direct involvement 
of SOCs or TRPC channels in cell proliferation. Recently, several studies have 
demonstrated the expression of TRPC in different types of cancer cells or cancer 
tissues, such as TRPC1, 3, 6 in breast cancer MCF7 cells (Aydar et al., 2009) and 
liver cancer HepG2 (El Boustany et al., 2008), TRPC1, 3, 4 in prostate cancer 
LNCaP cells (Thebault et al., 2006; Pigozzi et al., 2006), TRPC1, 4, 6, 7 in renal 
cell carcinoma (Veliceasa et al., 2007), TRPC1, 3, 5, 6 in human malignant gliomas 
(Bomben and Sontheimer, 2008), TRPC1, 3-7 in neuroblastoma IMR-32 cells 
(Nasman et al., 2006), TRPC3 in human astrocytoma 1321N1 cells (Nakao et al., 
2008), TRPC6 in esophageal and gastric cancer (Cai et al., 2009), TRPC3 in ovarian 
cancer (Yang et al., 2009b), and TRPC1, 4 in basal cell carcinoma (Beck et al., 
2008). However, the detection of splicing activity of TRPCs and systematic 
examination of the role of each TRPC isoform in cancer growth has not been 
addressed.  
In this chapter I aimed to identify the expression of TRPC genes and their splicing 
variants in human ovarian adenocarcinoma-derived cell line SKOV3, and determine 
the roles of TRPC isoforms in the regulation of cancer cell proliferation using TRPC 
siRNA interference and pharmacological tools including chemical modulators and 
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specific TRPC channel functional antibodies. I also examined the colony growth of 
ovarian cancer cells by overexpressing TRPC isoforms.  
7.2. Results 
7.2.1. Expression of TRPC spliced variants in SKOV3 Cells 
The expression of TRPC genes and their spliced variants in SKOV3 cells were 
examined by RT-PCR using specific primer sets across introns (Table 2.2). The 
spliced variant of TRPC1 with exon 3 deletion (TRPC1β) was detected using the 
primer set across exon 3 (P1). The band density of TRPC1β is much stronger than 
the full-length isoform (TRPC1α) (Fig. 7.1A), suggesting that the β isoform is 
highly expressed in SKOV3 cells. Using the primer set across the exon 9 and 10 
(P3), a novel spliced variant of TRPC1 with exon 9 deletion (TRPC1δ) was 
identified. The existence of TRPC1δ was also confirmed by using the TRPC1 primer 
set across exon 9 (P4). The band density of the TRPC1δ was less abundant than the 
non-spliced TRPC1 isoform in the region. The deletion of exon 9 did not cause open 
reading frame shift, suggesting this new spliced isoform may have a channel pore 
domain and C-terminus that seen in α or β isoforms. I also examined the possibility 
for other splicing regions using primer set P2 and P5, and the primer combination 
ranged from exon 1 to exon 13, but no other splicing site was identified.  
Full-length human TRPC3 has 12 exons and a 58-base pair insert between exon 2 
and exon 3. Using primer set across exon 2-5 (P1), or exon 3-5 (P2), exon 5-6 (P3) 
and exon 8-9 (P4), single PCR band with the expected size was detected (Fig. 7.1B). 
TRPC3 has an isoform with an extended N-terminus (TRPC3a) (Yildirim et al., 
2005). Using primer set across exon 1-5 (P0), this isoform was found to be 
expressed in SKOV3 cells. As shown in Fig. 7.1B, a band with an expected size of 
1405 bp was detected, suggesting the existence of the TRPC3a isoform in SKOV3 
cells. The regions across exon 5-9 and exon 8-12 were also amplified, but no other 
spliced isoforms were detected. 
Eight spliced variants of human TRPC4 have been reported, including α, β, γ, δ, ε, ζ, 
η and an unnamed isoform truncated at exon 6. The α, β, γ, δ, ε and ζ isoforms have 
100% identity for the region from exon 1 to exon 7 except that TRPC4ζ has exon 3  
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Fig. 7.1 Detection of TRPC spliced variants in human ovarian cancer SKOV-3 
cells. (A) RT-PCR products of TRPC1 were amplified by specific primer set 
labelled as P1 to P5. Two products were amplified using primer set P1 with a size of 
403 bp (TRPC1α) and 301 bp (TRPC1β). A small product with exon 9 deletion 
(TRPC1δ) was identified using primer set P4 (405 bp for TRPC1δ, and 549 bp for 
TRPC1α/β isoforms). The TRPC1δ was also detected using primer set P3 (423 bp 
for α/β isoforms; 279 bp for TRPC1δ). No other splicing region was detected using 
primer set P2 and P5. (B) The TRPC3 spliced variant with an extended N-terminus 
was detected using primer set P0 (1221 bp). Single PCR product was found using 
primer set P1, P3 and P4, or P2 and the primers amplifying exon 8 to exon 12. (C) 
TRPC4 isoforms were detected by primer set P1 and P4. The ε-isoform amplified by 
ε-specific primer was negative. The γ-isoform with exon 8 deletion was detected by 
primer set P3. Using primer set P7, both α-isoform (956 bp) and β-isoforms (704 bp) 
were detected. (D) Two TRPC6 spliced isoforms were detected using primer set P1. 
Single band of TRPC6 with expected size was detected by primer set P2 (551 bp) 
and P3 (476 bp).  
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deletion. The η-isoform has an early stop code due to open reading frame shift at the 
end of exon 3. Using primer set P1 and P4, TRPC4 fragments with the sizes of 740 
bp and 519 bp were found (Fig. 7.1C). The ζ-isoform with exon 3 deletion was 
undetectable using the primer set across exon 1-5 (P2). The ε isoform of TRPC4 was 
also undetectable with the forward primer in exon 7 and the ε-specific reverse 
primer. However, two bands were detected with an expected size of 428 bp and 623 
bp using the primer set (P3). The smaller band is specific for TRPC4γ with exon 8 
deletion and the bigger band is the unspliced isoforms of TRPC4 (Fig. 7.1C). 
Similarly, two bands were detected if the primer set across the exon 8 alone (P6) 
was used, suggesting the TRPC4γ and other isoforms coexisted in the SKOV3 cells. 
To further distinguish the TRPC4 isoforms, the primer set (P7) amplifying exon 7 to 
exon 12 were used, the detected band with a predicted size of 956 bp is the α 
isoform, and the small band (704 bp) is the β isoform (Fig. 7.1C). Other possible 
splicing regions were also examined using the forward and reverse primer 
combinations ranged from exon 1 to exon 11, and no more alternative splicing was 
found. These data indicate that α, β and γ isoforms of TRPC4 coexist in the SKOV3 
cells.  
There are 13 exons for human TRPC6. Three bands were detected using primer set 
(P1) to amplify exon 1-5 (Fig. 7.1D). The size for the full-length TRPC6 is 1222 bp. 
The spliced isoform with exon 3 deletion is 1039 bp, and the shorter one with exon 3 
and 4 deletion is 874 bp. No spliced region was found between exon 8 to exon 13 
using primer sets P2 and P3 (Fig. 7.1D).  
7.2.2. Ovarian cancer cell growth regulated by TRPC channel 
modulators 
2-APB is a non-selective blocker of TRPC channels (Xu et al., 2005a). The 
blockade of TRPC channels by 2-APB significantly inhibited the SKOV3 
proliferation in a concentration-dependent manner with an EC50 of 5.9 µM (Fig. 
7.2A). Since 2-APB has been shown to inhibit gap junctional channels, which might 
contribute to the anti-proliferative effect (Harks et al., 2003; Vinken et al., 2006), 
SKOV3 cells were pretreated with carbenoxolone, a gap junctional channel blocker, 
to pharmacologically dissect out the contribution of TRPC channels. Carbenoxolone 
at 200 µM and 400 µM significantly inhibited the cell proliferation (Fig. 7.2B), but  
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Fig. 7.2 Ovarian cancer cell proliferation was inhibited by store-operated 
channel blockers. (A) SKOV3 cells were incubated with different concentrations of 
2-APB for 24 h. The cell proliferation was monitored by WST-1 assay and the 
absorbance was measured at a wavelength of 450 nm with a reference at 600 nm. 
(B) SKOV3 cells treated with carbenoxolone for 24 h. (C) SKOV3 cells incubated 
with carbenoxolone and 2-APB for 24 h. (D) Effect of SKF-96365 on SKOV3 cells 
with an IC50 of 14.5 µM after incubation for 24 h. (E) Effect of Gd
3+
 incubation for 
24 h. (F) Incubation with trypsin for 24 h. Each experiment had 8 well repeats and 
the data were from ≥ two independent experiments. (*** P<0.001) 
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the anti-proliferative effect of 2-APB was still observed in the presence of 
carbenoxolone (Fig. 7.2C), suggesting that the anti-proliferative effect of 2-APB 
could be due to the inhibition of TRPC channels. The effect of SKF-96365, another 
non-specific TRPC channel blocker, was also tested. SKF-96365 significantly 
inhibited the proliferation of SKOV3 cells in a concentration-dependent manner 
with an EC50 of 14.5 µM (Fig. 7.2D). Gd
3+
 is an inhibitor of SOCs but selectively 
activates TRPC4 and TRPC5 channels. Gd
3+
 showed a stimulating effect on cell 
proliferation at the concentration of 10, 50 and 100 µM (Fig. 7.2E). In addition, the 
protease trypsin, which stimulates TRPC channels via protease-activated receptor 
activation, significantly promoted the cancer cell proliferation (Fig. 7.2F). These 
data suggest the importance of TRPC channel activity in regulating ovarian cancer 
cell growth, and the channel blockers have the potential for anti-cancer therapy. 
7.2.3. Role of TRPC isoforms in ovarian cancer cell proliferation 
To identify the role of individual TRPC isoforms on the cancer cell proliferation, 
SKOV3 cells were incubated with E3-targeting TRPC functional antibodies that can 
specifically inhibit Ca
2+
 influx via TRPC channels (Xu et al., 2005b; Xu and Beech, 
2001). The blockade of TRPC1, TRPC4 and TRPC6 channels by T1E3, T45E3 and 
T367E3 significantly decreased the cancer cell proliferation, but T5E3, which can 
block TRPC5 channel only, had no effect on cell proliferation (Fig. 7.3A), which 
confirmed the lack of TRPC5 expression in SKOV3 cells.  
The isoform-specific TRPC siRNAs were used to further demonstrate the role of 
TRPCs in cancer cell proliferation. There was no difference among the groups 
transfected with scramble siRNA, pool siRNA and mock control transfection (no 
siRNA) on SKOV3 cell proliferation (Fig. 7.3B). However, the cell proliferation 
was significantly inhibited by the transfection with TRPC1, TRPC3, TRPC4 and 
TRPC6 siRNAs for 48 h (Fig. 7.3B). Bcl-2 siRNA, which targets the anti-apoptotic 
Bcl-2 gene, was used as a positive control, also significantly inhibited cell 
proliferation (Fig. 7.3B). These results were similar to the observations using 
specific anti-TRPC functional antibodies, suggesting that the silencing of TRPC 
channel expression is important for the inhibition of cancer cell proliferation. 
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Fig. 7.3 Role of TRPC channels in the ovarian cancer cell growth. (A) SKOV3 
cells were incubated with functional antibodies (1:500 dilution for anti-TRPC1 
(T1E3); 1:250 dilution for anti-TRPC4 (T45E3), anti-TRPC5 (T5E3) and anti-
TRPC6 (T367E3)) for 24 h and the cell proliferation was measured by WST-1 assay. 
n =16 for each group. (B) SKOV3 cells were transfected with TRPC siRNAs (100 
nM siRNA for each group) using Lipofectamine 2000. Cell proliferation was 
measured by WST-1 assay 48 h after transfection. The sham transfection (control), 
pool siRNA and scramble siRNA were negative control. Bcl-2 siRNA was used as 
positive control. n =16 for each group. (*** P<0.001) 
7.2.4. Overexpression of TRPC isoforms promoted colony growth of 
SKOV3 cells  
There are no specific siRNAs or blocking antibody tools targeting to individual 
spliced variants of TRPCs, therefore I overexpressed different TRPC isoforms into 
SKOV3 cells to further confirm the role of TRPCs in ovarian cancer growth. 
SKOV3 cells were transfected with the plasmid encoding different TRPC isoforms 
and the cancer cell colony formation was observed. As shown in Figure 7.4A-B, the 
number of cell colonies larger than 2 mm
2
 was greatly increased in the groups 
transfected with TRPC1β, TRPC1δ, TRPC3, TRPC4 and TRPC6 plasmids. I also 
examined the cancer colony growth using soft agar assay. The number of larger 
colonies with diameters >100 µm was much higher in the groups transfected with 
TRPC1β, TRPC1δ, TRPC3, TRPC4 and TRPC6 plasmids than that in the vector 
control group (Fig. 7.4C-D), which further suggested the involvement of TRPCs in 
the ovarian cancer development.  
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Fig. 7.4 Overexpression of TRPC channels promoted the colony growth of 
ovarian cancer cells. (A) SKOV3 cell colony formation assay on flat surface. The 
SKOV3 cells were transfected with TRPC cDNA plasmids or vector as indicated. 
The cell colonies were stained with crystal violet. (B) Mean ± SE data show the 
number of large colonies (>2 mm
2
). Triplicate wells were used for each group. 
Results were reproduced in more than three independent experiments. (C) Examples 
of SKOV3 cell colonies grown in soft agar and stained with crystal violet. The cells 
were transfected with TRPC cDNA plasmids or vector as indicated. (D) Mean ± SE 
data show the number of large colonies with diameters >100 µm. Triplicate wells 
were used for each group. (** P<0.01, *** P<0.001) 
7.2.5. TRPC channel blocker and gene silencing arrested SKOV3 cells at 
G2/M phase 
The cell cycle progression of SKOV3 cells was examined by fluorescence-activated 
cell sorting (FACS) using the propidium iodide staining procedure (Riccardi and 
Nicoletti, 2006). Incubation with the non-selective TRPC channel blocker SKF-
96365 (10 µM) for 24 h substantially increased the population of SKOV3 cells at 
G2/M phase and decreased the percentage of cells at G0/G1 phase (Fig. 7.5A), which  
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is in consistent with the previous report (Yang et al., 2009b). SKF-96365 treatment 
also significantly increased the apoptosis of SKOV3 cells (Fig. 7.5A). To observe 
the effects of individual TRPC genes on cell cycle progress, SKOV3 cells were 
transfected with TRPC siRNAs. I found that more SKOV cells were arrested at 
G2/M phase after transfection with siTRPC1, siTRPC4, siTRPC3, and siTRPC6 for  
 
 
Fig. 7.5 Cell cycle arrested by TRPC channel blocker SKF-96365 and TRPC 
siRNAs in ovarian cancer cells. (A) The representative FACS histogram for 
SKOV3 cells treated with vehicle (DMSO) and SKF-96365 (10 µM) for 24 h. The 
mean ± SE data from three independent experiments are shown on the right. (B) Cell 
cycle analysis of SKOV3 cells transfected with scramble siRNA (siScramble) and 
TRPC siRNA (siTRPC1, siTRPC4, siTRPC3 and siTRPC6) for 72 hours. The 
percentages of propidium iodide-labelled cells at different phases of cell cycle were 
determined by FACS analysis. The mean ± SE data were from three independent 
experiments. * P<0.05, ** P<0.01, *** P<0.001 comparing with the vehicle group 
or the scramble siRNA-transfected group. 
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72 h comparing with the control group transfected with scramble siRNA (Fig. 7.5B), 
suggesting that the downregulation of TRPC gene expression can arrest the cell 
cycle progression through G2/M to G1. Unlike the channel blocker SKF-96365, the 
contribution of TRPC gene silencing on apoptosis was small. The down-regulation 
of TRPC expression did not significantly change the percentage of apoptotic ovarian 
cancer cells (Fig. 7.5B). 
7.3. Discussion 
7.3.1. Functional expression of TRPC isoforms in SKOV3 cells 
TRPC channels have been identified in many cell types (Xu et al., 2006b; Xu et al., 
2008a; Flemming et al., 2003; Riccio et al., 2002). These channels are differentially 
expressed at different stages of stem cell development, which may reflect their 
importance in cell differentiation (den Dekker et al., 2001; Bodding, 2007). On the 
other hand, the thapsigargin-induced store-operated Ca
2+
 influx is higher in tumour 
cells than that in normal cells (Kovacs et al., 2005), which further suggests the 
relevance of TRPC channels or store-operated channel molecules to cancer 
development. In this study, I have systematically detected the TRPC channels and 
their splice variants, and found that multiple TRPCs and their spliced isoforms 
existed in human ovarian cancer. TRPC1 has been suggested as a store-operated 
channel subunit and actively associates with other TRPC isoforms, such as TRPC1/4 
or TRPC1/5 (Xu et al., 2006b; Strubing et al., 2001), or interacts with other channel 
proteins, such as Orai1 or STIM1 (Ong et al., 2007), to constitute the 
heteromultimeric store-operated channels or channel complexes, which could be 
main molecular components in native cells. Interestingly, the existence of several 
spliced isoforms of TRPCs in a cell suggests the possibility of functional interaction 
or regulation on the channel activity. TRPC1γ1 and TRPC1γ2 have been reported in 
human myometrial cells (Yang et al., 2002), but none of them have been detected in 
the ovarian cancer cells, and no inserts found between exon 8 to exon 10. Instead, I 
have identified a new TRPC1 isoform with exon 9 deletion, suggesting this TRPC1 
spliced isoform lacks transmembrane segment 4 (S4). As shown in Chapter 2, 
TRPC1δ is mainly distributed in the cytosol with a similar subcellular distribution 
pattern to TRPC1β in HEK293 cells. However, other isoforms including TRPC3, 
TRPC4α, TRPC4β1, TRPC4ε1 and TRPC6 are located in the plasma membrane, 
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suggesting the potential functional difference between TRPC1 and other TRPC 
isoforms. Moreover, the spliced isoforms of TRPC1 with exon 2 and exon 3 deletion 
have been described in mice by Sakura & Ashcroft (Sakura and Ashcroft, 1997), but 
this splicing activity has not been found in human SKOV3 cells. TRPC3 and TRPC6 
have a high similarity in sequence. Both of them have been demonstrated as 
receptor-operated channels that mediate the diacylglycerol-induced Ca
2+
 influx, 
although TRPC3 may also have store-operated channel properties (Estacion et al., 
2004; Venkatachalam et al., 2002). In addition, co-existence of several TRPC4 
isoforms in the SKOV cells could be important for protein interactions among the 
TRPC isoforms that may be required for precisely regulating the functionality of 
Ca
2+
 permeable channel complexes in cancer cells, and thus control cell growth. 
Indeed, some spliced TRPC isoforms have been demonstrated as an inhibitory 
subunit for TRPC homomultimeric channels in HEK-293 cells if co-overexpressed 
with the full-length isoforms (Schaefer et al., 2002; Satoh et al., 2002). Further 
investigation is needed to explore the functional difference among the alternative 
splicing of TRPCs in cancer development.  
7.3.2. The role of TRPC channels in cancer cell proliferation and 
apoptosis 
The anti-proliferative effect of 2-APB has been demonstrated in gastric cancer cell 
lines (Sakakura et al., 2003), colonic cancer cells (Kazerounian et al., 2005) and 
human hepatoma cells (Enfissi et al., 2004). Here I found that the effect of 2-APB 
was not altered by the gap junctional channel blocker, carbenoxolone, further 
suggesting that the anti-proliferative action of 2-APB is due to the inhibition on 
SOCs. 2-APB and SKF-96365 are broad-spectrum TRPC channel blockers and 
cannot distinguish the contribution of individual TRPC isoforms; therefore the 
isoform-specific functional antibodies were used in this study. The specificity of the 
antibodies has been confirmed by ELISA, western blotting, in vitro functional 
testing on Ca
2+
 influx and FACS-based assay in previous studies (Xu et al., 2005b; 
Xu et al., 2006b; Xu et al., 2008a). The block on TRPC1, TRPC4 and TRPC6 
channels by E3-targeting functional antibodies caused a significant inhibition of cell 
proliferation, suggesting that TRPC1, TRPC4 and TRPC6 are important for cancer 
cell proliferation. This effect was further confirmed by the application of TRPC 
isoform-specific siRNAs. The inhibition of cancer cell proliferation by TRPC 
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knockdown is potentially due to the arrest of cells at G2/M phase, as revealed by the 
cell cycle analysis in this study, which is similar to previous report using TRPC3 
siRNA alone (Yang et al., 2009b).  
Cell apoptosis has been suggested to be related to SOCs (Skryma et al., 2000). 
Thapsigargin can induce apoptosis of prostate cancer cells, but this effect cannot be 
prevented by an intracellular Ca
2+
 chelator, suggesting that the increase of cytosol 
Ca
2+
 is unnecessary for apoptosis (Skryma et al., 2000). I found that the non-
selective channel blocker SKF-96365 can evoke ovarian cancer cell apoptosis, but 
the specific TRPC siRNAs do not significantly change the apoptosis, suggesting that 
TRPC channels may be less important in the regulation of cancer cell apoptosis. 
7.4. Conclusions 
In this chapter I detected the expression of TRPC genes and their alternatively 
spliced variants in the human ovarian adenocarcinoma-derived cell line SKOV3. 
Blockade of TRPC channel activity by 2-APB, SKF-96365, TRPC isoform-specific 
functional antibodies or the transfection with TRPC siRNAs significantly inhibited 
the cancer cell proliferation. Overexpression of TRPC genes increased colony 
growth of ovarian cancer cells on flat surface and in soft agar. The TRPC channel 
blocker SKF-96365 and knockdown of TRPC expression by siRNAs arrested 
SKOV3 cells at G2/M phase. These findings are novel and important for 
understanding the roles of TRPC channels in ovarian cancer development.  
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8.1. Main results and significance of this study 
8.1.1. Generation of HEK293 cells stably overexpressing STIM1, 
ORAI1/2/3 and TRPC1/3/4/6 channels 
As the fundamental part of this study, stable overexpression HEK293 cell lines for 
STIM1, ORAI1/2/3 and TRPC1/3/4/6 were generated, which includes three new 
alternatively spliced isoforms (TRPC1δ, TRPC4β1 and TRPC4ε1) identified from 
human aortic endothelial cells. Each of these exogenously expressed proteins is 
tagged with a fluorescent protein (mCFP, EYFP or mCherry) to show its distribution 
in the cells. STIM1 and TRPC1 proteins are localised at ER-like intracellular 
compartments at resting state, whilst other ion channel-forming proteins (ORAI1/2/3 
and TRPC3/4/6) are mostly found at the plasma membrane. Once the ER Ca
2+ 
store 
is depleted, STIM1 proteins aggregate with ORAI1/2/3 channels at the plasma 
membrane. When STIM1 is coexpressed with TRPC proteins in the same cells,  the 
translocation of STIM1 upon Ca
2+ 
store depletion does affect the localisation of 
TRPC proteins, i.e. TRPC1 is retained in the ER, and TRPC4 and TRPC6 do not 
aggregate with STIM1 at the plasma membrane.  
The electrophysioilogical properties of overexpressed ion channels are confirmed by 
patch-clamp recordings. Inward-rectifying currents are obtained from STIM1-
ORAI1/2 coexpressing cells after Ca
2+ 
store depletion with thapsigargin. ORAI3 
channels expressed alone or coexpressed with STIM1 are substantially stimulated by 
2-APB. TRPC4α and TRPC4β1 are potentiated by the selective activator Gd3+, 
however TRPC4ε1 is not activated by this lanthanide. Activation of PAR2 receptor 
by trypsin leads to transient but dramatic opening of TRPC4α/β1 and TRPC3/6 
channels, whereas TRPC4ε1 do not respond to this agonist.  
These results suggest that the functions of STIM1, ORAI and TRPC proteins are 
well presented in the stably transfected cells. These cells are very useful tools for 
investigating the molecular mechanism, electrophysiology and pharmacology of 
store-operated Ca
2+
 channels. New findings on the subcellular localisation of STIM1 
and TRPC channels, particularly the lack of direct association between STIM1 and 
TRPC1/4/6 after Ca
2+ 
store depletion, raise an important question that which protein, 
STIM1 or ORAI1, determines the opening of TRPC channels during store-operated 
Ca
2+
 entry (SOCE). As TRPC channels are not consistently considered store-
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operated Ca
2+
 channels, it is very important to understand the gating mechanism of 
TRPC channels when they are involed in the store-operated channel complex. 
Electrophysiological results on TRPC4ε1, a new TRPC4 variant found in endothelial 
cells, reveal that it is likely a dominant negative isoform of TRPC4 channels, which 
suppresses the activity of other TRPC4 subunits such as TRPC4α and TRPC4β1 in 
heterotetrameric channel configuration. The expression of this endogenous negative 
regulator may be associated with specific physiological or pathophysiological 
functions in endothelium, in which TRPC4 channels have been shown to play 
important roles, e.g. regulating endothelial permeability and vascular remodelling 
(Tiruppathi et al., 2002; Fantozzi et al., 2003).   
8.1.2. Cytosolic STIM1 clustering as a new mechanism for the inhibition 
of store-operated Ca
2+
 entry 
Cytosolic STIM1 clustering is a novel phenomenon observed in HEK293 cells 
overexpressing STIM1-EYFP fused proteins. Once cytosolic STIM1 clusters are 
formed, STIM1 proteins lose the ability to move to and aggregate at the 
subplasmalemmal region after Ca
2+
 store depletion, and the SOCE is also abolished. 
Cytosolic clustering of STIM1 proteins can be induced by pharmacological agents 
including 2-APB, flufenamic acid, 4-CEP, U73122 and FCCP. The triggering 
mechanism of cytosolic STIM1 clustering by 2-APB, 4-CEP and U73122 is 
unknown, whereas the action of flufenamic acid and FCCP is related to the Ca
2+ 
release from mitochondria. The formation of cytosolic STIM1 clusters is 
independent of the ER Ca
2+
 store. The ER-localised TRPC1 proteins do not cluster 
with STIM1 when they are coexpressed in the same cells exposed to 2-APB. 
The ER Ca
2+
 store-independent cytosolic clustering of STIM1 is a novel mechanism 
for the inhibition of SOCE. This mechanism is involved in the pharmacology of 
some channel blockers, and could be employed in the development of new drugs to 
selectively suppress SOCE. Since ORAI1 has been found to possess activity 
independent of the ER Ca
2+ 
store and STIM proteins (Feng et al., 2010), direct 
blockade of ORAI1 channel may result in unexpected pathophysiological 
consequence. Therefore, STIM1 could be a better target than ORAI1 for therapeutic 
store-operated channel blockers. Furthermore, gene silencing of STIM1 alone has 
been shown to sufficiently inhibit pathological cardiac hypertrophy in vitro and in 
vivo (Hulot et al., 2011; Luo et al., 2012), which is the first evidence for STIM1-
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targeted gene therapy in animals. Due to the safety concerns on gene-delivery 
techniques, pharmacological inhibition of STIM1 function would be more feasible 
for clinical use than reducing gene expression by RNA interference. The cytosolic 
clustering of STIM1 has provided an unambiguous pharmacological target for drug 
development with this purpose. 
8.1.3. The roles of cytoskeleton in STIM1 movement and store-operated 
Ca
2+
 entry 
Neither depolymerisation of microtubule by colchicine nor disruption of 
microfilament by cytochalasin D showed any blocking effects on STIM1 
translocation toward the plasma membrane upon Ca
2+ 
store depletion. Complete 
disassembly of these two types of cytoskeleton by coapplication of colchicine and 
cytochalasin D also failed to inhibit the formation of subplasmalemmal STIM1 
puncta. However, both colchicine and cytochalasin D significantly reduced SOCE in 
STIM1-overexpressing cells. The cytosolic clustering of STIM1 induced by 2-APB 
and 4-CEP was not affected by the disruption of microtubule and actin cytoskeleton. 
The increase of F-actin content in subplasmalemmal region, which spatially involves 
the junctions between the plasma membrane and the ER, blocked the translocation 
of STIM1 toward the plasma membrane after Ca
2+ 
store depletion. The two 
compounds U73122 and calyculin A are found to block thapsigargin-induced SOCE 
through this mechanism, which is independent of their roles as phospholipase C 
inhibitor or protein phosphatase inhibitor, respectively. Depolymerisation of F-actin 
by cytochalasin D recovered STIM1 translocation and partially restored SOCE in 
the presence of U73122 or calyculin A.  
Both the results from this study and other reports (Smyth et al., 2007; Galan et al., 
2011) suggest that the translocation of STIM1 proteins does not rely on cytoskeleton, 
instead they “slide” along the ER membrane. The reduction of SOCE in response to 
cytoskeleton depolymerisation is not unexpected because the store-operated channel 
subunits including STIM1, ORAI1 and TRPCs have been found to interact with 
several types of cytoskeleton (Grigoriev et al., 2008; Odell et al., 2008; Galan et al., 
2011; Stiber et al., 2012). Loss of cytoskeleton support may change the architecture 
of store-operated channel complex and thus the SOCE is impaired. Another way to 
inhibit SOCE by manupulating cytoskeleton is increasing the subplasmalemmal F-
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actin content, which disrupts the PM-ER junctions and blocks STIM1 translocation. 
This mechanism has been confirmed by a recent report using neuroendocrine-
differentiated cells (Vanoverberghe et al., 2012), suggesting that it is a common 
mechanism existing in different types of cells. 
8.1.4. Inhibition of ORAI1/2/3 and TRPC3/4/5/6 channels by the 
ryanodine receptor agonoist 4-CEP 
Apart from the roles in triggering Ca
2+  
release through ryanodine receptors and 
cytosolic STIM1 clustering, 4-CEP also inhibits SOCE by direct action on 
ORAI1/2/3 and TRPC3/4/5/6 channels. The chlorophenol analogues 4-CmC and 4-
ClP have similar inhibitory effects on these channels as 4-CEP, and the potencies of 
these three compounds are ranked as 4-CEP > 4-CmC > 4-ClP. The inhibition of 4-
CEP on ORAI3, TRPC4 and TRPC6 channels is concentrantion-dependent, with 
IC50 of 71.0, 85.6 and 108.4 µM, respectively. The activities of ORAI3 and 
TRPC3/4/5/6 channels are quickly recovered when 4-CEP is removed from the bath 
solution. The action sites of 4-CEP on ORAI3 and TRPC4 channels are located at 
the cell surface. 
Ryanodine receptors are ER/SR Ca
2+  
release channels particularly important for the 
contraction of cardiac and skeletal muscle cells. RyR1 mutations which increase the 
channel sensitivity to general anaesthetic agents are the main cause for malignant 
hyperthermia, a skeletal muscle-related disease. Several RyR agonists are currently 
used in the diagnosis of malignant hyperthermia, among which 4-CEP and  4-CmC 
have been shown to sucessfully distinguish the malignant hyperthermia-susceptible 
skeletal muscles from normal samples. However, both drugs have not been included 
in the standard protocols for malignant hyperthermia diagnosis. The findings in this 
study have revealed a novel pharmacological aspect of these compounds, which 
could be useful for future drug development based on this class of molecules.  
8.1.5. Cu
2+
 is a potent activator of TRPC3/4/5/6 channels and strong 
inhibitor of TRPM2 channel 
Cu
2+
 at micromolar concentrations potently stimulates TRPC3/4/5/6 channels but 
inhibits TRPM2 channel activated by intracellular ADP-Ribose. Site-directed 
mutagenesis identified that the E542, E543 and C554 residues within the outer pore 
of TRPC4 are potential molecular targets of Cu
2+
. The action site of Cu
2+
 on TRPM2 
is also extracellularly located. The effects of Cu
2+
 on TRPC and TRPM2 channels 
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are concentration-dependent and cannot be reversed by removel of Cu
2+
 from the 
bath solution.  
As copper has been considered an important pathophysiological factor of 
neurodegenerative diseases for long, understanding the modulation of TRP channels 
by Cu
2+ 
will be helpful to demonstrate the exact roles of these channels in 
neurodegenerative diseases. Although TRPM2 channel has been suggested to 
mediate neuronal cell death induced by oxdative stress and Ca
2+ 
overload, the 
findings in this study reveal that TRPC channels are much more likely to be 
responsible for this process, because the high concentrations of copper in the 
diseased regions of brain would completely abolish the activity of TRPM2 channel 
but substantially stimulate massive Ca
2+ 
 influx through TRPC channels. Therefore, 
blocking TRPC channels may be a novel and useful strategy in the treatment of 
neurodegenerative diseases.  
8.1.6. TRPC channels promote the proliferation of human ovarian cancer 
cells and tumourigenesis 
It is found that TRPC1/3/4/6 channels with multiple alternatively spliced variants 
are expressed in the human ovarian adenocarcinoma-derived SKOV3 cells. The 
proliferation of SKOV3 cells were significantly suppressed by TRPC channel 
blockers 2-APB and SKF-96365 and TRPC isoform-specific pore-blocking 
antibodies. Knockdown of TRPC gene expression by siRNAs also robustly inhibited 
the cancer cell proliferation. Colony growth of SKOV3 cells was promoted by 
overexpression of TRPC channels. Overall inhibition of TRPC channels by SKF-
96365 arrested SKOV3 cells at G2/M phase and significantly induced apoptosis, 
wheareas knockdown of individual TRPC gene expression by siRNA showed 
similar effect on cell cycle but did not increase the percentage of apoptotic cells.  
TRP channels are increasingly recognised as very promising targets for anti-acncer 
therapy (Nilius et al., 2007; Prevarskaya et al., 2007; Fiorio Pla et al., 2012). The 
abundant expression of TRPC channels in SKOV3 cells and their essential roles in 
cell proliferation and apoptosis discovered here have strongly evidenced the 
importance of Ca
2+
 homeostasis in ovarian cancer development. The inhibition of 
cell cycle progression by TRPC channel blockade and gene silencing provides a 
mechanistic view on the anti-proliferative effects of these treatments. As most TRPC 
channels are localised at the cell plasma membrane, they can be directly accessed by 
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pharmacological agents and antibodies delivered in blood stream, both of which 
have been used in this study and proved to be effective in vitro. These channel 
blockers are not only research tools for understanding the roles of TRPC channels in 
ovarian cancer development, but also potentially useful drugs for future anti-cancer 
therapy. 
8.2. Study limitations and future directions 
8.2.1. Localisation and functional interaction of store-operated channel 
components 
In this study the localisation of STIM1, ORAI and TRPC proteins in HEK293cells is 
visualised by tagged fluorescent proteins, which is a generally used method for 
studying protein localisation in live cells. As this method requires transfection and 
overexpression of the genes, it cannot be used to show the localisation of 
endogenously expressed proteins. Immunostaining with specific primary antibody 
and fluorescent dye-conjugated secondary antibody is an important method to 
visualise the localisation of both endogenous and overexpressed proteins in fixed 
cells. The protein localisation shown by tagged fluorescent proteins in this study can 
be validated by immunofluorescence if reliable primary antibodies are provided. 
Similarly, the interaction between co-localised proteins can be further confirmed by 
co-immunoprecipitation and Western blotting. 
8.2.2. Molecular mechanism of the cytosolic clustering of STIM1 
Cytosolic clustering of STIM1 is found to be an unrecognised effect of some SOCE 
blockers, such as 2-APB, 4-CEP and flufenamic acid. Although STIM1 is known to 
oligomerise and form protein complex with ORAI channels at the plasma 
membrane, it is still unknown whether the formation of cytosolic STIM1 clusters 
requires any binding partners or scaffold proteins adjacent to the ER. As this 
phenomenon is described only in STIM1-overexpressing HEK293 cells, it needs to 
be confirmed in other types of cells. The response of endogenous STIM1 proteins in 
native cells to these drugs is also worthy to be investigated by immunofluorescence. 
Moreover, it is important to know whether STIM2 is able to form cytosolic clusters 
as its homologue STIM1, which may reveal more structural and functional aspects 
of these two proteins. Design and screening of novel compounds which selectively 
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regulate cytosolic STIM1 clustering would be a promising field in future drug 
development aiming to control SOCE. 
8.2.3. Regulation of store-operated channel activity by cytoskeleton 
The disruption of either microtubule or microfilament cytoskeleton leads to impaired 
SOCE, but does not affect the translocation of STIM1 toward the plasma membrane. 
A speculative mechanism for this is that loss of cytoskeleton changes the 
architecture and reduces the activity of the store-operated channel complex, which 
includes STIM1, ORAIs and possibly TRPCs. To investigate this mechanism, it 
needs to be demonstrated that which store-operated channel subunit interacts 
directly with tubulin, actin or other cytoskeletal proteins. In addition, cytoskeleton 
also supports the structure of caveolae (van Deurs et al., 2003), which are a special 
type of lipid raft and important microdomains for Ca
2+ 
signalling (Pani and Singh, 
2009). Synchronous visualisation of lipid rafts and store-operated channels before 
and after cytoskeleton depolymerisation will further explain the regulatory 
mechanism of SOCE by cytoskeleton. 
8.2.4. Interaction between chlorophenol derivatives and plasma 
membrane ion channels at molecular level 
Three chlorophenol analogues, 4-CEP, 4-CmC and 4-ClP, are found to inhibit SOCE 
by blocking ORAI and TRPC channels. The action sites of 4-CEP on these channels 
are extracellularly located, but the exact target amino acids are not examined. 
Elongation of the 3-alkyl chain of these compounds is accompanied by increased 
potency on channel inhibition, which is an important clue for investigating the 
structural interaction between the drugs and channel proteins. Biophysical studies 
illustrating the crystal structures of the channel pore-forming regions will be helpful 
to understand the non-selective inhibitory mechanism of these compounds on ORAI 
and TRPC channels, and also voltage-gated Na
+
 channels (Haeseler et al., 1999; 
Haeseler et al., 2001). Future electrophysiological studies on other ion channels are 
also required to give a comprehensive view on the pharmacology of chlorophenol 
derivatives. 
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8.2.5. Regulatory mechanisms of TRP channels by copper 
The activation of TRPC channels by Cu
2+
 is a slow process compared to that by 
Gd
3+ 
and trypsin. The mechanism for the initial inhibition and late potentiation is 
unclear. Although the amino acid residues E542, E543 and C554 of TRPC4 are 
found to be involved in the channel activation by Cu
2+
, they seem not to be the 
exclusive determinants for the effect of Cu
2+
, given the evidence that these three 
residues are not conserved in the corresponding regions of TRPC3 and TRPC6. 
Therefore, further mutagenesis work on TRPC3 and TRPC6 is required to 
demonstrate whether there is a universal mechanism responsible for the activation of 
all TRPC channels by Cu
2+
.  
The mechanism underlying the inhibition of TRPM2 channel by Cu
2+
 is possibly 
similar to the action of Zn
2+
 (Yang et al., 2011). As the two residues K952 and 
D1002 of TRPM2 have been demonstrated to be the key determinants for the 
channel inactivation by Zn
2+
, it is worthy to test the effect of Cu
2+ 
on TRPM2 
mutants with these two residues altered, which will give a conclusive result for the 
inhibitory mechanism of Cu
2+ 
on TRPM2 channel. 
8.2.6. TRPC channels as therapeutic targets for cancer and other diseases 
Higher activity of TRPC channels is found to promote the proliferation and colony 
growth of human ovarian cancer cells. These findings from in vitro experiments are 
very important for ovarian cancer research if they can be confirmed in animal 
models and human patients. Genetically modified ovarian cancer cells with 
significantly upregulated or reduced TRPC expression can be injected into mice or 
rats to study the tumour growth in vivo, which will provide solid evidence for the 
role of TRPC channels in tumourigenesis. The expression levels of TRPC channels 
in human ovarian tumours and normal ovarian tissues can be compared by real-time 
quantitative PCR and Western blotting analyses, which may reveal a correlation 
between TRPC expression levels and the differentiation states of ovarian cancer. 
Development of clinically safe TRPC blockers will be an important field in 
pharmacological and pharmaceutical research, which would be useful in the 
treatment of cancer, pathological cardiac hypertrophy and many other diseases. 
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Appendix I: Pharmacological agents used in this study 
Drug Effect 
EGTA Ca
2+
 chelator (low affinity) 
BAPTA Ca
2+
 chelator (high affinity) 
Thapsigargin SERCA blocker, depleting ER/SR Ca
2+
 stores 
2-APB SOCE blocker; IP3R inhibitor; ORAI3 activator 
SKF-96365 Store-operated channel blocker 
Diethylstilbestrol Store-operated channel blocker 
Colchicine Microtubule polymerisation inhibitor 
Cytochalasin D Actin polymerisation inhibitor 
Caffeine RyR agonist 
4-Chloro-3-ethylphenol RyR agonist; store-operated channel blocker 
4-Chloro-m-cresol RyR agonist; store-operated channel blocker 
4-Chlorophenol Store-operated channel blocker 
Genistein Tyrosine kinase inhibitor 
Wortmannin Phosphatidylinositol 3-kinase (PI3K) inhibitor 
Y-27632 Rho-associated protein kinase (ROCK) inhibitor 
Forskolin Protein kinase A (PKA) activator 
GF109203X Protein kinase C (PKC) inhibitor 
Chelerythrine PKC inhibitor 
OAG TRPC3/6/7 activator; PKC activator 
U73122 Phospholipase C inhibitor; increasing F-actin content 
Calyculin A Protein phosphatase inhibitor; increasing F-actin content 
Flufenamic acid SOCE inhibitor; releasing mitochondrial Ca
2+
 
Niflumic acid SOCE inhibitor 
 FCCP Mitochondrial oxidative phosphorylation inhibitor 
Hg
2+
 Mitochondrial oxidative phosphorylation inhibitor 
Sodium azide Mitochondrial cytochrome oxidase inhibitor 
H2O2 Cellular oxidant, increasing oxidative stress 
ADP-Ribose TRPM2 channel activator 
Cu
2+
 TRPC3/4/5/6 activator; TRPM2 blocker 
Gd
3+
 TRPC4/5 activator; SOCE blocker 
Trypsin Protease-activated receptor 2 agonist 
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TRPC Channels and Their Splice Variants are Essential for Promoting 
Human Ovarian Cancer Cell Proliferation and Tumorigenesis  
Bo Zeng1, Cunzhong Yuan2, Xingsheng Yang2, Stephen L. Atkin1 and Shang-Zhong Xu1,* 
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Abstract: TRPC channels are Ca2+-permeable cationic channels controlling Ca2+ influx response to the activation of G 
protein-coupled receptors and protein tyrosine kinase pathways or the depletion of Ca2+ stores. Here we aimed to 
investigate whether TRPC can act as the potential therapeutic targets for ovarian cancer. The mRNAs of TRPC1, TRPC3, 
TRPC4 and TRPC6 were detected in human ovarian adenocarcinoma. The spliced variants of TRPC1β, TRPC3a, 
TRPC4β, TRPC4γ, and TRPC6 with exon 3 and 4 deletion were highly expressed in the ovarian cancer cells, and a novel 
spliced isoform of TRPC1 with exon 9 deletion (TRPC1E9del) was identified. TRPC proteins were also detected by 
Western blotting and immunostaining. The expression of TRPC1, TRPC3, TRPC4 and TRPC6 was significantly lower in 
the undifferentiated ovarian cancer cells, but all-trans retinoic acid up-regulated the gene expression of TRPCs. The 
expression level was correlated to the cancer differentiation grade. The non-selective TRPC channel blockers, 2-APB and 
SKF-96365, significantly inhibited the cell proliferation, whilst the increase of TRPC channel activity by trypsin 
promoted the cell proliferation. Transfection with siRNA targeting TRPC1, TRPC3, TRPC4 and TRPC6 or application of 
specific blocking antibodies targeting to TRPC channels inhibited the cell proliferation. On the contrary, overexpression 
of TRPC1, TRPC1E9del, TRPC3, TRPC4, and TRPC6 increased the cancer cell colony growth. These results suggest that 
TRPCs and their spliced variants are important for human ovarian cancer development and alteration of the expression or 
activity of these channels could be a new strategy for anticancer therapy. 
Keywords: Calcium channels, ovarian cancer, proliferation, SKOV3 cells, TRPC. 
INTRODUCTION 
Ca2+ is a second messenger which plays a major role in 
the regulation of cellular functions, such as contraction, 
secretion, cell growth and death. The concentration of 
cytosolic Ca2+ ([Ca2+]i) is tightly controlled by Ca2+ 
transporters in the plasma membrane and intracellular Ca2+ 
stores. The transient receptor potential (TRP) proteins are 
novel class of Ca2+-permeable cationic channels including 
six subfamilies, i.e., TRPC, TRPM, TRPV, TRPP, TRPML 
and TRPA. The canonical TRP (TRPC) is one of the 
subfamilies, which has been proposed as protein tyrosine 
kinase or G protein-coupled receptor-operated Ca2+ channels 
(ROCs) or internal Ca2+ store-operated channels (SOCs), 
which mediate the Ca2+ signalling pathway activated by 
many hormones and growth factors. TRPCs are ubiquitously 
distributed in the body and play essential roles in human 
physiology and pathophysiology [1, 2]. 
Ca2+ signalling is believed to play a central role in the 
signalling cascades of tumorigenesis and neoplastic 
progression by controlling gene expression, progression 
through the cell cycle, and DNA synthesis. The inhibitors  
of Ca2+-dependent signalling suppress the proliferation of 
cancer cells in vitro and in solid tumors in vivo [3]. Store-
operated Ca2+ influx is one of the Ca2+ entry pathways and  
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closely related to cell proliferation and apoptosis. The 
importance of store-operated Ca2+ influx or capacitative Ca2+ 
influx in cancer development has been recognised for many 
years, however the role of TRP channels that act as the 
molecular constituents or subunits of SOCs or ROCs in 
cancer cell proliferation are still unclear [4]. In 2005, we 
demonstrated that TRPC channel is involved in cell 
proliferation, and 2-aminoethoxydiphenyl borate (2-APB) 
significantly inhibits the proliferation in HEK-293 cells. The 
mechanism is unrelated to its inhibitory action on inositol 
1,4,5-trisphosphate receptors (IP3R), since 2-APB also 
inhibits the proliferation of triple IP3R knockout DT40 cells 
[5]. This suggests the direct involvement of SOCs or TRPC 
channels in cell proliferation. Recently, several studies have 
demonstrated the expression of TRPC in different types of 
cancer cells or cancer tissues, such as TRPC1, 3, 6 in breast 
cancer MCF7 cells [6] and liver cancer HepG2 [7], TRPC1, 
3, 4 in prostate cancer LNCaP cells [8, 9], TRPC1, 4, 6, 7 in 
renal cell carcinoma [10], TRPC1, 3, 5, 6 in human 
malignant gliomas [11], TRPC1, 3-7 in neuroblastoma IMR-
32 cells [12], TRPC3 in human astrocytoma 1321N1 cells 
[13], TRPC6 in esophageal and gastric cancer [14], TRPC3 
in ovarian cancer [15], and TRPC1, 4 in basal cell carcinoma 
[16]. However, the detection of splicing activity of TRPCs 
and systematic examination of the role of each TRPC 
isoform in cancer growth has not been addressed.  
Here we aimed to identify the expression of TRPCs and 
their splicing variants in human ovarian adenocarcinoma and 
the cancer-derived cell SKOV3, and determine the roles of 
TRPC isoforms in the regulation of cancer cell proliferation 
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using TRPC siRNA interference and the pharmacological 
tools, such as the specific TRPC channel functional 
antibodies [5]. We also examined the colony growth of 
ovarian cancer cells by over-expressing TRPC isoforms. In 
addition, we compared the expression of TRPC genes in the 
human ovarian cancer tissues from patients with the normal 
ovarian tissues, and their involvement in ovarian cancer cell 
differentiation.  
MATERIALS AND METHODS 
Human Ovarian Cancer Tissues 
Paraffin blocks of human ovarian adenocarcinoma tissue 
were obtained from patients undergoing ovariectomy at Hull 
and East Yorkshire NHS Trust (Hull, UK) with approval of 
the local ethics committee. The fresh ovarian cancer tissues 
were obtained from Qi Lu Hospital of Shandong University 
(Jinan, China) with ethical approval.  
Cell Culture 
Human ovarian adenocarcinoma cells (SKOV3, ATCC 
HTB-77) were purchased from LGC Promochem (Middlesex, 
UK). The SKOV3 cells were cultured in a flask with DMEM-
F12 medium (Invitrogen, UK) supplemented with 10% fetal 
calf serum, 100 units/ml penicillin and 100 µg/ml streptomycin, 
and maintained at 37°C under 95% air and 5% CO2.  
RT-PCR and Real-time PCR 
Total RNA was extracted from human ovarian tissues or 
cultured cells using Trizol reagent (Invitrogen, UK). The 
mRNA was reverse-transcribed to cDNA using M-MLV 
reserve transcriptase (RT) and random primers (Promega, 
UK). The primer set was designed across intron and the 
sequences were given in the Supplementary Table 1. Non-
template or non-RT was set as negative control, and the 
TRPC plasmid cDNAs or mouse brain cDNA were used as 
positive control. PCR products were detected on a 2 % 
agarose gel and confirmed by direct sequencing. Quantitative 
RT-PCR was performed using StepOne™ Real-Time PCR 
System (Applied Biosystems, UK). Each reaction volume 
was 10 µl, which contained 1 × Universal Master Mix 
(Applied Biosystems), 5 µl cDNA, 0.75 µl 300 nM forward 
primer, 0.75 µl 300 nM reverse primer. The human 
housekeeping gene GAPDH was used as an internal 
standard. Water was used as a non-template control. Non-
reverse transcribed samples were run in parallel to confirm 
that positive results were not due to amplification of 
genomic DNA. The PCR cycle consisted of an initial cycle 
of 50 °C for 2 min followed by 95 °C for 10 minutes, then 50 
repeated cycles of 95 °C for 15 s denaturation and 54 °C 
annealing temperature for 30 s, and primer extension at 72 °C 
for 30 s.  
Antibodies and Western Blotting 
Rabbit polyclonal anti-TRPC antibodies were generated 
against the extracellular third loop (E3) region near the 
channel pore [17] or targeting to C-terminus [18]. The 
specificity of E3-targeting antibodies (anti-TRPC1 (T1E3), 
anti-TRPC4 (T45E3), anti-TRPC5 (T5E3) and anti-TRPC6 
(T367E3)) was tested by ELISA, Western blotting and 
functional assays [17]. The specific binding of E3-targeting 
antibodies was also confirmed by fluorescence activated cell 
sorting (FACS) (Fig. S1). The Western blotting procedure 
has been previously described [17].  
Immunostaining 
Cells were fixed with 4% paraformaldehyde and 
permeabilised by incubation in -20°C methanol for 1 minute 
and 0.1% Triton X-100 in phosphate buffered saline (PBS) 
for 1 hour at room temperature. For unpermeabilised 
staining, the steps for methanol and Triton X-100 were 
omitted. Cells were incubated in the appropriate TRPC 
primary antibodies (T1E3 at 1:500 dilution, T45E3, T367E3, 
anti-TRPC3 at 1:250 dilution) in PBS with 1% BSA at 4°C 
overnight. The anti-TRPC3 targeting C-terminus and the 
anti-TRPC6 targeting to N-terminus were purchased from 
Alomone Labs (Jerusalem, Israel) and used for comparison. 
The procedures for fluorescent staining and paraffin section 
staining using VECTASTAIN ABC kit (Vector laboratories) 
were similar to the previous reports [19]. Immunostaining 
was quantified by imaging software (Image-Pro Plus, Media 
Cybernetics, USA). 
SiRNA Transfection 
The TRPC siRNAs were purchased from Sigma-Aldrich 
(UK) (Supplementary Table 2). TRPC siRNAs were 
transfected into SKOV3 cells using Lipofectamine 2000 
(Invitrogen, UK) [2]. The wells or dishes without siRNA (no 
siRNA) or with scramble siRNA (Sigma-Aldrich, UK) or 
non-specific pool siRNA were set as negative control in 
parallel. The Bcl-2 siRNA was used as positive control. For 
cell cycle experiment, SKOV3 cells were transfected with 
TRPC siRNAs using the Neon electroporation system 
(Invitrogen, UK). The cells were resuspended to a density of 
5×106/ml and mixed with 200 nM siRNA, and then pulsed 
twice at 1,170 V for 30 ms in a 100 µl tip. After 
electroporation the cells were maintained in antibiotic-free 
medium for 72 h and harvested for flow cytometry assay. 
TRPC Cloning, Plasmid Construction and Expression 
TRPC1, TRPC1E9del and TRPC6 tagged with monomeric 
cyan fluorescent protein (CFP) were subcloned into 
pcDNA4/TO vector (Invitrogen, UK). TRPC3 tagged with 
monomeric red fluorescent protein (mCherry) and TRPC4 
(α, β, and ε isoforms) tagged with enhanced yellow 
fluorescent protein (EYFP) were also subcloned into 
pcDNA4/TO vector. The plasmid cDNA of each TRPC 
isoform was transfected into HEK293 T-REx cells 
(Invitrogen, UK) using Lipofectamine 2000 and the 
expression was induced by tetracycline (1 µg/ml) and 
confirmed by fluorescent microscope examination. The 
channel activity was recorded by whole-cell patch clamp.  
Cell Proliferation Assay and Colony Growth 
Cell proliferation was determined using WST-1 assay 
(Roche, UK). This assay reflects the metabolic activity of the 
cultured cells. The overall cellular metabolic activity 
measured by optical absorption correlates well with the 
viable cell number in the culture dish/well. For colony 
growth, SKOV3 cells transfected with TRPC plasmid 
cDNAs using Lipofectamine 2000, and the cells were plated 
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in 6-cm culture dishes at a density of 500 cells per dish to 
allow to form colonies after 3-8 days culture. The colonies 
were fixed with 25% methanol, stained with 0.5% crystal 
violet dye in PBS, and automatically counted by CellC 
software (Version 1.2, Tampere University of Technology, 
Finland). For soft agar colony assay, the bottom layer of agar 
(0.7 %) was prepared in a 35-mm culture dish with 1.5 ml of 
DMEM-F12 medium containing agar, 10% FBS, 50 µg/ml 
penicillin and 50 µg/ml streptomycin. After solidification of 
the bottom layer, SKOV3 cells were suspended in 1 ml 
medium containing 0.35% agar at a density of 5000 cells/ml 
and poured into the dish to form a second layer. The dish 
was kept at 4 oC for 5 min and then the solidified second 
layer was covered with 1 ml medium to prevent the agar 
layer from drying out. The cells were incubated at 37°C in a 
humidified incubator and the top layer of medium was gently 
changed every 3 days. After 21 days of culture, the cells 
were stained with 0.005% crystal violet and the cell colonies 
with diameters >100 µm were counted under microscope 
with 4× objective. 
Cell Cycle and Apoptosis Analyses 
Simultaneous measurement of cell cycle and apoptosis 
was conducted using flow cytometric assay with propidium 
iodide staining as described by Riccardi and Nicoletti [20]. 
Briefly, SKOV3 cells at 70-80% confluency in a 100-mm 
culture dish were trypsinized, washed with PBS, fixed with 
70% cold ethanol, incubated with DNA extraction buffer 
(0.2 M Na2HPO4, 0.004% Triton X-100, pH 7.8), treated 
with RNase (200 µg/ml), and stained with propidium iodide 
(20 µg/ml). The cells were then analysed with BD 
FACSCalibur Flow Cytometry System (Becton Dickinson, 
UK) with the CellQuest software. Events were counted at the 
limit of 20,000 or 10,000 for the drug-treated or siRNA-
transfected groups. Cell debris was gated out according to 
the scatter plot and the percentages of cells at different 
phases of cell cycle were calculated based on the histogram 
plot of fluorescent intensities. 
Reagents and Chemicals 
2-Aminoethoxydiphenyl borate (2-APB), SKF-96365, 
carbenoxolone, trypsin, all-trans retinoic acid, PCR primers, 
TRPC1, 4, 6 siRNAs and scramble siRNA were purchased 
from Sigma-Aldrich. TRPC3 siRNA was purchased from 
Santa Cruz Biotechnology (USA). Bcl-2 siRNA and pool 
siRNA were from Upstate Biotech (USA). 
Statistical Analysis 
Data are expressed as mean ± S.E.M. The statistical 
significance was analysed using ANOVA and the difference 
among the groups was assessed with Dunnett's t-test in the 
SPSS software. The triplicate wells (or 8 wells/column) were 
set for cell proliferation assay. 
RESULTS 
Expression of TRPCs in Human Ovarian Cancer SKOV3 
Cells 
The mRNA of TRPCs in ovarian cancer cells was 
detected by RT-PCR (Fig. 1A). TRPC1, TRPC3, TRPC4 and 
TRPC6 were positive in human ovarian adenocarcinoma 
SKOV3 cells, while TRPC5 and TRPC7 were undetectable 
in the cells although the primer sets used for TRPC5 and 
TRPC7 was able to amplify the plasmid cDNAs (Fig. 1B) or 
the total RNA extracted from mouse brain (Fig. S2). Two 
bands for TRPC1 were detected, suggesting splicing 
isoforms may exist in the cells. 
The protein expression of TRPC channels was probed by 
western blotting (Fig. 1C). The protein bands for TRPC1, 
TRPC3, TRPC4 and TRPC6 were detected using anti-
TRPC1 (T1E3), anti-TRPC3, anti-TRPC4 (T45E3) and anti-
TRPC6 (T367E3) antibodies, respectively, while no specific 
band was detected using preimmune serum or antibody pre-
absorbed with antigenic peptide. Same size of TRPC6 
protein band was detected by anti-TRPC6 antibody targeting 
the N-terminus (Fig. 1C). 
Identification of TRPC Spliced Variants 
The expression of TRPC spliced variants in SKOV3 cells 
were examined by RT-PCR using specific primer sets across 
introns. The spliced variant of TRPC1 with exon 3 deletion 
(TRPC1β) was detected using the primer set across exon 3 
(P1). The band density of TRPC1β is much stronger than the 
full-length isoform (TRPC1α) (Fig. 2A), suggesting that the 
β-isoform is highly expressed in the cancer cells. Using the 
primer set across the exon 9 and 10 (P3), a novel spliced 
variant of TRPC1 with exon 9 deletion (TRPC1E9del) was 
identified (GenBank accession No. GQ293239). The 
existence of TRPC1E9del was also confirmed by using the 
TRPC1 primer set across exon 9 (P4). The band density of 
the TRPC1E9del was less abundant than the non-spliced 
TRPC1 isoform in the region. The deletion of exon 9 did not 
cause open reading frame shift, suggesting this new spliced 
isoform may have a channel pore domain and C-terminus 
that seen in α or β isoforms. Interestingly, the TRPC1E9del 
isoform was absent in normal mouse brain tissue (Fig. S2) 
and vascular smooth muscle cells or arteries detected by 
same primer set (P4) [21]. These data suggested that TRPC1 
is actively spliced in cancer cells. In addition, we also 
examined the possibility for other splicing regions using 
primer set P2 and P5, and the primer combination ranged 
from exon 1 to exon 13, but no other splicing site was 
identified.  
Full-length human TRPC3 has 12 exons and a 58-base 
pair insert between exon 2 and exon 3. Using primer set 
across exon 2-5 (P1), or exon 3-5 (P2), exon 5-6 (P3) and 
exon 8-9 (P4), single PCR band with the expected size was 
detected. TRPC3 has an isoform with an extended N-
terminus (TRPC3a) [22], so we detected this isoform using 
primer set across exon 1-5 (P0). As shown in Fig. (2B), a 
band with an expected size of 1405 bp was detected, 
suggesting the TRPC3a isoform existed in the SKOV3 cells. 
We also amplified the regions of exon 5-9 and exon 8-12, 
but no other spliced isoforms were found in SKOV3 cells. 
Eight spliced variants of human TRPC4 have been 
reported including α, β, γ, δ, ε, ζ, η and an unnamed isoform 
truncated at exon 6. Based on the sequence alignment (Fig. 
S3), the α, β, γ, δ, ε and ζ isoforms of TRPC4 have 100 % 
identity for the region from exon 1 to exon 7 except TRPC4ζ 
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that has exon 3 deletion. The η-isoform has an early stop 
code due to open reading frame shift at the end of exon 3. 
Using primer set P1 and P4, TRPC4 was positive in SKOV3 
cells with the size of 740 bp and 519 bp, respectively. 
However, the ζ-isoform with exon 3 deletion was 
undetectable using the primer set across exon 1-5 (P2) (data 
not shown). The ε-isoform of TRPC4 was also undetectable 
with the forward primer in exon 7 and the ε-isoform specific 
reverse primer. However, two bands were detected with an 
expected size of 428 bp and 623 bp using the primer set (P3). 
The smaller band is specific for TRPC4γ and the bigger band 
is the unspliced isoforms of TRPC4 without exon 8 deletion. 
Similarly, two bands were detected if the primer set across 
the exon 8 alone (P6) (data not shown) was used, suggesting 
the TRPC4γ and other isoforms co-existed in the SKOV3 
cells. To further distinguish the TRPC4 isoforms, the primer 
set (P7) amplifying exon 7 to exon 12 were used, the 
detected band with a predicted size of 956 bp is α-isoform, 
and the small band (704 bp) for the β-isoform (Fig. 2C). In 
addition, we also examined the possibility for other splicing 
regions using the forward and reverse primer combinations 
ranged from exon 1 to exon 11, and no other splicing region 
was found. These data indicated that α-, β- and γ-isoforms of 
TRPC4 coexist in the SKOV3 cells.  
There are 13 exons for human TRPC6. Three bands were 
detected using primer set (P1) to amplify exon 1-5. The size 
for the full-length TRPC6 is 1222 bp. The two spliced 
isoforms with exon 3 deletion is 1039 bp and with exon 3 
and 4 deletion is 874 bp, respectively. No spliced region was 
found between exon 8 to exon 13 (Fig. 2D).  
Functional Properties of TRPC Isoforms 
We examined the functional properties of TRPC isoforms 
using whole-cell patch recording. TRPC1, TRPC1E9del, 
TRPC3, TRPC4α, TRPC4β, TRPC4ɛ and TRPC6 were 
inducibly expressed in HEK293 T-REx cells using 
pcDNA4/TO expression system. TRPC1 and TRPC1E9del 
were mainly located intracellularly (See Fig. 6C) and the 
whole-cell current was small (data not shown), however the 
currents for TRPC3, TRPC4α and TRPC6 were robust and 
significantly evoked by trypsin via G protein-coupled 
 
Fig. (1). Expression of TRPC channels in human ovarian cancer cells. A. Detection of TRPC mRNAs by RT-PCR using the primer set 
for TRPC1 (P3), TRPC3 (P4), TRPC4 (P5), TRPC5, TRPC6 (P3) and TRPC7 (see supplementary Table 1). The β-actin was used as positive 
control, and the reverse transcript step omitting the reverse transcriptase (no RT) was set as negative control. B. TRPC5 and TRPC7 were 
undetectable in (A), but positive if the plasmid TRPC5 and TRPC7 cDNAs were used as positive control. C. Western blotting detection of 
TRPC proteins using anti-TRPC1 (T1E3), anti-TRPC3, anti-TRPC4 (T45E3) and anti-TRPC6 (T367E3 (i) and anti-TRPC6 targeting to N-
terminal (ii)) antibodies. No band was detected by anti-TRPC5 antibody (T5E3) in SKOV3, but positive for the rat brain lysate. Two bands 
were detected by anti-TRPC1 (T1E3) and competed by antigenic peptide. 
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receptor activation and blocked by 2-APB (Fig. S4). We 
compared the functionality of TRPC4α, TRPC4β and 
TRPC4ɛ isoforms. TRPC4α and TRPC4β showed a similar 
current-voltage (IV) relationship and both of them were 
activated by Gd3+ and blocked by 2-APB, however the 
current for TRPC4ɛ was much smaller and the IV curve was 
linear, which is different from the IV curves for TRPC4α and 
TRPC4β with double rectifications (Fig. S5). These results 
suggest the potential functional differences among the TRPC 
isoforms due to the different subcellular distribution and 
channel properties. 
Ovarian Cancer Cell Growth Regulated by TRPC 
Channel Modulators 
2-APB is a non-selective blocker of TRPC channels [5]. 
The blockade of TRPC channels by 2-APB significantly 
inhibited the SKOV3 proliferation in a concentration-
dependent manner with an EC50 of 5.9 µM (Fig. 3A). Since 
2-APB has been shown to inhibit gap junctional channels, 
which might contribute to the anti-proliferative effect [23, 
24], we pretreated the SKOV3 cells with carbenoxolone, a 
gap junctional blocker, to pharmacologically dissect out the 
 
Fig. (2). Detection of TRPC spliced variants in human ovarian cancer SKOV-3 cells. A. RT-PCR products of TRPC1 were amplified by 
specific primer set labelled as P1 to P5. Two products were amplified using primer set P1 with a size of 403 bp (TRPC1α) and 301 bp 
(TRPC1β). A small product with exon 9 deletion (C1E9del) was identified using primer set P4 (405 bp for C1E9del, and 549 bp for TRPC1α/β 
isoforms). The C1E9del was also detected using primer set P3 (423 bp for α/β isoforms; 279 bp for C1E9del). No other splicing region was 
detected using primer set P2, P5 and the primer combinations amplifying exon 1-6 and exon 11-13. B. The TRPC3 spliced variant with an 
extended N-terminus was detected using primer set P0 (1221 bp). Single PCR product was found using primer set P1, P3 and P4, or P2 and 
the primers amplifying exon 8 to exon 12 (not shown). C. TRPC4 isoforms were detected by primer set P1 and P4. The ζ-isoform with exon 
3 deletion (C4E3del) amplified by set P2 (not shown) and ε-isoform amplified by isoform-specific primer were negative The γ-isoform with 
exon 8 deletion (C4E8del) was detected by primer set P3, and P6 (not shown). Using primer set P7, both α-isoform (956 bp) and β-isoforms 
(704 bp) were detected. D. Two TRPC6 spliced isoforms were detected using primer set P1. Single band of TRPC6 with an expected size 
was detected by primer set P2 (551 bp) and P3 (476 bp). PCR products were confirmed by direct sequencing. 
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contribution of TRPC channels. Carbenoxolone at 200 µM 
and 400 µM significantly inhibited the cell proliferation  
(Fig. 3B), but the anti-proliferative effect of 2-APB was  
still reserved in the presence of carbenoxolone (Fig. 3C), 
suggesting that the anti-proliferative effect of 2-APB  
could be due to the inhibition on TRPC channels. We also 
observed the effect of SKF-96365, another non-specific 
TRPC channel blocker. SKF-96365 significantly inhibited 
the cell proliferation of SKOV3 in a concentration-dependent 
manner with an EC50 of 14.5 µM (Fig. 3D), however Gd3+ 
which can differentially activate TRPC4 and TRPC5 
channels showed a stimulating effect on cell proliferation 
(Fig. 3E). In addition, we tested the channel activator trypsin 
on cell proliferation. Trypsin significantly stimulated 
TRPC3, 4 and 6 channels as shown in Fig. (S4), which  
can be explained by the mechanism of protease-activated 
receptor activation. Incubation with trypsin promoted the 
cancer cell proliferation (Fig. 3F). These data suggest the 
importance of TRPC channel activity in regulating ovarian 
cancer cell growth, and the channel blockers could have the 
potential for anti-cancer therapy. 
Role of TRPC Isoforms in Ovarian Cancer Cell 
Proliferation 
To identify the role of individual TRPC isoforms on  
the cancer cell proliferation, SKOV3 cells were incubated 
 
Fig. (3). Ovarian cancer cell proliferation was inhibited by store-operated channel blockers. A. SKOV3 were incubated with different 
concentrations of 2-APB for 24 h. The cell proliferation was monitored by WST-1 assay and the absorbance was measured at a wavelength 
of 450 nm with a reference at 600 nm. B. SKOV3 treated with carbenoxolone for 24 h. C. SKOV3 cells were incubated with carbenoxolone 
and 2-APB for 24 h. D. Effect of SKF-96365 on SKOV with a IC50 of 14.5 µM after 24 hour incubation. E. Effect of Gd3+. F. Incubation 
with trypsin (0.1-10 nM). Each experiment had 8 well repeats and the data were from ≥ two independent experiments. *** P<0.001. 
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Fig. (4). Role of TRPC channels in the ovarian cancer growth. A. SKOV3 cells were incubated with functional antibodies (1:500 dilution 
for anti-TRPC1 (T1E3); 1:250 dilutions for anti-TRPC4 (T45E3), anti-TRPC5 (T5E3) and anti-TRPC6 (T367E3) for 24 hours and the cell 
proliferation was measured by WST-1 assay. n =16 for each group. B. SKOV3 cells were transfected with TRPC siRNAs (100 nM siRNA for 
each group) using Lipofectamine 2000. Cell proliferation was measured with WST-1 assay after 48 h transfection. The sham transfection 
(control), pool siRNA and scramble siRNA were negative control. Bcl-2 siRNA was used as positive control. n =16 for each group. C. 
Ovarian cancer colony formation assay. The SKOV3 cells over-expressing with plasmid TRPC cDNAs (indicated) or vector and the cancer 
colonies were stained with crystal violet. D. Mean ± SE data showed the large (>2 mm2) colony number. Triplicate wells were used for each 
group. Results were reproducible in more than three independent experiments. E. Examples of ovarian cancer colonies grown in soft agar and 
stained with crystal violet. The SKOV3 cells over-expressing with plasmid TRPC cDNAs (indicated) or vector. F. Mean ± SE data showed 
the number of large colony with a diameter >100 µm. Triplicate wells were used for each group. ** P<0.01, *** P<0.001. 
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with E3-targeting TRPC functional antibodies that can 
specifically inhibit Ca2+ influx via TRPC channels [17, 21]. 
The specificity of antibody binding was confirmed by 
ELISA and FACS as shown in Fig. (S1). The blockade of 
TRPC1, TRPC4 and TRPC6 channels by T1E3, T45E3 and 
T367E3 significantly decreased the cancer cell proliferation 
(Fig. 4A), but T5E3, which can block TRPC5 channel only, 
had no effect on cell proliferation, further suggesting the lack 
of TRPC5 expression in SKOV3 cells.  
The isoform-specific TRPC siRNAs were used to further 
demonstrate the role of TRPCs in cancer cell proliferation. 
The downregulation of TRPCs by siRNAs was confirmed by 
real-time PCR (data not shown). There was no difference 
 
Fig. (5). Cell cycle arrested by TRPC channel blocker SKF-96365 and TRPC siRNAs in ovarian cancer cells. A. The representative 
FACS histogram for vehicle (DMSO) and SKF-96365 (10 µM), and the mean ± SE data from three independent experiments. B. SKOV3 
cells transfected with scramble siRNA (siScramble) and TRPC siRNA (siTRPC1, siTRPC4, siTRPC3, and siTRPC6) for 72 hours. The 
percentage of propidium iodide -labelled cells at different cell cycle stage was determined by FACS analysis. The mean ± SE data were from 
three independent experiments. * P<0.05, ** P<0.01, *** P<0.001 comparing with the vehicle group or the scramble siRNA transfected group. 
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among the groups transfected with scramble siRNA, pool 
siRNA and mock control transfection (no siRNA) on 
SKOV3 cell proliferation. However, the cell proliferation 
was significantly inhibited by the transfection with TRPC1, 
TRPC3, TRPC4 and TRPC6 siRNAs for 48 hours. Bcl-2 
siRNA, which targets the anti-apoptotic Bcl-2 gene, was 
used as a positive control, also significantly inhibited cell 
proliferation (Fig. 4B). These results were similar to the 
observations using specific anti-TRPC functional antibodies, 
suggesting that the silencing of TRPC channel expression is 
important for the inhibition of cancer cell proliferation. 
Overexpression of TRPC Isoforms Promotes Cancer 
Colony Growth 
There are no specific siRNAs or blocking antibody tools 
targeting to individual spliced variants of TRPCs, therefore 
we overexpressed the TRPC isoforms to further confirm the 
role of TRPC in ovarian cancer growth. SKOV3 cells were 
transfected with the plasmid TRPC and TRPC1E9del cDNAs 
and the cancer cell colony formation was observed. As 
shown in Fig. (4C-D), the large colony number (>2 mm2) 
was greatly increased in the groups transfected with TRPC1, 
TRPC1E9del, TRPC3, TRPC4 and TRPC6. We also examined 
 
Fig. (6). TRPC expression detected in human ovarian adenocarcinoma. The mRNA was detected by RT-PCR. The PCR amplicons for 
TRPC1 (i: primer P1; ii: primer P3), TRPC3, TRPC4 and TRPC6 were shown in (A). Five cancer samples from patients with undifferentiated 
ovarian serous papillary adenocarcinoma, and five normal samples were run in parallel. The GAPDH was used as control. B. The band 
density was quantified by a gel documentation software (VisionWorks LS6.3). The relative expression of TRPC/GAPDH was given. * 
P<0.05, *** P<0.001. 
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Fig. (7). Distribution of TRPC isoforms in human ovarian adenocarcinoma tissues and cells and the dependence of cell 
differentiation. A. Human ovarian adenocarcinoma tissue sections were stained with anti-TRPC1 (T1E3), anti-TRPC4 (T45E3), anti-TRPC3 
(Alomone lab) and anti-TRPC6 (i:T367E3; ii:TRPC6 antibody from Alomone lab) using VECTASTAIN ABC Systems. The positive staining 
was shown as brown colour, and the nuclei were counter-stained by hematoxylin. The preimmue serum was used as control. Scale bar is 100 
µm. B. Mean data for the staining intensity of the ovarian cancer. The n number is 15 microscopy fields for the quantification of the 
undifferentiated ovarian cancer from three patients, and n = 12 for the well differentiated ovarian tumour group from three patients. C. TRPC 
expression enhanced by all-trans retinoic acid (atRA). The mRNA was detected by real-time PCR. The GAPDH was used as a housekeeping 
gene for relative quantification. The 2(-∆∆Ct) method was used for calculation. SKOV3 cells were treated with or without 1 µM atRA for 5 
days. The culture media were refreshed every 24 hours. D. (i): SKOV3 cells stained with anti-TRPC1 (T1E3), anti-TRPC3, anti-TRPC4 
(T45E3) and anti-TRPC6 antibodies at a dilution of 1:500 and the secondary anti-rabbit antibody conjugated with FITC (green). Same 
dilution of preimmune serum or no primary antibody was used as control. The nuclei were stained by 4',6-diamidino-2-phenylindole (DAPI, 
blue). Scale bar is 25 µm. (ii): Distribution of TRPC isoforms in the transfected HEK-293 T-REx cells. The TRPC1, TRPC1E9del and TRPC6 
cDNAs were tagged with CFP (blue), TRPC3 tagged with mCherry (Red), and TRPC4 (α, β and ε isoforms) tagged with EYFP. ** P<0.01, *** 
P<0.001. 
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the cancer colony growth using soft agar assay. The number 
of larger colony with a diameter >100 µm was much higher 
in the groups transfected with TRPC1, TRPC1E9del, TRPC3, 
TRPC4 and TRPC6 than that in the vector control group, 
which further suggested the involvement of TRPCs in the 
ovarian cancer development.  
Effects of TRPC Channel Blocker and Gene Silencing on 
Cell Cycle 
The ovarian cancer cell cycle was determined by FACS 
using propidium iodide staining procedure [20]. Incubation 
with the non-selective TRPC channel blocker SKF-96365 
(10 µM) substantially increased the G2/M phase and 
decreased the G0/G1 phase in the SKOV3 cells (Fig. 5A), 
which was accorded to the previous report [15]. To further 
observed the effects of individual TRPC genes on cell cycle 
progress, the SKOV3 cells were transfected with TRPC 
siRNAs. We found that more SKOV cells were arrested at 
G2/M phase after transfection with siTRPC1, siTRPC4, 
siTRPC3, and siTRPC6 for 72 hours comparing with the 
control group transfected with scramble siRNA (Fig. 5B), 
suggesting that the downregulation of TRPC gene expression 
can arrest the cell cycle progression through G2/M to G1. 
Unlike the channel blocker SKF-96365, the contribution of 
TRPC gene silencing on apoptosis was small (Fig. 5). The 
down-regulation of TRPC expression did not significantly 
change the apoptosis in ovarian cancer. 
Differentiation-associated TRPC Expression 
The expression of TRPC was examined by RT-PCR 
using ovarian cancer tissues from five patients with 
undifferentiated ovarian serous papillary adenocarcinoma. 
The five normal ovarian tissues obtained from patients at a 
similar age but without ovarian cancer were used as control. 
The mRNAs for TRPC1, TRPC3, TRPC4 and TRPC6 were 
positive in normal and ovarian cancer tissues. However, the 
mRNA level of TRPC1, TRPC3, TRPC4 and TRPC6 was 
significantly lower in the undifferentiated ovarian cancer 
than that in normal ovarian tissue (Fig. 6), suggesting that 
the expression of TRPCs was down-regulated in the cell type 
of undifferentiated ovarian cancer.  
We also examined the protein expression of TRPCs in 
human ovarian adenocarcinoma tissues by immunostaining. 
The paraffin-embedded ovarian cancer tissue sections were 
stained using Vectastain ABC systems. TRPC1, TRPC4 and 
TRPC6 were positively stained by T1E3, T45E3 and T367E3 
antibodies, while the control staining with preimmune serum 
or without primary anti-TRPC antibodies was negative.  
The staining pattern for TRPC6 was similar to that by an 
anti-TRPC6 antibody targeting to the N-terminus (Fig. 7A). 
We compared the immunostaining density between the 
undifferentiated or poorly differentiated (Grade 3) and well 
differentiated (Grade 1-2) ovarian tissue sections. The 
expression of TRPC1, TRPC4 and TRPC6 were significantly 
lower in the undifferentiated ovarian cancer tissues (Fig. 7B). 
TRPC Expression Enhanced by all-trans Retinoic Acid 
(atRA) 
AtRA is a potent regulator for cell differentiation in a 
variety of cell types and plays an important role in anticancer 
therapy by affecting gene transcription [25, 26]. To further 
examine the association of TRPC in ovarian cancer cell 
differentiation, we tested the effect of atRA on TRPC 
expression. Using real-time RT-PCR, we found that the 
mRNA level for TRPC1, TRPC3, TRPC4, and TRPC6 was 
significantly increased in the SKOV3 cells treated with 1 µM 
atRA for 5 days (Fig. 7C), suggesting that TRPC expression 
is associated with atRA-induced cell differentiation.  
Subcellular Distribution of TRPC Isoforms 
The subcellular distribution of TRPC channel proteins 
was investigated in the SKOV3 cells and the TRPC-
transfected cells. SKOV3 cells were stained with anti-
TRPC1 (T1E3), anti-TRPC3, anti-TRPC4 (T45E3) and anti-
TRPC6 (T367E3) antibodies. TRPC1 was more evident in 
the cytosol, but TRPC3, TRPC4 and TRPC6 were apparent 
in the plasma membrane (Fig. 7D(i)). The cultured SKOV3 
had an irregular and very flat cell shape and tightly attached 
onto the coverslips, so it was hard to obtain a Z-section with 
a typical imaging for plasma membrane staining. Therefore, 
the unpermeabilized staining was also performed for TRPC1, 
TRPC4 and TRPC6 using extracellular binding antibodies, 
and the stainings were also positive (Fig. S6). Due to the 
lack of TRPC spliced variant-specific antibodies, it is 
impossible to see the subcellular localization of TRPC1E9del 
and TRPC4 isoforms in the native ovarian cancer cells, 
therefore, we explored the subcellular localization in the 
HEK-293 T-REx cells by over-expressing the isoforms 
tagged with fluorescence proteins. TRPC1E9del protein was 
mainly intracellularly located, which is similar to that of the 
full-length TRPC1. However, channel proteins for TRPC3, 
TRPC4α, TRPC4β, TRPC4ε and TRPC6 were evident in the 
plasma membrane (Fig. 7D(ii)). 
DISCUSSION 
We have shown that TRPC1, TRPC3, TRPC4 and 
TRPC6 exist in the tissue section of human ovarian 
adenocarcinoma and the ovarian adenocarcinoma-derived 
cell line SKOV3. We have also shown that several spliced 
variants of TRPC1, TRPC3, TRPC4 and TRPC6 co-express 
in the ovarian cancer cells. In addition, a new TRPC1 spliced 
variant with exon 9 deletion has been identified in this study. 
Blockade of TRPC channel activity by 2-APB, SKF-96365, 
or by TRPC isoform-specific functional antibodies or by the 
transfection with TRPC siRNAs significantly inhibits the 
cancer cell proliferation, whilst the increase of TRPC 
channel activity by G protein-coupled receptor activation 
promotes the ovarian cancer cell growth. Overexpression of 
TRPC genes also increases ovarian cancer colony growth. 
Moreover, the expression in undifferentiated human ovarian 
cancer is significantly lower than in normal ovarian tissues. 
These findings are novel and important for understanding the 
roles of TRPC channels in ovarian cancer development.  
TRPC channels have been identified in many cell types 
[2, 18, 27, 28]. These channels are differentially expressed at 
different stages of stem cell development, which may reflect 
their importance in cell differentiation [29, 30]. On the other 
hand, the thapsigargin-induced store-operated Ca2+ influx is 
higher in tumour cells than that in normal cells [31], which 
further suggests the relevance of TRPC channels or store-
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operated channel molecules to cancer development. In this 
study, we have systematically detected the TRPC channels 
and their splice variants, and found that multiple TRPCs  
and their spliced isoforms exist in human ovarian cancer. 
TRPC1 has been suggested as a store-operated channel 
subunit and actively associates with other TRPC isoforms, 
such as TRPC1/4 or TRPC1/5 [18, 32], or interacts with 
other channel proteins, such as ORAI1 or STIM1 [33], to 
constitute the heteromultimeric store-operated channels  
or channel complexes, which could be main molecular 
components in native cells. Interestingly, the existence of 
several spliced isoforms of TRPCs in a cell suggests the 
possibility of functional interaction or regulation on the 
channel activity. TRPC1γ1 and TRPC1γ2 have been reported 
in human myometrial cells [34], but none of them have been 
detected in the ovarian cancer cells, and no inserts found 
between exon 8 to exon 10. Instead, we have identified a 
new TRPC1 isoform with exon 9 deletion, suggesting this 
TRPC1 spliced isoform lacks transmembrane segment 4 
(S4). TRPC1E9del is mainly distributed in the cytosol with a 
similar subcellular distribution pattern to the full length 
TRPC1. The nuclear membrane localisation for TRPC1 and 
TRPCE9del is also evident. However, other isoforms including 
TRPC3, TRPC4α, TRPC4β, TRPC4ɛ and TRPC6 are located 
in the plasma membrane, suggesting the potential functional 
difference between TRPC1 and other TRPC isoforms. Since 
the current of over-expressed TRPC1 is small and difficult to 
be distinguished from the endogenous current, we have not 
compared the biophysical difference between TRPC1 and 
TRPC1E9del. However, we believe that the TRPC1E9del is a 
functional subunit, because the colony growth is significantly 
increased by the overexpression of TRPC1E9del, although the 
underling mechanism is unclear and needed to be further 
investigated. Moreover, the spliced isoforms of TRPC1 with 
exon 2 and exon 3 deletion have been described in mice by 
Sakura & Ashcroft [35], but this splicing activity has not 
been found in human SKOV3 cells. TRPC3 and TRPC6 
have a high similarity in sequence. Both of them have been 
demonstrated as receptor-operated channels that mediate the 
diacylglycerol-induced Ca2+ influx, although TRPC3 may 
also have store-operated channel properties [36, 37]. In 
addition, co-existence of several TRPC4 isoforms in the 
SKOV cells could be important for protein interactions 
among the TRPC isoforms that may be required for precisely 
regulating the functionality of Ca2+ permeable channel 
complexes in cancer cells, and thus control cell growth. 
Indeed, some spliced TRPC isoforms have been demonstrated 
as an inhibitory subunit for TRPC homomultimeric channels 
in HEK-293 cells if co-overexpressed with the full-length 
isoforms [38, 39]. We also found that the channel property  
of TRPC4ɛ is different from other TRPC4 isoforms.  
Further investigation is needed to explore the functional 
difference among the alternative splicing of TRPCs in cancer 
development.  
The expression level of individual TRPCs in different 
type of cancer cells or cancer tissues are variable, suggesting 
the differential expression of TRPCs in cancer cells [4, 30]. 
We also found such differences in our study, such as TRPC4 
expressed in SKOV3, but not in breast cancer MCF7 cells 
(data not shown). In addition, the expression level may 
depend on the differentiation status of the cancer cells, 
because we found that the undifferentiated ovarian cancer 
has lower expression of TRPC1, TRPC4 and TRPC6, which 
is consistent to the observation of low level of TRPC4 and 
TRPC6 in immature stem cells [29]. This observation was 
further confirmed in the in vitro experiment using the cell 
differentiation regulator atRA. It has been reported that atRA 
at 1 µM inhibited SKOV3 cell proliferation and phenotype, 
although the ovarian cell line is less sensitive to atRA 
treatment [40, 41]. We were unable to compare the 
expression among the different ovarian cancer types and 
different grades of differentiation in this study due to the 
source of fresh ovarian sample, however, a large scale 
collaborative study is needed in the future.  
The anti-proliferative effect of 2-APB has been 
demonstrated in gastric cancer cell lines [42], colon cancer 
cell [43] and human hepatoma cells [44]. Here we found that 
the effect of 2-APB was not altered by the gap junctional 
channel blocker, carbenoxolone, further suggesting that the 
anti-proliferative action of 2-APB is due to the inhibition on 
store-operated channels. 2-APB and SKF-96365 are broad-
spectrum TRPC channel blockers and cannot distinguish the 
contribution of individual TRPC isoforms, therefore the 
isoform-specific functional antibody tools were used in this 
study. The specificity of the antibodies has been confirmed 
by ELISA, western blotting, in vitro functional testing on 
Ca2+ influx and FACS-based assay. The block on TRPC1, 
TRPC4 and TRPC6 channels by E3-targeting functional 
antibodies caused a significant inhibition of cell proliferation, 
suggesting that TRPC1, TRPC4 and TRPC6 are important 
for cancer cell proliferation. This effect was further 
confirmed by the application of TRPC isoform-specific 
siRNAs. The M phase was mainly arrested for the cell cycle 
progression, which is similar to the study using TRPC3 
siRNA alone [15].  
We have not examined other TRP subfamilies related to 
cancer, such as TRPM1 in melanoma [4], TRPM7 in human 
retinoblastoma cells [45] and human head and neck 
carcinoma cells [46], TRPM8 and TRPV6 in prostate cancer 
[30, 47]. The potential contribution of other molecules or 
subunits of store-operated channels, such as STIM and 
ORAI proteins and MS4A12 [48, 49], may also be important 
in the regulation of store-operated Ca2+ signalling in cancer. 
Cell apoptosis has been suggested to be related to store 
operated channel [50]. Thapsigargin can induce apoptosis of 
prostate cancer cells, but this effect cannot be prevented by 
an intracellular Ca2+ chelator, suggesting that the increase of 
cytosol Ca2+ is unnecessary for apoptosis [50]. We found 
that the non-selective channel blocker 2-APB (data not 
shown) and SKF-96365 can evoke ovarian cancer cell 
apoptosis, but the specific TRPC siRNAs do not significantly 
change the apoptosis, suggesting the TRPC channels may be 
less important in the regulation of cancer cell apoptosis, 
therefore we have not explored the details of TRPCs in 
cancer cell apoptosis in this study.  
Ca2+ is a key signal for cell growth or death. The specific 
activation of pathways and channels for precisely regulating 
Ca2+ influx is important for both normal and cancer cells. We 
found that TRPC1, TRPC3, TRPC4 and TRPC6 channels are 
expressed in ovary cancer, and the splicing variants of 
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TRPCs are highly expressed in the cancer cells, which is 
important for understanding the molecular pathways for Ca2+ 
entry. Inhibition of these channel activity or expression level 
leads to the anti-proliferative effect, so the TRPC channels 
should be considered as potential targets for cancer therapy. 
In addition, the lower expression of TRPC or its isoforms 
could be developed negative prognostic biomarkers for 
certain type of cancer, such as the undifferentiated type of 
ovarian cancer.  
FOOTNOTES 
GenBank accession number for TRPC1 spliced isoform: 
GQ293239. 
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A B S T R A C T
STIM1 is a Ca2+ sensing molecule. Once the Ca2+ stores are depleted, STIM1 moves towards the plasma
membrane (PM) (translocation), forms puncta (clustering), and triggers store-operated Ca2+ entry
(SOCE). Although this process has been regarded as a main mechanism for store-operated Ca2+ channel
activation, the STIM1 clustering is still unclear. Here we discovered a new phenomenon of STIM1
clustering, which is not triggered by endoplasmic reticulum (ER) Ca2+ depletion.
STIM1 subplasmalemmal translocation and clustering can be induced by ER Ca2+ store depletion with
thapsigargin (TG), G-protein-coupled receptor activator trypsin and ryanodine receptor (RyR) agonists
caffeine and 4-chloro-3-ethylphenol (4-CEP) in the HEK293 cells stably transfected with STIM1–EYFP.
The STIM1 clustering induced by TG was more sustained than that induced by trypsin and RyR agonists.
Interestingly, 4-CEP-induced STIM1 clustering also happened in the cytosol without ER Ca2+ store
depletion. Application of some pharmacological regulators including ﬂufenamic acid, 2-APB, and
carbonyl cyanide 4-(triﬂuoromethoxy)phenylhydrazone (FCCP) at concentrations without affecting ER
Ca2+ store also evoked cytosolic STIM1 clustering. However, the direct store-operated ORAI channel
blockers (SKF-96365, Gd3+ and diethylstilbestrol) or the signaling pathway inhibitors (genistein,
wortmannin, Y-27632, forskolin and GF109203X) did not change the STIM1 movement. Disruption of
cytoskeleton by colchicine and cytochalasin D also showed no effect on STIM1 movement.
We concluded that STIM1 clustering and translocation are two dynamic processes that can be
pharmacologically dissociated. The ER Ca2+ store-independent mechanism for STIM1 clustering is a new
alternative mechanism for regulating store-operated channel activity, which could act as a new
pharmacological target.
 2012 Elsevier Inc. All rights reserved.
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The activation of G-protein-coupled receptors (GPCRs) and
receptor tyrosine kinases (RTKs) induces a Ca2+ release from
internal stores, which in turn triggers a sustained Ca2+ inﬂux
across the plasma membrane (PM) via store-operated Ca2+
channels (SOCs). This Ca2+ inﬂux through SOCs, also called
store-operated Ca2+ entry or capacitative Ca2+ entry, mediates
numerous physiological functions including cell growth, muscle
contraction, exocytosis, gene transcription and apoptosis [1]. The
molecular basis for SOCs has been linked to the two major ion
channel families, i.e., ORAI channels and transient receptor
potential (TRP) channels. ORAI channels mediate a highly Ca2+-
selective and inward rectifying Ca2+ release-activated Ca2+
current (ICRAC) [2,3], while TRPC channels mediate a non-selective
Ca2+-permeable cationic current with a current–voltage (IV)* Corresponding author. Tel.: +44 01484 465372; fax: +44 01482 465390.
E-mail address: sam.xu@hyms.ac.uk (S.-Z. Xu).
0006-2952/$ – see front matter  2012 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.bcp.2012.07.013relationship of outward rectiﬁcation, such as TRPC1, TRPC3,
TRPC7 and the heteromeric TRPC1/TRPC5 channel [4–6], or ‘‘N’’
shape IV curve with inward and outward rectiﬁcation [7]. ORAI
channels, as well as TRPCs, are interacted or triggered by the
endoplasmic reticulum (ER) Ca2+ sensor STIM1 (stromal interac-
tion molecule 1) that signals the Ca2+ depletion of ER to the SOCs
[8–12].
STIM1 was originally identiﬁed as a stromal cell molecule that
is potentially relevant for interactions with pre-B cells. It is a type I
membrane protein and mainly located in the ER, but also to a
limited extent in the plasma membrane (PM) [8,13]. STIM1
relocation has been suggested as the mechanism for coupling the
ER Ca2+ store depletion to the store-operated channels in the PM
[9,10]. It has been demonstrated that the ER-luminal domain of
STIM1 is responsible for Ca2+ sensing, and the dissociation of Ca2+
from STIM1 leads to oligomerization (clustering) and redistribu-
tion of STIM1 to the subplasmalemmal area (translocation) [8,14].
STIM1 then triggers ORAI channels (ORAI1, 2 and 3) in the PM via
the binding to the N-terminus of ORAI, which results in Ca2+ entry
into the cell [8].
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diseases, for example, the mutations of ORAI1 and STIM1 causing
the deﬁciency of ICRAC in T cells that has been regarded as the
aetiology of severe combined immune deﬁciency syndrome [15].
ORAI1 deﬁciency in mice results in resistance to pathological
thrombus formation, which is an important new clue for
preventing ischemic cardiovascular and cerebrovascular events
[16]. In addition, the alteration of channel expression or channel
activity is implicated in angiogenesis [17], smooth muscle cell
proliferation and migration [18] and cardiomyocyte hypertrophy
[19], suggesting the signaling of STIM1 associated store-operated
Ca2+ channel activation could act as new therapeutic targets.
However, the pharmacological regulation of STIM1 movement is
still unclear.
In order to examine the possibility of STIM1 movement as a new
potential drug target, we proposed this study to investigate the
pharmacological proﬁle of STIM1 translocation and clustering
using store-operated Ca2+ channel modulators that potentially
change the store-operated Ca2+ channel activity or target to the
signaling pathways of store-operated channel activation. We
demonstrated that the localization of STIM1 puncta shows two
different patterns in response to different regulators, i.e., cytosolic
clusters and subplasmalemmal clusters, and found the existence of
an ER Ca2+ store-independent mechanism for the cytosolic STIM1
movement.
2. Materials and methods
2.1. Chemicals and reagents
Generally used salts and other chemicals including thapsigargin
(TG), 2-aminoethoxydiphenyl borate (2-APB), GdCl3, SKF-96365,
diethylstilbestrol (DES), colchicine, cytochalasin D (CytD), caffeine,
4-chloro-3-ethylphenol (4-CEP), genistein, wortmannin, Y-27632,
GF109203X, 1-oleoyl-2-acetyl-sn-glycerol (OAG), U73122, caly-
culin A (CalyA), ﬂufenamic acid (FFA), niﬂumic acid (NFA), carbonyl
cyanide 4-(triﬂuoromethoxy)phenylhydrazone (FCCP), sodium
azide, hydrogen peroxide (H2O2), HgCl2, forskolin, and Fura-PE3/
AM were purchased from Sigma–Aldrich (Poole, UK).
2.2. Gene cloning and plasmid construction
The coding sequences of monomeric red ﬂuorescent protein
(mCherry) and monomeric cyan ﬂuorescent protein (mCFP) were
subcloned into pcDNA4/TO vector (Invitrogen, Paisley, UK) using
the primers HindIII-GFP-F and BamHI-GFP-R (Supplementary
Table 1). Full-length ORAI1, ORAI2 and ORAI3 coding regions
were ampliﬁed from the cDNA of human aortic endothelial cells
with the primers in Supplementary Table 1. ORAI1 and ORAI2 were
subcloned into the downstream of mCherry in pcDNA4/TO vector
to make fused genes mCherry-ORAI1 and mCherry-ORAI2, and
ORAI3 and TRPC1 were subcloned into pcDNA4/TO-mCFP vector in
a same way to generate mCFP-ORAI3 and mCFP-TRPC1. The ORAI1,
ORAI2, ORAI3 and TRPC1 sequences were identical to the GenBank
reference sequences NM_032790, NM_032831, NM_152288 and
NM_003304, respectively. The STIM1–EYFP plasmids were kindly
provided by Prof AV Tepikin (University of Liverpool). The Lifeact
sequence encoding a 17-amino-acid peptide that binds to
ﬁlamentous actin (F-actin) in eukaryotic cells [20], was introduced
into pcDNA4/TO-mCFP vector by PCR mutagenesis with three
overlapped primers (Supplementary Table 1).
2.3. Cell culture and transfection
The plasmids encoding human STIM1 tagged with enhanced
yellow ﬂuorescent protein at the C-terminus (STIM1–EYFP) weretransfected into T-REx HEK293 cells using Lipofectamine 2000
transfection reagent (Invitrogen, Paisley, UK). The cells were
cultured in D-MEM/F-12 medium (Invitrogen, Paisley, UK)
supplemented with 10% fetal calf serum, 100 units/ml penicillin
and 100 mg/ml streptomycin, and maintained at 37 8C under 95%
air and 5% CO2. A cell line stably expressing STIM1–EYFP was
manually selected from the transfected cells under a Nikon Eclipse
Ti-E inverted ﬂuorescence microscope and maintained in the cell
culture medium containing G418 (200 mg/ml). Plasmids encoding
mCherry-ORAI1, mCherry-ORAI2, mCFP-ORAI3, mCFP-TRPC1 and
Lifeact-mCFP were transfected into STIM1–EYFP cells and the
expression of these genes were induced with 1 mg/ml tetracycline
in the culture medium. Stable cells coexpressing EYFP/mCherry or
EYFP/mCFP tagged genes were manually selected under a
ﬂuorescent microscope and maintained for experiments.
2.4. Live cell imaging and Ca2+ measurement
The stably transfected cells were seeded on 13-mm glass
coverslips and cultured for 24–48 h. Live cell images for EYFP/
mCherry/mCFP ﬂuorescence were captured using the microscope
equipped with a Nikon Plan Fluor 100/1.30 oil objective. The
images were analyzed with the NIS-Elements software (Version
3.2, Nikon, Tokyo, Japan).The puncta around the PM with 1 mm
thickness area (about one punctum) was counted as PM puncta,
and other puncta were counted as cytosolic puncta. The ﬂuores-
cence intensity of STIM1–EYFP was measured by NIS-Elements
software and the regions of interest (ROIs) were drawn manually.
For intracellular Ca2+ measurement, cells were loaded with 2 mM
Fura-PE3/AM in standard bath solution for 30 min at 37 8C,
followed by 5 min wash in standard bath solution at room
temperature. Cells were excited alternately by 340 and 380 nm
light and emission was collected via a 510-nm ﬁlter. Images were
sampled every 5 s in pairs for the two excitation wavelengths by a
CCD camera (ORCA-R2, Hamamatsu, Japan). The ratio of 340/
380 nm ﬂuorescence was used to represent the intracellular Ca2+
level. The standard bath solution contained (mM): NaCl 130, KCl 5,
MgCl2 1.2, HEPES 10, glucose 8, and CaCl2 1.5 (pH 7.4). Ca
2+-free
solution contained (mM): NaCl 130, KCl 5, MgCl2 1.2, HEPES 10,
glucose 8, and EGTA 0.4 (pH 7.4). All experiments were performed
at room temperature. The n values given are the numbers of cells
from at least three independent Ca2+ imaging experiments.
2.5. Statistics
All values are expressed as mean  SEM. The t test was used to
assess the statistical difference and a P value less than 0.05 was
considered as signiﬁcant.
3. Results
3.1. STIM1 translocation induced by Ca2+ store depletion
Passive depletion of ER Ca2+ store by sarco/endoplasmic
reticulum Ca2+-ATPase (SERCA) inhibitor thapsigargin (TG,
1 mM) induced STIM1–EYFP subplasmalemmal translocation and
puncta formation (Fig. 1A and Supplementary video 1), which is
consistent with previous reports [9,10,21]. The STIM1 puncta at PM
became evident after 4 min incubation with TG and achieved
maximum after 6 min (Fig. 1A). The TG-induced STIM1 clustering
and translocation occurred in both Ca2+ free and Ca2+ containing
bath solution, suggesting the extracellular Ca2+ is not the
determinant for intracellular STIM1 movement. However, longer
incubation (20 min) with the Ca2+ free bath solution containing
0.4 mM ethylene glycol-bis(2-aminoethylether)-N,N,N0,N0-tetraa-
cetic acid (EGTA) also increased STIM1 translocation, which could
Fig. 1. STIM1 subplasmalemmal translocation and clustering in response to Ca2+-store depletion in the stable transfected STIM1–EYFP cells. (A) TG (1 mM) induced STIM1
puncta formation at the PM of cells in Ca2+ bath solution. The time course of STIM1 subplasmalemmal translocation and clustering in the boxed area is showed in the lower
panels. The arrow indicates the subplasmalemmal STIM1 clusters (puncta). The ratio of ﬂuorescent intensity in the PM (FPM) and the cytosol (Fcytosol) of cells in response to TG
(1 mM) in 1.5 mM Ca2+ or Ca2+-free bath solution (n = 5 cells in each group). The regions of interest (ROIs) of the PM and the nearby cytosol were manually selected. (B)
Trypsin-induced STIM1 clustering and translocation in standard bath solution. The dynamic changes of ratio of ﬂuorescent intensity (FPM/Fcytosol) for the STIM1 translocation
induced by trypsin (0.1 nM) are shown in the chart (n = 5 cells in each group).
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is similar to the observation on STIM1 translocation with N,N,N0,N0-
Tetrakis(2-pyridylmethyl)-ethylenediamine (TPEN), a membrane-
permeable metal chelator that passively depletes ER Ca2+ store
[22]. The time course for the onset of the TG-induced STIM1
translocation was a slow process, which could be due to the slow
Ca2+ leakage from the ER induced by passive Ca2+ store depletion.
We also observed the STIM1 translocation induced by active ER
Ca2+ store depletion via G-protein-coupled receptor (GPCR)
activation. Protease-activated receptor is a unique subclass of
GPCRs and can be activated by cleavage of the extracellular N-
terminus with trypsin or thrombin [23]. We found trysin at 0.1 nM
signiﬁcantly induced STIM1 clustering and translocation in
standard bath solution or Ca2+ free bath solution (Fig. 1B). Unlike
the SERCA blockers or Ca2+ chelators, the STIM1 translocation
evoked by trypsin was much faster, but the subplasmalemmal
clustering was transient and the puncta gradually disappeared
after 4 min in standard bath solution containing 1.5 mM Ca2+
(Fig. 1B and Supplementary video 2), however, the disassembly of
STIM1 puncta was not observed in Ca2+ free solution, suggesting
that this process is dependent on Ca2+ inﬂux that leads to ER Ca2+
store reﬁlling. The relocation of STIM1 from PM to cytosol seen inthe active store-depletion suggests that the STIM1 clustering and
translocation is a reversible process, which may act as a drug
target.
3.2. Ryanodine-sensitive Ca2+ store and STIM1 movement
The entire ER/SR Ca2+ store could also be depleted by activation
of ryanodine receptors (RyRs), which leads to store-operated Ca2+
inﬂux [24]. Therefore, we observed the effect of ryanodine-
sensitive Ca2+ store depletion on STIM1 movement. The expression
of endogenous RyRs has been demonstrated in the HEK293 cells
[25]. Application of RyR1–3 direct activator 4-chloro-3-ethylphe-
nol (4-CEP, 500 mM) led to STIM1 translocation toward PM.
Interestingly, unlike trypsin, the 4-CEP-induced STIM1 puncta at
the PM disappeared after 3 min incubation with 4-CEP, and
followed by substantial STIM1 clusters retained in the cytosol
(Fig. 2A and Supplementary video 3). However, caffeine ranged
from 10 to 50 mM that can increase the sensitivity of RyRs to Ca2+
did not cause cytosolic STIM1 puncta, instead the formation of
subplasmalemmal STIM1 puncta (Fig. 2B). Both 4-CEP and caffeine
induced intracellular Ca2+ release, however, Ca2+ release induced
by 4-CEP was higher and lasted longer than that by caffeine. In
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1.5 mM Ca2+ was added, but caffeine had no such effect (Fig. 2C
and D), suggesting the pharmacological difference between
the two agonists in the regulation of STIM1 clustering and Ca2+
inﬂux.
In order to examine the relationship of cytosolic STIM1
clustering and Ca2+ release, the STIM1–EYFP cells were pretreatedFig. 2. STIM1 translocation induced by RyR agonists in the STIM1–EYFP cells. (A) 4-CEP
clustering. The time course of STIM1 translocation in the boxed area is shown in the lo
(10 mM) induced STIM1 puncta formation at the PM. (C) 4-CEP (500 mM) induced Ca2+ r
induced Ca2+ release and Ca2+ entry in the STIM1–EYFP cells (n = 21). (E) STIM1–EYFP cel
Ca2+ (n = 21). (F) Tetracaine (500 mM) prevented the subplasmalemmal STIM1 puncta fo
changes (FPM/Fcytosol) for the STIM1 translocation induced by 4-CEP (500 mM) in the abwith RyR antagonist tetracaine (500 mM) for 10 min and then
perfused with 4-CEP (500 mM). The 4-CEP-induced Ca2+ release
signal and STIM1 subplasmalemmal translocation were complete-
ly blocked by tetracaine pretreatment, however, the cytosolic
clustering of STIM1 was still present (Fig. 2E and F), suggesting that
the cytosolic STIM1 clustering is independent of ER Ca2+ store
release or store depletion. (500 mM) induced transient STIM1 puncta formation at the PM and then cytosolic
wer ﬁgures. The arrow indicates the subplasmalemmal STIM1 puncta. (B) Caffeine
elease but abolished Ca2+ entry in STIM1–EYFP cells (n = 23). (D) Caffeine (10 mM)
ls perfused with tetracaine (500 mM) for 10 min and followed by 4-CEP and 1.5 mM
rmation, but not the cytosolic clusters. (G) The time course of ﬂuorescent intensity
sence or presence of 500 mM tetracaine (n = 10 cells in each group).
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clustering
Mitochondria are important Ca2+-storing organelles closely
associated with ER. Although it has been established that depletion
of ER Ca2+ stores leads to STIM1 translocation to the PM, little is
known about the effect of mitochondrial Ca2+ release on STIM1
movement. FFA is a non-steroidal anti-inﬂammatory drug with
Ca2+ releasing effect from mitochondria whereas its analogue NFAFig. 3. Effects of ﬂufenamic acid (FFA) and niﬂumic acid (NFA) on STIM1 movement and
STIM1 clustering and blocked TG-induced STIM1 subplasmalemmal translocation. NFA (1
STIM1 clustering after addition of TG (1 mM). (B) The number of STIM1 clusters induced b
(100 mM) induced robust cytosolic Ca2+ increase in the absence of external Ca2+, but NFA 
of FFA and NFA on TG-induced Ca2+ release and Ca2+ entry. The standard bath solution 
release and Ca2+ inﬂux induced by FFA (100 mM), NFA (100 mM) and TG (1 mM) (n = 16–
STIM1 clusters. (G) FCCP (5 mM) induced a small Ca2+ release (n = 26).has little effect on mitochondrial Ca2+ release [26,27]. We therefore
compared the two chemicals on STIM1 movement. FFA (100 mM)
caused STIM1 clustering in the cytosol, and further addition of
1 mM TG failed to induce STIM1 puncta translocation toward the
PM in the standard bath solution (Fig. 3A), however, NFA (100 mM)
neither induced any cytosolic STIM1 clusters nor blocked the TG-
induced STIM1 subplasmalemmal translocation to the PM,
although much more sparse puncta were also observed in the
cytosol after addition of TG (Fig. 3A and B). We also observed the store-operated Ca2+ entry in STIM1–EYFP cells. (A) FFA (100 mM) caused cytosolic
00 mM) did not change STIM1 localisation at resting state, but potentiated cytosolic
y FFA or NFA before and after addition of 1 mM TG (n = 10 cells in each group). (C) FFA
(100 mM) had no signiﬁcant effect on Ca2+ release in the STIM1–EYFP cells. (D) Effect
containing 1.5 mM Ca2+ was perfused after store depletion. (E) Comparison of Ca2+
37 cells in each group). ***P < 0.001. (F) Example of FCCP (5 mM) induced cytosolic
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entry in the STIM1–EYFP cells. The Ca2+ release induced by FFA was
much higher than the group treated by NFA, but the inhibition on
the store-depleted Ca2+ entry was similar (Fig. 3C–E).
We examined mitochondrial metabolic inhibitors on STIM1
movement. The uncoupling agent FCCP that can abolish the
obligatory linkage between the respiratory chain and the
phosphorylation system and cause mitochondrial Ca2+ release
[28]. Pretreatment with FCCP (5 mM) for 10 min did not prevent
TG-induced STIM1 puncta formation near the plasma membrane,
however, some STIM1 puncta were observed in the cytosol after
FCCP treatment in both TG- or non-TG-treated cells (Fig. 3F), which
could be due to its small transient Ca2+ release effect from
mitochondria (Fig. 3G). Sodium azide is a potent inhibitor of
mitochondrial respiration that blocks cytochrome c oxidase.
Pretreament with sodium azide (2.5 mM) for 5 min did not change
the TG-induced STIM1 subplasmalemmal translocation and
clustering (Fig. S1). Application of azide alone did not evoke
STIM1 clustering and translocation (data not shown). Moreover,
we examined the reagents affecting mitochondrial oxidative
stress. Incubation with H2O2 (100–1000 mM) for 15 min did not
evoke STIM1 clustering and showed no effect on TG-induced STIM
translocation (Fig. S1). Mercury is a toxic heavy metal that causes
severe mitochondrial oxidative damage leading to cell death, but
STIM1 clustering and translocation showed no changes in the
presence of Hg2+ (5 mM) for 10 min. Hg2+ also showed no effect on
TG-induced STIM translocation and subplasmalemmal clustering
(Fig. S1). These data suggested the mitochondrial Ca2+ release is
involved in the formation of cytosolic STIM1 clustering, such as FFA
and FCCP, but the other inhibitors without affecting mitochondrial
Ca2+ movement may have less or no direct effect on STIM1
movement.
3.4. Cytosolic STIM1 clustering induced by 2-APB in cells with replete
ER Ca2+ stores
2-APB is a non-speciﬁc store-operated channel blocker with
multiple effects on other cationic channels [29]. 2-APB at 100 mM
signiﬁcantly induced STIM1 clustering in the cytosol in the absence
of TG (Fig. 4A and Supplementary video 4), and the clustering
induced by 2-APB was reversible (Fig. S2A). In addition, 2-APB at
100 mM did not cause Ca2+ release (Fig. 4B), which suggests that
the 2-APB-induced cytosolic STIM1 clustering is independent of
Ca2+ store depletion. We also observed the effect of 2-APB on TG-
induced STIM1 translocation. 2-APB at low concentrations (5–
50 mM) did not cause STIM1 clustering in the cells, but prevented
the subplasmalemmal translocation and clustering evoked by
1 mM TG, and resulted in the retention of STIM1 puncta in the
cytosol (Fig. 4C).
2-APB has been reported to inhibit ORAI1 and ORAI2, but
activate ORAI3 channels [30]. To understand the difference, we
observed the effect of 2-APB on STIM1 movement in the STIM1/
ORAI cotransfected cells. 2-APB induced a small transient increase
of ORAI1 and ORAI2 currents and followed by a sustained
inhibition, but activated ORAI3 current (Fig. S2B). The IV
relationship of STIM1/ORAI1 and STIM1/ORAI2 induced by TG or
STIM1/ORAI3 induced by 2-APB was similar to the report [30]. 2-
APB-evoked cytosolic STIM1 clustering occurred in all the three
cell lines coexpressing each ORAI isoform with STIM1 (Fig. S2C),
suggesting that the different sensitivity of ORAI isoforms to 2-APB
is unrelated to cytosolic STIM1clustering. However, the subplas-
malemmal clusters induced by TG were disassembled by perfusion
with 2-APB in the STIM1–EYFP cells, but 2-APB did not disassemble
the subplasmalemmal clusters in the cells coexpressing STIM1
with ORAI channels (Fig. 4D), suggesting that the clusters of STIM1/
ORAI complexes formed by store-depletion at the PM becomemore stable than the homomeric STIM1 clusters in the STIM1-EYFP
cells.
3.5. Coexpression with TRPC1 does not affect the cytosolic STIM1
clustering
The functional interaction of TRPC1 with STIM1 has been
demonstrated [12,31], therefore we tested the potential interfer-
ence of STIM1 movement by TRPC1. The stable STIM1–EYFP cells
were cotransfected with human TRPC1 tagged with mCFP. Like the
STIM1, the overexpressed mCFP-TRPC1 was mainly located in the
cytosol, which is accorded to the previous report [32]. The cytosolic
STIM1 clusters induced by 2-APB were evident and the logarithmic
ﬂuorescence spectra showed many ﬂuctuations by line-scan
intensity analysis, but the TRPC1 did not show signiﬁcant clusters
after 2-APB treatment (Fig. 5), suggesting the two proteins are not
physically associated in the cytosol during the STIM1 movement,
although the distribution pattern of STIM1 and TRPC1 in the cells
looks similar before the treatment of 2-APB. Moreover, the co-
expression of TRPC1 did not change the TG-induced STIM1
subplasmalemmal translocation (data not shown). These results
suggest that the cytosolic TRPC1 does not form STIM1/TRPC1
complexes in the cytosol or change the cytosolic STIM1 movement.
3.6. Effect of other store-operated channel blockers
Since the formation of cytosolic STIM1 clusters is related to
application of 2-APB, 4-CEP and FFA, and the three reagents are
cationic or store-operated channel inhibitors, we therefore
examined other commonly used store-operated channel blockers
for pharmacological comparison. Both SKF-96365 and Gd3+
showed no effect on TG-induced STIM1 clustering and transloca-
tion (Fig. S3). Pretreatment with diethylstilbestrol (DES, 10 mM), a
potent store-operated channel inhibitor [33], had no effect on
STIM1 clustering and translocation (Fig. S3). These results suggest
that the blockade on store-operated channels or Ca2+ inﬂux does
not change the cytosolic STIM1 clustering, and also suggest the
pharmacological difference on STIM1 movement among the store-
operated channel modulators.
3.7. Effect of signaling pathway inhibitors on STIM1 movement
STIM1 has been suggested as an important protein in regulating
cell survival, therefore we examined the potential mechanisms by
the application of inhibitors targeting to cell signaling pathways
regulating cell survival. Genistein at micromolar concentrations
has been regarded as a speciﬁc inhibitor for receptor tyrosine
kinase (RTK) [34]. Pretreatment with genistein (10 mM) for 5 min
did not alter the STIM1 clustering and translocation toward PM
evoked by store depletion (Fig. S4A). Incubation with phospha-
tidylinositol 3-kinase (PI3K) inhibitor wortmannin (20 mM) for
30 min also showed no signiﬁcant effect on TG-induced STIM1
translocation and clustering (Fig. S4B), suggesting the activity of
RTK/PI3K/Akt/mTOR pathway will not change the STIM1 move-
ment.
The RhoA/Rho kinase pathway has been implicated in various
cellular functions including cytoskeleton reorganization, cell
adhesion, motility and contraction and Y-27632 is a selective
inhibitor of Rho-associated protein kinase (ROCK). Incubation with
Y-27632 (30 mM) showed no effect on the TG-evoked STIM1
clustering and translocation (Fig. S4C).
The protein kinase C (PKC) inhibitor GF109203X (30 mM) and
activator OAG (100 mM) were examined. Both of them did not
change the TG-induced STIM1 movement (Fig. S4D–E). However,
we found that the phospholipase C (PLC) inhibitor U73122 (10 mM)
not only abolished TG-induced STIM1 translocation to the PM, but
Fig. 4. 2-APB induced STIM1 clustering in STIM1–EYFP cells. (A) Application of 100 mM 2-APB resulted in STIM1 clustering in the cytosol. Lower small ﬁgures show the time
course of STIM1 clustering in the boxed area. (B) No effect of 2-APB (100 mM) on Ca2+ release in the STIM1–EYFP cells. (C) 2-APB (50 mM) blocked the STIM1
subplasmalemmal translocation after addition of 1 mM TG and caused cytosolic STIM1 clustering. The mean  SEM data for the number of STIM1 at the PM or in the cytosol
induced by TG (1 mM) in the absence or presence of 2-APB (5–100 mM) are shown in the right chart (n = 5 cells in each group). (D) Application of 2-APB (100 mM) disassembled the
subplasmalemmal STIM1 clusters induced by TG (1 mM) in the STIM1–EYFP cells, but no disassembling effect was observed in the STIM1–EYFP cells coexpressing with mCherry-
ORAI1, mCherry-ORAI2, or mCFP-ORAI3. The boxed area is ampliﬁed and shown under each corresponding picture with STIM1 clusters alone (green) or co-localized with ORAI
channels (red) in the PM. The mCFP ﬂuorescence was converted into red pseudocolour in the images. (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
B. Zeng et al. / Biochemical Pharmacology 84 (2012) 1024–10351030also caused STIM1 clustering in the cytosol (Fig. 7A and B). This
unique effect of U73122 could be unrelated to the inhibition of PLC,
because GPCR agonist or RTK inhibitor did not cause cytosolic
STIM1 clustering. In addition, we tested the protein kinase A (PKA)
activator forskolin. Incubation with forskolin (50 mM) for 10 min
did not cause cytosolic STIM1 clusters. Forskolin also had no effect
on the TG-induced STIM1 translocation (Fig. S4F).
3.8. Disruption of cytoskeleton did not prevent STIM1
subplasmalemmal translocation
Microtubules are ﬁlamentous polymers essential for cell viability
and STIM1 has been shown to associate with the growth of
microtubule ends [35], therefore, the involvement of cytoskeleton inSTIM1 movement was examined. Incubation with CytD (10 mM) for
1 h, which inhibits actin polymerization [36], showed no effect on
TG-induced STIM1 subplasmalemmal clustering and translocation
(Fig. 6A), suggesting the actin is not directly involved in STIM1
movement. We then examined the microtubule polymerization
inhibitor, colchicine. Pretreatment of STIM1–EYFP cells with
100 mM colchicine for 30 min changed the cell morphology, but
did not show any effects on TG-induced STIM1 subplasmalemmal
clustering and translocation (Fig. 6A). The combined treatment with
CytD and colchicine also showed no effect (Fig. 6A). However, the
TG-induced SOCE was signiﬁcantly reduced by the two agents
(Fig. 6B and C). In addition, we found that the formation of cytosolic
STIM1 clusters did not rely on cytoskeleton as well, because cells
pretreated with CytD or colchicine showed the STIM1 clustering
Fig. 5. Coexpression of TRPC1 on the 2-APB induced STIM1 clustering. (A) The STIM1–EYFP cells were cotransfected with mCFP-TRPC1. The logarithmic ﬂuorescence spectra
showed the ﬂorescence intensity of STIM1 (green) and TRPC1 (blue) of the arrow area using line-scan intensity software. (B) Cytosolic STIM1 clusters induced by 2-APB
(100 mM) and more small ﬂuctuations were observed, but no more ﬂuctuations for TRPC1. (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
B. Zeng et al. / Biochemical Pharmacology 84 (2012) 1024–1035 1031induced by 2-APB or 4-CEP similar to that in the untreated cells
(Fig. S5).
3.9. STIM1 subplasmalemmal translocation inhibited by U73122 and
calyculin A
It has been demonstrated that the cellular architecture of PM–
ER junctions is the place for docking STIM1 clusters near PM and
coupling to ORAI channels [37]. The PLC inhibitor U73122 at 1–
10 mM has also been suggested to increase F-actin content [38,39],
we then examined this mechanism of U73122 on STIM1
movement. The STIM1–EYFP cells were cotransfected with Life-
act-mCFP cDNA, a marker to visualize F-actin [20]. We found the
ﬂuorescence of Lifeact-mCFP at the PM was increased by U73122
(Fig. 7A), suggesting the accumulation of F-actin in the sub-
plasmalemmal regions which spatially involve PM–ER junctions.
The STIM1 subplasmalemmal translocation was blocked by the
pretreatment of U73122, instead some STIM1 puncta in the cytosol
(Fig. 7A). In cells pretreated with 10 mM CytD for 1 h to
depolymerise F-actin ﬁlaments and then incubated with U73122
and TG, the TG-induced STIM1 subplasmalemmal translocation
and puncta formation was restored (Fig. 7B and C), suggesting that
the regulation of F-actin by U73122 is a novel mechanism for
regulating SOC channels. In order to conﬁrm the involvement of F-
actin in the STIM1 translocation, calyculin A (CalyA), a serine/
threonine phosphatase inhibitor that can disrupt the PM–ER
junctions by increasing F-actin content, was also used [36,40]. The
STIM1-EYFP cells incubated with CalyA (10 nM) for 10 min showed
no STIM1 subplasmalemmal translocation after TG treatment.
Pretreatment with 10 mM CytD for 1 h abolished the effect of CalyA
(Fig. 7B and C). Moreover, U73122 signiﬁcantly reduced the store-
operated Ca2+ entry, but had no effect on the amplitude of TG-
induced Ca2+ release signal (Fig. 7D). Pretreatment with CytD
partially reversed the inhibitory effect of U73122, but the Ca2+
entry was still much less than that in cells challenged with TG
alone (Fig. 7F). CalyA treatment did not affect TG-induced Ca2+release, and showed an effect on Ca2+ entry similar to that of
U73122 (Fig. 7E and F).
4. Discussion
In this study, we conﬁrm that STIM1 translocation and
clustering is regulated by ER Ca2+ store, and the extracellular
Ca2+ level is not the determinant for this process. We ﬁnd two
patterns of STIM1 clustering in the cells that can be pharmacologi-
cally distinguished, i.e., subplasmalemmal clusters and cytosolic
clusters. The subplasmalemmal clusters are mainly formed by
STIM1 translocation after passive or active ER Ca2+ store depletion,
whilst the cytosolic STIM1 clustering is speciﬁc for some drug
effects, such as 2-APB, FFA, 4-CEP, U73122 and FCCP. The formation
of cytosolic STIM1 clusters is independent of ER Ca2+ store. In
addition, increased content of F-actin in the PM–ER junctions by
U73122 and CalyA blocks the STIM1 subplasmalemmal transloca-
tion. The proposed models for STIM1 movement are given in Fig. 8.
The intracellular STIM1 clustering and translocation is a dynamic
and reversible process, which could be a drug target for modulating
store-operated channel activity.
Since the discovery of STIM1 as an essential component for
store-operated Ca2+ channel function, the coupling mechanisms of
STIM1 to the store-operated channels in the PM have been
described and the ER Ca2+ store depletion is an essential step for
STIM1 movement, such as by the application of SERCA blockers TG
and cyclopiazonic acid [9,10], or through IP3R activation by many
GPCR agonists including carbachol [14] and ATP/UTP [22,41]. To
further conﬁrm the ER-dependent mechanism, we have examined
the RyR sensitive ER Ca2+ store in this study. The Ca2+ release
induced by RyR agonists also evoke STIM1 subplasmalemmal
translocation, suggesting that STIM1 translocation can be regulat-
ed by the cooperation of the intracellular Ca2+ release channel
IP3Rs and RyRs. This ﬁnding could be an explanation of store-
operated channel activated by RyR activators seen in some studies
[42]. In addition, we noticed the difference of RyR agonists, 4-CEP
Fig. 6. Depolymerisation of cytoskeleton did not affect STIM1 translocation but reduced store-operated Ca2+ entry in STIM1–EYFP cells. (A) The cells were pretreated with
10 mM CytD for 1 h, or 100 mM colchicine for 30 min, or a combination of 10 mM CytD and 100 mM colchicine for 1 h. These procedures of cytoskeleton disruption did not
prevent TG-induced STIM1 translocation. (B) The effects of CytD and colchicine on TG-induced Ca2+ release and Ca2+ entry (n = 22–33 cells in each group). (C) CytD and
colchicine signiﬁcantly reduced TG-induced Ca2+ inﬂux in STIM1–EYFP cells. ***P < 0.001.
B. Zeng et al. / Biochemical Pharmacology 84 (2012) 1024–10351032and caffeine, on cytosolic STIM1 clustering, Ca2+ release and Ca2+
inﬂux. The concentration of 4-CEP used in this study is similar to
the report on Ca2+ release [43]. 4-CEP at this concentration may
cause membrane depolarization [44], however, STIM1 movement
is independent of extracellular Ca2+, which suggests the contribu-
tion of membrane depolarization-induced Ca2+ inﬂux mainly
through voltage-gated Ca2+ channels should be very little. RyR
antagonist tetracaine can prevent the Ca2+ release and STIM1
subplasmalemmal translocation induced by 4-CEP, but the
cytosolic STIM1 clustering is still present, suggesting that the
cytosolic STIM1 clustering is an ER Ca2+ store-independent
mechanism.
The existence of ER Ca2+ store-independent mechanism for
cytosolic STIM1 clustering is also conﬁrmed by the application of
2-APB. 2-APB at high concentrations inhibits IP3R and blocks theIP3-evoked ER Ca
2+ release, therefore the ER store should be
regarded as non-depleted or ﬁlled. However, the STIM1 clustering
can be quickly (10 s) induced by 2-APB and the STIM1 puncta are
retained in the cytosol without subplasmalemmal translocation. 2-
APB at high concentrations has been shown to inhibit SERCA [45],
however we have not observed any Ca2+ release signal induced by
2-APB at 100 mM. In addition, the STIM1 translocation induced by
SERCA blocker is a slow process with 1–2 min delay, however the
cytosolic clusters induced by 2-APB induced is a fast process, which
suggests that the effect of 2-APB on STIM1 clustering is unrelated
to the SERCA inhibition. These ﬁndings further suggest that the 2-
APB-induced STIM1 clustering is an ER-store-independent process.
2-APB at lower concentrations (10 and 50 mM) prevented the TG-
induced STIM1 subplasmalemmal translocation in our study,
which is in agreement with the recent report [46]. The detail
Fig. 7. Increase of F-actin content blocked TG-induced STIM1 translocation toward the PM and inhibited store-operated Ca2+ entry in STIM1–EYFP cells. (A) U73122 (10 mM)
increased the F-actin content marked as Lifeact-mCFP (blue) in the STIM1–EYFP cells cotransfected with Lifeact-mCFP. The TG-induced STIM1 clustering and
subplasmalemmal translocation were prevented by U73122 (A and B). Pretreatment with CytD abolished the effect of U73122 and CalyA (10 nM) on STIM1 movement (B). (C)
The number of TG-induced STIM1 clusters in the cytosol and plasma membrane (PM) in the presence of U73122 (10 mM) or CalyA (10 nM), with or without CytD (10 mM)
pretreatment (n = 10 cells in each group). (D) U73122 (10 mM) inhibited TG-induced Ca2+ entry that was partially reversed by CytD pretreatment (n = 19–27 cells in each
group). (E) CalyA (10 nM) inhibited TG-induced Ca2+ entry and partially reversed by CytD (n = 21–25 cells in each group). (F) Mean  SEM data show the comparison of TG-
induced Ca2+ inﬂux among the groups treated with U73122, CalyA and CytD (***P < 0.001). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred
to the web version of this article.)
B. Zeng et al. / Biochemical Pharmacology 84 (2012) 1024–1035 1033mechanism of cytosolic STIM1 clustering is still unclear, but it
could be unrelated to the inhibition on Ca2+ inﬂux, because other
store operated channel blockers Gd3+, SKF96365 and DES without
ER Ca2+ store releasing effect do not induce cytosolic STIM1
clustering. It is also unrelated to the coexpression of TRPC1 and
ORAI channels, because the two associated proteins do not change
the pattern of cytosolic STIM1 clustering, although the ORAI
channel coexpression can stabilize the subplasmalemmal clusters
of STIM1/ORAI complexes.
FFA is a fenamate anti-inﬂammatory drug with a mitochondrial
Ca2+ release effect, but has less effect on ER Ca2+ release [26,27].
Our data show that FFA induces cytosolic STIM1 clustering, but its
analogue NFA without affecting mitochondrial Ca2+ release does
not cause cytosolic STIM1 clustering, further suggesting that the
cytosolic STIM1 clustering is independent of ER store depletion,
but the mitochondrial Ca2+ release could be related to cytosolic
STIM1 clusters. To further conﬁrm this, we tested the inhibitors of
mitochondrial respiratory phosphorylation chain and metabolic
pathways. FCCP, a mitochondrial uncoupler, causes STIM1
clustering in the cytosol, which could be due to the mitochondrial
Ca2+ release effect [28], however, FCCP does not block the TG-
induced the STIM1 translocation. Similarly, the TG-induced STIM1
translocation cannot be prevented by oligomycin and antimycin A
[47]. Sodium azide, H2O2 and Hg
2+ are mitochondrial metabolic
inhibitors, however, acute application of these agents have no
signiﬁcant effect on STIM1 clustering and translocation, furthersuggesting that the agents only affecting mitochondrial Ca2+
release may change the intracellular STIM1 movement.
The signaling pathway inhibitors of PTK and PI3K, PKC and
ROCK pathways have been examined in our study and no
signiﬁcant effects on TG-induced STIM1 movement are found,
which is similar to the previous report [14]. We have not tested
those inhibitors on the STIM1 puncta induced by GPCR activation,
because unlike TG-induced STIM1 clustering and subplasmalem-
mal translocation, the STIM1 puncta or movement induced by
GPCR activation is transient and difﬁcult to be quantiﬁed precisely.
The importance of PM–ER junctions in the store-operated
channel activation has been described [48]. The increase of F-actin
content in the PM–ER junctional regions inhibits store-operated
channel activity [36,40]. Both CalyA and U73122 are PM–ER
disruptors by condensation of F-actin in the region. The inhibition
of store-operated Ca2+ entry by U73122 and CalyA could be
explained by the interruption of PM–ER junctions by the inhibition
of STIM1 subplasmalemmal translocation, which leads to the
uncoupling of STIM1 with the store-operated channels in the PM.
However, other mechanisms for U73122 and CalyA may also exist,
because the restore of STIM1 translocation by CytD only partially
recovered their inhibition on the store-operated Ca2+ inﬂux.
Moreover, we also examined the involvement of cytoskeleton in
the STIM1 movement. CytD signiﬁcantly inhibits the store-operated
Ca2+ entry in the STIM1–EYFP transfected cells, which is consistent
to the observations in platelets [49], polymorphonuclear neutrophil
Fig. 8. Models for pharmacological regulation of STIM1 translocation and clustering. (A) STIM1 at resting state. (B) ER Ca2+ store-dependent STIM1 clustering and
translocation to the newly formed PM–ER junction and Ca2+ inﬂux through ORAI channel, which are induced by ER Ca2+ store depletion by GPCR agonist, thapsigargin or
caffeine. (C) ER Ca2+ store-independent STIM1 clustering in the cytosol. 2-APB inhibits ER Ca2+ release through IP3R and induces cytosolic STIM1 clustering. FFA and 4-CEP
release Ca2+ from mitochondrion and ER respectively, and cause the formation of cytosolic STIM1 clusters. (D) U73122 blocks the activity of PLC, increases the cellular F-actin
content and potentiates cytosolic STIM1 clustering in the presence of thapsigargin. Calyculin A also increases the F-actin content, prevents the formation of PM–ER junction
and STIM1 translocation toward the PM.
B. Zeng et al. / Biochemical Pharmacology 84 (2012) 1024–10351034(PMN) [50], hepocytes [51], and vascular endothelial cells [52],
but no or increasing effects were reported in A7r5 cells, glioma C6
cells and transfected HEK293 cells [36,53,54]. We ﬁnd that the TG-
induced store-operated Ca2+ inﬂux is inhibited by CytD in the
STIM1–EYFP transfected cells, however, CytD has no effect on the
TG-induced STIM1 movement. In our study, CytD at 10 mM was
used, because we found a signiﬁcant cell death occurred at
the concentration of 100 mM, although this concentration has
been used in the A7r5 cells [36]. The rearrangement of
microtubules in the regulation of SOCE has also been demon-
strated by the application of colchicine [54–56], however,
colchicine has no effect on TG-induced STIM1 movement. In
addition, disruption of lipid rafts in the PM does not change the
STIM1 movement [57].
Store-operated Ca2+ entry coupled by STIM1 translocation has
been demonstrated for ORAI and TRPC1 channels [10,58]. The
activity of store-operated channels could be regulated by direct
channel blockers or indirectly regulated by those agents affecting
STIM1 clustering and subplasmalemmal translocation. The cyto-
solic STIM1 cluster formation independent of ER Ca2+ store
discovered in this study is a new mechanism for the pharmacology
of some channel blockers, which could be a useful target for future
drug development.
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Transient receptor potential melastatin 2 (TRPM2) is a Ca2+-permeable cationic channel in the TRP channel
family. The channel activity can be regulated by reactive oxygen species (ROS) and cellular acidiﬁcation,
which has been implicated to the pathogenesis of diabetes and some neuronal disorders. However, little
is known about the effect of redox-active metal ions, such as copper, on TRPM2 channels. Here we inves-
tigated the effect of divalent copper on TRPM2.
TRPM2 channel was over-expressed in HEK-293 cells and the whole-cell current was recorded by patch
clamp.We found thewhole-cell current evoked by intracellular ADP-ribose was potently inhibited by Cu2+
with a half maximal inhibitory concentration (IC50) of 2.59 lM. The inhibitory effect was irreversible. The
single channel activity was abolished in the outside-out patches, and intracellular application of Cu2+ did
not prevent the channel activation, suggesting that the action site of Cu2+ is located in the extracellular
domains of the channel. TRPM2 current was also blocked by Hg2+, Pb2+, Fe2+ and Se2+.
We concluded that Cu2+ is a potent TRPM2 channel blocker. The sensitivity of TRPM2 channel to heavy
metal ions could be a new mechanism for the pathogenesis of some metal ion–related diseases.
 2012 Elsevier Inc. All rights reserved.1. Introduction
Transient receptor potential melastatin 2 (TRPM2) is a member
of the melastatin subfamily of TRP channels which are permeable
to cations such as Ca2+ and Na+. TRPM2, previously known as TRPC7
or LTRPC2 [1,2], is abundantly expressed in the brain, and later stud-
ies show that TRPM2 is an ubiquitously expressed channel found in
many tissues including bonemarrow, spleen, heart, liver, lung, pan-
creatic islets and immunocytes [2,3]. Several important physiologi-
cal functions of TRPM2 channel have been demonstrated using
knockout animals or in vitro models including insulin release [3,4],
cytokines and reactive oxygen species (ROS) production [5], cell
motility and cell death [6], and immune response [7]. The genetic
variants of TRPM2 have been linked to the pathogenesis of several
neurological diseases like bipolar disorder [8], western paciﬁc
amyotrophic lateral sclerosis and parkinsonism-dementia [9], and
the regulation of amyloid beta-peptide (Ab)-induced striatal cell
death that involves in the Alzheimer’s disease [10]. In addition, a
number of endogenous modulators for TRPM2 channel have been
identiﬁed, among which the most efﬁcient direct channel activator
is adenosine diphosphate ribose (ADPR). Free ADPR opens TRPM2
channels by binding to the Nudix-like motif in the C-terminus,
and evokes a current with linear current–voltage (IV) relationshipll rights reserved.[1,11]. The activation of TRPM2 channel by ADPR is dependent on
the intracellular Ca2+ concentration [12] and negatively regulated
by adenosine monophosphate (AMP) [13] and acidic pH [14,15].
Hydrogen peroxide (H2O2) is another activator for TRPM2 channel,
although the mechanism of H2O2-induced TRPM2 activation is still
unclear [2]. Therefore, TRPM2 is a ROS-sensitive Ca2+-permeable
channel, which may play important roles in the oxidative stress-
related diseases.
Metal ions are important factors or cofactors in cellular physiol-
ogy [16]. Among them, copper is a redox-active element and par-
ticipates in many important cellular functions by binding to a
variety of proteins such as ceruloplasmin, cytochrome c oxidase
and superoxide dismutase [17]. Both deﬁciency and elevated level
of copper can induce oxidative stress that leads to cell or tissue
damage [18]. Copper deﬁciency is seen in infants with Menkes’ dis-
ease that is caused by genetic mutations in the copper transporter
ATP7A [19] and in patients with gastrointestinal surgery, such as
gastric bypass surgery [20]. In contrast, patients showing excessive
copper accumulation in the body are due to exposure to excess
copper in drinking water or other environmental sources [21], or
the genetic disorder (Wilson’s disease) with copper accumulation
in the liver and the basal ganglia of the brain, which is caused by
the mutations in ATP7B, a transporter responsible for exporting
copper out of the cells [22]. Moreover, the elevated copper level
has also been reported in the plasma of diabetic patients [23]
and in the brain of patients with neurodegenerative disorders
[24]. It is unclear that the increased blood copper concentration
280 B. Zeng et al. / Biochemical and Biophysical Research Communications 424 (2012) 279–284is just a consequence of diabetes or the cause of dysfunction of
insulin signaling and glucose homeostasis, however, the treatment
with Cu2+ chelator to reverse diabetic copper overload seems effec-
tive in preventing diabetic organ damage [25]. With regard to neu-
rological disorders, copper has been implicated in the pathogenesis
of many neurodegenerative disorders including Alzheimer’s
disease, amyotrophic lateral sclerosis, Huntington’s disease, Par-
kinson’s disease, and prion disease [26,27]. Excess copper can
initiate or stimulate the progression of Alzheimer’s disease by pro-
moting the aggregation of amyloid-beta peptides to form senile
plaques in the brain [28,29] or by oxidative stress-driven cell death
[17]. Nevertheless, the effect of copper in Alzheimer’s disease is
still in much debate. The protective effect against beta-sheet sec-
ondary structure formation by copper has also been demonstrated
[30,31]. These mixed results could be due to the imbalance of Cu2+C 2+ 10 M
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for each concentration).in the affected region, rather than a bulk Cu2+ accumulation or
deﬁciency [32,33]. Therefore, the identiﬁcation of potential new
Cu2+ target is important for understanding the pathogenesis of
Cu2+-related disorders.
Given the evidences that TRPM2 is a redox-sensitive channel
and mediates cell death, as well as its high expression in the brain
and the association with neurodegenerative disorders and diabetes
which are oxidative stress related diseases. It is intriguing to sup-
pose that the activity of TRPM2 channels could be modulated by
certain pathological factors related to these diseases, such as Cu2+
that plays an important role in regulating oxidative status in a cell.
Therefore, we investigated the effect of Cu2+ on TRPM2 channels in
the TRPM2 transfected HEK-293 cells by electrophysiological ap-
proach. Other heavy metal ions, such as Hg2+, Pb2+, Fe2+ and Gd3+,
and divalent selenium (Se2+) were also studied for comparison.10
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2.1. Cell culture and transfection
A tetracycline-controlled expression system for human TRPM2
channel was generated using pcDNA4/TO vector and stably trans-
fected into the HEK-293 T-REx cells (Invitrogen, Paisley, UK) as
previously described [34]. The cells were maintained in DMEM/F-
12 medium supplemented with 50 units/ml penicillin, 50 lg/ml
streptomycin (Gibco, Paisley, UK) and 10% fetal bovine serum
(Sigma–Aldrich, Poole, UK). The expression of TRPM2 was induced
by 1 lg/ml tetracycline in the cell culture medium for 24–72 h
before patch-clamp recording. Cells without tetracycline induction
were used as control.2.2. Electrophysiology
Whole-cell patch-clamp recording was performed at room tem-
perature (23–26 C). Brieﬂy, signal was ampliﬁed with an Axopatch
200B ampliﬁer and controlled by the software pClamp 10. A 1-s
ramp voltage protocol from100 mV to + 100 mV was applied at
a frequency of 0.2 Hz from a holding potential of 0 mV. Signals were
sampled at 10 kHz and ﬁltered at 1 kHz. The glass microelectrodes
with resistance of 3–5 MX were used. The 200 nM Ca2+ buffered
pipette solution contained (in mM) 115 CsCl, 10 EGTA, 2 MgCl2,
10 HEPES, and 5.7 CaCl2 (pH 7.2 adjustedwith CsOH, and osmolarity10 Cu2+10µM
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Fig. 2. Cu2+ inhibits TRPM2 channels from the cell surface. (A) Addition of Cu2+
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extracellular Cu2+ (n = 3, ⁄⁄⁄P < 0.001).290 mOsm adjusted with mannitol). The calculated free Ca2+ is
200 nM. ADP-ribose (0.5 mM) was included in the pipette solution
to activate TRPM2 channels in the whole-cell conﬁguration. The
standard bath solution contained (mM) 130 NaCl, 5 KCl, 8 D-glucose,
10 HEPES, 1.2 MgCl2 and 1.5 CaCl2. The pH was adjusted to 7.4 with
NaOH.
2.3. Chemicals
General salts, ADP-ribose (ADPR), H2O2, copper sulphate
(CuSO4), gadolinium chloride (GdCl3), lead nitrate (Pb(NO3)2), sele-
nium dioxide, mercury chloride (HgCl2) ferrous chloride tetrahy-
drate (FeCl24H2O) and 2-aminoethoxydiphenyl borate (2-APB)
were purchased from Sigma–Aldrich (Poole, UK).
2.4. Statistics
Data are expressed as mean ± SEM. Data sets were compared
using paired t test for the results before and after treatment with
signiﬁcance indicated if P < 0.05.
3. Results
3.1. TRPM2 channel inhibited by Cu2+
The effect of divalent Cu2+ on TRPM2 channel was investigated
using whole-cell patch clamp recording in the HEK-293 cells over-
expressed with human TRPM2 gene in a tetracycline-regulated
expression system [34]. The activity of TRPM2 channel was in-
duced by ADP-ribose (500 lM) in the pipette solution (Fig. 1A) or
by bath application of H2O2 (500 lM) (data not shown). The cur-
rent with a typical linear current–voltage (IV) relationship was
quickly evoked by ADP-ribose in the tetracycline-induced TRPM2
cells (Tet+) and achieved maximum within 1 min after membraneCu2+ 10µM 8 pA
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reports and others [1,12,35]. Perfusion with 10 lM divalent Cu2+
abolished the current of TRPM2. The inhibitory effect of Cu2+
seemed to be irreversible on washout, which suggests that
Cu2+ may form covalent bonds with the channel protein. In the
control cells without tetracycline induction (Tet-), the whole-cell
current evoked by ADP-ribose was very small, and also inhibited
by Cu2+ (10 lM), suggesting that there is an endogenous current
sensitive to Cu2+ in the native cells (Fig. 1C and D). The inhibition
of Cu2+ on TRPM2 was concentration-dependent with an IC50 of
2.59 ± 0.66 lM and a slope factor of 1.50 ± 0.35 (Fig. 1F).10 BeforenA
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Due to the ubiquitous expression of Cu2+ transporters in the plas-
ma membrane and intracellular membranes, and the different con-
centrations in the extracellular cleft and cytosol [16], we therefore
determined the action site of Cu2+ on TRPM2 channel. We included
higher concentration (20 lM) of Cu2+ into the pipette solution to
see whether the activation of TRPM2 current can be prevented. We
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surface of the transmembrane domains.
To further conﬁrm the extracellular effect, the outside-out patch
was performed. Cu2+ (10 lM) signiﬁcantly inhibited the TRPM2
current in the outside-out patches (Fig. 3A). We also recorded the
single channel activity of TRPM2. The slope conductance for the
TRPM2 induced by ADP-ribose was 65.8 ± 0.23 pS (n = 4), which is
similar to 64 pS [15] and close to 60 pS recorded under the condi-
tions of 100 nM Ca2+ and 100 lM ADP-ribose [1]. Bath perfusion
with 10 lM Cu2+ abolished the single channel activity (Fig. 3).3.3. Comparison with other metal ions on TRPM2 channels
Mercury and lead are important metal ions related to neuronal
development and dysfunction, therefore we investigated their ef-
fects on TRPM2 channel. Hg2+ at 10 lM completely inhibited the
TRPM2 current, whilst Pb2+, Fe2+, and Se2+ at 10 lM showed a par-
tial inhibition (Fig. 4A and D). The inhibitory effect of Hg2+ was dif-
ﬁcult to be washed out. Fe2+ at 50 lM also showed inhibitory effect
and the current was decreased by 25.3 ± 6.6% (n = 3), but higher
concentrations of Fe2+ (P100 lM) caused a leak current due to cell
damage. The percentage of inhibition was compared against the
normalized effect (100%) of 2-APB at 100 lM on the same cell.
The potency for Hg2+ and Cu2+ was similar, but stronger than that
of Pb2+, Fe2+ and Se2+ (Fig. 4F). No signiﬁcant effect was observed
for the trivalent cation Gd3+, which is in agreement with our previ-
ous report [36].4. Discussion
In this study, we demonstrate that Cu2+ at micromolar concen-
trations potently inhibits TRPM2 channel activity. The action site of
Cu2+ is extracellularly located and the inhibitory effect of Cu2+ is
irreversible. Hg2+, Pb2+, Fe2+ and Se2+ also show blocking effect on
TRPM2 channel, but Pb2+, Fe2+ and Se2+ are less potent than Cu2+
and Hg2+. These ﬁndings provide a novel mechanism for the path-
ophysiology of Cu2+ in human diseases.
Copper has been implicated in the pathogenesis of several neu-
rodegenerative disorders including Alzheimer’s disease, amyotro-
phic lateral sclerosis, Huntington’s disease, Parkinson’s disease,
and prion disease [26,27]. Excess of copper is associated with the
production of ROS, which in turn triggers a series of events includ-
ing oxidative stress-induced cell injury, intracellular protein
deposits (neuroﬁbrillary tangles), neuronal dysfunction and conse-
quently cell death [37]. On the other hand, ROS activate some Ca2+
channels, such as TRPM2, and cause the disruption of cellular Ca2+
homeostasis. The common change of Ca2+ homeostasis in Alzhei-
mer’s disease is an increased intracellular calcium level that could
occur either indirectly through Ab modulating an existing Ca2+
channel or directly through cation-selective channels formed by
Ab [38]. In this study, we found that extracellular Cu2+ signiﬁcantly
inhibited the TRPM2 channels, which provide a new evidence for
the relationship between ROS-sensitive Ca2+ channel TRPM2 and
Cu2+. The TRPM2 channel activity is activated by ROS or H2O2,
but inhibited by Cu2+, therefore Cu2+ seems to be protective in
the Ca2+ homeostasis. Because of the extremely high copper levels
in senile plaques (393 ± 123 lM) [24], we suppose that the activity
of TRPM2 enhanced by H2O2 and Ab in the affected regions of the
brain is likely to be completely inhibited by Cu2+. Nevertheless, the
physiological signiﬁcance of TRPM2 channel inhibited by Cu2+ still
needs to be further investigated, because the inhibition by Cu2+ is
an irreversible process, which may affect the normal function of
TRPM2 in these cells. In primary cultures of rat striatum, the Ab-in-
duced Ca2+ increase and cell death can be prevented by a dominant
negative isoform of TRPM2 (TRPM2-S), suggesting that loweringactivity of TRPM2 could be protective [10]. Moreover, the genetic
variants of TRPM2 have been identiﬁed in several neurological dis-
eases, but little is known about the channel functionality in the
native cells related to these diseases [9].
Copper concentration in blood plasma is around 15 lM in nor-
mal population [16], however, copper accumulates in the brain and
displays differential distribution patterns in the central nervous
system. Much higher concentration has been estimated in the cere-
brospinal ﬂuid (70 lM). The concentration in the synaptic cleft
may reach 200–400 lM in some neuronal diseases, whereas the
normal extracellular copper concentration in the brain is of the or-
der of 0.2–1.7 lM [16]. The elevated copper levels have also been
reported in patients with type 1 or type 2 diabetes [39], which
shares many pathogenetic mechanisms with Alzheimer’s disease
and vascular dementia. In addition, copper accumulation in the
body is caused by genetic variants of Cu2+ transporter genes
(ATP7A and ATP7B), i.e., Menkes syndrome and Wilson disease.
These suggest that the inhibitory mechanism by micromolar Cu2+
on TRPM2 channel should happen in normal subjects and under
some disease conditions.
Apart from the inhibition on the oxidative stress-sensitive
TRPM2 channels, Cu2+ also inhibits the voltage-gated Ca2+ channels
including T-, L-, N-, P-, and Q-type currents [16]. The Cav3.2 chan-
nel is more sensitive to Cu2+ than other types of voltage-gated Ca2+
channels with an IC50 = 0.9 lM [40]. In addition, high concentra-
tions of Cu2+ stimulate TRPV1 and TRPA1 channels [41,42], sug-
gesting that the overall effect of Cu2+ on intracellular Ca2+ level
may vary, which depends on the local concentration of Cu2+ and
the expression of individual Ca2+ channels.
We have not examined the molecular targets of Cu2+ in this
study, however, Cu2+ may bind directly to amino acids against
most likely cysteine or the hydrophilic-charged amino acids (histi-
dine, lysine, arginine, aspartate, and glutamate) to alter protein
function. Indeed, the residue substitution in the outer vestibule
of the pore including Lys952, His995 and Asp1002 signiﬁcantly
changed the sensitivity to Zn2+ [43]. Further investigation is
needed to conﬁrm these binding sites for Cu2+. In addition, the
binding to cysteine residues or oxidizing the residues may catalyse
the formation of disulphide bonds between physically adjacent
cysteine residues, and thereby indirectly change protein structure
and function. Moreover, a third more indirect way that copper
can modulate protein function is through the generation of free
radicals, which can profoundly alter protein and cell function, par-
ticularly for the ROS-sensitive channels, such as TRPM2 channels in
this study. Unlike the extracellular effect of Cu2+, the action site for
ROS or hydroxyl radical that generated by mixing with Fe2+ and
H2O2 has been demonstrated as an intracellular effect, which is
mainly related to the C-terminal Nudix-like domain [2,44]. There-
fore, the channel appears to be opened by intracellular ROS, and
closed by extracellular Cu2+. On the other hand, higher concentra-
tions of extracellular Cu2+ may enter cells via Cu2+ transporters that
in turn regulate the ROS production. Recently, Zn2+ has been shown
to inhibit TRPM2 channel, however, the potency of Zn2+ was much
lower than that of Cu2+ [43]. The difference in potency for the two
ions may have important physiological relevance because the plas-
ma levels of copper and zinc are oppositely correlated in many
diseased conditions such as diabetes and hypertension and the ra-
tio of Zn2+/Cu2+ have been evaluated in some diseases [16,45,46].
Excessive copper and deﬁcit of zinc would progressively disrupt
the cellular Ca2+ homeostasis by tuning the activity of a number
of TRP and other Ca2+ channels [16]. The inhibition of TRPM2 chan-
nel by Pb2+, Se2+ and Fe2+ was mild, suggesting these metal ions
could be less important as direct channel regulators.
Besides the neurological disorders, TRPM2 channel is also
important for insulin secretion in pancreatic b-cells [3,4]. Copper
deﬁciency enhances the insulin secretion in isolated pancreatic
284 B. Zeng et al. / Biochemical and Biophysical Research Communications 424 (2012) 279–284islets [47], suggesting that copper can regulate the insulin release,
which could be related to TRPM2 channels. Taken together, the
inhibition of TRPM2 by copper is an important mechanism for
the normal physiological function in the body. The imbalance of
TRPM2 channel activity caused by excess copper or ROS may be
one of the pathophysiological mechanisms for disruption of Ca2+
homeostasis in diabetes and neurodegenerative disorders.
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BACKGROUND AND PURPOSE
Fenamate analogues, econazole and 2-aminoethoxydiphenyl borate (2-APB) are inhibitors of transient receptor potential
melastatin 2 (TRPM2) channels and are used as research tools. However, these compounds have different chemical structures
and therapeutic applications. Here we have investigated the pharmacological profile of TRPM2 channels by application of
newly synthesized fenamate analogues and the existing channel blockers.
EXPERIMENTAL APPROACH
Human TRPM2 channels in tetracycline-regulated pcDNA4/TO vectors were transfected into HEK293 T-REx cells and the
expression was induced by tetracycline. Whole cell currents were recorded by patch-clamp techniques. Ca2+ influx or release
was monitored by fluorometry.
KEY RESULTS
Flufenamic acid (FFA), mefenamic acid (MFA) and niflumic acid (NFA) concentration-dependently inhibited TRPM2 current
with potency order FFA > MFA = NFA. Modification of the 2-phenylamino ring by substitution of the trifluoromethyl group in
FFA with –CH3, –F, –CF3, –OCH3, –OCH2CH3, –COOH, and –NO2 at various positions, reduced channel blocking potency. The
conservative substitution of 3-CF3 in FFA by –CH3 (3-MFA), however, gave the most potent fenamate analogue with an IC50
of 76 mM, comparable to that of FFA, but unlike FFA, had no effect on Ca2+ release. 3-MFA and FFA inhibited the channel
intracellularly. Econazole and 2-APB showed non-selectivity by altering cytosolic Ca2+ movement. Econazole also evoked a
non-selective current.
CONCLUSION AND IMPLICATIONS
The fenamate analogue 3-MFA was more selective than other TRPM2 channel blockers. FFA, 2-APB and econazole should be
used with caution as TRPM2 channel blockers, as these compounds can interfere with intracellular Ca2+ movement.
Abbreviations
2-APB, 2-aminoethoxydiphenyl borate; 3-MFA, 2-(3-methylphenyl)aminobenzoic acid; ACA,
N-(p-amylcinnamoyl)anthranilic acid; IP3, inositol trisphosphate; IV, current–voltage; FFA, flufenamic acid; MFA,
mefenamic acid; NFA, niflumic acid; NMDG, N-methyl-D-glucamine; NSAIDs, non-steroidal anti-inflammatory drugs;
SERCA, sarco(endo)plasmic reticulum Ca2+-ATPase; Tet, tetracycline; TRP, transient receptor potential; TRPC, transient
receptor potential canonical; TRPM2, transient receptor potential melastatin 2
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Introduction
Ca2+ ions are second messengers controlling many cell signal-
ling processes. The transient receptor potential (TRP) channel
family (channel and receptor nomenclature follows Alexan-
der et al., 2011) is a class of Ca2+-permeable cationic channels
that are important for maintaining intracellular Ca2+ level.
The transient receptor potential melastatin 2 (TRPM2)
channel is one member of the TRPM channel subfamily
(Ramsey et al., 2006), which was first cloned in 1998 (Nag-
amine et al., 1998). TRPM2 channels are highly expressed in
the brain and ubiquitously distributed in the body (Hecquet
et al., 2008; Wehrhahn et al., 2010). The pathophysiological
role of TRPM2 channels is still unclear, but they have been
implicated in the free radical-induced cell death of hippoc-
ampal neurons (Olah et al., 2009), striatal cells (Fonfria et al.,
2005) and other cell types (Zhang et al., 2003; Yang et al.,
2006; Ishii et al., 2007); the stress-related inflammatory proc-
esses (Yamamoto et al., 2008; Wehrhahn et al., 2010); insulin
secretion (Uchida et al., 2010); immune response (Sano et al.,
2001; Knowles et al., 2011); and oxidant-induced endothelial
injury (Hara et al., 2002; Hecquet and Malik, 2009).
Heterologous expression of TRPM2 protein gives rise
to a voltage-independent, Ca2+-permeable, non-selective cati-
onic channel with a linear current–voltage (IV) relationship
(Perraud et al., 2001; McHugh et al., 2003) and a characteristic
activation by intracellular ADP-ribose. Flufenamic acid (FFA),
econazole, 2-aminoethoxydiphenyl borate (2-APB) and Zn2+
as all act as blockers of TRPM2 channels (Hill et al., 2004a,b;
Yang et al., 2011). FFA is one of the fenamate non-steroidal
anti-inflammatory drugs (NSAIDs), which affects a variety
of channels, inducing inhibition of Cl– channels, voltage-
dependent Na+ or Ca2+ channels, and TRPM2, TRPM4,
TRPM5, TRPC3 and TRPC5 channels (Lee et al., 2003; Kraft
and Harteneck, 2005; Ullrich et al., 2005). FFA also activates
TRPC6 (Inoue et al., 2001; Jung et al., 2002; Foster et al., 2009)
and TRPA1 channels (Hu et al., 2010). The action of FFA on
ion channels is not mediated by cyclooxygenase (COX),
because selective COX inhibitors were found to have no
direct effect on TRP cationic channels (Jiang et al., 2012),
suggesting there is direct conformational interaction between
FFA and the channel protein. The fenamate NSAIDs are
anthranilic acid derivatives with structural similarity to the
PLA2 inhibitor N-(p-amylcinnamoyl)anthranilic acid (ACA).
However, although ACA inhibited TRPM2 channels (Kraft
et al., 2006), other PLA2 inhibitors without the skeleton of
anthranilic acid had no effect on these channels, suggesting
that the parent structure of anthranilic acid was essential for
the channel blockade. Moreover, other fenamates with dif-
ferent substituents on the 2-phenylamino ring, such as FFA,
mefenamic acid (MFA) and diclofenac, exert different
effects on elevation of intracellular Ca2+ (Poronnik et al.,
1992). Recently, we found that the substituents on the
2-phenylamino ring of the fenamate skeleton were important
for regulating TRPC4 and TRPC5 channel activity, especially
the position of the methyl groups in MFA. The replacement
of 2-methyl with a methoxy group gave an analogue showing
activation, rather than inhibition on TRPC4 and TRPC5
channels (Jiang et al., 2012). Therefore, we proposed that the
modification of 2-phenylamino ring would be important
for understanding the structure–activity relationship of
fenamate analogues on TRPM2 channels and might yield new
leads for drug discovery.
In this study, we examined the effect of some new fena-
mate analogues on TRPM2 channels using inducible cells
over-expressing TRPM2 protein. In order to understand the
structure–activity relationship of the fenamates, we synthe-
sized analogues with modifications of the 2-phenylamino
ring and compared their potency on TRPM2 channels. To
compare their pharmacological properties of the new com-
pounds with those of known TRPM2 channel blockers, the
effects of econazole and 2-APB were also investigated in our
model system.
Methods
Cell culture and transfection
Human TRPM2 protein (GenBank accession number
BC112342) in pcDNA4/TO tetracycline-regulatory vector was
transfected into HEK-293 T-REx cells (Invitrogen, Paisley, UK).
The expression was induced by 1 mg·mL-1 tetracycline for
24–72 h before recording. The non-induced cells without
addition of tetracycline were used as control. Cells were grown
in DMEM-F12 medium (Invitrogen) containing 10% fetal calf
serum (FCS), 100 units·mL-1 penicillin and 100 mg·mL-1 strep-
tomycin. Cells weremaintained at 37°C under 95% air and 5%
CO2 and seeded on coverslips prior to experiments.
Electrophysiology
The procedure for whole-cell clamp is similar to that
described earlier (Xu et al., 2012). Experiments were per-
formed at room temperature (25 °C). Briefly, electrical signal
was amplified with an Axopatch 200B patch clamp amplifier
and controlled with pClamp software 10. A 1 s ramp voltage
protocol from -100 to +100 mV was applied at a frequency
of 0.2 Hz from a holding potential of 0 mV. Signals were
sampled at 3 kHz and filtered at 1 kHz. Glass microelectrodes
with a resistance of 3–5 MW were used. The 200 nM Ca2+
buffered pipette solution (115 CsCl, 10 EGTA, 2 MgCl2, 10
HEPES and 5.7 CaCl2 in mM, pH was adjusted to 7.2 with
CsOH and osmolarity was adjusted to ~290 mOsm with
mannitol, and the calculated free Ca2+ was 200 nM) was
used. ADP-ribose (0.5 mM) was added in the pipette solution.
The same pipette solution was used for outside-out patches.
The standard bath solution contained (mM) 130 NaCl, 5 KCl,
8 D-glucose, 10 HEPES, 1.2 MgCl2 and 1.5 CaCl2; pH was
adjusted to 7.4 with NaOH.
Ca2+ measurement
Cells were pre-incubated with 2 mM fura-PE3 AM at 37°C for
30 min in Ca2+-free bath solution, followed by a 20 min wash
period in the standard bath solution at room temperature.
Fura-PE3 fluorescence was monitored with an inverted epif-
luorescence microscope with a cooled Orca-R2 CCD camera
(Hamamatsu, Hamamatsu City, Japan). The imaging system
was controlled by software NIS-Elements 3.0 (Nikon, Tokyo,
Japan). The ratio of Ca2+ dye fluorescence (F340/F380) was meas-
ured. For the experiment with single wavelength Ca2+ dye
Fluo3-AM, the cuvette-based [Ca2+]i assay system was used as
described previously (Xu et al., 2008). All experiments were
performed at room temperature.
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Materials
All general salts and reagents were from Sigma (Dorset, UK).
FFA, MFA, niflumic acid (NFA), diclofenac , aspirin, indome-
thacin, 2-APB, tetracycline, ADP-ribose, econazole and
N-methyl-D-glucamine (NMDG) were purchased from Sigma.
Fura-PE3 AM was purchased from Invitrogen. Fura-PE3 AM
(5 mM) and 2-APB (100 mM) were made up as stock solu-
tions in 100% dimethyl sulphoxide (DMSO). Fenamate
derivatives were synthesized in the Chemistry Department
following the method reported by Mei et al. (2006) using
the copper-catalysed coupling of either 2-chloro- or 2-
bromobenzoic acid with the appropriate aniline derivative.
For example, 2-chlorobenzoic acid (9.0 mmol), the appropri-
ate aniline (9.5 mmol), K2CO3 (9.0 mmol), Cu (0.8 mmol),
Cu2O (0.4 mmol) and 5 mL of 2-ethoxyethanol were heated
under a nitrogen atmosphere for 24 h. The cooled reaction
mixture was poured into water; activated charcoal was added
then the solution filtered. The crude product was precipi-
tated upon acidification of the filtrate with 1 M HCl. The
residue was purified by dissolution in 5% aqueous Na2CO3
solution, filtration and then re-precipitation by careful
addition of 1 M HCl. In the case of compound 8 in
Figure 3, 5[2-(4′-carboxyphenylamino)benzoic acid], the
starting material was ethyl 4-aminobenzoate, but the ethyl
ester group suffered in situ hydrolysis. All products gave sat-
isfactory 1H, 13C-NMR and mass spectra; and their purity was
estimated to be >95%.
Statistics
Data are expressed as mean SEM. where n is the cell number
for electrophysiological recordings and Ca2+ imaging. Mean
data were compared using paired t-test for the results before
and after treatment, or ANOVA with Dunnett’s post hoc test for
comparing more than two groups, with significance indicated
if P < 0.05.
Results
TRPM2 channels activated by ADP-ribose
and H2O2
The expression of human TRPM2 protein in HEK-293 T-REx
cells was induced by tetracycline and confirmed by Western
blotting as we previously described (Xu et al., 2008; 2012).
The whole cell current was recorded by patch clamp after
24–48 h induction of gene expression, and the current carried
by TRPM2 channels was activated by intracellular ADP-ribose
with a linear IV curve (Figure 1A and B), in accordance
with previous reports (Perraud et al., 2001; Sano et al., 2001;
Hara et al., 2002; Wehage et al., 2002; McHugh et al., 2003).
The activation achieved its maximum within 30 s after
the formation of whole-cell patch configuration and was
fully blocked by 2-APB (100 mM). Substitution of Na+ with
equimolar concentrations of NMDG+ rapidly abolished the
inward current and the outward current gradually decreased
(Figure 1C). In the non-induced cells, a small current (<1 nA)
was activated by ADP-ribose, which could be due to endog-
enous channel activity. 2-APB fully inhibited the endogenous
current (Figure 1D and E). We also examined the effect of
H2O2 on the cells with inducible TRPM2 channels. Bath appli-
cation of H2O2 activated TRPM2 channels, but the current
development was much slower and the maximum amplitude
of the current was smaller than that after activation by ADP-
ribose (Figure 1F). The IV curve induced by H2O2 showed an
outward rectification and 2-APB at 100 mM did not fully block
the current, suggesting that H2O2 may activate other 2-APB-
insensitive channels. In addition, cytosolic Ca2+ concentra-
tions were monitored using Ca2+ -sensitive dye. Influx of Ca2+
in cells with induced TRPM2 channels was robustly increased
after perfusion with H2O2, but the non-induced cells showed
a small increase (Figure 1G).
Comparison of the three experimental approaches
indicated that whole-cell patch recording with intracellular
ADP-ribose was the best methodology for examining TRPM2
channel pharmacology, as the large current (~10 nA) through
TRPM2 channels evoked by ADP-ribose was clearly distin-
guished from the small endogenous current (0.64  0.02 nA
measured at -80 mV, n = 12) in the non-induced cells which
also showed a linear IV relationship and 2-APB sensitivity.
Therefore, the whole-cell patch was used in the subsequent
experiments for pharmacological comparison.
Effect of NSAIDs on TRPM2 channels
We examined the effect of fenamates and non-fenamate
NSAIDs on TRPM2 channels. FFA, NFA and MFA significantly
inhibited the TRPM2 current; while diclofenac showed only
a small inhibition. The IC50 values for FFA, MFA and NFA was
70  2.5, 124  11.9 and 149  12.0 mM with a slope factor
of 0.01776, 0.00872 and 0.00763 respectively. The non-
fenamate NSAIDs, aspirin and indomethacin, had no signifi-
cant effect (Figure 2). These data suggested that the blocking
activity of fenamates could be a direct effect, rather than a
class effect of NSAIDs on COX signalling pathways, as the
non-fenamate COX inhibitors had no effect.
Fenamate analogues on TRPM2 channels
In order to explore the structure–activity relationship of
varying the substituents on the 2-phenylamino ring of the
fenamate skeleton, 10 analogues were synthesized replacing
the 3-trifluoromethyl group of FFA with –F, –CH3, –OCH3,
–OCH2CH3, –COOH and –NO2 substituents at various posi-
tions in the 2-phenylamino ring (Figure 3). Potency on the
TRPM2 current was compared with the known channel
blockers 2-APB and FFA. Substitution with -3-CH3 (1)
(abbreviated as 3-MFA), 3-F (2), 3-CH3O (3) and -3-NO2 (4)
showed a significant difference in the inhibition of TRPM2
channel. The methyl substituent in the meta position
(3-MFA) was critical for channel blocking effect. A –CH3
group in the ortho (5) or para (6) position reduced potency.
Other substituents at the meta position (2, 3, and 4) also
showed less potency. Substituents with -4-CH3CH2O (7)
and -4-COOH (8) showed weak inhibition. MFA and the
analogue (9) have two methyl substituents in the ring;
however, they showed a significant difference in their
inhibitory activity (see Figures 2C and 3), which further sug-
gested the importance of the methyl substituent at the meta
position. Substitution of the 2-methyl with a methoxy group
(10) or introduction of two Cl– substituents in the ortho
positions (as in diclofenac) showed reduced inhibition (see
Figures 2D and 3). Moreover, the replacement of the benzoic
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acid ring in FFA with a nicotinic acid group (as in NFA)
reduced potency, in comparison with FFA (Figure 2D). The
dose–response curves of 3-MFA (1) and FFA were determined
by single concentration application and fitted with the
Boltzmann equation to yield IC50 values of 76  2.8 and
70  2.5 mM respectively. The inhibitory effect of 3-MFA on
TRPM2 current was partially reversible but showed a voltage-
independent block.
Intracellular effect of FFA and 3-MFA
The whole-cell patch recordings were performed using
pipette solutions containing 200 mM FFA or 200 mM 3-MFA.
The current induced by ADP-ribose was significantly pre-
vented by the inclusion of FFA or 3-MFA in the pipette solu-
tion comparing with the control group with ADP-ribose only
in the pipette solution (Figure 4A). The outside-out excised
membrane patches also showed no effect for FFA and 3-MFA
but 2-APB significantly inhibited TRPM2 channel activity
(Figure 4B and C). In addition, the single channel activity was
recorded in the outside-out patches that formed immediately
by standard procedures after the whole-cell TRPM2 current
evoked by ADP-ribose. The mean slope conductance was
66 pS, which is similar to the channel conductance of TRPM2
channels (60–64 pS) recorded by others (Perraud et al., 2001;
Starkus et al., 2010). Perfusion with FFA (100 mM) and 3-MFA
(100 mM) did not change single channel conductance and
the events of channel opening. However, 2-APB (100 mM)
abolished the TRPM2 single channel events (Figure 4D).
These data suggest that the site of action for FFA and 3-MFA
was intracellularly located.
Figure 1
TRPM2 channels activated by ADP-ribose and H2O2. Whole-cell current in the HEK293 T-REx cells inducibly transfected with TRPM2 channels was
recorded by patch clamp. (A) The time course for TRPM2 channel activation by 0.5 mM ADP-ribose (ADP-r) in pipette solution. The arrow shows
the point of membrane breakthrough as whole-cell patch formation. 2-APB (100 mM) was used. (B) IV curve for (A). (C) Na+ was substituted by
equimolar concentrations of NMDG+. The IV curves are shown in the inset. (D) Current recorded in the non-induced cells. (E) Summary data
(means  SEM) for the current at -80 mV in cells with induced TRPM2 channels (TRPM2) and non-induced cells (control) (n = 6). (F) TRPM2
channels activated by H2O2 (500 mM). (G) H2O2-evoked Ca2+ influx via TRPM2 channels. The cells without tetracycline induction (non-induced)
were used as control.
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Figure 2
Effect of fenamates and non-fenamate NSAIDs on TRPM2 current. Representative time course and IV curves of TRPM2 channels were shown in
(A–F). (A) FFA (100 mM). (B) NFA (100 mM). (C) MFA (100 mM). (D) diclofenac (DFS; 100 mM). (E) aspirin (ASP; 100 mM). (F) indomethacin (IND;
100 mM). (G) Summary data (means  SEM) showing the percentage of inhibition of TRPM2 current. The amplitude was normalized to that
blocked by 2-APB (100 mM) (n = 3–8). ***P < 0.001. (H) Concentration–response curves for FFA, MFA and NFA for the inhibition of TRPM2 current
(n = 5–6 for each point).
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Comparison with fenamates, econazole and
2-APB
FFA, econazole and 2-APB are known to be TRPM2 channel
blockers (Hill et al., 2004a,b; Togashi et al., 2008). Here we
compared their pharmacological properties. FFA and 3-MFA
(1) showed a similar potency for blockade of TRPM2 channels
(Figure 3C), but FFA also caused a significant Ca2+ release
(Figure 5A). This effect was partly exerted on the endoplasmic
reticulum (ER) Ca2+ store, because the sarco(endo)plasmic
reticulum Ca2+-ATPase (SERCA) blocker thapsigargin reduced
by nearly half (46%), the effect of FFA-induced Ca2+ release
Figure 3
Synthetic fenamate analogues and the effect on TRPM2 current. (A) Time course showing the effect of fenamate analogues, compounds (1) to
(10) at 100 mM. The structures are shown at the top of each panel. (B) Summary data (means SEM) for the effect on TRPM2 current. The current
measured at 80 mV was normalized to that blocked by 2-APB (100 mM). ***P < 0.001, significantly different from FFA group; ANOVA. n = 3–6
for each group. (C) Comparison of the concentration–response curves for 3-MFA (1) and FFA. (D) Current–voltage relationship and the inhibition
of TRPM2 current by 3-MFA. (E) Inhibition of ADP-ribose-induced TRPM2 current by 3-MFA (100 mM) was partly reversed after wash-out and
abolished by 2-APB (100 mM).
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(Figure 5B). The other part of FFA-induced Ca2+ release could
be due to mitochondrial Ca2+ release which has been
described by us (Jiang et al., 2012) and other groups
(McDougall et al., 1988; Poronnik et al., 1992; Tu et al., 2009).
Although MFA had a small effect on Ca2+-release, but its
analogue 3-MFA (1) had no effect on this variable (Figure 5C
and D). FFA-induced Ca2+ release was unrelated to the expres-
sion of TRPM2 channels, because the amplitude of the Ca2+
release signal in the induced cells (after tetracycline) was
similar to that in the non-induced cells. These data suggested
that 3-MFA was more selective than FFA and MFA as it did not
affect Ca2+ release from intracellular stores.
Applicationof econazole (10 mM) inhibited TRPM2current
evoked by intracellular ADP-ribose. The onset of blockade was
rapid and partly reversed by wash-out. However, econazole at
10–100 mM showed an inhibition at first and followed by a
gradual increase of the whole cell current. 2-APB (100 mM) and
FFA (100 mM) were unable to block the current evoked by
econazole (Figure 6A–D, Supplementary Figure S1). Substitu-
tion of Na+ with equimolar NMDG+ showed a small reduction
of the inward current through TRPM2 channels, but the
inward current in the cells without econazole treatment was
nearly abolished. In addition, the econazole-induced current
was irreversible and resistant to the Cl– channel blocker tam-
oxifen (10 mM) (Supplementary Figure S1C). The non-induced
cells also showed the current induced by econazole (data not
shown), suggesting that this econazole-induced current could
be a non-selective current, which may result from the non-
specific effects of antifungal drugs onmembrane permeability.
On the other hand, econazole (100 mM) induced significant
Ca2+ oscillations in the T-REx cells. These oscillations were
reversed on washing and inhibited by 100 mM 2-APB
(Figure 6E and F). Pretreatment with the SERCA blocker thap-
sigargin (1 mM) prevented the Ca2+ oscillations (Figure 6G),
suggesting that the econazole-induced Ca2+ oscillations were
related to Ca2+ release from the ER.
2-APB at 100 mM nearly abolished the TRPM2 current,
which was consistent with recent reports (Togashi et al.,
Figure 4
Effect of 3-MFA or FFA applied intracellularly. (A) Whole-cell patch was recorded in the TRPM2 cells using pipette solution containing 0.5 mM
ADP-ribose (ADP-r) with or without FFA (200 mM) or 3-MFA (200 mM) (n = 5 for each group). (B) Example of outside-out patches showing the
effect of FFA (100 mM) and 2-APB (100 mM). (C) Example of the effect of 3-MFA (100 mM) and 2-APB (100 mM). (D) Single channel activity of
TRPM2 recorded by outside-out patches (n = 4). (E) Mean unitary current sizes for ADP-ribose-induced TRPM2 single channel events plotted
against voltage. Straight lines were fitted, and the mean unitary slope conductance was 65.76  0.23 pS (0.5 mM ADP-ribose). No effect of FFA
(100 mM, 65.81 pS) and 3-MFA (100 mM, 65.61 pS) on the single channel conductance in the outside-out patches.
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2008; Naziroglu et al., 2011). 2-APB not only blocked the
TRPM2 current in the induced cells but also inhibited the
current in the non-induced cells. The effect was rapid in
onset and the current recovered fully after wash-out (see
Figure 1). This result was contrary to our previous report
(Xu et al., 2005). After re-examining the effect of 2-APB, we
believe the difference could be due to cell injury and mem-
brane leak after long-lasting activation in our previous
study. The massive Ca2+ influx through TRPM2 channels
resulted in plasma membrane blebbing and cell shape
change (Supplementary Figure S2). The non-induced TRPM2
cells had no such membrane blebbing phenomena after
the membrane breakthrough with the patch pipette con-
taining 0.5 mM ADP-ribose, suggesting that the plasma
membrane blebbing was dependent on the activity of
TRPM2 channels.
Discussion
In this study, we have compared the effect of some fenamate
analogues, econazole and 2-APB on TRPM2 channels. Modi-
fication of the 2-phenylamino ring by substitution of the
trifluoromethyl group in FFA with various substituents led
to significant changes in channel blocking activity. The intro-
duction of a meta –CH3 group into the phenylamino ring
(3-MFA, 1) yielded a more selective inhibitor of TRPM2 chan-
nels that did not affect Ca2+ release from intracellular stores,
but with a potency similar to FFA. This compound could
therefore offer a new and useful tool for the selective study of
this TRPM2 channel.
FFA and its analogues inhibit several types of ion
channels. Early studies have shown that fenamates inhibited
Ca2+-activated Cl- channels (Korn et al., 1991; Hogg et al.,
Figure 5
Ca2+ release induced by FFA. Cytosolic Ca2+ concentrations were monitored in the T-REx cells perfused with Ca2+-free bath solution. (A) FFA
(100 mM) induced Ca2+ release in the Ca2+-free bath solution. (B) The FFA (100 mM) -induced Ca2+ release decreased in cells treated with 1 mM
thapsigargin (TG). (C) Perfusion with MFA (100 mM) followed by FFA (100 mM). (D) No effect of 3-MFA (1) (100 mM) on Ca2+ release, but FFA
(100 mM) evoked Ca2+ release. (E) FFA induced Ca2+ release in the non-induced cells [Tet(–)]. (F) Summary data (means  SEM) for the amplitude
of Ca2+ release signal. FFA, 3-MFA and MFA at 100 mM and TG at 1 mM were applied (n = 20–26 cells). ***P < 0.001, significantly different from
FFA Tet(+) group. #P < 0.05 significantly different from TG+FFA group; ANOVA.
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1994; Shaw et al., 1995), Ca2+-activated K+ channels (Green-
wood and Large, 1995), 1-oleoyl-2-acetyl-sn-glycerol (OAG)-
sensitive cationic current (Jung et al., 2002), Ca2+-activated
non-selective cationic channel (Yamashita and Isa, 2003)
and a cationic channel in cardiac myocytes (Macianskiene
et al., 2010). For the TRP channel family, FFA activated TRPC6
(Inoue et al., 2001) and TRPA1 (Hu et al., 2010), but inhibited
TRPM2, TRPM3, TRPM4 and TRPM5 channels (Hill et al.,
2004a; Ullrich et al., 2005; Harteneck et al., 2007; Wilkinson
et al., 2008; Klose et al., 2011; Naziroglu et al., 2011), suggest-
ing that fenamate analogues are useful tools in the study
of TRP cationic channels. However, there are several reports
that FFA induced mitochondrial Ca2+ release (Poronnik
et al., 1992; Hu et al., 2010), which could indirectly alter the
activity of TRP channels, especially the Ca2+-sensitive forms
including TRPM2 (Tang et al., 2001; McHugh et al., 2003;
Zeng et al., 2004). In order to find a relatively selective
channel blocker, we modified the structure of FFA and found
that 3-MFA (1) was the most promising compound among
the analogues we synthesized. This compound had no effect
on Ca2+ release and showed a slight inhibition of TRPC4 and
TRPC5 channels (Jiang et al., 2012) but was potent as FFA in
blocking TRPM2 channels, suggesting that 3-MFA (1) was a
more selective compound for analysing TRPM2 channel func-
tion. However, further study is still required to characterize its
specificity, because we have not tested the effect of 3-MFA on
other TRPM channels or native cationic channels. The IC50
value for FFA was lower in this study than that measured by
the FLIPRtetra system (Klose et al., 2011), which could be due to
different methodology and the channel activator used. We
noticed that the TRPM2 current showed significant rundown
after full current development, so we used a single concen-
tration to determine the IC50, rather than a series of cumula-
tive concentrations. In addition, the percentage of inhibition
was measured at 100 s after perfusion with each tested
reagent and the current rundown was corrected by linear
fitting.
Econazole is an antifungal imidazole and early reports
showed that it inhibited ICRAC channels (Franzius et al., 1994;
Gamberucci et al., 1998). Inhibition of TRPM2 channels was
reported by Hill et al. (2004b), and the binding site on TRPM2
channels was extracellularly located. Our data also showed
potent inhibition of TRPM2 channels by econazole, with
10 mM producing nearly full block of TRPM2 current.
However, longer perfusion with econazole evoked a non-
specific current. The amplitude of the non-specific current
induced by econazole was concentration-dependent and
achieved nano-amp values for the whole cell current, when
Figure 6
Effect of econazole on TRPM2 currents. (A–C) Examples of the time course for TRPM2 current inhibited by econazole (10, 30, 100 mM) and
followed by an increase of the whole cell current. The IV curves are shown in the inset and the traces labelled as a, b, c, and d are indicated in
the corresponding time course. (D) Summary data (means  SEM) for current evoked by econazole. (E) Cytosolic Ca2+ oscillations induced by
econazole (100 mM) in HEK-293 T-REx cells. (F) Ca2+ oscillations inhibited by 2-APB (100 mM) in the T-REx cells. (G) Ca2+ levels in cells pretreated
with thapsigargin (TG; 1 mM) for 30 min and then perfused with econazole (100 mM) and then with a bath solution containing 1.5 mM Ca2+.
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high concentrations of econazole (100 mM) were applied.
2-APB and FFA did not inhibit the econazole-evoked current.
Substitution of Na+ with NMDG slightly reduced the inward
current, and Cl– channel blocker tamoxifen did not affect the
current. These findings suggest that the econazole-induced
current was not mediated by endogenous TRPC channels or
gap junctional channels or a Cl- channel, but was a non-
specific current that could be due to the membrane hyperper-
meability caused by antifungal drugs (Georgopapadakou et al.,
1987; Matsui et al., 2008). In addition, we found econazole
at 100 mM caused significant cytosolic Ca2+ oscillations. These
oscillations were probably due to inositol trisphosphate-
mediated Ca2+ release from ER Ca2+ stores (Hajnoczky and
Thomas, 1997), because depletion of the ER Ca2+ stores by the
SERCA blocker thapsigargin or the inhibition of inositol tri-
sphosphate receptors by high concentration of 2-APB can
abolished the activity. Such cytosolic Ca2+ increase was also
reported by other groups with lower concentrations of econa-
zole in human osteosarcoma cells (Chang et al., 2005), corneal
epithelial cells (Chien et al., 2008) and lymphocytes (Mason
et al., 1993), suggesting that econazole should be used with
caution as a TRPM2 channel inhibitor.
The pH and temperature dependence of TRPM2 channels
have been described (Hill et al., 2004a; Togashi et al., 2008;
Yang et al., 2011). In our study, we did not measure blocking
activities of 3-MFA or FFA at different pH or temperature. All
the experiments were performed at room temperature (23–
25°C) with normal bath and pipette solutions. Unlike 2-APB,
which showed a rapid and reversible inhibition of TRPM2
channels, 3-MFA and FFA only showed a small recovery
after wash-out, which was comparable to that after FFA (Hill
et al., 2004a). The block of TRPM2 by 3-MFA was voltage-
independent and its site of action was intracellularly located,
in contrast to clotrimazole and 2-APB which are known to act
on an extracellular site on the channel (Hill et al., 2004b). The
TRPM2 channels are ubiquitously expressed Ca2+-permeable
channels. A relatively large TRPM2-like endogenous current
has been reported in the rat insulinoma cell line CRI-G1,
which was blocked by FFA (Hill et al., 2004a). We have not
tested the effect of 3-MFA on such cells, but we have exam-
ined the effect of 3-MFA, FFA and 2-APB on the endogenous
current in the non-induced HEK293 cells. 3-MFA only slightly
changed the endogenous current, whereas both FFA and
2-APB showed clear inhibition and their inhibition was fully
reversible after wash-out (data not shown), suggesting that
the endogenous current may have different properties from
the expressed TRPM2 channels or could be a non-specific
current, sensitive to 2-APB and FFA, which needs to be further
studied.
In conclusion, our results show that some fenamates,
econazole and 2-APB are all useful blockers of TRPM2 chan-
nels. However, FFA, econazole and 2-APB have non-specific
effects on intracellular Ca2+ movement and on other chan-
nels, so these unwanted effects should be considered when
the blockers are used for pharmacological studies of TRPM2
channels. The fenamate analogue, 3-MFA (1), was as potent
as FFA but had no effect on Ca2+ release from intracellular
stores and may thus be used as a more selective TRPM2
channel blocker. However, we have not yet tested the effect of
3-MFA on other ion channels, which are targeted by FFA;
therefore, the specificity and utility of 3-MFA as a TRPM2
blocker need to be further investigated. The information on
structure-activity correlations would be useful for further
improvement of the design of new fenamate-based channel
blockers.
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Figure S1 Econazole-induced current and the effect of
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by 0.5 mM ADP-ribose in the pipette solution. Perfusion with
econazole (30 mM) inhibited the TRPM2 current and followed
by the activation of another current. Perfusion with solutions
containing NMDG+ (140 mM), an equimolar substitute for
Na+, slightly reduced the inward current. (B) TRPM2 current
inhibited by Na+ substitution with NMDG+ in the cells
without econazole treatment. (C) Effect of FFA (100 mM) on
econazole-induced current. (D) Effect of tamoxifen (10 mM).
Figure S2 Plasma membrane blebbing in cells with induced
TRPM2 channels, during the patch recording. (A) Image
showing the cells after the formation of whole-cell configu-
ration for 3 min. (B) The same cells as in (A) photographed at
10 min after TRPM2 channels had been fully activated. Mem-
brane blebbing is indicated by arrow.
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A B S T R A C T
Non-steroidal anti-inﬂammatory drugs (NSAIDs) are widely used anti-inﬂammatory therapeutic agents,
among which the fenamate analogues play important roles in regulating intracellular Ca2+ transient and
ion channels. However, the effect of NSAIDs on TRPC4 and TRPC5 is still unknown. To understand the
structure–activity of fenamate analogues on TRPC channels, we have synthesized a series of fenamate
analogues and investigated their effects on TRPC4 and TRPC5 channels.
Human TRPC4 and TRPC5 cDNAs in tetracycline-regulated vectors were transfected into HEK293
T-REx cells. The whole cell current and Ca2+ movement were recorded by patch clamp and calcium
imaging, respectively.
Flufenamic acid (FFA), mefenamic acid (MFA), niﬂumic acid (NFA) and diclofenac sodium (DFS)
showed inhibition on TRPC4 and TRPC5 channels in a concentration-dependent manner. The potency
was FFA > MFA > NFA > DFS. Modiﬁcation of 2-phenylamino ring by substitution of the triﬂuoromethyl
group in FFA with –F, –CH3, –OCH3, –OCH2CH3, –COOH, and –NO2 led to the changes in their channel
blocking activity. However, 2-(20-methoxy-50-methylphenyl)aminobenzoic acid stimulated TRPC4 and
TRPC5 channels. Selective COX1-3 inhibitors (aspirin, celecoxib, acetaminophen, and indomethacin)
had no effect on the channels. Longer perfusion (>5 min) with FFA (100 mM) and MFA (100 mM) caused a
potentiation of TRPC4 and TRPC5 currents after their initial blocking effects that appeared to be partially
mediated by the mitochondrial Ca2+ release.
Our results suggest that fenamate analogues are direct modulators of TRPC4 and TRPC5 channels. The
substitution pattern and conformation of the 2-phenylamino ring could alter their blocking activity,
which is important for understanding fenamate pharmacology and new drug development targeting the
TRPC channels.
 2012 Elsevier Inc. All rights reserved.
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The transient receptor potential (TRP) channel family is a class
of Ca2+-permeable channels. To date, 28 mammalian TRP channels
have been identiﬁed and divided into six subfamilies on the basis
of amino acid sequence homology: TRPC (‘‘canonical’’), TRPM
(‘‘melastatin’’), TRPV (‘‘vanilloid’’), TRPA (‘‘ankyrin’’), TRPML
(‘‘mucolipin’’), and TRPP (or PKD) (‘‘polycystin’’). The canonical
TRP subfamily (TRPC) has seven members that can be grouped into
three subgroups: TRPC1/4/5, TRPC3/6/7, and TRPC2 (a pseudogene
in human) [1]. Human TRPC channels seem to be ubiqutously
distributed and mediate the Ca2+ inﬂux evoked by G-protein
coupled receptor activation or/and Ca2+ store depletion which are
involved in many cellular functions, such as cell proliferation,* Corresponding author. Tel.: +44 1482 465372; fax: +44 1482 465390.
E-mail address: sam.xu@hyms.ac.uk (S.-Z. Xu).
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doi:10.1016/j.bcp.2012.01.014apoptosis, secretion, smooth muscle contraction and migration
[2–4]. TRPCs have been demonstrated as the potential therapeutic
targets for neointimal growth, segmental glomerulosclerosis,
overexposure to mercury, and rheumatoid arthritis [2–7]. There-
fore, the identiﬁcation of regulators of these channels is important
for understanding their physiological properties in native cells that
may lead to new therapeutic agents.
Non-steroidal anti-inﬂammatory drugs (NSAIDs) are widely
used for the treatment of fever, pain and inﬂammation. Some like
aspirin have the potential for the prevention of ischemic heart
diseases, but some NSAIDs may increase the cardiovascular risk,
such as the fenamate analogue diclofenac [8–11]. The cardiovas-
cular risk associated with NSAIDs seems to be not determined by
the selectivity of COX-2 [8]. In addition, the risk of some types of
cancer was reduced by aspirin [12,13] and non-aspirin NSAIDs
[14]. These observations suggest that mechanisms other than COX-
2 inhibition may exist. Indeed, several possible mechanisms have
been proposed for the action of NSAIDs including anti-proliferative
H. Jiang et al. / Biochemical Pharmacology 83 (2012) 923–931924effects by regulating several target genes [12], stabilization of DNA
mismatch repair [15], and regulation of cytosolic and mitochon-
drial Ca2+ homeostasis [12,16].
The relevance of NSAIDs to Ca2+ signalling has been recognized
through the inhibition of production of prostaglandins and
leukotrienes from arachidonic acid (AA) by cyclooxygenase (COX)
inhibition, and AA and its metabolites themselves can inﬂuence Ca2+
inﬂux through a number of Ca2+-permeable channels [17–19]. In
addition, AA release from membrane phospholipids by phospholi-
pase A2 (PLA2) is also Ca2+-related, since the group IVA PLA2 (also
known as cytosol PLA2a) activation is Ca2+-dependent [20]. These
indirect effects on Ca2+ signal through COX inhibition could be a class
effect of NSAIDs. On the other hand, the PLA2 inhibitor N-(p-
amylcinnamoyl)anthranilic acid (ACA) inhibited TRPM2 channels,
but PLA2 inhibitors without the skeleton of anthranilic acid had no
effect on the channel [21], suggesting the parent structure of
anthranilic acid is essential for the channel blocking effect. The
fenamate NSAIDs are anthranilic acid derivatives with structural
similarity to ACA [22], and their effects on a variety of channels have
been demonstrated including the Ca2+-activated Cl channels, the
voltage-dependent Na+ or Ca2+ channels, and the TRP channels [23],
for example, ﬂufenamic acid (FFA) inhibited TRPM2, TRPM4, TRPM5,
TRPC3, and TRPC5 [24,25], but activated TRPC6 [26–28] and TRPA1
[29]. These observations indicated that NSAIDs can inﬂuence
intracellular Ca2+ level or Ca2+-permeable channels in both direct
and indirect ways, and the compounds with the skeleton of
anthranilic acid are critical for the direct effect. Therefore, we
hypothesized that non-fenamate NSAIDs may exert their effects
mainly through PLA2/COX pathway or other mechanisms, while the
fenamate NSAIDs could modulate Ca2+-permeable channel activity
directly. Structure modiﬁcation on the fenamate skeleton could
directly alter the potency of the channel blocking effect.
To test our hypothesis, we examined the effects of fenamate
analogues, non-fenamate NSAIDs, and selective COX1-3 inhibitors
on TRPC4 and TRPC5 channels. The subgroup of TRPC4/5 was used
in this study, because the current for TRPC4 and TRPC5 is robust
and stable after channel activation and therefore suitable for
screening new drugs to address the unknown effect of NSAIDs on
TRPC4/5 channels. To understand the structure–activity relation-
ship of fenamates, we synthesized fenamate analogues by the 2-
phenylamino ring modiﬁcation and compared their effects on the
TRPC channels. Moreover, as several reports have suggested that
NSAIDs may interfere with mitochondria Ca2+ release [30,31], the
involvement of intracellular Ca2+ homeostasis in the TRPC channel
activity regulated by NSAIDs was also investigated.
2. Materials and methods
2.1. Cell culture and transfection
Human TRPC4a (GenBank accession number NM_016179) and
TRPC5 (AF054568) in a tetracycline-regulatory vector were trans-
fected into HEK-293 T-REx cells (Invitrogen, Paisley, UK). TRPC4 was
tagged with enhanced yellow ﬂuorescent protein (EYFP) at the N-
terminus. The expression was induced by 1 mg ml1 tetracycline for
48–72 h before recording. The non-induced cells without addition of
tetracycline were used as control. Cells were grown in DMEM-F12
medium (Invitrogen, Paisley, UK) containing 10% foetal calf serum
(FCS), 100 units ml1penicillin and 100 mg ml1 streptomycin. Cells
were maintained at 37 8C under 95% air and 5% CO2 and seeded on
coverslips prior to experiments.
2.2. Smooth muscle cell isolation and culture
Eight-week-old male rats were killed by inhalation of CO2 in
accordance with the Schedule 1 in the Code of Practice of UKAnimals Scientiﬁc Procedures Act 1986. The thoracic aorta was
dissected out and the adventitia was carefully removed. The
endothelium was removed by gently rubbing the luminal
surface with a curved forceps. The smooth muscle layer was
cut into 0.5 mm2 segments and cultured in DMEM-F12 including
10% FBS and antibiotics for cell expansion. The cultured smooth
muscle cells at passage 4–5 were used for calcium imaging
experiment.
2.3. Electrophysiological recordings
Whole-cell clamp was performed at room temperature (23–
26 8C) [5]. Brieﬂy, signal was ampliﬁed with an Axoclamp 2B or
Axopatch B200 patch clamp ampliﬁer and controlled with
pClamp software 10. A 1-s ramp voltage protocol from
100 mV to +100 mV was applied at a frequency of 0.2 Hz from
a holding potential of 0 mV. Signals were sampled at 10 kHz
and ﬁltered at 1 kHz. The glass microelectrode with a resistance
of 3–5 MV was used. The 200 nM Ca2+ buffered pipette solution
contained 115 CsCl, 10 EGTA, 2 MgCl2, 10 HEPES, and 5.7 CaCl2
in mM, pH was adjusted to 7.2 with CsOH and osmolarity
was adjusted to 290 mOsm with mannitol, and the calculated
free Ca2+ was 200 nM using EQCAL (Biosoft, Cambridge, UK).
The standard bath solution contained (mM): 130 NaCl, 5 KCl, 8
D-glucose, 10 HEPES, 1.2 MgCl2 and 1.5 CaCl2. The pH was
adjusted to 7.4 with NaOH.
2.4. Ca2+ measurements
The rat aortic smooth muscle cells were preincubated with
2 mM fura-PE3 AM at 37 8C for 30 min in Ca2+-free bath solution,
followed by a 20-min wash period in the standard bath solution
at room temperature. Fura-PE3 ﬂuorescence was monitored
with an inverted epiﬂuorescence microscope (Nikon Ti-E, Japan).
A xenon arc lamp provided excitation light, the wavelength
of which was selected by a Nikon imaging system controlled
by software Element 3.0. Emission was collected via 510 nm
ﬁlter for fura-PE3 AM and a cooled Orca-R2 CCD camera
(Hamamatsu, Japan). Images were analyzed using regions of
interest (ROIs), which selected parts of the image frame
corresponding to individual smooth muscle cells. The ratio of
Ca2+ dye ﬂuorescence (F340/F380) was measured by NIS-Element
Ca2+ imaging software. Agents were applied to smooth muscle
cells using a continuous bath perfusion system with a ﬂow rate
of 4 ml min1. All the experiments were performed at room
temperature.
2.5. Reagents and drugs
All general salts and reagents were purchased from Sigma–
Aldrich (Poole, UK). FFA, mefenamic acid (MFA), niﬂumic acid
(NFA), diclofenac sodium (DFS), aspirin (ASP), acetaminophen
(APAP), indomethacin (IND), gadolinium chloride (Gd3+), 2-
aminoethoxydiphenyl borate (2-APB), cyclosporine A, and foetal
calf serum were purchased from Sigma–Aldrich. Celecoxib (CXB)
was purchased from Cayman Chemical (Ann Arbor, MI, USA) and
Fura-PE3 AM from Invitrogen (Paisley, UK). Fura-PE3 AM (5 mM)
and 2-APB (100 mM) were made up as stock solutions in 100%
dimethyl sulphoxide (DMSO). Ten fenamate derivatives (Fig. 2,
table entries 1–10) were synthesized by the copper-catalysed
coupling of either 2-chloro- or 2-bromobenzoic acid with the
appropriate aniline derivative [32]. In the case of entry 5 [2-(40-
carboxyphenylamino)benzoic acid] ethyl 4-aminobenzoate was
used but the ethyl ester group suffered in situ hydrolysis. Products
gave satisfactory 1H,13C-NMR and mass spectra and their purity
was estimated to be >95%.
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Data are expressed as mean  S.E.M. where n is the cell number
for electrophysiological recordings and Ca2+ imaging. Data sets were
compared using paired t-test for the results before and after
treatment, or the ANOVA Dunnett’s post hoc analysis for comparing
more than two groups with signiﬁcance indicated if P < 0.05.Fig. 1. Effect of fenamates on TRPC4 and TRPC5 channels. Whole cell currents in the HEK-2
clamp. (A) The time course (lower) and IV curve (upper) for the effect of fenamates (FFA
channel activator, and 2-APB (100 mM) was used at the end of fenamate perfusion. The c
recorded. (C) Concentration–response curves for FFA, MFA, NFA, and DFS on TRPC4 channel (n3. Results
3.1. Effect of fenamates on TRPC4 and TRPC5 channels
To examine the effect of fenamates on TRPC4 and TRPC5
channels, the whole-cell current was recorded in HEK-293 cells
stably transfected with human TRPC4 or TRPC5. The expression93 T-REx cells transfected with TRPC4 and TRPC5 were recorded by whole-cell patch
, MFA, NFA, and DFS) at 100 mM on TRPC4 channel. Gd3+ (100 mM) was used as a
urrent amplitude was measured at 80 mV. (B) Similar to (A), but TRPC5 current was
 = 6 for each group). (D) Concentration–response curves for TRPC5 (n = 6 for each group).
H. Jiang et al. / Biochemical Pharmacology 83 (2012) 923–931926of TRPC4 and TRPC5 was induced by tetracycline and the current
was characterized by the Gd3+ activation with a unique ‘‘N’’
shaped current–voltage (IV) relationship, and by fully blockade
by 100 mM 2-APB (Fig. 1). FFA, MFA, NFA and DFS signiﬁcantly
inhibited the TRPC4 and TRPC5 currents in a concentration-
dependent manner. The IC50 for FFA, MFA, NFA and DFS on TRPC4
was 55  5 mM, 84  8 mM, 102  9 mM, and 138  7 mM, respec-
tively; and the IC50 for TRPC5 was 37  5 mM, 80  5 mM,
80  9 mM, and 170  9 mM, respectively. These data suggested
that fenamates are inhibitors on TRPC4 and TRPC5 channels. The
potency of inhibition was FFA > MFA > NFA > DFS.
3.2. Synthesis of fenamate analogues and the effect on TRPC4
Ten analogues were synthesized based on the 2-phenylamino-
benzoic acid skeleton replacing the triﬂuoromethyl group of FFA
with –F, –CH3, –OCH3, –OCH2CH3, –COOH, and –NO2 substituents at
various positions in the 2-phenylamino ring (Fig. 2A). The effect of
these analogues at 100 mM on the TRPC4 current was compared
with FFA by whole-cell patch recording. The substitution with –CH3Fig. 2. Fenamate analogues and effect on TRPC4 channel. (A) The structures of fenamate a
R3 position. FFA group (100 mM) was used as control for comparison between the groups. (C) 
the modiﬁcation at R4 position. (E) Location of two methyl substituents on the TRPC4 channe
the groups. The current measured at 80 mV after exposure to each compound for 5 min wa
n = 6 for each group. *P < 0.05, **P < 0.01 and ***P < 0.001 for the comparisons with FFA (1), single –F atom (2), –OCH3 (3) and –NO2 (4) reduced the potency
of inhibition on TRPC4 channel, and the percentage of inhibition was
67%, 40%, 32%, and 14% of the FFA inhibition (100%), respectively
(Fig. 2B). The position of a single methyl substituent (analogue 1, 5,
and 6) also affected the potency (Fig. 2C). The substitution of –CH3
at R4 with –OCH2CH3 (7) increased the blocking activity with a
similar potency on the inward current, however the introduction of –
COOH (8) to the ring in the same position showed the loss of blocking
effect (Fig. 2D), suggesting that the polarity of modifying group at R4
could be important. In addition, we observed the effect of
modiﬁcations with two substituents in the ring (Fig. 2E). MFA
and analogue (9) showed a signiﬁcant difference in their inhibitory
activity. However replacement of the 2-methyl in (9) with a
methoxy group (10) gave an analogue which potentiated the
channel activity of TRPC4. The introduction of negative charges,
such as –COOH (8) and Cl– (DFS), decreased the potency of blocking
effect. Moreover, the modiﬁcation on the benzoic acid by C to N
substitution (i.e., NFA) showed a signiﬁcant decrease in the blocking
activity comparing to FFA (31  7% vs. 73  4% at the concentration
of 100 mM) (see Fig. 1C).nalogues. (B) Mean  S.E.M. data for the effect on TRPC4 current by the modiﬁcation at
Effect of the position of methyl substituent on the channel blocking activity. (D) Effect of
l activity. MFA group (100 mM) was used as control for statistical comparison between
s normalized by the amplitude blocked by 2-APB (100 mM). ANOVA test was used and
group in (B, C, and D).
AB 2   +80 mV
  -80 mV
-1
0
1
**N
o
rm
li
z
e
d
 r
e
s
p
o
n
s
e
-2 APAPcontrol ASP INDCXB
Fig. 3. Effect of non-fenamate COX inhibitors on TRPC4 channel. (A) Representative time course and IV curve for selective COX inhibitors on TRPC4 channels. Aspirin (ASP,
100 mM), celecoxib (CXB, 10 mM), acetaminophen (APAP, 100 mM), and indomethacin (IND, 10 mM) was used. (B) Mean  S.E.M. data (n = 6–8, **P < 0.01).
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The effect of selective COX inhibitors on TRPC channels is
unknown, therefore we examined the direct effect of non-
fenamate COX1-3 inhibitors on TRPC4 (Fig. 3). Aspirin, celecoxib
and acetaminophen are selective inhibitors for COX1, COX2
and COX3, and indomethacin inhibits both COX1 and COX2 [8].
The COX1 and COX3 inhibitors had no effect on TRPC4, however,
the COX2 inhibitor celecoxib showed a small stimulating effect
on TRPC4. Similar stimulating effect of celecoxib was observed on
TRPC5 current (Supplementary Fig. 1). Indomethacin showed no
effect on TRPC4, suggesting that the inhibition of COX1 and COX2
are not involved in the channel activation. Aspirin, celecoxib,
acetaminophen and indomethacin are structurally different from
the fenamate analogues, therefore the blocking effect of
fenamates is supposed to be a direct interaction between the
chemical structures and the channel protein, rather than the COX
pathways.
3.4. TRPC4 and TRPC5 channels potentiated by FFA but not by NFA
As shown in Fig. 4, FFA initially inhibited the TRPC4 and TRPC5,
and then gradually increased the currents of TRPC4 and TRPC5.
This delayed channel potentiation occurred after the exposure to
FFA for 3 min and achieved the steady-state at 8–10 min. This
channel potentiating effect was observed in the TRPC4 or TRPC5
transfected cells, but not the non-induced cells, after perfusionwith FFA and MFA at concentrations higher than 50 mM. However,
NFA and DFS did not show potentiation on TRPC4 and TRPC5
channels. The FFA-induced IV curve showed a typical TRPC4 or
TRPC5 current. These results suggested the delayed channel
potentiation is due to the increased activity of TRPC4 or TRPC5
channels and speciﬁc for some structures of fenamate analogues.
3.5. Mitochondria Ca2+ release involved in the channel potentiation
In order to examine the underlying mechanism of the delayed
channel potentiation on TRPC4 and TRPC5 channels, we compared
the effects of FFA and NFA on mitochondrial Ca2+ release using
primary cultured rat aortic smooth muscle cells (SMCs). The Ca2+
dye distribution in the mitochondria was evident after incubation
with Fura-PE3 AM in Ca2+-free solution for 30 min (Fig. 5). The
pattern of mitochondrial Ca2+ dye loaded in the SMCs was similar
to the previous report [33]. FFA robustly increased the intracellular
Ca2+ concentration in both Ca2+-free and 1.5 mM Ca2+ standard
bath solutions, but MFA, NFA, DFS, ASP, and IND showed a small
cytosolic Ca2+ increase compared to FFA, and CXB and APAP had no
effect (Fig. 5C). The Ca2+ increase induced by FFA in the SMCs could
be mainly contributed to by mitochondrial Ca2+ release, because
pre-application of the sarco/endoplasmic reticulum Ca2+-ATPase
(SERCA) blocker thapsigargin (TG) did not inhibit the FFA-induced
Ca2+ release (Fig. 5D).
Cytosolic Ca2+ increase evoked by FFA was also evident in the
TRPC4 transfected HEK-293 cells even in the presence of TG, but
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Fig. 4. Delayed potentiation on TRPC4 and TRPC5 currents by FFA. (A) FFA (100 mM) initially blocked the TRPC4 current and the gradually increased the amplitude of TRPC4
current in the presence of 100 mM Gd3+. The IV curves were showed at 3, 5, and 7.5 min after initial blockade. (B) No potentiation by NFA (100 mM). The IV curves were shown
in the right panel. (C) Mean  S.E.M. data for the TRPC4 amplitude measured at 80 mV after perfusion with FFA, MFA, NFA, and DFS for 3, 5 and 7.5 min. (D–F) As shown in A–C, but
the cells expressing TRPC5 were used. n = 6–8 for each group, *P < 0.05, **P < 0.01, and ***P < 0.001.
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(Supplementary Fig. 2), suggesting that Ca2+ release from ER also
contributes to the FFA-induced Ca2+ increase in this cell type.
However, ER Ca2+ store depletion with TG was unable to abolish
the channel potentiating effect of FFA (Fig. 5E and F), which further
suggested the involvement of mitochondrial Ca2+ store in the
mechanism.
To examine the role of mitochondrial Ca2+ release in the FFA-
induced channel potentiation, we pre-treated the stable TRPC4
cells with cyclosporine A (CsA). CsA is an inhibitor of mitochondrial
permeability transition pore, which also inhibits mitochondrial
Ca2+ movement across the membrane [34,35]. Preincubation with
CsA (10 mM) signiﬁcantly decreased the FFA-induced TRPC4
channel potentiation (Fig. 5G), suggesting the involvement of
mitochondrial Ca2+ release in the FFA-induced TRPC4 channel
potentiation.
4. Discussion
In this study, we have found that the fenanates FFA, MFA, NFA
and DFS showed inhibition on TRPC4 and TRPC5 channels with apotency sequence of FFA > MFA > NFA > DFS. Replacement of the
triﬂuoromethyl group in FFA with a range of substituents leads to a
signiﬁcant change in the channel blocking activity for those
derivatives. Introduction of 2-methoxy-5-methyl substituents to
the phenylamino ring (10) gave an analogue with a stimulating
effect on the channels. COX-1 and COX-3 inhibitors did not show
any direct effect on TRPC4 or TRPC5 channels, but the highly
selective COX-2 inhibitor celecoxib slightly increased the activity
of TRPC4 and TRPC5. Interestingly, there was differential effect of
fenamate analogues on TRPC4 and TRPC5 channels, i.e., FFA and
MFA showed a potentiating effect after initial inhibition, but NFA
and DFS did not potentiate the channels. The TRPC4 and TRPC5
channel potentiation by FFA is likely explained by Ca2+ release
from mitochondria, because the inhibition of mitochondrial
permeability transition pore by CsA partially prevented the FFA-
induced channel potentiation. In addition, NFA did not show any
channel potentiation, which could be explained by its low potency
in mitochondrial Ca2+ release compared with FFA [31].
Fenamates are effective anti-inﬂammatory agents through
COX-1 and COX-2 inhibition, and also inhibit a variety of ion
channel activities in many cell types. Early studies have shown that
Fig. 5. Involvement of mitochondrial Ca2+ release on the TRPC4 channel potentiation. (A) Rat aortic smooth muscle cells were loaded with Fura-PE3 AM. The cytosolic Ca2+
increase induced by FFA at 100 mM. (i) and (ii) are the images before and after FFA treatment. The thin trace is the background (BG) signal and the thick line is smooth muscle
cell (SMC). (B) Effect of NFA (100 mM). (C) Mean  S.E.M. data for the intracellular Ca2+ increase in the SMCs induced by 100 mM of FFA, MFA, NFA, DFS, ASP, APAP, and IND and CXB
(10 mM), n = 17–26 cells for each group. (D) SMCs were incubated with 1 mM TG (n = 7) or without TG (n = 10). (E) TRPC4 cells were pre-treated with TG (1 mM) for 10 min. The
whole cell current was recorded in the presence of TG. FFA (100 mM), Gd3+ (100 mM) and 2-APB (100 mM) were used. (F) Mean data for FFA-induced current after perfusion with FFA
for 3 and 7.5 min. The amplitude of TRPC4 current was measured at 80 mV (n = 6). (G) Pretreatment with CsA (10 mM) for 5 min, the amplitude of TRPC4 current was measured at
80 mV after perfusion with FFA for 3, 5 and 7.5 min. n = 6–8 for each group, *P < 0.05, **P < 0.01, ***P < 0.001.
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Ca2+-activated potassium channels [39], and the Ca2+-activated
non-selective cationic channel [40]. Recently, it has been
demonstrated that FFA activated TRPC6 [28], TRPA1 [29], and an
OAG-sensitive cationic current in A7r5 cells [26], but inhibited
TRPM2, TRPM3, TRPM4 and TRPM5 channels [22,24,41–44]. Here
we give the new evidence that fenamates also inhibit TRPC4 and
TRPC5. The potency of inhibition depends on the modiﬁcation on
the skeleton of the 2-phenylaminobenzoate. Apart from the initial
inhibition, there is a delayed channel potentiation evoked by some
fenamate analogues, such as FFA and MFA. The delayed channel
potentiation could be explained by the mitochondrial Ca2+ releaseevoked by FFA, because both TRPC4 and TRPC5 channels have been
demonstrated as Ca2+-sensitive channels [45–48], and thus the
increased cytosolic Ca2+ level caused by Ca2+ release from
mitochondria in turn facilitates TRPC4/TRPC5 channel activity
[45,47]. Our data showed that the FFA-induced Ca2+ increase in the
cytosol was fast, robust and reversible in SMCs, while the effect for
NFA was small. This difference has also been described in mouse
submandibular salivary cells [31]. Our data suggested that the FFA-
induced Ca2+ increase in the smooth muscle cells was mainly
contributed by mitochondrial Ca2+ release, because the Ca2+
release signal was not inﬂuenced by the depletion of ER Ca2+ store.
Tu and co-workers also showed that FFA-induced mitochondrial
H. Jiang et al. / Biochemical Pharmacology 83 (2012) 923–931930Ca2+ release occurred in the presence of TG [30]. Therefore the
TRPC4 and TRPC5 channel potentiation by FFA could be explained
as the increased cytosolic Ca2+ due to mitochondrial Ca2+ release. In
addition, the contribution of mitochondrial Ca2+ release to the
channel potentiation was further demonstrated by the application
of CsA that can partially prevent the mitochondrial Ca2+movement
in this study.
The delayed potentiation on TRPC4 and TRPC5 channel could be
a mechanism for the pharmacology of fenamate NSAIDs, especially
in situations with high dosage or long-term medication. The peak
plasma concentration of FFA or MFA achieved 6-20 mg ml1 (equal
to 21–71 mM) in volunteers [49,50], suggesting that the effect on
mitochondrial Ca2+ release and channel potentiation could happen
in patients receiving fenamate drug treatment. The cardiovascular
risks of some NSAIDs have been recognized and some NSAIDs have
been withdrawn from the market by FDA due to the cardiovascular
side effects [51]. The mechanisms for these side effects are unclear,
but the interference with intracellular Ca2+ homeostasis or TRPC4/
5 channel potentiation could be a new explanation for hyperten-
sion related to some fenamate analogues and celecoxib, which
needs to be investigated further.
The effect of non-fenamate selective COX inhibitors was also
examined in this study. COX-1 is involved in platelet aggregation,
gastric mucosa protection and renal electrolyte homeostasis.
Aspirin is a selective COX-1 inhibitor and irreversibly acetylates
platelet COX-1 and inhibits the formation of the potent platelet
agonist thromboxane A2 (TXA2) [52]. Perfusion with aspirin did not
change the activity of TRPC4 and TRPC5 channels, suggesting that
COX-1 is not directly involved in their modulation. In order to
dissect COX-2 involvement, we tested the selective inhibitor
celecoxib that signiﬁcantly increased the channel activity of TRPC4
and TRPC5. The activation mechanism for celecoxib is unknown,
but unlikely due to the COX2 inhibition, because other COX2
inhibitors have no direct effect.
Modiﬁcation of the phenylamino ring in FFA is useful for ﬁnding
the structure–activity relationship of those analogues. The
substituents at R3 position (analogues 1–4) signiﬁcantly changed
the channel blocking potency, suggesting the importance of R3
in the structural modiﬁcation. The comparison between the
methyl substituents at R2, R3 and R4 (5, 1 and 6) showed that
the modiﬁcation at meta and para positions could be more effective
than the ortho position. Substituents at para position gave a
compound (7) with similar potency to FFA, but the introduction of
a polar substituent (8) could be ineffective. Our data also showed
that the combination of groups at R2 and R5 could be a determinant
as a channel opener or blocker, since the substituent –OCH3 at R
2
(in 10) yielded a channel stimulator, while the substituent –CH3 at
R2 (in 9) yielded a channel antagonist. We suggest that this could
be due to the conformational changes in the diphenylamine core as
the bulkier methoxy group is introduced into an ortho position.
Introduction of a single –CH3 or –OCH3 group at R
3 (1 or 5
respectively) however, without the second meta methyl residue,
yielded channel inhibitors less effective than FFA.
In summary, our results show that fenamate analogues have
differential effects on TRPC4 and TRPC5 channels with inhibition
acutely and potentiation with long exposure. The analogues may
have different properties for mitochondrial Ca2+ release and
caution should be exercised in the explanation of drug class effect
of these agents. The development of new fenamate analogues may
have potential for identiﬁcation of selective TRPC activators and
inhibitors, which could yield new tools for investigating the roles
of these channels in pathophysiological conditions.
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Mercury is an established worldwide environmental pollutant
with well-known toxicity affecting neurodevelopment in humans,
but the molecular basis of cytotoxicity and the detoxification
procedure are still unclear. Here we examined the involvement of
the canonical transient receptor potential (TRPC) channel in the
mercury-induced cytotoxicity and the potential detoxification
strategy. Whole-cell and excised patches, Ca21 imaging, and site-
directed mutagenesis were used to determine the mechanism of
action of mercurial compounds on TRPC channels overexpressed
in HEK293 cells, and cytotoxicity and preventive effect were
investigated in cell culture models using small interfering RNA
and pharmacological blockers. Mercury potently activates TRPC4
and TRPC5 channels. The extracellular cysteine residues (C553 and
C558) near the channel pore region of TRPC5 are the molecular
targets for channel activation by mercury. The sensitivity of
mercury to TRPC5 is presumed to be specific because other
divalent heavy metal pollutants, such as Cd21, Ni21, and Zn21, had
no stimulating effect, and TRPC3, TRPC6, TRPV1, and TRPM2
were resistant to mercurial compounds. The channel activity of
TRPC5, as well as TRPC4, induced by mercury, was prevented by
2-aminoethoxydiphenyl borate and modified by a reducing envi-
ronment. The inhibition of TRPC5 channels by specific TRPC5
pore-blocking antibody or by SKF-96365 alleviated the cytotoxicity,
whereas the mercury chelator, meso-2,3-dimercaptosuccinic acid,
showed nonselective prevention of cell survival. Silencing of the
TRPC5 gene reduced the mercury-induced neuronal damage. These
results indicate that mercurial compounds are activators for
TRPC5 and TRPC4 channels. Blockade of TRPC channels could
be a novel strategy for preventing mercury-induced cytotoxicity and
neurodevelopment impairment.
Key Words: cationic channel; calcium channel; TRPC; mercury;
methylmercury; dimercaptosuccinic acid; SKF-96365;
2-aminoethoxydiphenyl borate.
Despite increasing attempts to control industrial pollution,
mercury poisoning still occurs through methylmercury (MeHg)
from fish, ethylmercury from vaccine products, metallic mercury
from dental amalgam fillings, cinnabar from Chinese herbal
balls, and other domestic mercury pollution (Counter and
Buchanan, 2004). There are three primary forms of mercury
in the environment, that is, metallic, inorganic, and organic
mercury. They can convert from one form to another in the
environment and in the human body. Three forms show different
clinical toxicological features including major damage to the
brain by organic mercury, the kidney by inorganic divalent
mercury, and the lungs by inhalation of mercury vapor, although
many organs are susceptible to mercury exposure (Clarkson
et al., 2003). Young children are vulnerable to mercury
exposure, which may cause the impairment of brain de-
velopment and mental retardation (Costa et al., 2004; Trasande
et al., 2005). In the elderly, the elevated mercury level in the
blood has been suggested as a potential risk factor for
cardiovascular and neurodegenerative diseases (Guallar et al.,
2002; Landrigan et al., 2005).
MeHg exposure is of particular concern because of its high
accumulation in fish, complete absorption from gastrointestinal
tract, easy transportation across the placenta and blood-brain
barrier, and tissue accumulation. MeHg can affect brain
development in children and result in a lower IQ; however,
the correlation of MeHg exposure to children’s learning and
performance capacity is still disputed, as the recent epidemi-
ological studies from the Faroe Island, the Seychelles, and New
Zealand have produced contradictory results (Axelrad et al.,
2007; Cohen et al., 2005; Davidson et al., 2011; Spurgeon,
2006). The mechanisms of how MeHg causes brain damage
may include abnormality of neuronal migration, neuronal
apoptosis, retraction of growth cone formation and extensions,
and the loss of interneuronal contacts (Costa et al., 2004). The
network connections between neurons are critical for short-
term and long-term memories, which require a series of
biophysical and biochemical processes (Dasari and Yuan,
2009). Ca2þ is a second messenger in the processes and plays
an essential role in axonal transport, growth cone motility, and
extension (Zheng, 2000). The disturbance of Ca2þ homeostasis
has been linked to mercury toxicity; for example, MeHg blocks
voltage-gated Ca2þ channels (VGCC) but increases intracellu-
lar [Ca2þ] in isolated nerve terminals (Limke et al., 2004);
MeHg inhibits the action potential–evoked neurotransmitter
release but increases the spontaneous transmitter release
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(Denny and Atchison, 1996). These observations suggest that
an unidentified Ca2þ influx pathway might exist.
Canonical transient receptor potential (TRPC) channels are
Ca2þ-permeable cationic channels. Seven members (TRPC1–
7) have been identified in the TRPC subfamily, and TRPC2 is
a pseudogene in human (Clapham, 2003). TRPC1, TRPC3, and
TRPC6 have been shown to mediate chemotropic-guided
axonal turning (Li et al., 2005; Wang and Poo, 2005), and
TRPC3 and TRPC6 are also involved in the survival of
cerebellum granule neuron (Jia et al., 2007). TRPC5 channel is
highly expressed in the brain, which is encoded by the TRPC5
gene located in a region of human X-chromosome associated
with nonsyndromic mental retardation, and thus, there is
a putative genetic link with neuronal development (Sossey-
Alaoui et al., 1999). It has also been shown that TRPC5 is
involved in retardation of neurite outgrowth (Greka et al.,
2003; Hui et al., 2006) and in vivo neurofunction (Riccio et al.,
2009). Because TRPC channels play important roles in
neuronal function and are critical for regulating Ca2þ
homeostasis in a cell, we then hypothesized that TRPC
channels could be important for the mechanisms of mercury-
induced cytotoxicity and neuronal impairment.
In this study, we have examined the effect and underlying
mechanism of TRPC channels acting as the molecular targets of
mercury-evoked cytotoxicity. We found that mercurial com-
pounds potently activated TRPC5 as well as TRPC4 channels via
binding to the two extracellular cysteine residues near the channel
pore. Silence of TRPC5 gene with small interfering RNA
(siRNA) or blockade of TRPC channel activity with pharmaco-
logical tools alleviated the mercury-related cytotoxicity.
MATERIALS AND METHODS
Cell culture, cloning, and transfection. HEK-293 cells were transfected
with human TRPC5 (accession number AF054568), TRPC3 (accession number
U47050), TRPC6 (accession number BC093660), mouse TRPC4 (accession
number NM_016984), mouse TRPM2 (NM_138301), and human TRPV1
(accession number AY131289) plasmid complementary DNAs (cDNAs) in
a pcDNA3 vector using Lipofectamine 2000 (Invitrogen, U.K.). The procedure
was previously described (Xu et al., 2005b). The stable transfected cells for
TRPC3, TRPC6, TRPV1, and TRPM2 were selected and maintained in the cell
culture medium containing G418 (400 lg/ml). The human TRPC4a
(NM_016179) tagged with enhanced yellow fluorescent protein in a tetracy-
cline-regulatory vector was stably expressed in HEK-293 T-REx cells
(Invitrogen). For some electrophysiological experiments, the tetracycline-
inducible TRPC5 cells were used as we reported (Xu et al., 2005a, 2005b; Zeng
et al., 2004), where the expression of TRPC5 was induced by 1 lg/ml
tetracycline for 24–72 h before recording. There was no difference in the
current-voltage (IV) curve and Ca2þ influx response to stimuli for the TRPC5
stable cells and the tetracycline-induced TRPC5 cells. The noninduced cells
without addition of tetracycline or the nontransfected cells were used as control.
Cells were grown in Dulbecco’s Modified Eagle Medium (DMEM)-F12
(Gibco, U.K.) medium containing 10% fetal calf serum (FCS), 100 units/ml
penicillin, and 100 lg/ml streptomycin. Cells were maintained at 37C under
95% air and 5% CO2 and seeded on coverslips prior to experiments.
PC12 cells were grown in F12 medium containing 15% FCS and 50 ng/ml
of nerve growth factor (NGF; Invitrogen) using collagen type IV–coated cell
culture dishes (Hui et al., 2006). The cell number and axonal growth were
measured manually on photos taken by a digital microscope camera (Nikon,
Japan). The TRPC5 siRNA was purchased from Sigma (U.K.) and the
effectiveness was validated by real-time PCR as described in a previous
publication (Xu et al., 2008a). The electroporation was used for PC12 cell
transfection using BTX Electro Square Porator ECM 830 with three pulses
(Genetronics, San Diego, CA) and the efficiency achieved ~85% at optimal
conditions.
Primary cell cultures. The isolation and culture of human umbilical vein
endothelial cells (HUVECs) were similar to that published previously (Xu
et al., 2008b). Patients gave informed consent in accordance with the
Declaration of Helsinki, and the project was approved by the local ethical
committee. Briefly, the isolated cells were cultured in a T-75 flask with
endothelial cell growth media (PromoCell, Germany) supplemented with 2%
FCS, 5.0 ng/ml epidermal growth factor, 0.5 ng/ml vascular endothelial growth
factor, 10 ng/ml basic fibroblast factor, 20 ng/ml insulin-like growth factor-1,
and 22.5 ng/ml heparin. Cells were kept at 37C in a CO2 incubator with
a humidified atmosphere of 5% CO2 in air and used at passages 2–3. Cells were
seeded into 96- or 48-well cell culture plates at a density of 3.0 3 104 cells/ml
and cultured for 15 h to allow the cells to attach before further treatments.
Electrophysiology and fluorescence measurements. Voltage clamp was
performed at room temperature (23–26C) with the whole-cell, outside-out, or
inside-out patch configuration (Xu et al., 2006). Briefly, signal was amplified with
an Axopatch 200B patch clamp amplifier and controlled with pClamp software
10. A 1-s ramp voltage protocol from –100 to þ100 mV was applied at
a frequency of 0.1 Hz from a holding potential of –60 mV. Signals were sampled
at 3 kHz and filtered at 1 kHz. The salt-agar bridge was used to connect the ground
wire (Ag-AgCl) in the bath chamber. The 200nM Ca2þ-buffered pipette solution
(115 CsCl, 10 ethylene glycol-bis(2-aminoethylether)-N,N,N#,N#-tetraacetic
acid, 2 MgCl2, 10 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid [HEPES],
and 5.7 CaCl2 in mM, pH was adjusted to 7.2 with CsOH and osmolarity
was adjusted to ~290 mOsm with mannitol, and the calculated free Ca2þ was
200nM) was used. The standard bath solution contained (mM): 130 NaCl, 5 KCl,
8 D-glucose, 10 HEPES, 1.2 MgCl2, and 1.5 CaCl2. The pH was adjusted to
7.4 with NaOH. The recording chamber had a volume of 150 ll and was perfused
at a rate of about 2 ml/min.
For fluorescence measurements, HEK-293 cells transfected with in-
dividual genes were incubated with Fluo3-AM (5lM) for 30 min at room
temperature in Ca2þ-free standard bath solution. Intracellular Ca2þ experi-
ments were performed using cuvette-based [Ca2þ]i assay. Briefly, the loaded
cells were washed and resuspended in standard bath solution. Volumes of 2
ml were pipetted into a cuvette as required and equilibrated to 22C (3 min) in
the chamber of a Perkin Elmer LS50B fluorimeter. The ratio of Ca2þ dye
fluorescence (Fura-PE3 AM, F340/F380) was measured by a Nikon Ti-E
system with NIS-Element Ca2þ imaging software. All the experiments were
performed at room temperature.
Western blotting. The protocol was similar to that described previously
(Xu et al., 2008a). Cells were lysed in Laemmli buffer. Proteins were separated
on 8% SDS-PAGE gels and transferred to nitrocellulose membrane (Millipore)
and probed with custom-made rabbit anti-TRPC5 (T5C3, 1:250 dilution)
antibody (Xu et al., 2005b). Secondary antibody was conjugated with
horseradish peroxidase. Membranes were washed with PBS and labeling
detected by ECLplus (Amersham).
RT-PCR. Total RNA was isolated from HUVECs using a standard
TriReagent protocol and treated with DNase I (Ambion). The isolated RNA
was used for cDNA synthesis with oligo-dT primer and AMV reverse
transcriptase, and the reaction without reverse transcriptase (no-RT) was set in
parallel as a negative control. PCR primer sequences for TRPC5 were
CATGACTGGTGGAACC and GTGGGAGTTGGCTGTGAA. Thermal cy-
cling was 40 cycles of 94C (30 s), 56.6C (1 min), and 72C (1 min). PCR
products were electrophoresed on 1.5% agarose gels containing ethidium
bromide and confirmed by direct sequencing.
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Assay for cell viability/proliferation. The cell viability was determined
using WST-1 assay (Roche; Xu et al., 2008b). WST-1 is a tetrazolium salt and
can be cleaved by cellular enzymes, and thus, the assay reflects the metabolic
activity of the cells. The overall metabolic activity measured by optical
absorption correlates well with the viable cell number as determined by cell
counting. Cell proliferation was also observed by direct cell counting with
ethidium bromide nucleus staining (Xu et al., 2008b).
Materials. All general salts and reagents were from Sigma (U.K.) or from
British Drug House (Poole, U.K.). Methylmercury chloride (PESTANAL),
HgCl2, gadolinium chloride (Gd
3þ), Pb(NO3)2, NiCl2, ZnCl2, hydrogen
peroxide, p-chloromercuricbenzene sulfonate sodium salt (pCMBS), dithio-
threitol (DTT), dimercaptosuccinic acid (DMSA), 2-aminoethoxydiphenyl
borate (2-APB), and bovine serum albumin were purchased from Sigma. Fura-
PE3 AM and Fluo-3 AM were from Molecular Probes. Fluo-3 AM or Fura-PE3
AM (5mM) and 2-APB (75mM) were made up as stock solutions in 100%
dimethyl sulfoxide, and MeHg (10mM) was dissolved in water.
Statistics. Data are expressed as mean ± SEM, where n is the cell number
for electrophysiological recordings. For Ca2þ assay and cell proliferation study,
the number of experiments was given. Data sets were compared using unpaired
Student’s t-test and ANOVA Dunnett’s post hoc analysis with significance
indicated if p < 0.05.
RESULTS
Activation of TRPC5 Channels by Mercurial Compounds
To assess the effect of mercury compounds on TRPC
channels, the Ca2þ influx and current were measured in HEK-
293 cells stably transfected with TRPC5. The expression of
human TRPC5 channel was characterized by the activation by
lanthanides and the unique ‘‘N’’-shaped IV relationship (Figs.
1A and 1B), which has been previously described (Xu et al.,
2005a). MeHg and divalent mercury (Hg2þ) significantly
increased the Ca2þ influx via TRPC5 in a concentration-
dependent manner (Figs. 1C–F). For the acute experiments with
accumulative application of mercurial compounds, the EC50 for
MeHg was 2.03lM with a slope of 0.22, and the EC50 for HgCl2
was 3.07lM with a slope factor of 0.40. We also observed the
effect of a single concentration of MeHg with longer incubation
time, and the cytosolic Ca2þ in the TRPC5-transfected cells was
significantly elevated by MeHg at as low as 0.01lM after
incubation for 20 min (n ¼ 5, p < 0.001). These results
suggested that MeHg is a potent activator of TRPC5.
Mercurial compounds with different ionic charge and/or
lipophilicity may have differential effects (Hewett and
Atchison, 1992); therefore, we compared the divalent mercury
(HgCl2), monovalent (MeHg), and organomercurial pCMBS.
The pCMBS has been regarded as a cell-impermeable reagent
due to its lowest lipophilicity. The current of TRPC5 was
significantly activated by pCMBS as well as MeHg and Hg2þ
(Fig. 2), suggesting that the activation of TRPC5 channel by
mercurial compounds is independent of lipophilicity and ion
charge. This also indicated that the binding site to mercurials
could be extracellularly accessible.
In addition, we found that the stimulating effect of mercurial
compounds on TRPC5 channel was additive to lanthanides.
The rectification property of TRPC5 shown in the IV curve was
distorted after perfusion with Hg2þ (Supplementary fig. 1B),
suggesting that mercurials may have a different extracellular
binding site beyond the glutamic acid residues that have been
identified as the extracellular binding sites for lanthanides
(Jung et al., 2003). The binding site could be located within the
electrical field near the channel pore region.
Extracellular Effect on TRPC Channel
We performed outside-out excised membrane patches and
found that the extracellular perfusion with MeHg significantly
increased the TRPC5 current (Figs. 3A and 3B), but no effect
if the intracellular surface was exposed to MeHg using the
inside-out patch configuration recordings (Fig. 3C). Similarly,
Hg2þ also showed the external effect (Figs. 3D–F). The
orientation of excised membrane was confirmed by perfusion
with 2-APB or Gd3þ, both of which have been shown to have
extracellular effects (Xu et al., 2005a). These data suggested
that the target for mercurial compounds is extracellularly
located.
Role of Extracellular Cysteine Residues in the E3 Loop
Sequence alignment and channel topology analysis showed
that two cysteine residues (C553 and C558) are predicted in the
third extracellular loop (E3) near the channel pore (Fig. 4A).
The two cysteine residues have the highest probability to form
a disulfide bond predicted by the software (Cheng et al., 2006).
The predicted structures with and without disulfide bond
between S5 and S6 were shown in Figure 4B. We substituted
the two cysteines with alanines (C553A and C558A) and found
that the double-cysteine mutant TRPC5 channel (TRPC5C553A/
C558A) was in the open state with a high basal activity, which is
consistent with our observation (Xu et al., 2008a). The
TRPC5C553A/C558A mutant channel was resistant to mercury
(Fig. 4C), suggesting that the two cysteine residues are
essential for the action of mercurial compounds. In addition,
TRPC5 associates with TRPC1 to form a heteromultimeric
TRPC1/5 channel (Strubing et al., 2001; Xu et al., 2006);
therefore, we tested the mutant TRPC1/5 heteromultimeric
channel (TRPC5C553A/C558A þ TRPC1C537A), and no effect
was observed (Fig. 4D). However, these cysteine mutant
channels were still sensitive to TRPC5 channel blocker 2-APB.
Effect of Mercurial Compounds on Other TRP Channels
The sensitivity of TRPC to mercury is presumed to be isoform
specific because the effect was absent if a TRPC member without
cysteine residues was present in the region, for example, TRPC3
and TRPC6 (Figs. 4E and 4F). TRPV1 and TRPM2 have
cysteine residues in the S5–S6 region (C621 and C635 for TRPV1,
C994 and C1006 for TRPM2), but there was no direct channel
activation by MeHg (Figs. 4G and 4H), which suggested that
both cysteine position and channel conformation are important
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for mercury sensitivity. TRPC4 not only has a high identity to
TRPC5 in amino acid sequence but also shows functional
similarity, such as the sensitivity to lanthanides (Jung et al.,
2003). We found that human TRPC4awas also sensitive to Hg2þ
and the channel activity was blocked by 2-APB (Supplementary
fig. 2). However, we were unable to examine TRPC1 due to its
relatively small Ca2þ signal in the transfected cells, which was
difficult to distinguish from the endogenous channel signal.
Effect of Other Heavy Metals on TRPC5 Channel
The ion sensitivity of TRPC5 led us to examine other
heavy metals. Pb2þ is another important pollutant in the
environment and causes neurodevelopment disorders (Costa
et al., 2004). Pb2þ at low concentrations (0.01–5lM) had no
effect but mildly increased Ca2þ influx at higher concentrat-
ions (Supplementary fig. 3A). In contrast, Pb2þ showed an
inhibitory effect if the TRPC5 channel is at the opening state
FIG. 1. Activation of TRPC5 channel by mercury compounds. (A) Ca2þ influx was activated by Gd3þ (100lM) in the TRPC5-transfected HEK-293 cells
(n ¼ 30 cells). The nontransfected HEK-293 cells (control) were set as control (n ¼ 28 cells). (B) TRPC5 current with a typical ‘‘N’’-shaped IV curve was
recorded with whole-cell patch in the presence of 100lM Gd3þ. The current in the nontransfected cells was small with a linear IV curve. (C) MeHg (0.01–
10lM) activated the Ca2þ influx via TRPC5 channel, and the concentration-response curve is shown in (D) (n ¼ 6). (E) Divalent Hg2þ (0.1–10lM) also
significantly evoked the Ca2þ influx in the TRPC5 cells but only a very small effect in the nontransfected cells (control). The concentration-response curve for Hg2þ
is shown in (F) (n ¼ 5).
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by pretreatment with 50lM Gd3þ (data not shown), suggesting
a differential toxicological mechanism for Pb2þ. Ni2þ partially
inhibited the Ca2þ influx, but Cd2þ and Zn2þ had no significant
effect (Supplementary fig. 3B).
TRPC Channel Regulators on Mercury Exposure
We tested the potential of TRP channel blockers for the
treatment for mercury exposure. We found that 2-APB, a potent
TRPC channel blocker, significantly inhibited the whole-cell
current of TRPC5 activated by Hg2þ (Figs. 5A and 5B). This
therapeutic effect was also demonstrated by outside-out excised
membrane patch (see Figs. 3A and 3B). In addition,
preincubation of 2-APB fully prevented the channel activation
by Hg2þ (Fig. 5C).
Reducing agents with thiols or dithiols have been used for
mercury detoxification (Rooney, 2007); therefore, we tested
DTT and the therapeutic drug DMSA. Similar to our previous
observation (Xu et al., 2008a), DTT itself displayed channel
activation on TRPC5; however, the TRPC5-transfected cells
pretreated with DTT resulted in the loss of stimulating action by
Hg2þ, instead of a partial inhibition (Figs. 5D and 5E),
suggesting that the reducing environment is important for
modifying the action of mercury on TRPC channels. DMSA
has been widely used in clinic as a thiol-reducing agent to chelate
heavy metal ions. We found DMSA stimulated TRPC5 channels,
and DMSA did not prevent the TRPC5 channel activation by
Hg2þ (Supplementary fig. 4), suggesting that TRPC channel
blocker could be developed as a potential therapeutic drug for
mercury poisoning.
Involvement of TRPC in Mercury-Induced Cytotoxicity
We examined the involvement of TRPC5 channel in the
cytotoxicity of mercury exposure. The expression of TRPC5 in
HEK293 T-REx cells was induced by tetracycline using
a tetracycline-regulatory gene expression system. The nonindu-
cible cells (without tetracycline) were used as control (Xu et al.,
2005a; Zeng et al., 2004). We found that the overexpression of
FIG. 2. TRPC5 current activated by mercury compounds. (A) The current was activated by Hg2þ (5lM) in the HEK-293 cells transfected with TRPC5. (B) IV
relationship of Hg2þ-activated TRPC5 as shown in (A). (C) Mean ± SEM data for Hg2þ treatment. (D) Activation by MeHg (5lM) in the TRPC5-transfected cells.
(E) IV curve for (D). (F) Mean ± SEM data for MeHg. (G) Effect of pCMBS (50lM) on TRPC5 channel. (H) The IV curve and the mean ± SEM data (I). The n
numbers are given in the parentheses. Normalized unit (n.u.) is given as the ratio (after/before treatment) of the current at –60 mV. ANOVA test was used. **p < 0.01
and ***p < 0.001.
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TRPC5 increased the proliferation of HEK-TRx cells by 27.6 ±
3.1% after 24 h cell culture determined by WST-1 assay.
Incubation with Hg2þ at 1 and 5lM inhibited the cell proliferation
in both TRPC5-transfected and nontransfected cells, but the
inhibitory effect was more evident in the cells overexpressing
TRPC5 (Fig. 6A), suggesting that the enhanced cytotoxicity
could be due to the channel opening by Hg2þ and thus lead
to the intracellular toxicological processes through Hg2þ
influx.
To explore the potential protection against mercury-
induced cytotoxicity, the TRPC5-specific blocking antibody
and the two nonselective TRPC channel blockers, 2-APB and
SKF-96365, were tested (Xu et al., 2005b). After incubation
with Hg2þ for 24 h, the cell viability was significantly lower
FIG. 3. Extracellular effect of mercury identified with excised membrane patches. (A) The current of TRPC5 channel was evoked by MeHg (0.5 and 5lM) in
outside (o)-out patches and blocked by 2-APB (75lM). (B) Representative IV curve for TRPC5 as shown in (A) indicated as solid circle. (C) No effect was
observed when MeHg (5lM) was applied in the intracellular surface via inside (i)-out patch recordings. Gd3þ (100lM) had no effect in inside-out membrane
orientation because the binding site for Gd3þ was extracellularly located (Jung et al., 2003; Xu et al., 2005a). (D) Divalent Hg2þ (1lM) had a similar channel
stimulating effect, and the representative IV curve is shown in (E). (F) Mean data for the outside-out patch experiments (n ¼ 6, * p < 0.05 and ***p < 0.001). The
currents in (A), (C), and (D) were given at the potential of ± 80 mV.
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in the tetracycline-induced group (TRPC5) than that in the
noninduced group (control). 2-APB (75lM) did not show any
protective action on the Hg2þ-evoked cytotoxicity; instead,
a deteriorating effect, which could be due to its inhibition on
intracellular inositol trisphosphate (IP3) receptors (Szatkowski
et al., 2010). However, SKF-96365 significantly prevented
the Hg2þ-evoked cytotoxicity in the TRPC5-transfected
cells (Fig. 6A). The TRPC5-specific pore-blocking antibody also
significantly showed protection against the mercury-induced
cytotoxicity (Fig. 6B). In addition, we examined nonsulfhydryl
and sulfhydryl-reducing agents. Tris (2-carboxyethyl) phosphine
hydrochloride (TCEP), a membrane-impermeable nonsulfuric
FIG. 4. Cysteine residues in the transmembrane domain (S5–S6) are essential for channel activation. (A) Sequence alignment of TRP channels near the
putative channel pore region between S5 and S6 transmembrane. Two cysteine residues were highlighted. (B) Predicted topology of TRPC5 channel pore region
(i) and mutant TRPC5 with double-cysteine substitution by alanine (TRPC5C553AþC558A) (ii). Figures prepared by PYMOL (DeLano Scientific). The positions of
C553 and C558 were indicated by dot circle, and disulfide bond was labeled as S–S. (C) TRPC5C553AþC558A mutant channel showed resistance to Hg2þ (5lM).
(D) The heteromultimeric mutant channel (TRPC5C553AþC558A / TRPC1C537A) was also resistant to Hg2þ (5lM) but sensitive to 2-APB (75lM). (E and F) No
effect of Hg2þ (5lM) on TRPC3 and TRPC6 that has no cysteine residue in the region (n ¼ 5 for each isoform) but sensitive to trypsin (0.1nM) or carbachol
(100lM) (Xu et al., 2005a). The IV curves of before (a) and after treatment with 5lM Hg2þ (b) and 0.1nM trypsin (c) are shown in the insets. (G and H) TRPM2
(n ¼ 4) and TRPV1 (n ¼ 3) did not display direct channel activation by MeHg (0.01–10lM); however, the expressed channels are sensitive to H2O2 (1mM;
McHugh et al., 2003) and capsaicin (1lM).
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reducing agent that can activate TRPC5 channels (Xu et al.,
2008a), had no protective effect, whereas the membrane-perme-
able sulfuric reducing agent DTT enhanced the cytotoxicity (Fig.
6C). DMSA with two thiol groups showed a significant protective
effect on cell survival; however, the effect is more evident in the
noninduced cells (Fig. 6D), suggesting that the protective
mechanism for DMSA could be due to Hg2þ chelation, rather
than the action on TRPC5 channels. The cell viability in the
TRPC5-transfected group was decreased, which could be
explained as the direct TRPC4 and TRPC5 channel activation
by DMSA (Supplementary fig. 4) that may cause more Hg2þ
influx and thus enhance the cytotoxicity via other mechanisms.
TRPC5 is widely expressed in central nervous system and
involved in axonal growth (Greka et al., 2003; Hui et al.,
2006). Therefore, we examined the TRPC5 channel in the
neurotoxicity of mercury exposure. We found that the NGF-
induced axonal growth was dramatically inhibited by mercurial
compounds in a neuronal cell line (PC12), whereas Pb2þ at
1lM had no effect on axonal growth (Fig. 7A). The cell
proliferation was also inhibited (Fig. 7B). Transfection with
TRPC5 siRNA inhibited cell proliferation and axonal extension
and partially alleviated Hg2þ-induced cytotoxicity (Figs. 7C
and 7D).
Massive loss of cerebral cortex is another important
pathological change in patients with mercury poisoning, and
microvasculature formation is critical for maintaining the
thickness of cerebral cortex (Eto and Takeuchi, 1978); we
therefore tested the vascular hypothesis using endothelial cells
derived from newborns. As shown in Figure S5A, TRPC5 was
highly expressed in HUVECs. The cell growth of HUVECs was
substantially inhibited by Hg2þ and MeHg, but not by Pb2þ.
Inhibition of TRPC5 expression by TRPC5 siRNA also
prevented the cell proliferation inhibition induced by 1lM
Hg2þ (Supplementary fig. 5), suggesting that the Ca2þ-over-
loaded mechanism of mercury exposure via TRPC activation
could be extended to vascular system.
FIG. 5. Mercury-evoked current was blocked by 2-APB and modified by reducing agent DTT. TRPC5 channel activity was activated by Hg2þ (1lM) in
TRPC5 cells in the presence of 10lM Gd3þ (A) but a small current in the nontransfected cells if high concentrations of Hg2þ (10–100lM) were applied (B). The
IV curves are shown in the inset. (C) The activation by Hg2þ (1lM) was prevented by 2-APB (75lM). (D) Hg2þ (5lM) displayed as an inhibitory effect if the
channel was activated by the reducing agent DTT (10 mM; Xu et al., 2008a). (E) Mean ± SEM data showing mercury effect on TRPC5 (n ¼ 9) and TRPC6 (n ¼ 6)
currents with DTT treatment.
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DISCUSSION
Our results provide first evidence that mercurial compounds
can activate TRPC5 channels. The action site is related to the
two extracellular cysteine residues (C553 and C558) near the
channel pore. The blockade of TRPC channel by 2-APB not
only prevents the channel activation evoked by mercurial
compounds but also shows therapeutic effect against the channel
activation by mercury. TRPC channel blockers (SKF-96365 and
TRPC5 pore-blocking antibody) modestly alleviate the cytotox-
icity. These results give a new insight of TRPC4 and TRPC5 as
the target proteins of mercury toxicity and a clue for the
development of TRPC channel blockers as new therapeutic
agents for mercury exposure.
The sensitivity of TRPC5 channels to trivalent lanthanides
(La3þ or Gd3þ) has been described by Jung et al. (2003);
however, the physiological or pathophysiological significance
of the trivalent sensitivity of TRPC5 channel is unclear,
especially lanthanides are very rare elements in the human
body except their chelating complexes used as diagnostic and
therapeutic agents (Bottrill et al., 2006; Kostova, 2005).
Therefore, we screened other heavy metal ions. Interestingly,
we found that TRPC5 channel is sensitive to mercurial
compounds. The channel can be activated by mercurials at
micromolar concentrations, suggesting that TRPC5 channel is
a novel target for mercury exposure. We examined the binding
sites using excised membrane patch clamp and site mutagen-
esis and identified that two cysteine residues in the third
extracellular loop of transmembrane region mediate the
channel activation. This result suggested that there are at least
two extracellular binding sites for heavy metal ions in TRPC5,
that is, the two cysteine residues (C553 and C558) bound to
mercurial compounds and the glutamic acid residues (Glu543
and Glu595/Glu598) for lanthanides (Jung et al., 2003).
Although nearly all ion channel proteins contain cysteine
residues and the cytotoxicity of mercurials has been related to
the formation of stable complexes with sulfhydryl-containing
amino acids (Carvalho et al., 2008; Rooney, 2007), the effect
of mercurials is still specific for some ion channels; for
FIG. 6. Effect of pharmacological regulators on the mercury-induced inhibition of cell proliferation. The HEK-293 cells were inducibly expressed with
TRPC5 with (TRPC5) and without tetracycline (control). The cell proliferation was detected by WST-1 assay. (A) Cells were incubated with Hg2þ in the DMEM-
F12 medium containing 10% FCS for 24 h in the presence or absence of 2-APB (75lM) and SKF-96365 (25lM), n ¼ 8 wells for each treated group. (B) TRPC5
E3-targeting pore-blocking antibody (TRPC5-Ab, 1:250) was used (Xu et al., 2005b). Boiled TRPC5-Ab was used as control. (C) The reducing agents TCEP
(100lM) and DTT (1mM) were used. The cells were incubated with Hg2þ for 24 h with and without reducing agents (n ¼ 16 wells for each group). (D) Cells were
incubated with and without chelating agent DMSA (100lM) for 24 h (n ¼ 16 wells for each group). *p < 0.05; **p < 0.01; ***p < 0.001.
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example, TRPC3 and TRPC6 without extracellular cysteine
residues did not show any sensitivity to mercurial compounds;
TRPM2 or TRPV1 with cysteine residues at different positions
showed no direct activation, suggesting that the effect of
mercurials on TRP channels is determined by the location and
function of individual cysteine residue in a protein. This
hypothesis needs to be further tested on other TRP channels in
the future. In addition, we found that the action of mercury on
TRPC5 channel could be modified by reducing agents. These
findings suggested that both the cysteine residue position and
channel conformation are important for mercury activation on
TRP channels.
Several types of VGCC have been shown to be inhibited by
mercurial compounds, such as L-type and T-type (Hajela et al.,
2003; Tarabova et al., 2006); however, the cytosol [Ca2þ] was
increased in cells treated with mercury (Limke et al., 2004).
The activation of TRPC5 channel found in this study provides
a good explanation for the increased [Ca2þ]i seen in mercury
exposure. Although we tested TRPM2 in the TRPM subfamily
and TRPV1 in the TRPV subfamily, we were unable to
examine all the members in TRP superfamily; however, the
sequence alignment of TRP superfamily shows no similar
location of cysteine residues in the S5–S6 regions (see
Supplementary fig. 1C), suggesting that the TRPC5 or TRPC4
in TRPC subfamily is probably the only isoform for mercury
activation.
The potential protective effect on the mercury cytotoxicity
was examined in this study using in vitro cell models. The
more evident inhibition on cell proliferation was seen in the
TRPC5 overexpressing cells, which could be due to the
channel activation and thus facilitates Hg2þ and Ca2þ influxes.
The TRPC channel blocker 2-APB can potently protect against
the channel-stimulating effect by mercurial compounds;
however, there was no protective effect against cytotoxicity,
which could be explained by the additional effects of 2-APB on
cell survival, such as the inhibition on IP3 receptor (Xu et al.,
2005a) or the blockage on gap junctional channel (Bai et al.,
2006). However, SKF-96365, another nonselective TRPC
channel blocker, showed a significantly protective effect,
suggesting that TRPC channel blocker may be useful for the
treatment of mercury exposure. Importantly, we found that
TRPC5-blocking antibody specifically prevented the
cytotoxicity induced by mercury, which provided the direct
evidence of TRPC5 acting as a therapeutic target for mercury
FIG. 7. Inhibition of axonal growth by mercury compounds in PC12 cells. PC12 cells were cultured in DMEM-F12 medium with 15% FCS and NGF (50 ng/ml)
and treated with Hg2þ, MeHg, and Pb2þ for 4 days before taking photos. (A) Effect on axonal growth of PC12 cells (***p < 0.001, n ¼ 143–338 neurite
measurements for Hg2þ, and 68–201 measurements for MeHg, and 335 measurements for Pb2þ). (B) Effect on PC12 cell proliferation (***p < 0.001, n ¼ 40
microscopic fields for each group). (C) The effect on axonal growth in PC12 cells after transfection with TRPC5 siRNA (TRPC5-si) and pool siRNA (pool-si) and
mock transfection without siRNA (control) (***p < 0.001, n ¼ 112–253 neurite measurements for each group). (D) Effect on PC12 cell proliferation after siRNA
transfection (***p < 0.001, n ¼ 36 microscopic fields for each group).
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exposure. The protective effects are modest, which suggest that
other toxicological mechanisms are also important, for
example, the intracellular mechanisms (Calamita et al., 2005;
Castoldi et al., 2000). On the other hand, thiol chemicals or
thiol-containing proteins have been investigated for the
treatment of mercury toxicity (Patrick, 2002). The reducing
agents DTT and TCEP that can activate TRPC5 channel (Xu
et al., 2008a) did not show any protective effects, whereas
DMSA, a chelating thiol agent with stimulating action on
TRPC5 and TRPC4 channels, showed a nonselective pro-
tection. These results may give the explanations why mercury
detoxification with reducing agents is not very effective.
Numerous studies have demonstrated that exposure to
mercurial compounds causes neurodevelopmental disorders.
Therefore, we examined the neuronal cell growth and the role
of TRPC channels in mercury-induced neurotoxicity. We
found that mercurial compounds significantly inhibited the PC
12 cell growth and axonal extension; this result is consistent
with other reports (Leong et al., 2001; Radio et al., 2008).
The inhibition on axonal extension and cell proliferation by
Hg2þ was alleviated when the TRPC5 gene was silenced by
the specific TRPC5 siRNA (Xu et al., 2008a), suggesting that
the TRPC5 channel mediates the mercury neurotoxicity. On the
other hand, the inhibition of VGCC has no direct relevance
to the impairment of IQ or intelligence but rather to an
improvement of memory or recognition (Veng et al., 2003);
therefore, we suppose that the IQ loss due to mercury exposure
might be caused by the elevated [Ca2þ]i through TRPC5
activation and consequently affecting growth cone formation,
axonal extension, and the connections between synapses. We
also confirm the hypothesis that mercury cytotoxicity is
mediated by TRPC5 channel in the vascular endothelial cells
where the expression level of TRPC5 is high.
According to the U.S. Environment Protection Agency’s
reference dose, the level of mercury in blood less than 5.8 lg/l
(equivalent to 0.029lM) has been considered ‘‘safe’’ without
causing adverse health effects (Hightower et al., 2006; Weil
et al., 2005), although it has been argued that the concentration
should be lowered to 3.5 lg/l (Hightower et al., 2006). In this
study, we found that longer incubation with 10nM MeHg
slightly increased Ca2þ influx and Hg2þ at 100nM significantly
increased the outside-out patch current of TRPC5, which
suggests that the effect of mercurial compounds on TRPC
channel activity could happen in the population with elevated
blood mercury level. In addition, the distribution and
disposition of mercurial compounds in the body are tissue
and organ specific; for example, the concentration of MeHg in
brain is much higher than in plasma (50 times; Cernichiari
et al., 2007). Higher level (> 5.8 lg/l) of mercury has also been
reported in the population living in polluted areas and frequent
fish consumers (Trasande et al., 2005). Therefore, the novel
toxicological mechanism we reported here should be applicable
for all cases of mercury overexposure. The removal of MeHg
in the body is difficult, presumably due to its enterohepatic
recirculation and poor reaction with chelating agents; therefore,
the search for specific TRPC channel blockers may give rise to
new therapeutics for mercury poisoning.
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